<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>Norvir, INN-ritonavir</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Courier;
	panose-1:2 7 4 9 2 2 5 2 4 4;}
@font-face
	{font-family:"Tms Rmn";
	panose-1:2 2 6 3 4 5 5 2 3 4;}
@font-face
	{font-family:Helv;
	panose-1:2 11 6 4 2 2 2 3 2 4;}
@font-face
	{font-family:"New York";
	panose-1:2 4 5 3 6 5 6 2 3 4;}
@font-face
	{font-family:System;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:Batang;
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:PMingLiU;
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:Dotum;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimHei;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:MingLiU;
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:Mincho;
	panose-1:2 2 6 9 4 3 5 8 3 5;}
@font-face
	{font-family:Gulim;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:Century;
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:"Angsana New";
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"Cordia New";
	panose-1:2 11 3 4 2 2 2 2 2 4;}
@font-face
	{font-family:Mangal;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Latha;
	panose-1:2 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sylfaen;
	panose-1:1 10 5 2 5 3 6 3 3 3;}
@font-face
	{font-family:Vrinda;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Raavi;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Shruti;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sendnya;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Gautami;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tunga;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Estrangelo Edessa";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:DengXian;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Calibri Light";
	panose-1:2 15 3 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Palatino Linotype";
	panose-1:2 4 5 2 5 5 5 3 3 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Segoe UI Emoji";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Cambria;
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Segoe UI Symbol";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:BISansCond;}
@font-face
	{font-family:Marlett;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Black";
	panose-1:2 11 10 4 2 1 2 2 2 4;}
@font-face
	{font-family:"Bahnschrift Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Bahnschrift;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight SemiConde";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold SemiConden";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Candara;
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Candara Light";
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Comic Sans MS";
	panose-1:3 15 7 2 3 3 2 2 2 4;}
@font-face
	{font-family:Consolas;
	panose-1:2 11 6 9 2 2 4 3 2 4;}
@font-face
	{font-family:Constantia;
	panose-1:2 3 6 2 5 3 6 3 3 3;}
@font-face
	{font-family:Corbel;
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"Corbel Light";
	panose-1:2 11 3 3 2 2 4 2 2 4;}
@font-face
	{font-family:Ebrima;
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Franklin Gothic Medium";
	panose-1:2 11 6 3 2 1 2 2 2 4;}
@font-face
	{font-family:Gabriola;
	panose-1:4 4 6 5 5 16 2 2 13 2;}
@font-face
	{font-family:Gadugi;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Georgia;
	panose-1:2 4 5 2 5 4 5 2 3 3;}
@font-face
	{font-family:Impact;
	panose-1:2 11 8 6 3 9 2 5 2 4;}
@font-face
	{font-family:"Ink Free";
	panose-1:3 8 4 2 0 5 0 0 0 0;}
@font-face
	{font-family:"Javanese Text";
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Leelawadee UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Leelawadee UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Lucida Console";
	panose-1:2 11 6 9 4 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Unicode";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Malgun Gothic";
	panose-1:2 11 5 3 2 0 0 2 0 4;}
@font-face
	{font-family:"\@Malgun Gothic";}
@font-face
	{font-family:"Malgun Gothic Semilight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Malgun Gothic Semilight";}
@font-face
	{font-family:"Microsoft Himalaya";
	panose-1:1 1 1 0 1 1 1 1 1 1;}
@font-face
	{font-family:"Microsoft JhengHei";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei";}
@font-face
	{font-family:"Microsoft JhengHei UI";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI";}
@font-face
	{font-family:"Microsoft JhengHei Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei Light";}
@font-face
	{font-family:"Microsoft JhengHei UI Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI Light";}
@font-face
	{font-family:"Microsoft New Tai Lue";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft PhagsPa";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft Sans Serif";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Microsoft Tai Le";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft YaHei";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei";}
@font-face
	{font-family:"Microsoft YaHei UI";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei UI";}
@font-face
	{font-family:"Microsoft YaHei Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei Light";}
@font-face
	{font-family:"Microsoft YaHei UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei UI Light";}
@font-face
	{font-family:"Microsoft Yi Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:MingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU-ExtB";}
@font-face
	{font-family:PMingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@PMingLiU-ExtB";}
@font-face
	{font-family:MingLiU_HKSCS-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU_HKSCS-ExtB";}
@font-face
	{font-family:"Mongolian Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:"MS UI Gothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS UI Gothic";}
@font-face
	{font-family:"MS PGothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS PGothic";}
@font-face
	{font-family:"MV Boli";
	panose-1:2 0 5 0 3 2 0 9 0 0;}
@font-face
	{font-family:"Myanmar Text";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Segoe Print";
	panose-1:2 0 6 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Segoe Script";
	panose-1:3 11 5 4 2 0 0 0 0 3;}
@font-face
	{font-family:"Segoe UI Black";
	panose-1:2 11 10 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Historic";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semibold";
	panose-1:2 11 7 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:NSimSun;
	panose-1:2 1 6 9 3 1 1 1 1 1;}
@font-face
	{font-family:"\@NSimSun";}
@font-face
	{font-family:SimSun-ExtB;
	panose-1:2 1 6 9 6 1 1 1 1 1;}
@font-face
	{font-family:"\@SimSun-ExtB";}
@font-face
	{font-family:"Sitka Small";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Text";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Subheading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Heading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Display";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Banner";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Trebuchet MS";
	panose-1:2 11 6 3 2 2 2 2 2 4;}
@font-face
	{font-family:Webdings;
	panose-1:5 3 1 2 1 5 9 6 7 3;}
@font-face
	{font-family:"\@Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Yu Gothic UI";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI";}
@font-face
	{font-family:"Yu Gothic UI Semibold";
	panose-1:2 11 7 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semibold";}
@font-face
	{font-family:"Yu Gothic Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Light";}
@font-face
	{font-family:"Yu Gothic UI Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Light";}
@font-face
	{font-family:"Yu Gothic Medium";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Medium";}
@font-face
	{font-family:"Yu Gothic UI Semilight";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semilight";}
@font-face
	{font-family:"HoloLens MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Agency FB";
	panose-1:2 11 5 3 2 2 2 2 2 4;}
@font-face
	{font-family:Algerian;
	panose-1:4 2 7 5 4 10 2 6 7 2;}
@font-face
	{font-family:"Book Antiqua";
	panose-1:2 4 6 2 5 3 5 3 3 4;}
@font-face
	{font-family:"Arial Narrow";
	panose-1:2 11 6 6 2 2 2 3 2 4;}
@font-face
	{font-family:"Arial Rounded MT Bold";
	panose-1:2 15 7 4 3 5 4 3 2 4;}
@font-face
	{font-family:"Baskerville Old Face";
	panose-1:2 2 6 2 8 5 5 2 3 3;}
@font-face
	{font-family:"Bauhaus 93";
	panose-1:4 3 9 5 2 11 2 2 12 2;}
@font-face
	{font-family:"Bell MT";
	panose-1:2 2 5 3 6 3 5 2 3 3;}
@font-face
	{font-family:"Bernard MT Condensed";
	panose-1:2 5 8 6 6 9 5 2 4 4;}
@font-face
	{font-family:"Bodoni MT";
	panose-1:2 7 6 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Black";
	panose-1:2 7 10 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Condensed";
	panose-1:2 7 6 6 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Poster Compressed";
	panose-1:2 7 7 6 8 6 1 5 2 4;}
@font-face
	{font-family:"Bookman Old Style";
	panose-1:2 5 6 4 5 5 5 2 2 4;}
@font-face
	{font-family:"Bradley Hand ITC";
	panose-1:3 7 4 2 5 3 2 3 2 3;}
@font-face
	{font-family:"Britannic Bold";
	panose-1:2 11 9 3 6 7 3 2 2 4;}
@font-face
	{font-family:"Berlin Sans FB";
	panose-1:2 14 6 2 2 5 2 2 3 6;}
@font-face
	{font-family:"Berlin Sans FB Demi";
	panose-1:2 14 8 2 2 5 2 2 3 6;}
@font-face
	{font-family:Broadway;
	panose-1:4 4 9 5 8 11 2 2 5 2;}
@font-face
	{font-family:"Brush Script MT";
	panose-1:3 6 8 2 4 4 6 7 3 4;}
@font-face
	{font-family:"Bookshelf Symbol 7";
	panose-1:5 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Californian FB";
	panose-1:2 7 4 3 6 8 11 3 2 4;}
@font-face
	{font-family:"Calisto MT";
	panose-1:2 4 6 3 5 5 5 3 3 4;}
@font-face
	{font-family:Castellar;
	panose-1:2 10 4 2 6 4 6 1 3 1;}
@font-face
	{font-family:"Century Schoolbook";
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:Centaur;
	panose-1:2 3 5 4 5 2 5 2 3 4;}
@font-face
	{font-family:Chiller;
	panose-1:4 2 4 4 3 16 7 2 6 2;}
@font-face
	{font-family:"Colonna MT";
	panose-1:4 2 8 5 6 2 2 3 2 3;}
@font-face
	{font-family:"Cooper Black";
	panose-1:2 8 9 4 4 3 11 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Bold";
	panose-1:2 14 7 5 2 2 6 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Light";
	panose-1:2 14 5 7 2 2 6 2 4 4;}
@font-face
	{font-family:"Curlz MT";
	panose-1:4 4 4 4 5 7 2 2 2 2;}
@font-face
	{font-family:Dubai;
	panose-1:2 11 5 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Light";
	panose-1:2 11 3 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Medium";
	panose-1:2 11 6 3 3 4 3 3 2 4;}
@font-face
	{font-family:Elephant;
	panose-1:2 2 9 4 9 5 5 2 3 3;}
@font-face
	{font-family:"Engravers MT";
	panose-1:2 9 7 7 8 5 5 2 3 4;}
@font-face
	{font-family:"Eras Bold ITC";
	panose-1:2 11 9 7 3 5 4 2 2 4;}
@font-face
	{font-family:"Eras Demi ITC";
	panose-1:2 11 8 5 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Light ITC";
	panose-1:2 11 4 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Medium ITC";
	panose-1:2 11 6 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Felix Titling";
	panose-1:4 6 5 5 6 2 2 2 10 4;}
@font-face
	{font-family:Forte;
	panose-1:3 6 9 2 4 5 2 7 2 3;}
@font-face
	{font-family:"Franklin Gothic Book";
	panose-1:2 11 5 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi";
	panose-1:2 11 7 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi Cond";
	panose-1:2 11 7 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Heavy";
	panose-1:2 11 9 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Medium Cond";
	panose-1:2 11 6 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Freestyle Script";
	panose-1:3 8 4 2 3 2 5 11 4 4;}
@font-face
	{font-family:"French Script MT";
	panose-1:3 2 4 2 4 6 7 4 6 5;}
@font-face
	{font-family:"Footlight MT Light";
	panose-1:2 4 6 2 6 3 10 2 3 4;}
@font-face
	{font-family:Garamond;
	panose-1:2 2 4 4 3 3 1 1 8 3;}
@font-face
	{font-family:Gigi;
	panose-1:4 4 5 4 6 16 7 2 13 2;}
@font-face
	{font-family:"Gill Sans MT";
	panose-1:2 11 5 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans MT Condensed";
	panose-1:2 11 5 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold Condensed";
	panose-1:2 11 10 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold";
	panose-1:2 11 10 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gloucester MT Extra Condensed";
	panose-1:2 3 8 8 2 6 1 1 1 1;}
@font-face
	{font-family:"Gill Sans MT Ext Condensed Bold";
	panose-1:2 11 9 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Century Gothic";
	panose-1:2 11 5 2 2 2 2 2 2 4;}
@font-face
	{font-family:"Goudy Old Style";
	panose-1:2 2 5 2 5 3 5 2 3 3;}
@font-face
	{font-family:"Goudy Stout";
	panose-1:2 2 9 4 7 3 11 2 4 1;}
@font-face
	{font-family:"Harlow Solid Italic";
	panose-1:4 3 6 4 2 15 2 2 13 2;}
@font-face
	{font-family:Harrington;
	panose-1:4 4 5 5 5 10 2 2 7 2;}
@font-face
	{font-family:Haettenschweiler;
	panose-1:2 11 7 6 4 9 2 6 2 4;}
@font-face
	{font-family:"High Tower Text";
	panose-1:2 4 5 2 5 5 6 3 3 3;}
@font-face
	{font-family:"Imprint MT Shadow";
	panose-1:4 2 6 5 6 3 3 3 2 2;}
@font-face
	{font-family:"Informal Roman";
	panose-1:3 6 4 2 3 4 6 11 2 4;}
@font-face
	{font-family:"Blackadder ITC";
	panose-1:4 2 5 5 5 16 7 2 13 2;}
@font-face
	{font-family:"Edwardian Script ITC";
	panose-1:3 3 3 2 4 7 7 13 8 4;}
@font-face
	{font-family:"Kristen ITC";
	panose-1:3 5 5 2 4 2 2 3 2 2;}
@font-face
	{font-family:Jokerman;
	panose-1:4 9 6 5 6 13 6 2 7 2;}
@font-face
	{font-family:"Juice ITC";
	panose-1:4 4 4 3 4 10 2 2 2 2;}
@font-face
	{font-family:"Kunstler Script";
	panose-1:3 3 4 2 2 6 7 13 13 6;}
@font-face
	{font-family:"Wide Latin";
	panose-1:2 10 10 7 5 5 5 2 4 4;}
@font-face
	{font-family:"Lucida Bright";
	panose-1:2 4 6 2 5 5 5 2 3 4;}
@font-face
	{font-family:"Lucida Calligraphy";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Fax";
	panose-1:2 6 6 2 5 5 5 2 2 4;}
@font-face
	{font-family:"Lucida Handwriting";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Sans";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Typewriter";
	panose-1:2 11 5 9 3 5 4 3 2 4;}
@font-face
	{font-family:Magneto;
	panose-1:4 3 8 5 5 8 2 2 13 2;}
@font-face
	{font-family:"Maiandra GD";
	panose-1:2 14 5 2 3 3 8 2 2 4;}
@font-face
	{font-family:"Matura MT Script Capitals";
	panose-1:3 2 8 2 6 6 2 7 2 2;}
@font-face
	{font-family:Mistral;
	panose-1:3 9 7 2 3 4 7 2 4 3;}
@font-face
	{font-family:"Modern No\. 20";
	panose-1:2 7 7 4 7 5 5 2 3 3;}
@font-face
	{font-family:"Monotype Corsiva";
	panose-1:3 1 1 1 1 2 1 1 1 1;}
@font-face
	{font-family:"Niagara Engraved";
	panose-1:4 2 5 2 7 7 3 3 2 2;}
@font-face
	{font-family:"Niagara Solid";
	panose-1:4 2 5 2 7 7 2 2 2 2;}
@font-face
	{font-family:"OCR A Extended";
	panose-1:2 1 5 9 2 1 2 1 3 3;}
@font-face
	{font-family:"Old English Text MT";
	panose-1:3 4 9 2 4 5 8 3 8 6;}
@font-face
	{font-family:Onyx;
	panose-1:4 5 6 2 8 7 2 2 2 3;}
@font-face
	{font-family:"MS Outlook";
	panose-1:5 1 1 0 1 0 0 0 0 0;}
@font-face
	{font-family:"Palace Script MT";
	panose-1:3 3 3 2 2 6 7 12 11 5;}
@font-face
	{font-family:Papyrus;
	panose-1:3 7 5 2 6 5 2 3 2 5;}
@font-face
	{font-family:Parchment;
	panose-1:3 4 6 2 4 7 8 4 8 4;}
@font-face
	{font-family:Perpetua;
	panose-1:2 2 5 2 6 4 1 2 3 3;}
@font-face
	{font-family:"Perpetua Titling MT";
	panose-1:2 2 5 2 6 5 5 2 8 4;}
@font-face
	{font-family:Playbill;
	panose-1:4 5 6 3 10 6 2 2 2 2;}
@font-face
	{font-family:"Poor Richard";
	panose-1:2 8 5 2 5 5 5 2 7 2;}
@font-face
	{font-family:Pristina;
	panose-1:3 6 4 2 4 4 6 8 2 4;}
@font-face
	{font-family:"Rage Italic";
	panose-1:3 7 5 2 4 5 7 7 3 4;}
@font-face
	{font-family:Ravie;
	panose-1:4 4 8 5 5 8 9 2 6 2;}
@font-face
	{font-family:"MS Reference Sans Serif";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"MS Reference Specialty";
	panose-1:5 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Rockwell Condensed";
	panose-1:2 6 6 3 5 4 5 2 1 4;}
@font-face
	{font-family:Rockwell;
	panose-1:2 6 6 3 2 2 5 2 4 3;}
@font-face
	{font-family:"Rockwell Extra Bold";
	panose-1:2 6 9 3 4 5 5 2 4 3;}
@font-face
	{font-family:"Script MT Bold";
	panose-1:3 4 6 2 4 6 7 8 9 4;}
@font-face
	{font-family:"Showcard Gothic";
	panose-1:4 2 9 4 2 1 2 2 6 4;}
@font-face
	{font-family:"Snap ITC";
	panose-1:4 4 10 7 6 10 2 2 2 2;}
@font-face
	{font-family:Stencil;
	panose-1:4 4 9 5 13 8 2 2 4 4;}
@font-face
	{font-family:"Tw Cen MT";
	panose-1:2 11 6 2 2 1 4 2 6 3;}
@font-face
	{font-family:"Tw Cen MT Condensed";
	panose-1:2 11 6 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Tw Cen MT Condensed Extra Bold";
	panose-1:2 11 8 3 2 2 2 2 2 4;}
@font-face
	{font-family:"Tempus Sans ITC";
	panose-1:4 2 4 4 3 13 7 2 2 2;}
@font-face
	{font-family:"Viner Hand ITC";
	panose-1:3 7 5 2 3 5 2 2 2 3;}
@font-face
	{font-family:Vivaldi;
	panose-1:3 2 6 2 5 5 6 9 8 4;}
@font-face
	{font-family:"Vladimir Script";
	panose-1:3 5 4 2 4 4 7 7 3 5;}
@font-face
	{font-family:"Wingdings 2";
	panose-1:5 2 1 2 1 5 7 7 7 7;}
@font-face
	{font-family:"Wingdings 3";
	panose-1:5 4 1 2 1 8 7 7 7 7;}
@font-face
	{font-family:AngsanaUPC;}
@font-face
	{font-family:CordiaUPC;}
@font-face
	{font-family:Abadi;}
@font-face
	{font-family:"Abadi Extra Light";}
@font-face
	{font-family:Aharoni;}
@font-face
	{font-family:Aldhabi;}
@font-face
	{font-family:Aparajita;}
@font-face
	{font-family:"Arabic Typesetting";}
@font-face
	{font-family:"Arial Nova";}
@font-face
	{font-family:"Arial Nova Cond";}
@font-face
	{font-family:"Arial Nova Cond Light";}
@font-face
	{font-family:"Arial Nova Light";}
@font-face
	{font-family:"Avenir Next LT Pro";}
@font-face
	{font-family:"Avenir Next LT Pro Light";}
@font-face
	{font-family:BatangChe;}
@font-face
	{font-family:Bembo;}
@font-face
	{font-family:Biome;}
@font-face
	{font-family:"Biome Light";}
@font-face
	{font-family:"Browallia New";}
@font-face
	{font-family:BrowalliaUPC;}
@font-face
	{font-family:Cavolini;}
@font-face
	{font-family:Dante;}
@font-face
	{font-family:DaunPenh;}
@font-face
	{font-family:David;}
@font-face
	{font-family:Daytona;}
@font-face
	{font-family:"Daytona Condensed";}
@font-face
	{font-family:"Daytona Condensed Light";}
@font-face
	{font-family:"Daytona Light";}
@font-face
	{font-family:"DengXian Light";}
@font-face
	{font-family:DilleniaUPC;}
@font-face
	{font-family:DokChampa;}
@font-face
	{font-family:DotumChe;}
@font-face
	{font-family:"Elephant Pro";}
@font-face
	{font-family:EucrosiaUPC;}
@font-face
	{font-family:Euphemia;}
@font-face
	{font-family:FangSong;}
@font-face
	{font-family:FrankRuehl;}
@font-face
	{font-family:FreesiaUPC;}
@font-face
	{font-family:"Georgia Pro";}
@font-face
	{font-family:"Georgia Pro Black";}
@font-face
	{font-family:"Georgia Pro Cond";}
@font-face
	{font-family:"Georgia Pro Cond Black";}
@font-face
	{font-family:"Georgia Pro Cond Light";}
@font-face
	{font-family:"Georgia Pro Cond Semibold";}
@font-face
	{font-family:"Georgia Pro Light";}
@font-face
	{font-family:"Georgia Pro Semibold";}
@font-face
	{font-family:"Gill Sans Nova";}
@font-face
	{font-family:"Gill Sans Nova Cond";}
@font-face
	{font-family:"Gill Sans Nova Cond Lt";}
@font-face
	{font-family:"Gill Sans Nova Cond Ultra Bold";}
@font-face
	{font-family:"Gill Sans Nova Cond XBd";}
@font-face
	{font-family:"Gill Sans Nova Light";}
@font-face
	{font-family:"Gill Sans Nova Ultra Bold";}
@font-face
	{font-family:Gisha;}
@font-face
	{font-family:Grotesque;}
@font-face
	{font-family:"Grotesque Light";}
@font-face
	{font-family:GulimChe;}
@font-face
	{font-family:Gungsuh;}
@font-face
	{font-family:GungsuhChe;}
@font-face
	{font-family:"Hadassah Friedlaender";}
@font-face
	{font-family:HGGothicE;}
@font-face
	{font-family:HGMaruGothicMPRO;}
@font-face
	{font-family:HGMinchoE;}
@font-face
	{font-family:HGPGothicE;}
@font-face
	{font-family:HGPMinchoE;}
@font-face
	{font-family:HGPSoeiKakugothicUB;}
@font-face
	{font-family:HGSGothicE;}
@font-face
	{font-family:HGSMinchoE;}
@font-face
	{font-family:HGSoeiKakugothicUB;}
@font-face
	{font-family:HGSSoeiKakugothicUB;}
@font-face
	{font-family:IrisUPC;}
@font-face
	{font-family:"Iskoola Pota";}
@font-face
	{font-family:JasmineUPC;}
@font-face
	{font-family:KaiTi;}
@font-face
	{font-family:Kalinga;}
@font-face
	{font-family:Kartika;}
@font-face
	{font-family:"Khmer UI";}
@font-face
	{font-family:Kigelia;}
@font-face
	{font-family:"Kigelia Arabic";}
@font-face
	{font-family:"Kigelia Arabic Light";}
@font-face
	{font-family:"Kigelia Light";}
@font-face
	{font-family:KodchiangUPC;}
@font-face
	{font-family:Kokila;}
@font-face
	{font-family:"Lao UI";}
@font-face
	{font-family:Leelawadee;}
@font-face
	{font-family:"Levenim MT";}
@font-face
	{font-family:LilyUPC;}
@font-face
	{font-family:"Mangal Pro";}
@font-face
	{font-family:Meiryo;}
@font-face
	{font-family:"Meiryo UI";}
@font-face
	{font-family:"Microsoft GothicNeo";}
@font-face
	{font-family:"Microsoft GothicNeo Light";}
@font-face
	{font-family:"Microsoft Uighur";}
@font-face
	{font-family:MingLiU_HKSCS;}
@font-face
	{font-family:Miriam;}
@font-face
	{font-family:"Miriam Fixed";}
@font-face
	{font-family:"Modern Love";}
@font-face
	{font-family:"Modern Love Caps";}
@font-face
	{font-family:"Modern Love Grunge";}
@font-face
	{font-family:MoolBoran;}
@font-face
	{font-family:"MS PMincho";}
@font-face
	{font-family:"MT Extra";}
@font-face
	{font-family:Narkisim;}
@font-face
	{font-family:"Neue Haas Grotesk Text Pro";}
@font-face
	{font-family:"News Gothic MT";}
@font-face
	{font-family:Nyala;}
@font-face
	{font-family:OCRB;}
@font-face
	{font-family:"Plantagenet Cherokee";}
@font-face
	{font-family:Posterama;}
@font-face
	{font-family:"Quire Sans";}
@font-face
	{font-family:"Quire Sans Light";}
@font-face
	{font-family:"Quire Sans Pro Light";}
@font-face
	{font-family:"Rockwell Light";}
@font-face
	{font-family:"Rockwell Nova";}
@font-face
	{font-family:"Rockwell Nova Cond";}
@font-face
	{font-family:"Rockwell Nova Cond Light";}
@font-face
	{font-family:"Rockwell Nova Extra Bold";}
@font-face
	{font-family:"Rockwell Nova Light";}
@font-face
	{font-family:Rod;}
@font-face
	{font-family:"Sabon Next LT";}
@font-face
	{font-family:"Sagona Book";}
@font-face
	{font-family:"Sagona ExtraLight";}
@font-face
	{font-family:"Sakkal Majalla";}
@font-face
	{font-family:"Sanskrit Text";}
@font-face
	{font-family:Selawik;}
@font-face
	{font-family:"Selawik Light";}
@font-face
	{font-family:"Selawik Semibold";}
@font-face
	{font-family:"Shonar Bangla";}
@font-face
	{font-family:"Simplified Arabic";}
@font-face
	{font-family:"Simplified Arabic Fixed";}
@font-face
	{font-family:"Sitka Banner Semibold";}
@font-face
	{font-family:"Sitka Display Semibold";}
@font-face
	{font-family:"Sitka Heading Semibold";}
@font-face
	{font-family:"Sitka Small Semibold";}
@font-face
	{font-family:"Sitka Subheading Semibold";}
@font-face
	{font-family:"Sitka Text Semibold";}
@font-face
	{font-family:"Source Sans Pro";}
@font-face
	{font-family:"Source Sans Pro Black";}
@font-face
	{font-family:"Source Sans Pro ExtraLight";}
@font-face
	{font-family:"Source Sans Pro Light";}
@font-face
	{font-family:"Source Sans Pro SemiBold";}
@font-face
	{font-family:"Speak Pro";}
@font-face
	{font-family:"Speak Pro Light";}
@font-face
	{font-family:STCaiyun;}
@font-face
	{font-family:STFangsong;}
@font-face
	{font-family:STHupo;}
@font-face
	{font-family:STKaiti;}
@font-face
	{font-family:STXihei;}
@font-face
	{font-family:STXingkai;}
@font-face
	{font-family:STXinwei;}
@font-face
	{font-family:STZhongsong;}
@font-face
	{font-family:"TH SarabunPSK";}
@font-face
	{font-family:"The Hand";}
@font-face
	{font-family:"The Hand Black";}
@font-face
	{font-family:"The Hand Extrablack";}
@font-face
	{font-family:"The Hand Light";}
@font-face
	{font-family:"The Serif Hand";}
@font-face
	{font-family:"The Serif Hand Black";}
@font-face
	{font-family:"The Serif Hand Extrablack";}
@font-face
	{font-family:"The Serif Hand Light";}
@font-face
	{font-family:"Tisa Offc Serif Pro";}
@font-face
	{font-family:"Tisa Offc Serif Pro Thin";}
@font-face
	{font-family:"Trade Gothic Next";}
@font-face
	{font-family:"Trade Gothic Next Cond";}
@font-face
	{font-family:"Trade Gothic Next Cond Hv";}
@font-face
	{font-family:"Trade Gothic Next Heavy";}
@font-face
	{font-family:"Trade Gothic Next Light";}
@font-face
	{font-family:"Traditional Arabic";}
@font-face
	{font-family:"UD Digi Kyokasho N-B";}
@font-face
	{font-family:"UD Digi Kyokasho N-R";}
@font-face
	{font-family:"UD Digi Kyokasho NK-B";}
@font-face
	{font-family:"UD Digi Kyokasho NK-R";}
@font-face
	{font-family:"UD Digi Kyokasho NP-B";}
@font-face
	{font-family:"UD Digi Kyokasho NP-R";}
@font-face
	{font-family:Univers;}
@font-face
	{font-family:"Univers Condensed";}
@font-face
	{font-family:"Univers Condensed Light";}
@font-face
	{font-family:"Univers Light";}
@font-face
	{font-family:"Urdu Typesetting";}
@font-face
	{font-family:Utsaah;}
@font-face
	{font-family:Vani;}
@font-face
	{font-family:"Verdana Pro";}
@font-face
	{font-family:"Verdana Pro Black";}
@font-face
	{font-family:"Verdana Pro Cond";}
@font-face
	{font-family:"Verdana Pro Cond Black";}
@font-face
	{font-family:"Verdana Pro Cond Light";}
@font-face
	{font-family:"Verdana Pro Cond SemiBold";}
@font-face
	{font-family:"Verdana Pro Light";}
@font-face
	{font-family:"Verdana Pro SemiBold";}
@font-face
	{font-family:Vijaya;}
@font-face
	{font-family:"Walbaum Display";}
@font-face
	{font-family:"Walbaum Display Heavy";}
@font-face
	{font-family:"Walbaum Display Light";}
@font-face
	{font-family:"Walbaum Display SemiBold";}
@font-face
	{font-family:"Walbaum Heading";}
@font-face
	{font-family:"Walbaum Text";}
@font-face
	{font-family:"Yu Mincho";}
@font-face
	{font-family:"Yu Mincho Demibold";}
@font-face
	{font-family:"Yu Mincho Light";}
@font-face
	{font-family:"TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRomanPSMT;}
@font-face
	{font-family:"Times New Roman Bold";
	panose-1:2 2 8 3 7 5 5 2 3 4;}
@font-face
	{font-family:PraxisCom-Regular;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:EUAlbertina;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Times;
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"\@TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:"\@Batang";
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@BatangChe";}
@font-face
	{font-family:"\@Gungsuh";}
@font-face
	{font-family:"\@GungsuhChe";}
@font-face
	{font-family:"\@DengXian Light";}
@font-face
	{font-family:"\@Gulim";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@GulimChe";}
@font-face
	{font-family:"\@Dotum";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@DotumChe";}
@font-face
	{font-family:"\@Meiryo";}
@font-face
	{font-family:"\@Meiryo UI";}
@font-face
	{font-family:"\@MingLiU";
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:"\@PMingLiU";
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"\@MingLiU_HKSCS";}
@font-face
	{font-family:"\@MS PMincho";}
@font-face
	{font-family:"\@STXingkai";}
@font-face
	{font-family:"\@STZhongsong";}
@font-face
	{font-family:"\@Yu Mincho";}
@font-face
	{font-family:"\@Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Times-Roman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:CourierNewPSMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"SAS Monospace";}
@font-face
	{font-family:"Bookshelf Symbol 3";}
@font-face
	{font-family:Goudy;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Garamond-Italic;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial\,Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:DIN-Bold;}
@font-face
	{font-family:"CG Times \(W1\)";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"HelveticaNeue Condensed";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@HGMaruGothicMPRO";}
@font-face
	{font-family:CourierStd;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Roman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:EFPPNA+TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@TimesNewRoman";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRomanPSMT\,Times New Rom";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRoman\,Times New Roman";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRoman\,Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"CG Times";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Minion;}
@font-face
	{font-family:CourierNew;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Noto Sans Symbols";}
@font-face
	{font-family:LZLLQG+TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRomanPS;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:HelveticaNeueLTStd-Cn;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Wingdings-Regular;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@HelveticaNeueLTStd-Cn";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Wingdings-Regular";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Geneva;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"TimesNewRoman\,BoldItalic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:ArialMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h1
	{mso-style-name:"Heading 1\,D70AR\,Info rubrik 1\,titel 1";
	mso-style-link:"Heading 1 Char\,D70AR Char\,Info rubrik 1 Char\,titel 1 Char";
	margin:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	text-decoration:underline;}
h2
	{mso-style-link:"Heading 2 Char";
	margin:0in;
	text-align:center;
	line-height:-150%;
	page-break-after:avoid;
	font-size:18.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h3
	{mso-style-link:"Heading 3 Char";
	margin:0in;
	text-align:center;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h4
	{mso-style-link:"Heading 4 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	page-break-after:avoid;
	background:#BFBFBF;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h5
	{mso-style-name:"Heading 5\,DO NOT USE";
	mso-style-link:"Heading 5 Char\,DO NOT USE Char";
	margin:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:normal;
	text-decoration:underline;}
h6
	{mso-style-link:"Heading 6 Char";
	margin:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:normal;
	font-style:italic;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{mso-style-link:"Heading 7 Char";
	margin:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{mso-style-link:"Heading 8 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{mso-style-link:"Heading 9 Char";
	margin:0in;
	text-align:justify;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoIndex1, li.MsoIndex1, div.MsoIndex1
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex2, li.MsoIndex2, div.MsoIndex2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex3, li.MsoIndex3, div.MsoIndex3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex4, li.MsoIndex4, div.MsoIndex4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex5, li.MsoIndex5, div.MsoIndex5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex6, li.MsoIndex6, div.MsoIndex6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex7, li.MsoIndex7, div.MsoIndex7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex8, li.MsoIndex8, div.MsoIndex8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex9, li.MsoIndex9, div.MsoIndex9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:99.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc1, li.MsoToc1, div.MsoToc1
	{margin-right:0in;
	margin-left:0in;
	font-size:14.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoToc2, li.MsoToc2, div.MsoToc2
	{margin-right:0in;
	margin-left:.05in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc3, li.MsoToc3, div.MsoToc3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc4, li.MsoToc4, div.MsoToc4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc5, li.MsoToc5, div.MsoToc5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc6, li.MsoToc6, div.MsoToc6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc7, li.MsoToc7, div.MsoToc7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc8, li.MsoToc8, div.MsoToc8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc9, li.MsoToc9, div.MsoToc9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNormalIndent, li.MsoNormalIndent, div.MsoNormalIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText
	{mso-style-link:"Footnote Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-link:"Comment Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-style-link:"Header Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-link:"Footer Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndexHeading, li.MsoIndexHeading, div.MsoIndexHeading
	{margin:0in;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.MsoCaption, li.MsoCaption, div.MsoCaption
	{margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoTof, li.MsoTof, div.MsoTof
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoEnvelopeAddress, li.MsoEnvelopeAddress, div.MsoEnvelopeAddress
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:2.0in;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;}
p.MsoEnvelopeReturn, li.MsoEnvelopeReturn, div.MsoEnvelopeReturn
	{margin:0in;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;}
p.MsoEndnoteText, li.MsoEndnoteText, div.MsoEndnoteText
	{mso-style-link:"Endnote Text Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToa, li.MsoToa, div.MsoToa
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoMacroText, li.MsoMacroText, div.MsoMacroText
	{mso-style-link:"Macro Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoToaHeading, li.MsoToaHeading, div.MsoToaHeading
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.MsoList, li.MsoList, div.MsoList
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet, li.MsoListBullet, div.MsoListBullet
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber, li.MsoListNumber, div.MsoListNumber
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2, li.MsoList2, div.MsoList2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3, li.MsoList3, div.MsoList3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4, li.MsoList4, div.MsoList4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5, li.MsoList5, div.MsoList5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2, li.MsoListBullet2, div.MsoListBullet2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3, li.MsoListBullet3, div.MsoListBullet3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4, li.MsoListBullet4, div.MsoListBullet4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5, li.MsoListBullet5, div.MsoListBullet5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2, li.MsoListNumber2, div.MsoListNumber2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3, li.MsoListNumber3, div.MsoListNumber3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4, li.MsoListNumber4, div.MsoListNumber4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5, li.MsoListNumber5, div.MsoListNumber5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoTitle, li.MsoTitle, div.MsoTitle
	{mso-style-link:"Title Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	font-size:16.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.MsoClosing, li.MsoClosing, div.MsoClosing
	{mso-style-link:"Closing Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:212.6pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoSignature, li.MsoSignature, div.MsoSignature
	{mso-style-link:"Signature Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:212.6pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{mso-style-link:"Body Text Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{mso-style-link:"Body Text Indent Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:27.0pt;
	text-indent:-9.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue, li.MsoListContinue, div.MsoListContinue
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2, li.MsoListContinue2, div.MsoListContinue2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:28.3pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3, li.MsoListContinue3, div.MsoListContinue3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:42.45pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4, li.MsoListContinue4, div.MsoListContinue4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:56.6pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5, li.MsoListContinue5, div.MsoListContinue5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.75pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoMessageHeader, li.MsoMessageHeader, div.MsoMessageHeader
	{mso-style-link:"Message Header Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.7pt;
	text-indent:-56.7pt;
	background:#CCCCCC;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;}
p.MsoSubtitle, li.MsoSubtitle, div.MsoSubtitle
	{mso-style-link:"Subtitle Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;}
p.MsoSalutation, li.MsoSalutation, div.MsoSalutation
	{mso-style-link:"Salutation Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoDate, li.MsoDate, div.MsoDate
	{mso-style-link:"Date Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextFirstIndent, li.MsoBodyTextFirstIndent, div.MsoBodyTextFirstIndent
	{mso-style-link:"Body Text First Indent Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-indent:10.5pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextFirstIndent2, li.MsoBodyTextFirstIndent2, div.MsoBodyTextFirstIndent2
	{mso-style-link:"Body Text First Indent 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	text-indent:10.5pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNoteHeading, li.MsoNoteHeading, div.MsoNoteHeading
	{mso-style-link:"Note Heading Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{mso-style-link:"Body Text 2 Char";
	margin:0in;
	text-align:justify;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText3, li.MsoBodyText3, div.MsoBodyText3
	{mso-style-link:"Body Text 3 Char";
	margin:0in;
	text-align:justify;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextIndent2, li.MsoBodyTextIndent2, div.MsoBodyTextIndent2
	{mso-style-link:"Body Text Indent 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-align:justify;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextIndent3, li.MsoBodyTextIndent3, div.MsoBodyTextIndent3
	{mso-style-link:"Body Text Indent 3 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;
	font-style:italic;}
p.MsoBlockText, li.MsoBlockText, div.MsoBlockText
	{margin-top:0in;
	margin-right:1.0in;
	margin-bottom:6.0pt;
	margin-left:1.0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{mso-style-link:"Document Map Char";
	margin:0in;
	background:navy;
	font-size:10.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoPlainText, li.MsoPlainText, div.MsoPlainText
	{mso-style-link:"Plain Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoAutoSig, li.MsoAutoSig, div.MsoAutoSig
	{mso-style-link:"E-mail Signature Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p
	{margin:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
address
	{mso-style-link:"HTML Address Char";
	margin:0in;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
pre
	{mso-style-link:"HTML Preformatted Char";
	margin:0in;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{mso-style-link:"Comment Subject Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-link:"Balloon Text Char";
	margin:0in;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoNoSpacing, li.MsoNoSpacing, div.MsoNoSpacing
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.MsoQuote, li.MsoQuote, div.MsoQuote
	{mso-style-link:"Quote Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;
	font-style:italic;}
p.MsoIntenseQuote, li.MsoIntenseQuote, div.MsoIntenseQuote
	{mso-style-link:"Intense Quote Char";
	margin-top:10.0pt;
	margin-right:.65in;
	margin-bottom:14.0pt;
	margin-left:.65in;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:#4F81BD;
	font-weight:bold;
	font-style:italic;}
p.MsoBibliography, li.MsoBibliography, div.MsoBibliography
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoTocHeading, li.MsoTocHeading, div.MsoTocHeading
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:16.0pt;
	font-family:"Cambria",serif;
	font-weight:bold;}
p.TableText, li.TableText, div.TableText
	{mso-style-name:"Table Text";
	margin:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.Institutionquisigne, li.Institutionquisigne, div.Institutionquisigne
	{mso-style-name:"Institution qui signe";
	margin-top:.5in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	text-align:justify;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.BodyText1, li.BodyText1, div.BodyText1
	{mso-style-name:"Body Text1";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:57.55pt;
	text-align:justify;
	line-height:120%;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Reporttext, li.Reporttext, div.Reporttext
	{mso-style-name:"Report text";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:.2in;
	margin-left:57.55pt;
	text-align:justify;
	line-height:120%;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.HeaderText, li.HeaderText, div.HeaderText
	{mso-style-name:HeaderText;
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.Considrant, li.Considrant, div.Considrant
	{mso-style-name:Considrant;
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.5in;
	text-align:justify;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.a, li.a, div.a
	{mso-style-name:_;
	margin:0in;
	font-size:12.0pt;
	font-family:Roman;}
p.pedtablecenter, li.pedtablecenter, div.pedtablecenter
	{mso-style-name:pedtablecenter;
	margin:0in;
	text-align:center;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.pedtable, li.pedtable, div.pedtable
	{mso-style-name:pedtable;
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.Corpsdetex, li.Corpsdetex, div.Corpsdetex
	{mso-style-name:"Corps de tex";
	margin:0in;
	font-size:11.0pt;
	font-family:"Book Antiqua",serif;}
p.Style6, li.Style6, div.Style6
	{mso-style-name:Style6;
	margin:0in;
	text-autospace:none;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;}
p.times, li.times, div.times
	{mso-style-name:times;
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.tableentry, li.tableentry, div.tableentry
	{mso-style-name:"table entry";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman Bold",serif;
	font-weight:bold;}
p.EMEABullet, li.EMEABullet, div.EMEABullet
	{mso-style-name:"EMEA Bullet";
	mso-style-link:"EMEA Bullet Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.EMEAHeading1, li.EMEAHeading1, div.EMEAHeading1
	{mso-style-name:"EMEA Heading 1";
	margin-top:10.0pt;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:0in;
	font-size:11.0pt;
	font-family:"Times New Roman Bold",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.EMEANormal, li.EMEANormal, div.EMEANormal
	{mso-style-name:"EMEA Normal";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.EMEAHeading2SPC, li.EMEAHeading2SPC, div.EMEAHeading2SPC
	{mso-style-name:"EMEA Heading 2 SPC";
	margin-top:5.0pt;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:0in;
	font-size:11.0pt;
	font-family:"Times New Roman Bold",serif;
	font-weight:bold;}
p.EMEAHeadingBoxed, li.EMEAHeadingBoxed, div.EMEAHeadingBoxed
	{mso-style-name:"EMEA Heading Boxed";
	margin-top:10.0pt;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:28.1pt;
	text-indent:-28.1pt;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman Bold",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.EMEAHeadingItalic, li.EMEAHeadingItalic, div.EMEAHeadingItalic
	{mso-style-name:"EMEA Heading Italic";
	margin-top:5.0pt;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.EMEAHeadingLeaflet, li.EMEAHeadingLeaflet, div.EMEAHeadingLeaflet
	{mso-style-name:"EMEA Heading Leaflet";
	margin-top:5.0pt;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:0in;
	font-size:11.0pt;
	font-family:"Times New Roman Bold",serif;
	font-weight:bold;}
p.EMEAHeadingUI, li.EMEAHeadingUI, div.EMEAHeadingUI
	{mso-style-name:"EMEA Heading UI";
	margin-top:5.0pt;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;
	text-decoration:underline;}
p.EMEAHeadingUnderline, li.EMEAHeadingUnderline, div.EMEAHeadingUnderline
	{mso-style-name:"EMEA Heading Underline";
	margin-top:5.0pt;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	text-decoration:underline;}
p.EMEAHint, li.EMEAHint, div.EMEAHint
	{mso-style-name:"EMEA Hint";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:green;
	font-style:italic;}
p.EMEAFigureTitle, li.EMEAFigureTitle, div.EMEAFigureTitle
	{mso-style-name:"EMEA Figure Title";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.EMEATitle, li.EMEATitle, div.EMEATitle
	{mso-style-name:"EMEA Title";
	margin:0in;
	text-align:center;
	font-size:11.0pt;
	font-family:"Times New Roman Bold",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.EMEAFooter, li.EMEAFooter, div.EMEAFooter
	{mso-style-name:"EMEA Footer";
	margin:0in;
	text-align:center;
	font-size:8.0pt;
	font-family:"Helvetica",sans-serif;}
p.EMEAHeading2SPCEmpty, li.EMEAHeading2SPCEmpty, div.EMEAHeading2SPCEmpty
	{mso-style-name:"EMEA Heading 2 SPC Empty";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:0in;
	font-size:11.0pt;
	font-family:"Times New Roman Bold",serif;
	font-weight:bold;}
p.EMEAHeading1Para1, li.EMEAHeading1Para1, div.EMEAHeading1Para1
	{mso-style-name:"EMEA Heading 1 Para 1";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:0in;
	font-size:11.0pt;
	font-family:"Times New Roman Bold",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.EMEANormal1, li.EMEANormal1, div.EMEANormal1
	{mso-style-name:"EMEA Normal1";
	mso-style-link:"EMEA Normal Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.EMEAHeadingBoxedEmpty, li.EMEAHeadingBoxedEmpty, div.EMEAHeadingBoxedEmpty
	{mso-style-name:"EMEA Heading Boxed Empty";
	margin-top:10.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.1pt;
	text-indent:-28.1pt;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman Bold",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.EMEAHeadingBoxedTitle, li.EMEAHeadingBoxedTitle, div.EMEAHeadingBoxedTitle
	{mso-style-name:"EMEA Heading Boxed Title";
	margin-top:24.0pt;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:30.0pt;
	text-indent:-30.0pt;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;
	text-transform:uppercase;
	font-weight:bold;}
span.bold1
	{mso-style-name:bold1;
	font-weight:bold;}
span.sub1
	{mso-style-name:sub1;}
span.sup1
	{mso-style-name:sup1;}
span.italics1
	{mso-style-name:italics1;
	font-style:italic;}
p.EMEABodyText, li.EMEABodyText, div.EMEABodyText
	{mso-style-name:"EMEA Body Text";
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"EFPPNA+TimesNewRoman",serif;}
span.Fill-In
	{mso-style-name:Fill-In;
	color:fuchsia;}
p.TitleA, li.TitleA, div.TitleA
	{mso-style-name:"Title A";
	margin:0in;
	text-align:center;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.TitleB, li.TitleB, div.TitleB
	{mso-style-name:"Title B";
	margin-top:0in;
	margin-right:70.8pt;
	margin-bottom:0in;
	margin-left:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.BMCENTRED, li.BMCENTRED, div.BMCENTRED
	{mso-style-name:"BM CENTRED";
	margin:0in;
	text-align:center;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.BMLeftAligned, li.BMLeftAligned, div.BMLeftAligned
	{mso-style-name:"BM Left Aligned";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.msoins0
	{mso-style-name:msoins;
	font-family:"Times New Roman",serif;}
span.EMEANormalChar
	{mso-style-name:"EMEA Normal Char";
	mso-style-link:"EMEA Normal1";}
p.BodytextAgency, li.BodytextAgency, div.BodytextAgency
	{mso-style-name:"Body text \(Agency\)";
	mso-style-link:"Body text \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.BodytextAgencyChar
	{mso-style-name:"Body text \(Agency\) Char";
	mso-style-link:"Body text \(Agency\)";
	font-family:"Verdana",sans-serif;}
span.FooterChar
	{mso-style-name:"Footer Char";
	mso-style-link:Footer;}
p.Default, li.Default, div.Default
	{mso-style-name:Default;
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.EMEABullet2, li.EMEABullet2, div.EMEABullet2
	{mso-style-name:"EMEA Bullet 2";
	margin:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.EMEABulletChar
	{mso-style-name:"EMEA Bullet Char";
	mso-style-link:"EMEA Bullet";}
span.Heading1Char
	{mso-style-name:"Heading 1 Char\,D70AR Char\,Info rubrik 1 Char\,titel 1 Char";
	mso-style-link:"Heading 1\,D70AR\,Info rubrik 1\,titel 1";
	font-weight:bold;
	text-decoration:underline;}
span.Heading2Char
	{mso-style-name:"Heading 2 Char";
	mso-style-link:"Heading 2";
	font-weight:bold;}
span.Heading3Char
	{mso-style-name:"Heading 3 Char";
	mso-style-link:"Heading 3";
	font-weight:bold;}
span.Heading4Char
	{mso-style-name:"Heading 4 Char";
	mso-style-link:"Heading 4";
	background:#BFBFBF;
	font-weight:bold;}
span.Heading5Char
	{mso-style-name:"Heading 5 Char\,DO NOT USE Char";
	mso-style-link:"Heading 5\,DO NOT USE";
	text-decoration:underline;}
span.Heading6Char
	{mso-style-name:"Heading 6 Char";
	mso-style-link:"Heading 6";
	font-style:italic;}
span.Heading7Char
	{mso-style-name:"Heading 7 Char";
	mso-style-link:"Heading 7";
	font-weight:bold;}
span.Heading8Char
	{mso-style-name:"Heading 8 Char";
	mso-style-link:"Heading 8";
	font-weight:bold;}
span.Heading9Char
	{mso-style-name:"Heading 9 Char";
	mso-style-link:"Heading 9";
	font-weight:bold;}
span.HeaderChar
	{mso-style-name:"Header Char";
	mso-style-link:Header;}
span.BodyTextChar
	{mso-style-name:"Body Text Char";
	mso-style-link:"Body Text";}
span.BodyText2Char
	{mso-style-name:"Body Text 2 Char";
	mso-style-link:"Body Text 2";}
span.BodyText3Char
	{mso-style-name:"Body Text 3 Char";
	mso-style-link:"Body Text 3";}
span.BodyTextIndentChar
	{mso-style-name:"Body Text Indent Char";
	mso-style-link:"Body Text Indent";}
span.EndnoteTextChar
	{mso-style-name:"Endnote Text Char";
	mso-style-link:"Endnote Text";}
span.BodyTextIndent3Char
	{mso-style-name:"Body Text Indent 3 Char";
	mso-style-link:"Body Text Indent 3";
	color:black;
	font-style:italic;}
span.BodyTextIndent2Char
	{mso-style-name:"Body Text Indent 2 Char";
	mso-style-link:"Body Text Indent 2";}
span.CommentTextChar
	{mso-style-name:"Comment Text Char";
	mso-style-link:"Comment Text";}
span.BalloonTextChar
	{mso-style-name:"Balloon Text Char";
	mso-style-link:"Balloon Text";
	font-family:"Tahoma",sans-serif;}
span.CommentSubjectChar
	{mso-style-name:"Comment Subject Char";
	mso-style-link:"Comment Subject";
	font-weight:bold;}
span.BodyTextFirstIndentChar
	{mso-style-name:"Body Text First Indent Char";
	mso-style-link:"Body Text First Indent";}
span.BodyTextFirstIndent2Char
	{mso-style-name:"Body Text First Indent 2 Char";
	mso-style-link:"Body Text First Indent 2";}
span.ClosingChar
	{mso-style-name:"Closing Char";
	mso-style-link:Closing;}
span.DateChar
	{mso-style-name:"Date Char";
	mso-style-link:Date;}
span.DocumentMapChar
	{mso-style-name:"Document Map Char";
	mso-style-link:"Document Map";
	font-family:"Tahoma",sans-serif;
	background:navy;}
span.E-mailSignatureChar
	{mso-style-name:"E-mail Signature Char";
	mso-style-link:"E-mail Signature";}
span.FootnoteTextChar
	{mso-style-name:"Footnote Text Char";
	mso-style-link:"Footnote Text";}
span.HTMLAddressChar
	{mso-style-name:"HTML Address Char";
	mso-style-link:"HTML Address";
	font-style:italic;}
span.HTMLPreformattedChar
	{mso-style-name:"HTML Preformatted Char";
	mso-style-link:"HTML Preformatted";
	font-family:"Courier New";}
span.MacroTextChar
	{mso-style-name:"Macro Text Char";
	mso-style-link:"Macro Text";
	font-family:"Courier New";}
span.MessageHeaderChar
	{mso-style-name:"Message Header Char";
	mso-style-link:"Message Header";
	font-family:"Arial",sans-serif;
	background:#CCCCCC;}
span.NoteHeadingChar
	{mso-style-name:"Note Heading Char";
	mso-style-link:"Note Heading";}
span.PlainTextChar
	{mso-style-name:"Plain Text Char";
	mso-style-link:"Plain Text";
	font-family:"Courier New";}
span.SalutationChar
	{mso-style-name:"Salutation Char";
	mso-style-link:Salutation;}
span.SignatureChar
	{mso-style-name:"Signature Char";
	mso-style-link:Signature;}
span.SubtitleChar
	{mso-style-name:"Subtitle Char";
	mso-style-link:Subtitle;
	font-family:"Arial",sans-serif;}
span.TitleChar
	{mso-style-name:"Title Char";
	mso-style-link:Title;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.GTCBodyTextAlignLeft, li.GTCBodyTextAlignLeft, div.GTCBodyTextAlignLeft
	{mso-style-name:"GTC Body Text Align Left";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:0in;
	line-height:125%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.GTCTableText, li.GTCTableText, div.GTCTableText
	{mso-style-name:"GTC Table Text";
	margin-right:0in;
	margin-left:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.gtcbold1
	{mso-style-name:gtcbold1;
	font-weight:bold;}
p.Heading1Unnumbered, li.Heading1Unnumbered, div.Heading1Unnumbered
	{mso-style-name:"Heading 1 Unnumbered";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:1.25in;
	text-indent:-1.25in;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
span.IntenseQuoteChar
	{mso-style-name:"Intense Quote Char";
	mso-style-link:"Intense Quote";
	color:#4F81BD;
	font-weight:bold;
	font-style:italic;}
span.QuoteChar
	{mso-style-name:"Quote Char";
	mso-style-link:Quote;
	color:black;
	font-style:italic;}
span.st1
	{mso-style-name:st1;}
span.msoIns
	{mso-style-name:"";
	text-decoration:underline;
	color:teal;}
span.msoDel
	{mso-style-name:"";
	text-decoration:line-through;
	color:red;}
.MsoChpDefault
	{font-size:10.0pt;}
 /* Page Definitions */
 @page WordSection1
	{size:595.35pt 842.0pt;
	margin:56.7pt 70.85pt 56.7pt 70.85pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link=blue vlink=purple style='word-wrap:break-word'>

<div class=WordSection1>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle><span lang=EN-GB>ANNEX I</span></p>

<p class=MsoNormal align=center style='text-align:center'><b>&nbsp;</b></p>

<p class=BMCENTRED>SUMMARY OF PRODUCT CHARACTERISTICS</p>

<span lang=EN-GB style='font-size:14.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=EMEANormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
color:black;text-transform:uppercase'>1. Name of the medicinal product </span></b></p>

<p class=EMEANormal1><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Norvir 100&nbsp;mg
powder for oral suspension</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
color:black;text-transform:uppercase'>2. Qualitative and quantitative
composition </span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
color:black;text-transform:uppercase'>&nbsp;</span></b></p>

<p class=MsoNormal><span style='color:black'>Each sachet of powder for oral
suspension contains 100&nbsp;mg of ritonavir.</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black'>For the full list of excipients,
see section 6.1. </span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
color:black;text-transform:uppercase'>3. Pharmaceutical Form<i> </i></span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
color:black;text-transform:uppercase'>&nbsp;</span></b></p>

<p class=MsoNormal><span style='color:black'>Powder for oral suspension.</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black'>Beige/pale yellow to yellow powder.</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
color:black;text-transform:uppercase'>4. Clinical Particulars</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
color:black;text-transform:uppercase'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
color:black'>4.1 Therapeutic indications</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
color:black'>&nbsp;</span></b></p>

<p class=MsoNormal><span style='color:black'>Ritonavir is indicated in
combination with other antiretroviral agents for the treatment of HIV-1
infected patients (adults and children of 2 years of age and older).</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
color:black'>4.2 Posology and method of administration</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
color:black'>&nbsp;</span></b></p>

<p class=MsoNormal><span style='color:black'>Ritonavir should be administered
by physicians who are experienced in the treatment of HIV infection.</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><u><span style='color:black'>Posology</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span style='color:black'>Ritonavir
dosed as a pharmacokinetic enhancer</span></i></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black'>When ritonavir is used as a
pharmacokinetic enhancer with other protease inhibitors the Summary of Product
Characteristics for the particular protease inhibitor must be consulted.</span></p>

<p class=MsoNormal><span style='color:black'>The following HIV-1 protease
inhibitors have been approved for use with ritonavir as a pharmacokinetic
enhancer at the noted doses. </span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>Adults</span></i></p>

<p class=MsoNormal style='margin-left:28.35pt'><span style='color:black'>Amprenavir
600&nbsp;mg twice daily with ritonavir 100&nbsp;mg twice daily.</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span style='color:black'>Atazanavir
300&nbsp;mg once daily with ritonavir 100&nbsp;mg once daily.</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span style='color:black'>Fosamprenavir
700&nbsp;mg twice daily with ritonavir 100&nbsp;mg twice daily.</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span style='color:black'>Lopinavir
co&#8209;formulated with ritonavir (lopinavir/ritonavir) 400&nbsp;mg/100&nbsp;mg
or 800&nbsp;mg/200&nbsp;mg.</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span style='color:black'>Saquinavir
1000&nbsp;mg twice daily with ritonavir 100&nbsp;mg twice daily in ART
experienced patients.</span><span style='color:black'> Initiate treatment with </span><span
lang=EN-GB style='color:black'>saquinavir 500&nbsp;mg twice daily with
ritonavir 100&nbsp;mg twice daily for the first 7&nbsp;days, then saquinavir
1000&nbsp;mg twice daily with ritonavir 100&nbsp;mg twice daily</span><span
style='color:black'> in ART-nave patients</span><span lang=EN-GB
style='color:black'>.</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span style='color:black'>Tipranavir
500&nbsp;mg twice daily with ritonavir 200&nbsp;mg twice daily. Tipranavir
with ritonavir should not be used in treatment-nave patients.</span></p>

<p class=MsoNormal style='margin-left:27.5pt;text-indent:-27.5pt;page-break-after:
avoid'><span style='color:black'> Darunavir </span><span
style='color:black'>600&nbsp;mg twice daily with ritonavir 100&nbsp;mg </span><span
style='color:black'>twice daily in </span><span style='color:black'>antiretroviral
treatment (ART) experienced patients. Darunavir 800&nbsp;mg once daily with
ritonavir 100&nbsp;mg once daily may be used in some ART experienced patients.
Refer to the darunavir Summary of Product Characteristics for further
information on once daily dosing in ART experienced patients.</span></p>

<p class=MsoNormal style='margin-left:27.5pt;text-indent:-27.5pt'><span
style='color:black'> </span><span style='color:black'>Darunavir
800&nbsp;mg once daily with ritonavir 100&nbsp;mg once daily in ART-nave
patients.</span></p>

<p class=MsoNormal style='margin-left:27.5pt;text-indent:-27.5pt'><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB
style='color:black'>Children and adolescents</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span style='color:black'>Ritonavir
is recommended for children 2 years of age and older. For further dosage recommendations,
refer to the product information of other protease inhibitors approved for co&#8209;administration
with ritonavir.</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><u><span style='color:black'>Special populations</span></u></p>

<p class=MsoNormal><i><span style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal><i><span style='color:black'>Renal impairment</span></i></p>

<p class=MsoNormal><span style='color:black'>As ritonavir is primarily</span><span
lang=EN-GB style='color:black'> metabolised</span><span style='color:black'> by
the liver, ritonavir may be appropriate for use with caution as a
pharmacokinetic enhancer in patients with renal insufficiency depending on the
specific protease inhibitor with which it is co&#8209;administered. </span><span
style='color:black'>However, since the renal clearance of ritonavir is
negligible, the decrease in the total body clearance is not expected in
patients with renal impairment. </span><span style='color:black'>For specific
dosing information in patients with renal impairment, refer to the Summary of
Product Characteristics (SPC) of the co&#8209;administered protease inhibitor.</span><span
style='color:black'> </span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><i><span style='color:black'>Hepatic impairment</span></i></p>

<p class=MsoNormal><span style='color:black'>Ritonavir should not be given as a
pharmacokinetic enhancer to patients with decompensated liver disease (see
section 4.3). In the absence of pharmacokinetic studies in patients with
stable severe hepatic impairment (Child Pugh Grade C) without decompensation,
caution should be exercised when ritonavir is used as a pharmacokinetic
enhancer as increased levels of the co-administered PI may occur. Specific
recommendations for use of ritonavir as a pharmacokinetic enhancer in patients
with hepatic impairment are dependent on the protease inhibitor with which it
is co&#8209;administered. The SPC of the co&#8209;administered PI should be
reviewed for specific dosing information in this patient population. </span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span style='color:black'>Ritonavir
dosed as an antiretroviral agent</span></i></p>

<p class=MsoNormal><i><span style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal><i><span style='color:black'>Adult</span></i><span
style='color:black'>s</span></p>

<p class=MsoNormal><span style='color:black'>The recommended dose of Norvir
powder for oral suspension is 600&nbsp;mg (six sachets) twice daily by mouth
and should be given with food. </span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black'>Gradually increasing the dose of
ritonavir when initiating therapy may help to improve tolerance. Treatment
should be initiated at 300&nbsp;mg (three sachets) twice daily for a period of
three days and increased by 100&nbsp;mg (one sachet) twice daily increments up
to 600&nbsp;mg twice daily over a period of no longer than 14&nbsp;days. Patients
should not remain on 300&nbsp;mg twice daily for more than 3&nbsp;days.</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black'>Refer to Method of Administration
section below and section 6.6 for details on preparing doses.</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><i><span style='color:black'>Children and adolescents (2
years of age and above)</span></i></p>

<p class=MsoNormal><span style='color:black'>The recommended dosage of Norvir
powder for suspension in children is 350&nbsp;mg/m<sup></sup> by mouth twice
daily and should not exceed 600&nbsp;mg twice daily. Norvir should be started
at 250&nbsp;mg/m<sup></sup> and increased at 2 to 3 day intervals by 50&nbsp;mg/m<sup></sup>
twice daily. </span></p>

<p class=MsoNormal align=center style='margin-top:7.5pt;margin-right:0in;
margin-bottom:6.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
style='color:black'>Paediatric dosage guidelines for Norvir powder for oral
suspension (prepared as 100&nbsp;mg/10&nbsp;ml)*</span></b></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="90%"
 style='width:90.66%;border-collapse:collapse'>
 <thead>
  <tr>
   <td width=94 valign=top style='width:70.35pt;border-top:solid windowtext 1.0pt;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
   padding:0in 0in 0in 0in'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span style='font-size:10.0pt;color:black'>Body Surface Area (m</span></b><b><sup><span
   style='font-size:12.0pt;color:black'>2</span></sup></b><b><span
   style='font-size:10.0pt;color:black'>)</span></b></p>
   </td>
   <td width=152 valign=bottom style='width:114.2pt;border-top:solid windowtext 1.0pt;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
   padding:0in 0in 0in 0in'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span style='font-size:10.0pt;color:black'>Twice Daily Dose
   250&nbsp;mg/m</span></b><b><sup><span style='font-size:12.0pt;color:black'>2</span></sup></b></p>
   </td>
   <td width=156 valign=bottom style='width:116.95pt;border-top:solid windowtext 1.0pt;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
   padding:0in 0in 0in 0in'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span style='font-size:10.0pt;color:black'>Twice Daily Dose
   300&nbsp;mg/m</span></b><b><sup><span style='font-size:12.0pt;color:black'>2</span></sup></b></p>
   </td>
   <td width=146 valign=bottom style='width:109.75pt;border-top:solid windowtext 1.0pt;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
   padding:0in 0in 0in 0in'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span style='font-size:10.0pt;color:black'>Twice Daily Dose
   350&nbsp;mg/m</span></b><b><sup><span style='font-size:12.0pt;color:black'>2</span></sup></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width=94 valign=top style='width:70.35pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:10.0pt;color:black'>0.25</span></p>
  </td>
  <td width=152 valign=top style='width:114.2pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:10.0pt;color:black'>6.4&nbsp;ml (62.5&nbsp;mg)</span></p>
  </td>
  <td width=156 valign=top style='width:116.95pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 0in 0in 0in'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:10.0pt;color:black'>7.6&nbsp;ml (76&nbsp;mg)</span></p>
  </td>
  <td width=146 valign=top style='width:109.75pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 0in 0in 0in'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:10.0pt;color:black'>8.8&nbsp;ml (88 mg)</span></p>
  </td>
 </tr>
 <tr>
  <td width=94 valign=top style='width:70.35pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:10.0pt;color:black'>0.50</span></p>
  </td>
  <td width=152 valign=top style='width:114.2pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:10.0pt;color:black'>12.6&nbsp;ml (126&nbsp;mg)</span></p>
  </td>
  <td width=156 valign=top style='width:116.95pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 0in 0in 0in'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:10.0pt;color:black'>15.0&nbsp;ml (150&nbsp;mg)</span></p>
  </td>
  <td width=146 valign=top style='width:109.75pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 0in 0in 0in'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:10.0pt;color:black'>17.6&nbsp;ml (176&nbsp;mg)</span></p>
  </td>
 </tr>
 <tr>
  <td width=94 valign=top style='width:70.35pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:10.0pt;color:black'>0.75</span></p>
  </td>
  <td width=152 valign=top style='width:114.2pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:10.0pt;color:black'>18.8 ml (188 mg)</span></p>
  </td>
  <td width=156 valign=top style='width:116.95pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 0in 0in 0in'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:10.0pt;color:black'>22.6 ml (226 mg)</span></p>
  </td>
  <td width=146 valign=top style='width:109.75pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 0in 0in 0in'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:10.0pt;color:black'>26.4 ml (262.5 mg)</span></p>
  </td>
 </tr>
 <tr>
  <td width=94 valign=top style='width:70.35pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:10.0pt;color:black'>1.00</span></p>
  </td>
  <td width=152 valign=top style='width:114.2pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:10.0pt;color:black'>25.0&nbsp;ml (250&nbsp;mg)</span></p>
  </td>
  <td width=156 valign=top style='width:116.95pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 0in 0in 0in'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:10.0pt;color:black'>30.0&nbsp;ml (300&nbsp;mg)</span></p>
  </td>
  <td width=146 valign=top style='width:109.75pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 0in 0in 0in'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:10.0pt;color:black'>35.0&nbsp;ml (350&nbsp;mg)</span></p>
  </td>
 </tr>
 <tr>
  <td width=94 valign=top style='width:70.35pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:10.0pt;color:black'>1.25</span></p>
  </td>
  <td width=152 valign=top style='width:114.2pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:10.0pt;color:black'>31.4&nbsp;ml
  (312.5&nbsp;mg)</span></p>
  </td>
  <td width=156 valign=top style='width:116.95pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 0in 0in 0in'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:10.0pt;color:black'>37.6&nbsp;ml (376&nbsp;mg)</span></p>
  </td>
  <td width=146 valign=top style='width:109.75pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 0in 0in 0in'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:10.0pt;color:black'>43.8&nbsp;ml (438mg)</span></p>
  </td>
 </tr>
 <tr>
  <td width=94 valign=top style='width:70.35pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:10.0pt;color:black'>1.50</span></p>
  </td>
  <td width=152 valign=top style='width:114.2pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:10.0pt;color:black'>37.6&nbsp;ml (376&nbsp;mg)</span></p>
  </td>
  <td width=156 valign=top style='width:116.95pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 0in 0in 0in'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:10.0pt;color:black'>45.0&nbsp;ml (450&nbsp;mg)</span></p>
  </td>
  <td width=146 valign=top style='width:109.75pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 0in 0in 0in'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:10.0pt;color:black'>52.6&nbsp;ml (526&nbsp;mg)</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span style='font-size:10.0pt;color:black'>*When mixed with
9.4&nbsp;ml of liquid the concentration of the suspension is 10&nbsp;mg/ml. </span></p>

<p class=MsoNormal><span style='font-size:10.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='font-size:10.0pt;color:black'></span><span
style='font-size:10.0pt;color:black'>In some instances, the volumes and/or
doses have been adjusted to ensure the recommended final dose and dosing
volume. </span></p>

<p class=MsoNormal><span style='font-size:10.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='font-size:10.0pt;color:black'>Body surface area
can be calculated with the following equation: BSA (m</span><sup><span
style='font-size:12.0pt;color:black'>2</span></sup><span style='font-size:10.0pt;
color:black'>) = </span><b>&#8730;</b><span lang=EN-GB style='font-size:10.0pt;
color:black'>(Height (cm) X Weight (kg) <b>/ </b>3600)</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black'>To calculate the volume to be
administered (in ml) for intermediate body surface areas not included in the
above table, the body surface area should be multiplied by a factor of: 25 for
a dose of 250&nbsp;mg/m; 30 for 300&nbsp;mg/m; and 35 for 350&nbsp;mg/m. </span></p>

<p class=MsoNormal><span style='font-size:10.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black'>Refer to Method of Administration
section below and section 6.6 for details on preparing doses.</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='color:black'>Special populations</span></u></p>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>Elderly</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Pharmacokinetic data
indicated that no dose adjustment is necessary for elderly patients (see
section 5.2).</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><a name=s4-ccds></a><i><span style='color:black'>Renal
impairment</span></i></p>

<p class=MsoNormal><span style='color:black'>Currently, there are no data
specific to this patient population and therefore specific dosage
recommendations cannot be made. The renal clearance of ritonavir is
negligible; therefore, a decrease in the total body clearance is not expected
in patients with renal impairment. Because ritonavir is highly protein bound
it is unlikely that it will be significantly removed by haemodialysis or
peritoneal dialysis.</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><i><span style='color:black'>Hepatic impairment</span></i></p>

<p class=MsoNormal><span style='color:black'>Ritonavir</span><i><span
style='color:black'> </span></i><span style='color:black'>is principally
metabolised and eliminated by the liver. Pharmacokinetic data indicate that no
dose adjustment is necessary in patients with mild to moderate hepatic
impairment (see section 5.2). Ritonavir must not be given to patients with
severe hepatic impairment (see section 4.3). </span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='color:black'>Paediatric
population</span></u></p>

<p class=MsoNormal>The safety and efficacy of Norvir in children aged below 2
years has not been established. Currently available data are described in
sections 5.1 and 5.2 but no recommendation on a posology can be made.</p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><u><span style='color:black'>Method of administration</span></u></p>

<p class=MsoNormal><span style='color:black'>Norvir powder for oral suspension
is administered orally, poured on soft food (apple sauce or vanilla pudding) or
mixed with liquid (water, chocolate milk, or infant formula). For details on
preparation and administration of the Norvir powder for oral suspension, see
section 6.6. Any mixing outside the recommendations is the responsibility of
the health care professional or the user. </span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal>Norvir powder for oral suspension should be taken with food.
The bitter aftertaste of Norvir powder for oral suspension may be lessened if
peanut butter, hazelnut chocolate spread, or black currant syrup are taken
immediately after dose administration.</p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black'>The prescribed dose of Norvir powder
for oral suspension can be administered via a feeding tube after being mixed
with water as detailed in section 6.6. Follow the instructions for the feeding
tube to administer the medicine.</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
color:black'>4.3  Contraindications</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
color:black'>&nbsp;</span></b></p>

<p class=MsoNormal><span style='color:black'>Hypersensitivity to the active
substance or to any of the excipients listed in section 6.1. </span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black'>When ritonavir is used as a pharmacokinetic
enhancer of other PIs, consult the Summary of Product Characteristics of the co&#8209;administered
protease inhibitor for contraindications.</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black'>Ritonavir should not be given as a
pharmacokinetic enhancer or as an antiretroviral agent to patients with
decompensated liver disease.</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><i><span style='color:black'>In vitro</span></i><span
style='color:black'> and <i>in vivo</i> studies have demonstrated that
ritonavir is a potent inhibitor of CYP3A&#8209; and CYP2D6&#8209; mediated
biotransformations. The following medicines are contraindicated when used with
ritonavir and unless otherwise noted, the contraindication is based on the
potential for ritonavir to inhibit metabolism of the co&#8209;administered
medicinal product, resulting in increased exposure to the co&#8209;administered
medicinal product and risk of clinically significant adverse effects.</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black'>The enzyme-modulating effect of
ritonavir may be dose dependent. For some products, contraindications may be
more relevant when ritonavir is used as an antiretroviral agent than when
ritonavir is used as a pharmacokinetic enhancer (e.g. rifabutin and
voriconazole):</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.1pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in'><b><span style='color:black'>Medicinal Product Class</span></b></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in'><b><span style='color:black'>Medicinal Products within
  Class</span></b></p>
  </td>
  <td width=310 valign=top style='width:232.25pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in;page-break-after:avoid'><b><span style='color:black'>Rationale</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=3 valign=top style='width:464.45pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in;page-break-after:avoid'><b><span style='color:black'>Concomitant
  medicinal product levels increased or decreased</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='font-family:Symbol;color:black'>a</span><sub><span
  style='color:black'>1</span></sub><span style='color:black'>-Adrenoreceptor
  Antagonist</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Alfuzosin</span></p>
  </td>
  <td width=310 valign=top style='width:232.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Increased plasma concentrations
  of alfuzosin which may lead to severe hypotension (see section 4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Analgesics</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Pethidine, piroxicam,
  propoxyphne</span></p>
  </td>
  <td width=310 valign=top style='width:232.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Increased plasma concentrations
  of norpethidine, piroxicam and propoxyphene. Thereby, increasing the risk of
  serious respiratory depression or haematologic abnormalities, or other
  serious adverse effects from these agents.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Antianginal</p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=ES-MX>Ranolazine</span></p>
  </td>
  <td width=310 valign=top style='width:232.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Increased plasma concentrations of ranolazine which may
  increase the potential for serious and/or life-threatening reactions (see
  section 4.5).</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 rowspan=2 valign=top style='width:116.1pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Anticancer</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Neratinib</p>
  </td>
  <td width=310 valign=top style='width:232.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Increased plasma concentrations of neratinib which may
  increase the potential for serious and/or life-threatening reactions including
  hepatotoxicity (see section 4.5).</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Venetoclax</p>
  </td>
  <td width=310 valign=top style='width:232.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Increased plasma concentrations of venetoclax. Increased
  risk of tumor lysis syndrome at the dose initiation and during the dose&#8209;titration
  phase (see section 4.5).</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Antiarrhythmics</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=ES-MX style='color:black'>Amiodarone, bepridil,
  dronedarone, encainide, flecanide, propafenone, quinidine</span></p>
  <p class=MsoNormal><span lang=ES-MX style='color:black'>&nbsp;</span></p>
  </td>
  <td width=310 valign=top style='width:232.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Increased plasma concentrations
  of amiodarone, bepridil, dronedarone, encainide, flecanide, propafenone,
  quinidine. Thereby, increasing the risk of arrhythmias or other serious
  adverse reactions from these agents.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Antibiotic</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Fusidic Acid</span></p>
  </td>
  <td width=310 valign=top style='width:232.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Increased plasma concentrations
  of fusidic acid and ritonavir.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.1pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Antifungal</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Voriconazole</span></p>
  </td>
  <td width=310 valign=top style='width:232.25pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Concomitant use of ritonavir
  (400&nbsp;mg twice daily and more) and voriconazole is contraindicated due to
  a reduction in voriconazole plasma concentrations and possible loss of effect
  (see section 4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Anti-gout</p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Colchicine</p>
  </td>
  <td width=310 valign=top style='width:232.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Potential for serious and/or life&#8209;threatening
  reactions in patients with renal and/or hepatic impairment (see sections 4.4
  and 4.5).</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Antihistamines</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Astemizole, terfenadine</span></p>
  </td>
  <td width=310 valign=top style='width:232.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Increased plasma concentrations
  of astemizole and terfenadine. Thereby, increasing the risk of serious
  arrhythmias from these agents.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Antimycobacterial</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Rifabutin</span></p>
  </td>
  <td width=310 valign=top style='width:232.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Concomitant use of ritonavir (500&nbsp;mg
  twice daily) dosed as an antiretroviral agent and rifabutin due to an
  increase of rifabutin serum concentrations and risk of adverse events
  including uveitis (see section 4.4). Recommendations regarding use of
  ritonavir dosed as a pharmacokinetic enhancer with rifabutin are noted in
  section 4.5. </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 rowspan=2 valign=top style='width:116.1pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Antipsychotics/ Neuroleptics</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Lurasidone</p>
  </td>
  <td width=310 valign=top style='width:232.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Increased plasma concentrations of lurasidone which may
  increase the potential for serious and/or life-threatening reactions (see
  section 4.5).</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Clozapine, pimozide</span></p>
  </td>
  <td width=310 valign=top style='width:232.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Increased plasma concentrations
  of clozapine and pimozide. Thereby, increasing the risk of serious
  haematologic abnormalities, or other serious adverse effects from these
  agents.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Quetiapine</span></p>
  </td>
  <td width=310 valign=top style='width:232.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Increased plasma concentrations
  of quetiapine which may lead to coma. The concomitant administration with
  quetiapine is contraindicated (see section 4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Ergot Derivatives</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Dihydroergotamine, ergonovine,
  ergotamine, methylergonovine</span></p>
  </td>
  <td width=310 valign=top style='width:232.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Increased plasma concentrations
  of ergot derivatives leading to acute ergot toxicity, including vasospasm and
  ischaemia.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>GI motility agent</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Cisapride</span></p>
  </td>
  <td width=310 valign=top style='width:232.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Increased plasma concentrations
  of cisapride. Thereby, increasing the risk of serious arrhythmias from this
  agent.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=3 valign=top style='width:464.45pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Lipid-modifying agents</span></p>
  <p class=MsoNormal><span style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>HMG Co-A Reductase Inhibitors</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Lovastatin, simvastatin</span></p>
  </td>
  <td width=310 valign=top style='width:232.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Increased plasma concentrations
  of lovastatin and simvastatin; thereby, increasing the risk of myopathy
  including rhabdomyolysis (see section 4.5).</span></p>
  <p class=MsoNormal><span style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Microsomal triglyceride transfer
  protein (MTTP) inhibitor</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Lomitapide</span></p>
  </td>
  <td width=310 valign=top style='width:232.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Increased plasma concentrations of lomitapide (see section
  4.5).</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.1pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>PDE5 inhibitors</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Avanafil</span></p>
  </td>
  <td width=310 valign=top style='width:232.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Increased plasma concentrations
  of avanafil (see section 4.4. and 4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Sildenafil </span></p>
  </td>
  <td width=310 valign=top style='width:232.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Contraindicated when used for
  the treatment of pulmonary arterial hypertension (PAH) only. Increased
  plasma concentrations of sildenafil. Thereby, increasing the potential for
  sildenafil-associated adverse events (which include hypotension and
  syncope). See section 4.4 and section 4.5 for co&#8209;administration of
  sildenafil in patients with erectile dysfunction.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=PT-BR style='color:black'>Vardenafil</span></p>
  </td>
  <td width=310 valign=top style='width:232.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Increased plasma concentrations
  of vardenafil (see section 4.4. and 4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Sedatives/hypnotics</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=PT-BR style='color:black'>Clorazepate,
  diazepam, estazolam, flurazepam, oral midazolam </span><span lang=PT-BR
  style='color:black'>and triazolam</span></p>
  </td>
  <td width=310 valign=top style='width:232.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Increased plasma concentrations
  of clorazepate, diazepam, estazolam, flurazepam, oral midazolam </span><span
  style='color:black'>and triazolam</span><span style='color:black'>. Thereby,
  increasing the risk of extreme sedation and respiratory depression from these
  agents. (For caution on parenterally administered midazolam, see section
  4.5).</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=3 valign=top style='width:464.45pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in'><b><span style='color:black'>Ritonavir medicinal
  product level decreased</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Herbal Preparation</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>St. Johns wort</span></p>
  </td>
  <td width=310 valign=top style='width:232.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Herbal preparations containing
  St Johns wort (<i>Hypericum perforatum)</i> due to the risk of decreased
  plasma concentrations and reduced clinical effects of ritonavir </span><span
  style='color:black'>(see section 4.5).</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-family:"Times New Roman Bold",serif;color:black'>4.4  Special
warnings and precautions for use</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-family:"Times New Roman Bold",serif;color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span style='color:black'>Ritonavir
is not a cure for HIV-1 infection or AIDS. Patients receiving ritonavir or any
other antiretroviral therapy may continue to develop opportunistic infections
and other complications of HIV-1 infection. </span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black'>While effective viral suppression
with antiretroviral therapy has been proven to substantially reduce the risk of
sexual transmission, a residual risk cannot be excluded. Precautions to
prevent transmission should be taken in accordance with national guidelines.</span></p>

<p class=MsoNormal><span style='font-size:10.0pt;font-family:"Geneva",sans-serif;
color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>When ritonavir is used
as a pharmacokinetic enhancer with other PIs, full details on the warnings and
precautions relevant to that particular PI should be considered, therefore the
Summary of Product Characteristics for the particular PI must be consulted.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>Ritonavir dosed as
an antiretroviral agent or as a pharmacokinetic enhancer </span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><u><span style='color:black'>Patients with chronic diarrhoea
or malabsorption</span></u></p>

<p class=MsoNormal><span style='color:black'>Extra monitoring is recommended
when diarrhoea occurs. The relatively high frequency of diarrhoea during
treatment with ritonavir may compromise the absorption and efficacy (due to
decreased compliance) of ritonavir or other concurrent medicinal products.
Serious persistent vomiting and/or diarrhoea associated with ritonavir use
might also compromise renal function. It is advisable to monitor renal
function in patients with renal function impairment.</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><u><span style='color:black'>Haemophilia</span></u></p>

<p class=MsoNormal><span style='color:black'>There have been reports of
increased bleeding, including spontaneous skin haematomas and haemarthroses, in</span><span
lang=EN-GB style='color:black'> haemophiliac</span><span style='color:black'>
patients type A and B treated with protease inhibitors. In some patients
additional factor VIII was given. In more than a half of the reported cases,
treatment with protease inhibitors was continued or reintroduced if treatment
had been discontinued. A causal relationship has been evoked, although the
mechanism of action has not been elucidated. Haemophiliac patients should,
therefore, be made aware of the possibility of increased bleeding.</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Weight
and metabolic parameters: </span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>An increase
in weight and in levels of blood lipids and glucose may occur during
antiretroviral therapy. Such changes may in part be linked to disease control
and life style. For lipids, there is in some cases evidence for a treatment
effect, while for weight gain there is no strong evidence relating this to any
particular treatment. For monitoring of blood lipids and glucose, reference is
made to established HIV treatment guidelines. Lipid disorders should be
managed as clinically appropriate.</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><u><span style='color:black'>Pancreatitis</span></u></p>

<p class=MsoNormal><span style='color:black'>Pancreatitis should be considered
if clinical symptoms (nausea, vomiting, abdominal pain) or abnormalities in
laboratory values (such as increased serum lipase or amylase values) suggestive
of pancreatitis should occur. Patients who exhibit these signs or symptoms
should be evaluated and Norvir therapy should be discontinued if a diagnosis of
pancreatitis is made (see section 4.8).</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='color:black'>Immune Reconstitution Inflammatory Syndrome</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='color:black'>In HIV-infected patients with severe immune deficiency at
the time of institution of combination antiretroviral therapy (CART), an
inflammatory reaction to asymtomatic or residual opportunistic pathogens may
arise and cause serious clinical conditions, or aggravation of symptoms.
Typically, such reactions have been observed within the first few weeks or
months of initiation of CART. Relevant examples are cytomegalovirus retinitis,
generalised and/or focal mycobacterial infections, and Pneumocystis jiroveci
pneumonia. Any inflammatory symptoms should be evaluated and treatment
instituted when necessary.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Autoimmune disorders
(such as Graves disease </span><span lang=EN-GB>and autoimmune hepatitis</span><span
lang=EN-GB style='color:black'>) have also been reported to occur in the
setting of immune reconstitution; however, the reported time to onset is more
variable and can occur many months after initiation of treatment.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='color:black'>Liver disease</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='color:black'>Ritonavir should not be given to patients with
decompensated liver disease (see section 4.2).</span><span lang=EN-GB
style='color:black'> Patients with chronic hepatitis B or C and treated with
combination antiretroviral therapy are at an increased risk for severe and
potentially fatal hepatic adverse reactions. In case of concomitant antiviral
therapy for hepatitis B or C, please refer to the relevant product information
for these medicinal products.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Patients with
pre-existing liver dysfunction including chronic active hepatitis have an
increased frequency of liver function abnormalities during combination
antiretroviral therapy and should be monitored according to standard practice.
If there is evidence of worsening liver disease in such patients, interruption
or discontinuation of treatment must be considered.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><u><span style='color:black'>Renal disease</span></u></p>

<p class=MsoNormal><span style='color:black'>Since the renal clearance of
ritonavir is negligible, the decrease in the total body clearance is not
expected in patients with renal impairment</span><span style='color:black'> (see
also section 4.2).</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Renal failure, renal
impairment, elevated creatinine, hypophosphataemia and proximal tubulopathy
(including Fanconi syndrome) have been reported with the use of tenofovir
disoproxil fumarate (DF) in clinical practice (see section 4.8).</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><u><span style='color:black'>Medication error</span></u></p>

<p class=MsoNormal><span style='color:black'>Special attention should be given
to the accurate calculation of the dose of Norvir, transcription of the
medication order, dispensing information and dosing instructions to minimise
the risk for medication errors and underdose. This is especially important for
infants and young children.</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='color:black'>Osteonecrosis</span></u></p>

<p class=MsoNormal><span style='color:black'>Although the aetiology is
considered to be multifactorial (including corticosteroid use, alcohol
consumption, severe immunosuppression, higher body mass index), cases of
osteonecrosis have been reported in patients with advanced HIV&#8209;disease
and/or long&#8209;term exposure to combination antiretroviral therapy (CART).
Patients should be advised to seek medical advice if they experience joint
aches and pain, joint stiffness or difficulty in movement.</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='color:black'>PR interval
prolongation</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Ritonavir has been
shown to cause modest asymptomatic prolongation of the PR interval in some
healthy adult subjects.</span><span lang=EN-GB style='color:black'> </span><span
lang=EN-GB style='color:black'>Rare reports of 2<sup>nd</sup> or 3<sup>rd</sup>
degree atrioventricular block in patients with underlying structural heart
disease and pre</span><span style='color:black'>&#8209;</span><span lang=EN-GB
style='color:black'>existing conduction system abnormalities or in patients
receiving medicinal products known to prolong the PR interval (such as
verapamil or atazanavir) have been reported in patients receiving ritonavir. </span><span
lang=EN-GB style='color:black'></span><span lang=EN-GB style='color:black'>Norvir
should be used with caution in such patients</span><span style='color:black'>
(see section 5.1).</span></p>

<p class=MsoNormal><span style='font-size:10.0pt;font-family:"Geneva",sans-serif;
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='color:black'>Interactions with other medicinal products</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB
style='color:black'>Ritonavir dosed as an antiretroviral agent</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='color:black'>The following warnings and precautions should be considered
when ritonavir is used as an antiretroviral agent. When ritonavir is used as a
pharmacokinetic enhancer at the 100&nbsp;mg and 200&nbsp;mg level it cannot be
assumed that the following warnings and precautions will also apply. When
ritonavir is used as a pharmacokinetic enhancer, full details on the warnings
and precautions relevant to that particular PI must be considered, therefore
the Summary of Product Characteristics, section&nbsp;4.4, for the particular PI
must be consulted to determine if the information below is applicable.</span></p>

<p class=MsoNormal><i><span style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span style='color:black'>PDE5
inhibitors</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span style='color:black'>Particular
caution should be used when prescribing sildenafil or tadalafil for the
treatment of erectile dysfunction in patients receiving ritonavir. Co-administration
of ritonavir with these medicinal products is expected to substantially
increase their concentrations and may result in associated adverse reactions
such as hypotension and prolonged erection (see section 4.5). Concomitant use
of avanafil or vardenafil with ritonavir is contraindicated (see section 4.3).
Concomitant use of sildenafil with ritonavir is contraindicated in pulmonary
arterial hypertension patients (see section 4.3).</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><i><span style='color:black'>HMG-CoA reductase inhibitors</span></i></p>

<p class=MsoNormal><span style='color:black'>The HMG-CoA reductase inhibitors
simvastatin and lovastatin are highly dependent on CYP3A for metabolism, thus
concomitant use of ritonavir with simvastatin or lovastatin is not recommended
due to an increased risk of myopathy including rhabdomyolysis. Caution must
also be exercised and reduced doses should be considered if ritonavir is used
concurrently with atorvastatin, which is metabolised to a lesser extent by
CYP3A. While rosuvastatin elimination is not dependent on CYP3A, an elevation
of rosuvastatin exposure has been reported with ritonavir co-administration.
The mechanism of this interaction is not clear, but may be the result of
transporter inhibition. When used with ritonavir dosed as a pharmacokinetic
enhancer or as an antiretroviral agent, the lowest doses of atorvastatin or
rosuvastatin should be administered. The metabolism of pravastatin and
fluvastatin is not dependent of CYP3A, and interactions are not expected with
ritonavir. If treatment with an HMG-CoA reductase inhibitor is indicated,
pravastatin or fluvastatin is recommended (see section 4.5).</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEANormal1><i><span lang=EN-GB>Colchicine</span></i></p>

<p class=EMEANormal1><span lang=EN-GB>Life-threatening and fatal drug
interactions have been reported in patients treated with colchicine and strong
inhibitors of CYP3A like ritonavir (see sections 4.3 and 4.5).</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>Digoxin</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Particular caution should
be used when prescribing ritonavir in patients taking digoxin since co&#8209;administration
of ritonavir with digoxin is expected to increase digoxin levels. The
increased digoxin levels may lessen over time (see section 4.5).</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>In patients who are
already taking digoxin when ritonavir is introduced, the digoxin dose should be
reduced to one-half of the patients normal dose and patient need to be
followed more closely than usual for several weeks after initiating
co-administration of ritonavir and digoxin.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black'>In patients who are already taking
ritonavir when digoxin is introduced, digoxin should be introduced more
gradually than usual. Digoxin levels should be monitored more intensively than
usual during this period, with dose adjustments made, as necessary, based on
clinical, electrocardiographic and digoxin level findings.</span><span
style='color:black'> </span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><i><span style='color:black'>Ethinyl estradiol</span></i></p>

<p class=MsoNormal><span style='color:black'>Barrier or other non-hormonal
methods of contraception should be considered when administering ritonavir at
therapeutic or low doses as ritonavir is likely to reduce the effect and change
the uterine bleeding profile when co-administered with estradiol-containing
contraceptives.</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB
style='color:black'>Glucocorticoids</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='color:black'>Concomitant use of ritonavir and fluticasone or other
glucocorticoids that are metabolised by CYP3A4 is not recommended unless the
potential benefit of treatment outweighs the risk of systemic corticosteroid
effects, including Cushings syndrome and adrenal suppression (see section
4.5).</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><i><span style='color:black'>Trazodone</span></i></p>

<p class=MsoNormal><span style='color:black'>Particular caution should be used
when prescribing ritonavir in patients using trazodone. Trazodone is a CYP3A4
substrate and co-administration of ritonavir is expected to increase trazodone
levels. Adverse reactions of nausea, dizziness, hypotension and syncope have
been observed in single dose interaction studies in healthy volunteers (see
section 4.5)</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>Rivaroxaban</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>It is not recommended
to use ritonavir in patients receiving rivaroxaban, due to the risk of
increased bleeding (see section 4.5).</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEANormal1><i><span lang=EN-GB>Riociguat</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The concomitant use of ritonavir is not
recommended due to potential increase in riociguat exposure (see section 4.5).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal1><i><span lang=EN-GB>Vorapaxar</span></i></p>

<p class=EMEANormal1><span lang=EN-GB>The concomitant use of ritonavir is not
recommended due to potential increase in vorapaxar exposure (see section 4.5).</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><i>Bedaquiline</i></p>

<p class=MsoNormal>Strong CYP3A4 inhibitors such as protease inhibitors may
increase bedaquiline exposure which could potentially increase the risk of
bedaquiline-related adverse reactions. Therefore, combination of bedaquiline
with ritonavir should be avoided. However, if the benefit outweighs the risk,
co-administration of bedaquiline with ritonavir must be done with caution. More
frequent electrocardiogram monitoring and monitoring of transaminases is
recommended (see section 4.5 and refer to the bedaquiline Summary of Product
Characteristics).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><i>Delamanid</i> </p>

<p class=MsoNormal>Co&#8209;administration of delamanid with a strong inhibitor
of CYP3A (ritonavir) may increase exposure to delamanid metabolite, which has
been associated with QTc prolongation. Therefore, if co&#8209;administration
of delamanid with ritonavir is considered necessary, very frequent ECG
monitoring throughout the full delamanid treatment period is recommended (see
section 4.5 and refer to the delamanid Summary of Product Characteristics). </p>

<p class=MsoNormal><i>&nbsp;</i></p>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>Ritonavir dosed as a
pharmacokinetic enhancer</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>The interaction
profiles of HIV-protease inhibitors, co-administered with low dose ritonavir,
are dependent on the specific co&#8209;administered protease inhibitor. </span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>For a description of
the mechanisms and potential mechanisms contributing to the interaction profile
of the PIs, see section 4.5. Please also review the Summary of Product
Characteristics for the particular boosted PI.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>Saquinavir</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Doses of ritonavir
higher than 100&nbsp;mg twice daily should not be used. Higher doses of
ritonavir have been shown to be associated with an increased incidence of
adverse reactions. Co&#8209;administration of saquinavir and ritonavir has led
to severe adverse reactions, mainly diabetic ketoacidosis and liver disorders,
especially in patients with pre-existing liver disease. </span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Saquinavir/ritonavir
should not be given together with rifampicin, due to the risk of severe
hepatotoxicity (presenting as increased hepatic transaminases) if the three
medicines are given together (see section 4.5).</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB
style='color:black'>Tipranavir</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='color:black'>Co-administration of tipranavir with 200&nbsp;mg of
ritonavir has been associated with reports of clinical hepatitis and hepatic
decompensation including some fatalities. Extra vigilance is warranted in
patients with chronic hepatitis B or hepatitis C co-infection, as these
patients have an increased risk of hepatotoxicity. </span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Doses of ritonavir
lower than 200&nbsp;mg twice daily should not be used as they might alter the
efficacy profile of the combination.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'></span></p>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>Fosamprenavir</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Co-administration of
fosamprenavir with ritonavir in doses greater than 100&nbsp;mg twice daily has
not been clinically evaluated. The use of higher ritonavir doses might alter
the safety profile of the combination and therefore is not recommended.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>Atazanavir</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Co-administration of
atazanavir with ritonavir at doses greater than 100&nbsp;mg once daily has not
been clinically evaluated. The use of higher ritonavir doses may alter the
safety profile of atazanavir (cardiac effects, hyperbilirubinemia) and therefore
is not recommended. Only when atazanavir with ritonavir is co-administered
with efavirenz, a dose increase of ritonavir to 200mg once daily could be
considered. In this instance, close clinical monitoring is warranted. Refer
to the Summary of Product Characteristics for atazanavir for further details.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
color:black'>4.5  Interaction with other medicinal products and other forms
of interaction</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
color:black'>&nbsp;</span></b></p>

<p class=MsoNormal><u><span style='color:black'>Ritonavir dosed as a
pharmacokinetic enhancer or as an antiretroviral agent</span></u></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black'>Ritonavir has a high affinity for
several cytochrome P450 (CYP) isoforms and may inhibit oxidation with the
following ranked order: CYP3A4 &gt;&nbsp;CYP2D6. Co-administration of ritonavir
and medicinal products primarily metabolised by CYP3A may result in increased
plasma concentrations of the other medicinal product, which could increase or
prolong its therapeutic and adverse effects. For selected medicinal products
(e.g. alprazolam) the inhibitory effects of ritonavir on CYP3A4 may decrease
over time. Ritonavir also has a high affinity for P&#8209;glycoprotein and may
inhibit this transporter. The inhibitory effect of ritonavir (with or without
other protease inhibitors) on P&#8209;gp activity may decrease over time (e.g.
digoxin and fexofenadine-see table </span><span style='color:black'>Ritonavir
effects on non-antiretroviral medicinal products below</span><span
style='color:black'>). Ritonavir may induce glucuronidation and oxidation by
CYP1A2, CYP2C8, CYP2C9 and CYP2C19 thereby increasing the biotransformation of
some medicinal products metabolised by these pathways, and may result in
decreased systemic exposure to such medicinal products, which could decease or
shorten their therapeutic effect</span><span style='color:black'>. </span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black'>Important information regarding
medicinal product interactions when ritonavir is used as a pharmacokinetic
enhancer is also contained in the Summary of Product Characteristics of the co&#8209;administered
protease inhibitor.</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span style='color:black'>Medicinal
products that affect ritonavir levels</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span style='color:black;
text-transform:uppercase'>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span style='color:black'>Serum
levels of ritonavir can be reduced by concomitant use of herbal preparations
containing St&nbsp;Johns wort (<i>Hypericum perforatum).</i> This is due to
the induction of medicinal product metabolising enzymes by St Johns wort.
Herbal preparations containing St Johns wort must not be used in combination
with ritonavir. If a patient is already taking St Johns wort, St Johns wort should
be stopped and if possible check viral levels. Ritonavir levels may increase
on stopping St Johns wort. The dose of ritonavir may need adjusting. The
inducing effect may persist for at least 2 weeks after cessation of treatment
with St Johns wort (see section 4.3). </span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black'>Serum levels of ritonavir may be
affected by select co&#8209;administered medicinal products </span><span
style='color:black'>(e.g. delavirdine, efavirenz, phenytoin and rifampicin)</span><span
style='color:black'>. These interactions are noted in the medicinal product
interaction tables below.</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span style='color:black'>Medicinal
product that are affected by the use of ritonavir</span></u></p>

<p class=MsoNormal><i><span style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal><span style='color:black'>Interactions between ritonavir and
protease inhibitors, antiretroviral agents other than protease inhibitors and
other non-antiretroviral medicinal products are listed in the tables below.
This list is not intended to be inclusive or comprehensive. Individual SmPCs
should be consulted.</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="98%"
 style='width:98.96%;border-collapse:collapse'>
 <tr>
  <td colspan=11 style='border:none;border-bottom:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span style='color:black'>Medicinal Product Interactions 
  Ritonavir with Protease Inhibitors</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="15%" colspan=2 valign=top style='width:15.7%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span style='font-size:9.5pt;color:black'>Co-administered Medicinal
  Product</span></b></p>
  </td>
  <td width="26%" colspan=2 valign=top style='width:26.62%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span style='font-size:9.5pt;color:black'>Dose of Co-administered
  Medicinal Product (mg)</span></b></p>
  </td>
  <td width="18%" valign=top style='width:18.44%;border:none;border-bottom:
  solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span style='font-size:9.5pt;color:black'>Dose of NORVIR (mg)</span></b></p>
  </td>
  <td width="14%" colspan=2 valign=top style='width:14.34%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span style='font-size:9.5pt;color:black'>Medicinal Product
  Assessed</span></b></p>
  </td>
  <td width="12%" colspan=2 valign=top style='width:12.8%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span style='font-size:9.5pt;color:black'>AUC</span></b></p>
  </td>
  <td width="12%" colspan=2 valign=top style='width:12.1%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span style='font-size:
  9.5pt;color:black'>C</span></b><b><sub><span style='font-size:9.5pt;
  color:black'>min</span></sub></b></p>
  </td>
 </tr>
 <tr>
  <td width="15%" colspan=2 valign=top style='width:15.7%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>Amprenavir</span></p>
  </td>
  <td width="26%" colspan=2 valign=top style='width:26.62%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>600 q12h</span></p>
  </td>
  <td width="18%" valign=top style='width:18.44%;border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>100 q12h</span></p>
  </td>
  <td width="14%" colspan=2 valign=top style='width:14.34%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:9.5pt;color:black'>Amprenavir<sup>1</sup></span></p>
  </td>
  <td width="12%" colspan=2 valign=top style='width:12.8%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&#8593; 64%</span></p>
  </td>
  <td width="12%" colspan=2 valign=top style='width:12.1%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&#8593; 5 fold</span></p>
  </td>
 </tr>
 <tr>
  <td width="15%" colspan=2 valign=top style='width:15.7%;border:none;
  border-top:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="84%" colspan=9 valign=top style='width:84.3%;border:none;
  border-top:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>Ritonavir increases the serum levels of amprenavir as a
  result of CYP3A4 inhibition. Clinical trials confirmed the safety and
  efficacy of 600&nbsp;mg amprenavir twice daily with ritonavir 100&nbsp;mg
  twice daily. For further information, physicians should refer to the Summary
  of Product Characteristics for amprenavir.</span></p>
  </td>
 </tr>
 <tr>
  <td width="15%" colspan=2 valign=top style='width:15.7%;border:none;
  border-top:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>Atazanavir</span></p>
  </td>
  <td width="26%" colspan=2 valign=top style='width:26.62%;border:none;
  border-top:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>300 q24h</span></p>
  </td>
  <td width="18%" valign=top style='width:18.44%;border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>100 q24h</span></p>
  </td>
  <td width="14%" colspan=2 valign=top style='width:14.34%;border:none;
  border-top:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:9.5pt;color:black'>Atazanavir</span></p>
  </td>
  <td width="12%" colspan=2 valign=top style='width:12.8%;border:none;
  border-top:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&#8593; 86%</span></p>
  </td>
  <td width="12%" colspan=2 valign=top style='width:12.1%;border:none;
  border-top:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&#8593; 11 fold</span></p>
  </td>
 </tr>
 <tr>
  <td width="15%" colspan=2 valign=top style='width:15.7%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="26%" colspan=2 valign=top style='width:26.62%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="18%" valign=top style='width:18.44%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="14%" colspan=2 valign=top style='width:14.34%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:9.5pt;color:black'>Atazanavir<sup>2</sup></span></p>
  </td>
  <td width="12%" colspan=2 valign=top style='width:12.8%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&#8593; 2 fold</span></p>
  </td>
  <td width="12%" colspan=2 valign=top style='width:12.1%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&#8593; 3-7 fold</span></p>
  </td>
 </tr>
 <tr>
  <td width="15%" colspan=2 valign=top style='width:15.7%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="84%" colspan=9 valign=top style='width:84.3%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>Ritonavir increases the serum levels of atazanavir as a
  result of CYP3A4 inhibition. Clinical trials confirmed the safety and
  efficacy of 300&nbsp;mg atazanavir once daily with ritonavir 100&nbsp;mg once
  daily in treatment experienced patients. For further information, physicians
  should refer to the Summary of Product Characteristics for atazanavir.</span></p>
  </td>
 </tr>
 <tr>
  <td width="15%" colspan=2 valign=top style='width:15.7%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Darunavir</span></p>
  </td>
  <td width="26%" colspan=2 valign=top style='width:26.62%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>600, single </span></p>
  </td>
  <td valign=top style='border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>100 q12h</span></p>
  </td>
  <td width="14%" colspan=2 valign=top style='width:14.34%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.5pt;color:black'>Darunavir</span></p>
  </td>
  <td width="12%" colspan=2 valign=top style='width:12.8%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 14 fold</span></p>
  </td>
  <td width="12%" colspan=2 valign=top style='width:12.1%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="15%" colspan=2 valign=top style='width:15.7%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="84%" colspan=9 valign=top style='width:84.3%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Ritonavir
  increases the serum levels of darunavir as a result of CYP3A inhibition.
  Darunavir must be given with ritonavir to ensure its therapeutic effect.
  Ritonavir doses higher than 100&nbsp;mg twice daily have not been studied
  with darunavir. For further information, refer to the Summary of Product
  Characteristics for darunavir.</span></p>
  </td>
 </tr>
 <tr>
  <td width="15%" colspan=2 valign=top style='width:15.7%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Fosamprenavir</span></p>
  </td>
  <td width="26%" colspan=2 valign=top style='width:26.62%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>700 q12h</span></p>
  </td>
  <td valign=top style='border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>100 q12h</span></p>
  </td>
  <td width="14%" colspan=2 valign=top style='width:14.34%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.5pt;color:black'>Amprenavir</span></p>
  </td>
  <td width="12%" colspan=2 valign=top style='width:12.8%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 2.4 fold</span></p>
  </td>
  <td width="12%" colspan=2 valign=top style='width:12.1%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 11 fold</span></p>
  </td>
 </tr>
 <tr>
  <td width="15%" colspan=2 valign=top style='width:15.7%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="84%" colspan=9 valign=top style='width:84.3%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Ritonavir
  increases the serum levels of amprenavir (from fosamprenavir) as a result of
  CYP3A4 inhibition. Fosamprenavir must be given with ritonavir to ensure its
  therapeutic effect. Clinical trials confirmed the safety and efficacy of
  fosamprenavir 700&nbsp;mg twice daily with ritonavir 100&nbsp;mg twice
  daily. Ritonavir doses higher than 100&nbsp;mg twice daily have not been
  studied with fosamprenavir. For further information, physicians should refer
  to the Summary of Product Characteristics for fosamprenavir.</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.84%;border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Indinavir</span></p>
  </td>
  <td width="22%" colspan=2 valign=top style='width:22.24%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>800 q12h</span></p>
  </td>
  <td width="23%" colspan=3 valign=top style='width:23.8%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>100 q12h</span></p>
  </td>
  <td width="14%" colspan=2 valign=top style='width:14.66%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.5pt;color:black'>Indinavir</span><sup><span
  style='font-size:9.5pt;color:black'>3</span></sup></p>
  </td>
  <td width="12%" colspan=2 valign=top style='width:12.7%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 178%</span></p>
  </td>
  <td width="11%" valign=top style='width:11.78%;border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>ND</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.84%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="22%" colspan=2 valign=top style='width:22.24%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="23%" colspan=3 valign=top style='width:23.8%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="14%" colspan=2 valign=top style='width:14.66%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.5pt;color:black'>Ritonavir</span></p>
  </td>
  <td width="12%" colspan=2 valign=top style='width:12.7%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 72%</span></p>
  </td>
  <td width="11%" valign=top style='width:11.78%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>ND</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.84%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="22%" colspan=2 valign=top style='width:22.24%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>400 q12h</span></p>
  </td>
  <td width="23%" colspan=3 valign=top style='width:23.8%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>400 q12h</span></p>
  </td>
  <td width="14%" colspan=2 valign=top style='width:14.66%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.5pt;color:black'>Indinavir</span><sup><span
  style='font-size:9.5pt;color:black'>3</span></sup></p>
  </td>
  <td width="12%" colspan=2 valign=top style='width:12.7%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8596;</span></p>
  </td>
  <td width="11%" valign=top style='width:11.78%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 4 fold </span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.84%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="22%" colspan=2 valign=top style='width:22.24%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="23%" colspan=3 valign=top style='width:23.8%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="14%" colspan=2 valign=top style='width:14.66%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.5pt;color:black'>Ritonavir</span></p>
  </td>
  <td width="12%" colspan=2 valign=top style='width:12.7%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8596;</span></p>
  </td>
  <td width="11%" valign=top style='width:11.78%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8596;</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.84%;border:none;border-bottom:
  solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="85%" colspan=10 valign=top style='width:85.16%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Ritonavir
  increases the serum levels of indinavir as a result of CYP3A4 inhibition.
  Appropriate doses for this combination, with respect to efficacy and safety,
  have not been established. Minimal benefit of ritonavir-mediated
  pharmacokinetic enhancement is achieved with doses higher than 100&nbsp;mg
  twice daily. In cases of co&#8209;administration of ritonavir (100&nbsp;mg
  twice daily) and indinavir (800&nbsp;mg twice daily) caution is warranted as
  the risk of nephrolithiasis may be increased. </span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.84%;border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Nelfinavir</span></p>
  </td>
  <td width="22%" colspan=2 valign=top style='width:22.24%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>1250 q12h </span></p>
  </td>
  <td colspan=3 valign=top style='border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>100 q12h</span></p>
  </td>
  <td colspan=2 valign=top style='border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.5pt;color:black'>Nelfinavir</span></p>
  </td>
  <td width="12%" colspan=2 valign=top style='width:12.7%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 20to39%</span></p>
  </td>
  <td width="11%" valign=top style='width:11.78%;border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>ND</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.84%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="22%" colspan=2 valign=top style='width:22.24%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>750, single</span></p>
  </td>
  <td colspan=3 valign=top style='padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>500 q12h</span></p>
  </td>
  <td colspan=2 valign=top style='padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.5pt;color:black'>Nelfinavir</span></p>
  </td>
  <td width="12%" colspan=2 valign=top style='width:12.7%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 152%</span></p>
  </td>
  <td width="11%" valign=top style='width:11.78%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>ND</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.84%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="22%" colspan=2 valign=top style='width:22.24%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td colspan=3 valign=top style='padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td colspan=2 valign=top style='padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.5pt;color:black'>Ritonavir</span></p>
  </td>
  <td width="12%" colspan=2 valign=top style='width:12.7%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8596;</span></p>
  </td>
  <td width="11%" valign=top style='width:11.78%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8596;</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.84%;border:none;border-bottom:
  solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="85%" colspan=10 valign=top style='width:85.16%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Ritonavir
  increases the serum levels of nelfinavir as a result of CYP3A4 inhibition.
  Appropriate doses for this combination, with respect to efficacy and safety,
  have not been established. Minimal benefit of ritonavir-mediated
  pharmacokinetic enhancement is achieved with doses higher than 100&nbsp;mg
  twice daily.</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.84%;border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Saquinavir</span></p>
  </td>
  <td width="22%" colspan=2 valign=top style='width:22.24%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>1000 q12h</span></p>
  </td>
  <td colspan=3 valign=top style='border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>100 q12h</span></p>
  </td>
  <td colspan=2 valign=top style='border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.5pt;color:black'>Saquinavir<sup>4</sup></span></p>
  </td>
  <td width="12%" colspan=2 valign=top style='width:12.7%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 15-fold</span></p>
  </td>
  <td width="11%" valign=top style='width:11.78%;border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 5-fold</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.84%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="22%" colspan=2 valign=top style='width:22.24%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td colspan=3 valign=top style='padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td colspan=2 valign=top style='padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.5pt;color:black'>Ritonavir</span></p>
  </td>
  <td width="12%" colspan=2 valign=top style='width:12.7%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8596;</span></p>
  </td>
  <td width="11%" valign=top style='width:11.78%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8596;</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.84%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="22%" colspan=2 valign=top style='width:22.24%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>400 q12h </span></p>
  </td>
  <td colspan=3 valign=top style='padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>400 q12h </span></p>
  </td>
  <td colspan=2 valign=top style='padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.5pt;color:black'>Saquinavir<sup>4</sup></span></p>
  </td>
  <td width="12%" colspan=2 valign=top style='width:12.7%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 17-fold </span></p>
  </td>
  <td width="11%" valign=top style='width:11.78%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>ND</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.84%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="22%" colspan=2 valign=top style='width:22.24%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td colspan=3 valign=top style='padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td colspan=2 valign=top style='padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.5pt;color:black'>Ritonavir</span></p>
  </td>
  <td width="12%" colspan=2 valign=top style='width:12.7%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8596;</span></p>
  </td>
  <td width="11%" valign=top style='width:11.78%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8596;</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.84%;border:none;border-bottom:
  solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="85%" colspan=10 valign=top style='width:85.16%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='line-height:95%'><span style='font-size:9.5pt;
  line-height:95%;color:black'>Ritonavir increases the serum levels of
  saquinavir as a result of CYP3A4 inhibition. Saquinavir should only be given
  in combination with ritonavir. Ritonavir 100&nbsp;mg twice daily with
  saquinavir 1000&nbsp;mg twice daily provides saquinavir systemic exposure over
  24 hours similar to or greater than those achieved with saquinavir
  1200&nbsp;mg three times daily without ritonavir. </span></p>
  <p class=MsoNormal><span style='font-size:6.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>In a clinical
  study investigating the interaction of rifampicin 600&nbsp;mg once daily and
  saquinavir 1000&nbsp;mg with ritonavir 100&nbsp;mg twice daily in healthy
  volunteers, severe hepatocellular toxicity with transaminase elevations up to
  &gt;&nbsp;20&#8209;fold the upper limit of normal after 1 to 5 days of co&#8209;administration
  was noted. Due to the risk of severe hepatoxicity, saquinavir/ritonavir
  should not be given together with rifampicin.</span></p>
  <p class=MsoNormal><span style='font-size:6.0pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>For further
  information, physicians should refer to the Summary of Product
  Characteristics for saquinavir.</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.84%;border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Tipranavir</span></p>
  </td>
  <td width="22%" colspan=2 valign=top style='width:22.24%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>500 q12h</span></p>
  </td>
  <td colspan=3 valign=top style='border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>200 q12h</span></p>
  </td>
  <td colspan=2 valign=top style='border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.5pt;color:black'>Tipranavir</span></p>
  </td>
  <td width="12%" colspan=2 valign=top style='width:12.7%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 11 fold</span></p>
  </td>
  <td width="11%" valign=top style='width:11.78%;border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 29 fold</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.84%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="22%" colspan=2 valign=top style='width:22.24%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td colspan=3 valign=top style='padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td colspan=2 valign=top style='padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.5pt;color:black'>Ritonavir</span></p>
  </td>
  <td width="12%" colspan=2 valign=top style='width:12.7%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8595; 40%</span></p>
  </td>
  <td width="11%" valign=top style='width:11.78%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>ND</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.84%;border:none;border-bottom:
  solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="85%" colspan=10 valign=top style='width:85.16%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Ritonavir
  increases the serum levels of tipranavir as a result of CYP3A inhibition.
  Tipranavir must be given with low dose ritonavir to ensure its therapeutic
  effect. Doses of ritonavir less than 200&nbsp;mg twice daily should not be
  used with tipranavir as they might alter the efficacy of the combination.
  For further information, physicians should refer to the Summary of Product
  Characteristics for tipranavir.</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.84%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="85%" colspan=10 valign=top style='width:85.16%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>ND: Not
  determined.</span></p>
  <p class=MsoNormal style='margin-left:.5in;text-indent:-.25in'><span
  style='font-size:9.5pt;color:black'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
  </span></span><span style='font-size:9.5pt;color:black'>Based on cross-study
  comparison to 1200&nbsp;mg amprenavir twice daily alone.</span></p>
  <p class=MsoNormal style='margin-left:.5in;text-indent:-.25in'><span
  style='font-size:9.5pt;color:black'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
  </span></span><span style='font-size:9.5pt;color:black'>Based on cross-study comparison
  to 400&nbsp;mg atazanavir once daily alone.</span></p>
  <p class=MsoNormal style='margin-left:.5in;text-indent:-.25in'><span
  style='font-size:9.5pt;color:black'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;
  </span></span><span style='font-size:9.5pt;color:black'>Based on cross-study
  comparison to 800&nbsp;mg indinavir three times daily alone.</span></p>
  <p class=MsoNormal style='margin-left:.5in;text-indent:-.25in'><span
  style='font-size:9.5pt;color:black'>4.<span style='font:7.0pt "Times New Roman"'>&nbsp;
  </span></span><span style='font-size:9.5pt;color:black'>Based on cross-study
  comparison to 600&nbsp;mg saquinavir three times daily alone.</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=104 style='border:none'></td>
  <td width=6 style='border:none'></td>
  <td width=150 style='border:none'></td>
  <td width=37 style='border:none'></td>
  <td width=129 style='border:none'></td>
  <td width=1 style='border:none'></td>
  <td width=100 style='border:none'></td>
  <td width=3 style='border:none'></td>
  <td width=87 style='border:none'></td>
  <td width=2 style='border:none'></td>
  <td width=82 style='border:none'></td>
 </tr>
</table>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="98%"
 style='width:98.96%;border-collapse:collapse'>
 <tr>
  <td width="100%" colspan=6 valign=top style='width:100.0%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span style='font-size:
  10.5pt;color:black'>Medicinal product interactions  Ritonavir with antiretroviral
  agents other than protease inhibitors</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.2%;border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span style='font-size:
  9.5pt;color:black'>Co-administered Medicinal Product</span></b></p>
  </td>
  <td width="14%" valign=top style='width:14.74%;border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span style='font-size:
  9.5pt;color:black'>Dose of Co-administered Medicinal Product (mg)</span></b></p>
  </td>
  <td valign=top style='border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span style='font-size:
  9.5pt;color:black'>Dose of NORVIR (mg)</span></b></p>
  </td>
  <td valign=top style='border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span style='font-size:9.5pt;color:black'>Medicinal Product </span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span style='font-size:9.5pt;color:black'>Assessed</span></b></p>
  </td>
  <td width="12%" valign=top style='width:12.82%;border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span style='font-size:
  9.5pt;color:black'>AUC</span></b></p>
  </td>
  <td width="11%" valign=top style='width:11.78%;border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span style='font-size:
  9.5pt;color:black'>C</span></b><b><sub><span style='font-size:9.5pt;
  color:black'>min</span></sub></b></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.2%;border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>Didanosine</span></p>
  </td>
  <td width="14%" valign=top style='width:14.74%;border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>200 q12h</span></p>
  </td>
  <td valign=top style='border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>600 q12h 2 h later</span></p>
  </td>
  <td valign=top style='border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:9.5pt;color:black'>Didanosine</span></p>
  </td>
  <td width="12%" valign=top style='width:12.82%;border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&#8595; 13% </span></p>
  </td>
  <td width="11%" valign=top style='width:11.78%;border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&#8596;</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.2%;border:none;border-bottom:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="85%" colspan=5 valign=top style='width:85.8%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>As ritonavir is
  recommended to be taken with food and didanosine should be taken on an empty
  stomach, dosing should be separated by 2.5 h. Dose alterations should not be
  necessary.</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.2%;border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Delavirdine</span></p>
  </td>
  <td width="14%" valign=top style='width:14.74%;border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>400 q8h</span></p>
  </td>
  <td valign=top style='border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>600 q12h</span></p>
  </td>
  <td valign=top style='border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.5pt;color:black'>Delavirdine<sup>1</sup></span></p>
  </td>
  <td width="12%" valign=top style='width:12.82%;border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8596;</span></p>
  </td>
  <td width="11%" valign=top style='width:11.78%;border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8596;</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.2%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="14%" valign=top style='width:14.74%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td valign=top style='padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td valign=top style='padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.5pt;color:black'>Ritonavir</span></p>
  </td>
  <td width="12%" valign=top style='width:12.82%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 50%</span></p>
  </td>
  <td width="11%" valign=top style='width:11.78%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 75%</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.2%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="85%" colspan=5 valign=top style='width:85.8%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Based on
  comparison to historical data, the pharmacokinetics of delavirdine did not
  appear to be affected by ritonavir. When used in combination with
  delavirdine, dose reduction of ritonavir may be considered.</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.2%;border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Efavirenz</span></p>
  </td>
  <td width="14%" valign=top style='width:14.74%;border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>600 q24h</span></p>
  </td>
  <td valign=top style='border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>500 q12h</span></p>
  </td>
  <td valign=top style='border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.5pt;color:black'>Efavirenz</span></p>
  </td>
  <td width="12%" valign=top style='width:12.82%;border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 21%</span></p>
  </td>
  <td width="11%" valign=top style='width:11.78%;border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.2%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="14%" valign=top style='width:14.74%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td valign=top style='padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td valign=top style='padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.5pt;color:black'>Ritonavir</span></p>
  </td>
  <td width="12%" valign=top style='width:12.82%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 17%</span></p>
  </td>
  <td width="11%" valign=top style='width:11.78%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.2%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="85%" colspan=5 valign=top style='width:85.8%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>A higher
  frequency of adverse reactions (e.g., dizziness, nausea, paraesthesia) and
  laboratory abnormalities (elevated liver enzymes) have been observed when efavirenz
  is co-administered with ritonavir dosed as an antiretroviral agent.</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.2%;border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Maraviroc</span></p>
  </td>
  <td width="14%" valign=top style='width:14.74%;border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>100&nbsp;q12h</span></p>
  </td>
  <td valign=top style='border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>100 q12h</span></p>
  </td>
  <td width="29%" valign=top style='width:29.18%;border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.5pt;color:black'>Maraviroc</span></p>
  </td>
  <td width="12%" valign=top style='width:12.82%;border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593;161%</span></p>
  </td>
  <td width="11%" valign=top style='width:11.78%;border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593;28%</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="14%" valign=top style='width:14.2%;border:none;border-bottom:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="85%" colspan=5 valign=top style='width:85.8%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Ritonavir
  increases the serum levels of maraviroc as a result of CYP3A inhibition.
  Maraviroc may be given with ritonavir to increase the maraviroc exposure.
  For further information, refer to the Summary of Product Characteristics for maraviroc.</span></p>
  </td>
 </tr>
 <tr style='height:13.6pt'>
  <td width="14%" valign=top style='width:14.2%;border:none;padding:.75pt 6.0pt .75pt 6.0pt;
  height:13.6pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Nevirapine</span></p>
  </td>
  <td width="14%" valign=top style='width:14.74%;border:none;padding:.75pt 6.0pt .75pt 6.0pt;
  height:13.6pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>200 q12h</span></p>
  </td>
  <td valign=top style='border:none;padding:.75pt 6.0pt .75pt 6.0pt;height:
  13.6pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>600 q12h</span></p>
  </td>
  <td valign=top style='border:none;padding:.75pt 6.0pt .75pt 6.0pt;height:
  13.6pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.5pt;color:black'>Nevirapine</span></p>
  </td>
  <td width="12%" valign=top style='width:12.82%;border:none;padding:.75pt 6.0pt .75pt 6.0pt;
  height:13.6pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8596;</span></p>
  </td>
  <td width="11%" valign=top style='width:11.78%;border:none;padding:.75pt 6.0pt .75pt 6.0pt;
  height:13.6pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8596;</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.2%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="14%" valign=top style='width:14.74%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td valign=top style='padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td valign=top style='padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.5pt;color:black'>Ritonavir</span></p>
  </td>
  <td width="12%" valign=top style='width:12.82%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8596;</span></p>
  </td>
  <td width="11%" valign=top style='width:11.78%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8596;</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.2%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="85%" colspan=5 valign=top style='width:85.8%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Co-administration
  of ritonavir with nevirapine does not lead to clinically relevant changes in
  the pharmacokinetics of either nevirapine or ritonavir.</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.2%;border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Raltegravir</span></p>
  </td>
  <td width="14%" valign=top style='width:14.74%;border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>400 single </span></p>
  </td>
  <td valign=top style='border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>100 q12h</span></p>
  </td>
  <td valign=top style='border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.5pt;color:black'>Raltegravir</span></p>
  </td>
  <td width="12%" valign=top style='width:12.82%;border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8595; 16%</span></p>
  </td>
  <td width="11%" valign=top style='width:11.78%;border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8595; 1%</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.2%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="85%" colspan=5 valign=top style='width:85.8%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Co-adminsitration
  of ritonavir and raltegravir results in a minor reduction in raltegravir
  levels</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.2%;border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Zidovudine</span></p>
  </td>
  <td width="14%" valign=top style='width:14.74%;border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>200 q8h</span></p>
  </td>
  <td valign=top style='border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>300 q6h</span></p>
  </td>
  <td valign=top style='border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.5pt;color:black'>Zidovudine</span></p>
  </td>
  <td width="12%" valign=top style='width:12.82%;border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8595; 25% </span></p>
  </td>
  <td width="11%" valign=top style='width:11.78%;border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>ND</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.2%;border:none;border-bottom:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="85%" colspan=5 valign=top style='width:85.8%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Ritonavir may
  induce the glucuronidation of zidovudine, resulting in slightly decreased
  levels of zidovudine. Dose alterations should not be necessary.</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.2%;border:none;border-bottom:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="85%" colspan=5 valign=top style='width:85.8%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>ND: Not
  determined</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>1. Based on
  parallel group comparison.</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="103%"
 style='margin-left:-6.0pt;border-collapse:collapse;border:none'>
 <thead>
  <tr>
   <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
   <td width="97%" colspan=20 valign=top style='width:97.42%;border-top:solid windowtext 1.0pt;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
   padding:.75pt 6.0pt .75pt 6.0pt'>
   <p class=MsoNormal align=center style='margin-top:6.0pt;margin-right:0in;
   margin-bottom:6.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
   style='color:black'>Ritonavir effects on Non-antiretroviral Co-administered
   Medicinal Products</span></b></p>
   </td>
   <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  </tr>
  <tr>
   <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
   <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
   border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span style='font-size:
   9.5pt;font-family:"Times New Roman Bold",serif;color:black'>Co-administered Medicinal
   Products</span></b></p>
   </td>
   <td width="16%" colspan=3 valign=top style='width:16.22%;border:none;
   border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span style='font-size:
   9.5pt;font-family:"Times New Roman Bold",serif;color:black'>Dose of
   Co-administered Medicinal Products (mg)</span></b></p>
   </td>
   <td width="12%" colspan=5 valign=top style='width:12.4%;border:none;
   border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span style='font-size:
   9.5pt;font-family:"Times New Roman Bold",serif;color:black'>Dose of NORVIR
   (mg)</span></b></p>
   </td>
   <td width="16%" colspan=6 valign=top style='width:16.14%;border:none;
   border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span style='font-size:
   9.5pt;font-family:"Times New Roman Bold",serif;color:black'>Effect on
   Co-administered Medicinal Products AUC </span></b></p>
   </td>
   <td width="14%" colspan=4 valign=top style='width:14.82%;border:none;
   border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span style='font-size:
   9.5pt;font-family:"Times New Roman Bold",serif;color:black'>Effect on
   Co-administered Medicinal Products C</span></b><b><sub><span
   style='font-size:9.5pt;font-family:"Times New Roman Bold",serif;color:black'>max</span></sub></b><b><span
   style='font-size:9.5pt;font-family:"Times New Roman Bold",serif;color:black'>
   </span></b></p>
   </td>
   <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid;height:2.75pt'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt;
  height:2.75pt'>
  <p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in;page-break-after:avoid'><b><span style='color:black'>Alpha</span></b><b><sub><span
  style='color:black'>1</span></sub></b><b><span style='color:black'>-Adrenoreceptor
  Antagonist</span></b></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt;
  height:2.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>Alfuzosin</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>Ritonavir co-administration is likely to result in
  increased plasma concentrations of alfuzosin and is therefore <b>contraindicated
  </b>(see section 4.3). </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in;page-break-after:avoid'><b><span style='color:black'>Amphetamine
  </span></b><b><span style='color:black'>Derivatives</span></b></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in'><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid;height:62.2pt'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt;
  height:62.2pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Amphetamine </span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt;
  height:62.2pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Ritonavir dosed
  as an antiretroviral agent is likely to inhibit CYP2D6 and as a result is
  expected to increase concentrations of amphetamine and its derivatives.
  Careful monitoring of therapeutic and adverse effects is recommended when
  these medicines are concomitantly administered with antiretroviral doses of
  ritonavir (see section 4.4).</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in;page-break-after:avoid'><b><span style='color:black'>Analgesics</span></b></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Buprenorphine</span></p>
  </td>
  <td width="18%" colspan=6 valign=top style='width:18.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>16 q24h</span></p>
  </td>
  <td width="19%" colspan=7 valign=top style='width:19.48%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>100 q12h</span></p>
  </td>
  <td width="12%" colspan=4 valign=top style='width:12.14%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 57%</span></p>
  </td>
  <td width="9%" valign=top style='width:9.14%;border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 77%</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Norbuprenorphine</span></p>
  </td>
  <td width="18%" colspan=6 valign=top style='width:18.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="19%" colspan=7 valign=top style='width:19.48%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="12%" colspan=4 valign=top style='width:12.14%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 33%</span></p>
  </td>
  <td width="9%" valign=top style='width:9.14%;border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 108%</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Glucuronide
  metabolites</span></p>
  </td>
  <td width="18%" colspan=6 valign=top style='width:18.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="19%" colspan=7 valign=top style='width:19.48%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="12%" colspan=4 valign=top style='width:12.14%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;font-family:Symbol;
  color:black'></span></p>
  </td>
  <td width="9%" valign=top style='width:9.14%;border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;font-family:Symbol;
  color:black'></span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>The increases of
  plasma levels of buprenorphine and its active metabolite did not lead to clinically
  significant pharmacodynamic changes in a population of opioid tolerant
  patients. Adjustment to the dose of buprenorphine or ritonavir may therefore
  not be necessary when the two are dosed together. When ritonavir is used in
  combination with another protease inhibitor and buprenorphine, the SPC of the
  co&#8209;administered protease inhibitor should be reviewed for specific
  dosing information.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Pethidine,
  piroxicam, propoxyphene</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Ritonavir
  co-administration is likely to result in increased plasma concentrations of
  pethidine, piroxicam, and propoxyphene and is therefore <b>contraindicated </b>(see
  section 4.3).</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Fentanyl</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Ritonavir dosed
  as a pharmacokinetic enhancer or as an antiretroviral agent inhibits CYP3A4
  and as a result is expected to increase the plasma concentrations of
  fentanyl. Careful monitoring of therapeutic and adverse effects (including
  respiratory depression) is recommended when fentanyl is concomitantly
  administered with ritonavir.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Methadone</span><sup><span
  style='font-size:9.5pt;color:black'>1</span></sup></p>
  </td>
  <td width="18%" colspan=6 valign=top style='width:18.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>5, single dose </span></p>
  </td>
  <td width="19%" colspan=7 valign=top style='width:19.48%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>500 q12h, </span></p>
  </td>
  <td width="12%" colspan=4 valign=top style='width:12.14%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8595; 36% </span></p>
  </td>
  <td width="9%" valign=top style='width:9.14%;border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8595; 38% </span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Increased
  methadone dose may be necessary when concomitantly administered with
  ritonavir dosed as an antiretroviral agent or as a pharmacokinetic enhancer
  due to induction of glucuronidation. Dose adjustment should be considered
  based on the patients clinical response to methadone therapy. </span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Morphine</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Morphine levels
  may be decreased due to induction of glucuronidation by co-administered
  ritonavir dosed as an antiretroviral agent or as a pharmacokinetic enhancer.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoHeading7 style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in'>Antianginal</p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=ES-MX
  style='font-size:9.5pt;color:black'>Ranolazine</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>Due to CYP3A inhibition by ritonavir, concentrations of
  ranolazine are expected to increase. The concomitant administration with
  ranolazine is contraindicated (see section 4.3).</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in;page-break-after:avoid'><b><span style='color:black'>Antiarrthymics</span></b></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span lang=ES-MX style='font-size:9.5pt;color:black'>Amiodarone,
  bepridil, dronedarone, encainide, flecainide, propafenone, quinidine</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Ritonavir
  co-administration is likely to result in increased plasma concentrations of
  amiodarone, bepridil, dronedarone, encainide, flecainide, propafenone, and
  quinidine and is therefore <b>contraindicated </b>(see section 4.3).</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Digoxin</span></p>
  </td>
  <td width="18%" colspan=5 valign=top style='width:18.32%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>0.5 single IV
  dose</span></p>
  </td>
  <td width="20%" colspan=8 valign=top style='width:20.0%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>300 q12h, 3 days
  </span></p>
  </td>
  <td width="12%" colspan=4 valign=top style='width:12.14%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 86%</span></p>
  </td>
  <td width="9%" valign=top style='width:9.14%;border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>ND</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="18%" colspan=5 valign=top style='width:18.32%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>0.4 single oral
  dose</span></p>
  </td>
  <td width="20%" colspan=8 valign=top style='width:20.0%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>200 q12h, 13
  days</span></p>
  </td>
  <td width="12%" colspan=4 valign=top style='width:12.14%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 22%</span></p>
  </td>
  <td width="9%" valign=top style='width:9.14%;border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;font-family:Symbol;
  color:black'></span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>This interaction
  may be due to modification of P-glycoprotein mediated digoxin efflux by
  ritonavir dosed as an antriretroviral agent or as a pharmacokinetic
  enhancer. Increased digoxin levels observed in patients receiving ritonavir
  may lessen over time as induction develops </span><span style='font-size:
  9.5pt;color:black'>(see section 4.4). </span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in;page-break-after:avoid'><b><span style='color:black'>Antiasthmatic</span></b></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Theophylline<sup>1</sup></span></p>
  </td>
  <td width="16%" colspan=2 valign=top style='width:16.04%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>3&nbsp;mg/kg q8h</span></p>
  </td>
  <td width="12%" colspan=6 valign=top style='width:12.6%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>500 q12h </span></p>
  </td>
  <td width="16%" colspan=6 valign=top style='width:16.14%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8595; 43% </span></p>
  </td>
  <td width="14%" colspan=4 valign=top style='width:14.82%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8595; 32% </span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>An increased
  dose of theophylline may be required when co&#8209;administered with
  ritonavir, due to induction of CYP1A2.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in;page-break-after:avoid'><b><span style='color:black'>Anticancer
  agents and kinase inhibitors</span></b></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 rowspan=2 valign=top style='width:37.84%;
  border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Afatinib</span></p>
  </td>
  <td width="16%" colspan=2 valign=top style='width:16.04%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>20&nbsp;mg,
  single dose</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>40&nbsp;mg,
  single dose</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>40&nbsp;mg,
  single dose</span></p>
  </td>
  <td width="12%" colspan=6 valign=top style='width:12.6%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>200 q12h/1h
  before</span></p>
  <p class=MsoNormal style='margin-right:-4.6pt'><span style='font-size:9.5pt;
  color:black'>200 q12h/ co-administered</span></p>
  <p class=MsoNormal style='margin-right:-4.6pt'><span style='font-size:9.5pt;
  color:black'>200 q12h/6h after</span></p>
  </td>
  <td width="16%" colspan=6 valign=top style='width:16.14%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 48% </span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 19%</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 11%</span></p>
  </td>
  <td width="14%" colspan=4 valign=top style='width:14.82%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 39% </span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 4%</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 5%</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Serum
  concentrations may be increased due to </span><span class=st1><span
  style='font-size:9.5pt'>Breast Cancer Resistance Protein (BCRP) </span></span><span
  style='font-size:9.5pt;color:black'>and acute P&#8209;gp inhibition by
  ritonavir. The extent of increase in AUC and C<sub>max</sub> depends on the
  timing of ritonavir administration. Caution should be exercised in
  administering afatinib with Norvir (refer to the afatinib SmPC). Monitor for
  ADRs related to afatinib.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Abemaciclib</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Serum
  concentrations may be increased due to CYP3A4 inhibition by ritonavir.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.5pt'>Co&#8209;administration
  of abemaciclib and Norvir should be avoided. If this co&#8209;administration
  is judged unavoidable, refer to the abemaciclib SmPC for dosage adjustment
  recommendations. Monitor for ADRs related to abemaciclib.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Apalutamide</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Apalutamide is a
  moderate to strong CYP3A4 inducer and this may lead to a decreased exposure
  of ritonavir and potential loss of virologic response. In addition, serum
  concentrations may be increased when co&#8209;administered with ritonavir
  resulting in the potential for serious adverse events including seizure. </span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Concomitant use
  of ritonavir with apalutamide is not recommended.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Ceritinib</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Serum
  concentrations may be increased due to CYP3A and P-gp inhibition by
  ritonavir. Caution should be exercised in administering ceritinib with
  Norvir. Refer to the ceritinib SmPC for dosage adjustment recommendations.
  Monitor for ADRs related to ceritinib.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Dasatinib,
  nilotinib, vincristine, vinblastine</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Serum
  concentrations may be increased when co&#8209;administered with ritonavir
  resulting in the potential for increased incidence of adverse events.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Encorafenib</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Serum
  concentrations may be increased when co&#8209;administered with ritonavir
  which may increase the risk of toxicity, including the risk of serious
  adverse events such as QT interval prolongation. Co&#8209;administration of
  encorafenib and ritonavir should be avoided. If the benefit is considered to
  outweigh the risk and ritonavir must be used, patients should be carefully
  monitored for safety.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'></span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="38%" colspan=2 valign=top style='width:38.82%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='margin-left:7.1pt'><span style='font-size:9.5pt;
  color:black'>Fostamatinib</span></p>
  <p class=MsoNormal style='margin-left:7.1pt'><span style='font-size:9.5pt;
  color:black'>&nbsp;</span></p>
  </td>
  <td width="61%" colspan=20 valign=top style='width:61.18%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='margin-left:2.4pt;text-indent:.35pt'><span
  style='font-size:9.5pt;color:black'>Co-administration of fostamatinib with ritonavir
  may increase fostamatinib metabolite R406 exposure resulting in dose-related
  adverse events such as hepatotoxicity, neutropenia, hypertension, or diarrhoea.
  Refer to the fostamatinib SmPC for dose reduction recommendations if such
  events occur.</span></p>
  <p class=MsoNormal style='margin-left:2.4pt;text-indent:.35pt'><span
  style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Ibrutinib</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Serum
  concentrations of ibrutinib may be increased due to CYP3A inhibition by
  ritonavir, resulting in increased risk for toxicity including risk of tumor
  lysis syndrome. Co&#8209;administration of ibrutinib and ritonavir should be
  avoided. If the benefit is considered to outweigh the risk and ritonavir
  must be used, reduce the ibrutinib dose to 140&nbsp;mg and monitor patient
  closely for toxicity.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Neratinib</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Serum
  concentrations may be increased due to CYP3A4 inhibition by ritonavir.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Concomitant use
  of neratinib with Norvir is contraindicated due to serious and/or life&#8209;threatening
  potential reactions including hepatotoxicity (see section 4.3).</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Venetoclax</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Serum
  concentrations may be increased due to CYP3A inhibition by ritonavir,
  resulting in increased risk of tumor lysis syndrome at the dose initiation
  and during the ramp&#8209;up phase (see section 4.3 and refer to the
  venetoclax SmPC).</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt'>For patients who have
  completed the ramp&#8209;up phase and are on a steady daily dose of
  venetoclax, reduce the venetoclax dose by at least 75% when used with strong
  CYP3A inhibitors (refer to the venetoclax SmPC for dosing instructions).</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in;page-break-after:avoid'><b><span style='color:black'>Anticoagulants</span></b></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=DE
  style='font-size:9.5pt;color:black'>Rivaroxaban</span></p>
  </td>
  <td width="16%" colspan=2 valign=top style='width:16.04%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>10, single dose</span></p>
  </td>
  <td width="12%" colspan=6 valign=top style='width:12.6%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>600 q12h</span></p>
  </td>
  <td width="16%" colspan=6 valign=top style='width:16.14%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&#8593; 153%</span></p>
  </td>
  <td width="14%" colspan=4 valign=top style='width:14.82%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&#8593; 55%</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=DE
  style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>Inhibition of CYP3A and P-gp lead to increased plasma
  levels and pharmacodynamic effects of rivaroxaban which may lead to an
  increased bleeding risk. Therefore, the use of ritonavir is not recommended
  in patients receiving rivaroxaban.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span lang=DE style='font-size:9.5pt;color:black'>Vorapaxar</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Serum
  concentrations may be increased due to CYP3A inhibition by ritonavir. The co&#8209;administration
  of vorapaxar with Norvir is not recommended (see section 4.4 and refer to the
  vorapaxar SmPC).</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span lang=DE style='font-size:9.5pt;color:black'>Warfarin<br>
  S-Warfarin <br>
  R-Warfarin</span></p>
  </td>
  <td width="16%" colspan=2 valign=top style='width:16.04%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>5, single dose </span></p>
  </td>
  <td width="12%" colspan=6 valign=top style='width:12.6%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>400 q12h </span></p>
  </td>
  <td width="16%" colspan=6 valign=top style='width:16.14%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'><br>
  &#8593; 9% <br>
  &#8595; 33% </span></p>
  </td>
  <td width="14%" colspan=4 valign=top style='width:14.82%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'><br>
  &#8595; 9% <br>
  &#8596; </span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Induction of
  CYP1A2 and CYP2C9 lead to decreased levels of R-warfarin while little
  pharmacokinetic effect is noted on S- warfarin when co-administered with
  ritonavir. Decreased R-warfarin levels may lead to reduced anticoagulation,
  therefore it is recommended that anticoagulation parameters are monitored
  when warfarin is co-administered with ritonavir dosed as an antiretroviral
  agent or as a pharmacokinetic enhancer.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in;page-break-after:avoid'><b><span style='color:black'>Anticonvulsants</span></b></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Carbamazepine</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Ritonavir dosed
  as a pharmacokinetic enhancer or as an antiretroviral agent inhibits CYP3A4
  and as a result is expected to increase the plasma concentrations of carbamazepine.
  Careful monitoring of therapeutic and adverse effects is recommended when
  carbamazepine is concomitantly administered with ritonavir.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Divalproex,
  lamotrigine, phenytoin</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Ritonavir dosed
  as a pharmacokinetic enhancer or as an antiretroviral agent induces oxidation
  by CYP2C9 and glucuronidation and as a result is expected to decrease the
  plasma concentrations of anticonvulsants. Careful monitoring of serum levels
  or therapeutic effects is recommended when these medicines are concomitantly
  administered with ritonavir. Phenytoin may decrease serum levels of
  ritonavir.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in;page-break-after:avoid'><b><span style='color:black'>Antidepressants</span></b></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span lang=FR style='font-size:9.5pt;color:black'>Amitriptyline,
  fluoxetine, imipramine, nortriptyline, paroxetine, sertraline</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Ritonavir dosed
  as an antiretroviral agent is likely to inhibit CYP2D6 and as a result is
  expected to increase concentrations of imipramine, amitriptyline,
  nortriptyline, fluoxetine, paroxetine or sertraline. Careful monitoring of
  therapeutic and adverse effects is recommended when these medicines are
  concomitantly administered with antiretroviral doses of ritonavir (see
  section 4.4).</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Desipramine</span></p>
  </td>
  <td width="19%" colspan=7 valign=top style='width:19.46%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>100, single oral
  dose</span></p>
  </td>
  <td width="13%" colspan=5 valign=top style='width:13.72%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>500 q12h</span></p>
  </td>
  <td width="14%" colspan=4 valign=top style='width:14.94%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 145%</span></p>
  </td>
  <td width="11%" colspan=2 valign=top style='width:11.46%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 22%</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>The AUC and C<sub>max</sub>
  of the 2-hydroxy metabolite were decreased 15 and 67%, respectively. Dosage
  reduction of desipramine is recommended when co-administered with ritonavir
  dosed as an antiretroviral agent.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>Trazodone</span></p>
  </td>
  <td width="16%" colspan=2 valign=top style='width:16.04%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>50, single dose </span></p>
  </td>
  <td width="12%" colspan=6 valign=top style='width:12.6%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>200 q12h </span></p>
  </td>
  <td width="16%" colspan=6 valign=top style='width:16.14%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&#8593; 2.4-fold</span></p>
  </td>
  <td width="14%" colspan=4 valign=top style='width:14.82%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&#8593; 34%</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>An increase in the incidence in trazodone-related adverse
  reactions was noted when co-administered with ritonavir dosed as an
  antiretroviral agent or as a pharmacokinetic enhancer. If trazodone is
  co-administered with ritonavir, the combination should be used with caution,
  initiating trazodone at the lowest dosage and monitoring for clinical
  response and tolerability.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in;page-break-after:avoid'><b><span style='font-family:
  "TimesNewRoman\,BoldItalic";color:black'>Anti-gout treatments</span></b></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='text-autospace:none'><span style='font-size:9.5pt;
  font-family:"TimesNewRoman\,Italic";color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;font-family:"TimesNewRoman\,Italic";
  color:black'>Colchicine</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;font-family:"TimesNewRoman\,Italic";
  color:black'>Concentrations of colchicine are expected to increase when
  coadministered with ritonavir.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt'>Life-threatening and fatal
  drug interactions have been reported in patients treated with colchicine and
  ritonavir (CYP3A4 and P-gp inhibition) in patients with renal and/or hepatic
  impairment (see sections 4.3 and 4.4). Refer to the colchicine prescribing
  information.</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in;page-break-after:avoid'><b><span style='color:black'>Antihistamines</span></b></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Astemizole,
  terfenadine</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Ritonavir
  co-administration is likely to result in increased plasma concentrations of
  astemizole and terfenadine and is therefore <b>contraindicated </b>(see
  section 4.3).</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Fexofenadine</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Ritonavir may modify
  P-glycoprotein mediated fexofenadine efflux when dosed as an antriretroviral
  agent or as a pharmacokinetic enhancer resulting in increased concentrations
  of fexofenadine. Increased fexofenadine levels may lessen over time as
  induction develops.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Loratadine</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Ritonavir dosed
  as a pharmacokinetic enhancer or as an antiretroviral agent inhibits CYP3A
  and as a result is expected to increase the plasma concentrations of
  loratadine. Careful monitoring of therapeutic and adverse effects is
  recommended when loratidine is concomitantly administered with ritonavir.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in;page-break-after:avoid'><b><span style='color:black'>Anti&#8209;infectives</span></b></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Fusidic Acid</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Ritonavir
  co-administration is likely to result in increased plasma concentrations of
  both fusidic acid and ritonavir and is therefore <b>contraindicated </b>(see
  section 4.3).</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span lang=IT style='font-size:9.5pt;color:black'>Rifabutin</span><sup><span
  lang=IT style='font-size:9.5pt;color:black'>1</span></sup><span lang=IT
  style='font-size:9.5pt;color:black'><br>
  <br>
  </span></p>
  <p class=MsoNormal><span lang=IT style='font-size:9.5pt;color:black'>25-<i>O</i>-desacetyl
  rifabutin metabolite </span></p>
  </td>
  <td width="14%" valign=top style='width:14.94%;border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>150 daily </span></p>
  </td>
  <td width="16%" colspan=9 valign=top style='width:16.08%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>500 q12h, </span></p>
  </td>
  <td width="16%" colspan=5 valign=top style='width:16.04%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 4-fold </span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'><br>
  &#8593; 38-fold </span></p>
  </td>
  <td width="12%" colspan=3 valign=top style='width:12.52%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 2.5-fold
  </span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'><br>
  &#8593; 16-fold</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Due to the large
  increase in rifabutin AUC, the concomitant use of rifabutin with ritonavir
  dosed as an antiretroviral agent is <b>contraindicated </b>(see section
  4.3). The reduction of the rifabutin dose to 150&nbsp;mg 3 times per week</span><span
  style='font-size:9.5pt;color:black'> may be indicated for select PIs when co&#8209;administered
  with ritonavir as a pharmacokinetic enhancer. </span><span style='font-size:
  9.5pt;color:black'>The Summary of Product Characteristics of the co&#8209;administered
  protease inhibitor should be consulted for specific recommendations. </span><span
  style='font-size:9.5pt;color:black'>Consideration should be given to official
  guidance on the appropriate treatment of tuberculosis in HIV-infected
  patients. </span><span style='font-size:9.5pt;color:black'></span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Rifampicin</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Although
  rifampicin may induce metabolism of ritonavir, limited data indicate that
  when high doses of ritonavir (600&nbsp;mg twice daily) is co&#8209;administered
  with rifampicin, the additional inducing effect of rifampicin (next to that
  of ritonavir itself) is small and may have no clinical relevant effect on
  ritonavir levels in high-dose ritonavir therapy. The effect of ritonavir on
  rifampicin is not known.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Voriconazole</span></p>
  </td>
  <td width="14%" valign=top style='width:14.94%;border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>200 q12h</span></p>
  </td>
  <td width="16%" colspan=9 valign=top style='width:16.08%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>400 q12h </span></p>
  </td>
  <td width="16%" colspan=5 valign=top style='width:16.04%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8595; 82%</span></p>
  </td>
  <td width="12%" colspan=3 valign=top style='width:12.52%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8595; 66%</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width="14%" valign=top style='width:14.94%;border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>200 q12h</span></p>
  </td>
  <td width="16%" colspan=9 valign=top style='width:16.08%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>100 q12h</span></p>
  </td>
  <td width="16%" colspan=5 valign=top style='width:16.04%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8595; 39%</span></p>
  </td>
  <td width="12%" colspan=3 valign=top style='width:12.52%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8595; 24%</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Concomitant use
  of ritonavir dosed as an antiretroviral agent and voriconazole is <b>contraindicated</b>
  due to reduction in voriconazole concentrations (see section 4.3). </span><span
  style='font-size:9.5pt;color:black'>Co-administration of voriconazole and
  ritonavir dosed as a pharmacokinetic enhancer should be avoided, unless an
  assessment of the benefit/risk to the patient justifies the use of
  voriconazole.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Atovaquone</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Ritonavir dosed
  as a pharmacokinetic enhancer or as an antiretroviral agent induces
  glucuronidation and as a result is expected to decrease the plasma
  concentrations of atovaquone. Careful monitoring of serum levels or
  therapeutic effects is recommended when atovaquone is concomitantly
  administered with ritonavir.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Bedaquiline</span><span
  style='font-size:9.5pt'> </span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>No interaction study is
  available with ritonavir only. In an interaction study of single-dose
  bedaquiline and multiple dose lopinavir/ritonavir, the AUC of bedaquiline was
  increased by 22%. This increase is likely due to ritonavir and a more
  pronounced effect may be observed during prolonged co-administration. Due to
  the risk of bedaquiline related adverse events, co-administration should be
  avoided. If the benefit outweighs the risk, co-administration of bedaquiline
  with ritonavir must be done with caution. More frequent electrocardiogram
  monitoring and monitoring of transaminases is recommended (see section 4.4
  and refer to the bedaquiline</span><span style='font-size:9.5pt'> </span><span
  style='font-size:9.5pt'>S<span style='color:black'>ummary of Product
  Characteristics</span>).</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Clarithromycin<br>
  <br>
  14-OH clarithromycin metabolite </span></p>
  </td>
  <td width="16%" colspan=2 valign=top style='width:16.04%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>500 q12h </span></p>
  </td>
  <td width="12%" colspan=6 valign=top style='width:12.6%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>200 q8h</span></p>
  </td>
  <td width="16%" colspan=6 valign=top style='width:16.14%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 77% <br>
  <br>
  &#8595; 100% </span></p>
  </td>
  <td width="14%" colspan=4 valign=top style='width:14.82%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 31% <br>
  <br>
  &#8595; 99% </span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Due to the large
  therapeutic window of clarithromycin no dose reduction should be necessary in
  patients with normal renal function. Clarithromycin doses greater than
  1&nbsp;g per day should not be co&#8209;administered with ritonavir dosed as
  an antiretroviral agent or as a pharmacokinetic enhancer. For patients with
  renal impairment, a clarithromycin dose reduction should be considered: for
  patients with creatinine clearance of 30 to 60&nbsp;ml/min the dose should be
  reduced by 50%, for patients with creatinine clearance less than
  30&nbsp;ml/min the dose should be reduced by 75%.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Delamanid</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>No interaction
  study is available with ritonavir only. In a healthy volunteer drug
  interaction study of delamanid 100&nbsp;mg twice daily and
  lopinavir/ritonavir 400/100&nbsp;mg twice daily for 14 days, the exposure of the
  delamanid metabolite DM-6705 was 30% increased. Due to the risk of QTc
  prolongation associated with DM&#8209;6705, if co&#8209;administration of
  delamanid with ritonavir is considered necessary, very frequent ECG
  monitoring throughout the full delamanid treatment period is recommended (see
  section 4.4 and refer to the delamanid Summary of Product Characteristics).</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Erythromycin,
  itraconazole</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Ritonavir dosed
  as a pharmacokinetic enhancer or as an antiretroviral agent inhibits CYP3A4
  and as a result is expected to increase the plasma concentrations of erythromycin
  and itraconazole. Careful monitoring of therapeutic and adverse effects is
  recommended when erythromycin or itraconazole is used concomitantly
  administered with ritonavir.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Ketoconazole</span></p>
  </td>
  <td width="16%" colspan=2 valign=top style='width:16.04%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>200 daily</span></p>
  </td>
  <td width="12%" colspan=6 valign=top style='width:12.6%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>500 q12h</span></p>
  </td>
  <td width="16%" colspan=6 valign=top style='width:16.14%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 3.4-fold
  </span></p>
  </td>
  <td width="14%" colspan=4 valign=top style='width:14.82%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 55% </span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Ritonavir inhibits
  CYP3A-mediated metabolism of ketoconazole. Due to an increased incidence of
  gastrointestinal and hepatic adverse reactions, a dose reduction of
  ketoconazole should be considered when co-administered with ritonavir dosed
  as an antiretroviral agent or as a pharmacokinetic enhancer.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Sulfamethoxazole/Trimethoprim</span><sup><span
  style='font-size:9.5pt;color:black'>2</span></sup></p>
  </td>
  <td width="16%" colspan=2 valign=top style='width:16.04%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>800/160, single
  dose </span></p>
  </td>
  <td width="12%" colspan=6 valign=top style='width:12.6%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>500 q12h </span></p>
  </td>
  <td width="16%" colspan=6 valign=top style='width:16.14%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8595; 20% / &#8593;
  20%</span></p>
  </td>
  <td width="14%" colspan=4 valign=top style='width:14.82%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8596;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Dose alteration
  of sulfamethoxazole/trimethoprim during concomitant ritonavir therapy should
  not be necessary.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in;page-break-after:avoid'><b><span style='color:black'>Antipsychotics/Neuroleptics</span></b></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Clozapine,
  pimozide</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Ritonavir
  co-administration is likely to result in increased plasma concentrations of
  clozapine or pimozide and is therefore <b>contraindicated </b>(see section
  4.3).</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Haloperidol,
  risperidone, thioridazine</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Ritonavir dosed
  as an antiretroviral agent is likely to inhibit CYP2D6 and as a result is
  expected to increase concentrations of haloperidol, risperidone and
  thioridazine. Careful monitoring of therapeutic and adverse effects is
  recommended when these medicines are concomitantly administered with antiretroviral
  doses of ritonavir.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Lurasidone</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.5pt;color:black'>Due
  to CYP3A inhibition by ritonavir, concentrations of lurasidone are expected
  to increase. The concomitant administration with lurasidone is
  contraindicated (see section 4.3).</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Quetiapine</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.5pt;color:black'>Due
  to CYP3A inhibition by ritonavir, concentrations of quetiapine are expected
  to increase. Concomitant administration of Norvir and quetiapine is
  contraindicated as it may increase quetiapine-related toxicity (see section
  4.3).</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in;page-break-after:avoid'><b><span style='color:black'>&#946;2-agonist
  (long acting)</span></b></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><b><span style='color:black'>&nbsp;</span></b></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Salmeterol</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Ritonavir
  inhibits CYP3A4 and as a result a pronounced increase in the plasma
  concentrations of salmeterol is expected. Therefore concomitant use is not
  recommended.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in;page-break-after:avoid'><b><span style='color:black'>Calcium
  channel antagonists</span></b></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span lang=IT style='font-size:9.5pt;color:black'>Amlodipine,
  diltiazem, nifedipine</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Ritonavir dosed
  as a pharmacokinetic enhancer or as an antiretroviral agent inhibits CYP3A4
  and as a result is expected to increase the plasma concentrations of calcium
  channel antagonists. Careful monitoring of therapeutic and adverse effects
  is recommended when these medicines are concomitantly administered with
  ritonavir.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in;page-break-after:avoid'><b><span style='font-family:
  "TimesNewRoman\,BoldItalic";color:black'>Endothelin antagonists</span></b></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in;page-break-after:avoid'><span style='font-size:9.5pt;
  color:black'>Bosentan</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='text-autospace:none'><span style='font-size:9.5pt;
  font-family:"TimesNewRoman\,Italic";color:black'>Co-administration of
  bosentan and ritonavir may increase steady state</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;font-family:"TimesNewRoman\,Italic";
  color:black'>bosentan maximum concentrations (C<sub>max</sub>) and area under
  the curve (AUC)</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoHeading7 style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in'><span style='font-size:9.5pt;font-weight:normal'>Riociguat</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='text-autospace:none'><span style='font-size:9.5pt;
  font-family:"TimesNewRoman\,Italic"'>Serum concentrations may be increased
  due to CYP3A and P-gp inhibition by ritonavir. The co&#8209;administration
  of riociguat with Norvir is not recommended (see section 4.4 and refer to
  riociguat SmPC).</span></p>
  <p class=MsoNormal style='text-autospace:none'><span style='font-size:9.5pt;
  font-family:"TimesNewRoman\,Italic"'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in;page-break-after:avoid'><b><span style='color:black'>Ergot
  Derivatives</span></b></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span lang=IT style='font-size:9.5pt;color:black'>Dihydroergotamine,
  ergonovine, ergotamine, methylergonovine</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Ritonavir
  co-administration is likely to result in increased plasma concentrations of
  ergot derivatives and is therefore <b>contraindicated </b>(see section 4.3).</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in;page-break-after:avoid'><b><span style='color:black'>GI
  motility agent</span></b></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span lang=IT style='font-size:9.5pt;color:black'>Cisapride</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Ritonavir
  co-administration is likely to result in increased plasma concentrations of
  cisapride and is therefore <b>contraindicated </b>(see section 4.3).</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><b>HCV Direct Acting Antiviral</b></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>Glecaprevir/pibrentasvir</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='margin-right:-1.0pt;text-autospace:none'><span
  style='font-size:9.5pt'>Serum concentrations may be increased due to <span
  style='color:black'>P-glycoprotein, BCRP and OATP1B</span></span><span
  style='color:black'> </span><span style='font-size:9.5pt'>inhibition by
  ritonavir.</span></p>
  <p class=MsoNormal style='margin-right:-1.0pt;text-autospace:none'><span
  style='font-size:9.5pt'>&nbsp;</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt'>Concomitant administration
  of glecaprevir/pibrentasvir and Norvir is not recommended due to an increased
  risk of ALT elevations associated with increased glecaprevir exposure.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><b>HCV Protease Inhibitor</b></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>Simeprevir</span></p>
  </td>
  <td width="14%" valign=top style='width:14.94%;border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>200 qd</span></p>
  </td>
  <td width="14%" colspan=8 valign=top style='width:14.88%;border:none;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>100 q12h</span></p>
  </td>
  <td width="14%" colspan=5 valign=top style='width:14.94%;border:none;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>&#8593; 7.2-fold</span></p>
  </td>
  <td width="14%" colspan=4 valign=top style='width:14.82%;border:none;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>&#8593; 4.7-fold</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span lang=IT style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='margin-right:-1.0pt;text-autospace:none'><span
  style='font-size:9.5pt'>Ritonavir increases plasma concentrations of
  simeprevir as a result of CYP3A4 inhibition. </span><span style='font-size:
  9.5pt;letter-spacing:-.15pt'>It is not recommended to co-administer </span><span
  style='font-size:9.5pt;letter-spacing:.05pt'>ritonavir</span><span
  style='font-size:9.5pt;letter-spacing:-.15pt'> with simeprevir.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in;page-break-after:avoid'><b><span style='color:black'>HMG
  Co-A Reductase Inhibitors</span></b></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span lang=IT style='font-size:9.5pt;color:black'>Atorvastatin,
  Fluvastatin, Lovastatin, Pravastatin, Rosuvastatin, Simvastatin</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>HMG-CoA
  reductase inhibitors which are highly dependent on CYP3A metabolism, such as
  lovastatin and simvastatin, are expected to have markedly increased plasma
  concentrations when co-administered with ritonavir dosed as an antiretroviral
  agent or as a pharmacokinetic enhancer. Since increased concentrations of
  lovastatin and simvastatin may predispose patients to myopathies, including
  rhabdomyolysis, the combination of these medicinal products with ritonavir is
  <b>contraindicated</b> (see section 4.3). Atorvastatin is less dependent on
  CYP3A for metabolism. While rosuvastatin elimination is not dependent on
  CYP3A, an elevation of rosuvastatin exposure has been reported with ritonavir
  co-administration. </span><span style='font-size:9.5pt;color:black'>The
  mechanism of this interaction is not clear, but may be the result of
  transporter inhibition. </span><span style='color:black'></span><span
  style='font-size:9.5pt;color:black'>When used with ritonavir dosed as a
  pharmacokinetic enhancer or as an antiretroviral agent, the lowest possible
  doses of atorvastatin or rosuvastatin should be administered. The metabolism
  of pravastatin and fluvastatin is not dependent on CYP3A, and interactions
  are not expected with ritonavir. If treatment with an HMG-CoA reductase
  inhibitor is indicated, pravastatin or fluvastatin is recommended.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in;page-break-after:avoid'><b><span style='color:black'>Hormonal
  contraceptive</span></b></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>Ethinyl estradiol</span></p>
  </td>
  <td width="17%" colspan=4 valign=top style='width:17.22%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>50 g, single dose </span></p>
  </td>
  <td width="13%" colspan=6 valign=top style='width:13.8%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>500 q12h</span></p>
  </td>
  <td width="16%" colspan=5 valign=top style='width:16.04%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&#8595; 40% </span></p>
  </td>
  <td width="12%" colspan=3 valign=top style='width:12.52%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&#8595; 32% </span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Due to
  reductions in ethinyl estradiol concentrations, barrier or other non-hormonal
  methods of contraception should be considered with concomitant ritonavir use
  when dosed as an antiretroviral agent or as a pharmacokinetic enhancer.
  Ritonavir is likely to change the uterine bleeding profile and reduce the
  effectiveness of estradiol-containing contraceptives (see section 4.4).</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in;page-break-after:avoid'><b><span style='color:black'>Immunosupressants</span></b></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Cyclosporine, tacrolimus,
  everolimus</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Ritonavir dosed
  as a pharmacokinetic enhancer or as an antiretroviral agent inhibits CYP3A4
  and as a result is expected to increase the plasma concentrations of
  cyclosporine, tacrolimus or everolimus. Careful monitoring of therapeutic
  and adverse effects is recommended when these medicines are concomitantly
  administered with ritonavir.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in;page-break-after:avoid'><b>Lipid-modifying agents</b></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Lomitapide</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>CYP3A4
  inhibitors increase the exposure of lomitapide, with strong inhibitors
  increasing exposure approximately 27&#8209;fold. Due to CYP3A inhibition by
  ritonavir, concentrations of lomitapide are expected to increase.
  Concomitant use of Norvir with lomitapide is contraindicated (see prescribing
  information for lomitapide) (see section 4.3).</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in;page-break-after:avoid'><b><span style='color:black'>Phosphodiesterase
  (PDE5) inhibitors</span></b></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Avanafil</span></p>
  </td>
  <td width="17%" colspan=4 valign=top style='width:17.22%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>50, single dose</span></p>
  </td>
  <td width="13%" colspan=6 valign=top style='width:13.8%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>600 q12h</span></p>
  </td>
  <td width="16%" colspan=5 valign=top style='width:16.04%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 13-fold</span></p>
  </td>
  <td width="12%" colspan=3 valign=top style='width:12.52%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 2.4-fold</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:9.5pt;
  color:black'>Concomitant use of avanafil with ritonavir is contraindicated
  (see section 4.3).</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:9.5pt;
  color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Sildenafil</span></p>
  </td>
  <td width="17%" colspan=4 valign=top style='width:17.22%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>100, single dose
  </span></p>
  </td>
  <td width="13%" colspan=6 valign=top style='width:13.8%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>500 q12h</span></p>
  </td>
  <td width="16%" colspan=5 valign=top style='width:16.04%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 11-fold</span></p>
  </td>
  <td width="12%" colspan=3 valign=top style='width:12.52%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 4-fold</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Concomitant use
  of sildenafil for the treatment of erectile dysfunction, with ritonavir dosed
  as an antiretroviral agent or as a pharmacokinetic enhancer should be used
  with caution and in no instance should sildenafil doses exceed 25&nbsp;mg in
  48 hours (see also section 4.4). Concomitant use of sildenafil with
  ritonavir is <b>contraindicated</b> in pulmonary arterial hypertension
  patients (see section 4.3).</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>Tadalafil</span></p>
  </td>
  <td width="17%" colspan=4 valign=top style='width:17.22%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>20, single dose </span></p>
  </td>
  <td width="13%" colspan=6 valign=top style='width:13.8%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>200 q12h </span></p>
  </td>
  <td width="16%" colspan=5 valign=top style='width:16.04%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&#8593; 124%</span></p>
  </td>
  <td width="12%" colspan=3 valign=top style='width:12.52%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&#8596;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>The concomitant use of tadalafil for the treatment of erectile
  dysfunction with ritonavir dosed as an antiretroviral agent or as a
  pharmacokinetic enhancer should be with caution at reduced doses of no more
  than 10&nbsp;mg tadalafil every 72 hours with increased monitoring for
  adverse reactions (see section 4.4).</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>When tadalafil is used concurrently with ritonavir in
  patients with</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>pulmonary arterial hypertension, refer to the tadalafil Summary
  of Product Characteristics.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Vardenafil</span></p>
  </td>
  <td width="17%" colspan=4 valign=top style='width:17.22%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>5, single dose</span></p>
  </td>
  <td width="13%" colspan=6 valign=top style='width:13.8%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>600 q12h</span></p>
  </td>
  <td width="16%" colspan=5 valign=top style='width:16.04%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 49-fold</span></p>
  </td>
  <td width="12%" colspan=3 valign=top style='width:12.52%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 13-fold</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Concomitant use
  of vardenafil with ritonavir is contraindicated (see section 4.3).</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in;page-break-after:avoid'><b><span style='color:black'>Sedatives/hynoptics</span></b></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-top:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span lang=PT-BR style='font-size:9.5pt;color:black'>Clorazepate,
  diazepam, estazolam, flurazepam, oral and parenteral midazolam </span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-top:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Ritonavir
  co-administration is likely to result in increased plasma concentrations of
  clorazepate, diazepam, estazolam and flurazepam and is therefore <b>contraindicated
  </b>(see section 4.3). </span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Midazolam is
  extensively metabolised by CYP3A4. Co&#8209;administration with Norvir may
  cause a large increase in the concentration of this benzodiazepine. No
  medicinal product interaction study has been performed for the co&#8209;administration
  of Norvir with benzodiazepines. Based on data for other CYP3A4 inhibitors,
  plasma concentrations of midazolam are expected to be significantly higher
  when midazolam is given orally. Therefore, Norvir should not be co&#8209;administered
  with orally administered midazolam (see section 4.3), whereas caution should
  be used with co&#8209;administration of Norvir and parenteral midazolam.
  Data from concomitant use of parenteral midazolam with other protease
  inhibitors suggest a possible 3&nbsp;&nbsp;4 fold increase in midazolam
  plasma levels. If Norvir is co&#8209;administered with parenteral midazolam,
  it should be done in an intensive care unit (ICU) or similar setting which
  ensures close clinical monitoring and appropriate medical management in case
  of respiratory depression and/or prolonged sedation. Dosage adjustment for
  midazolam should be considered, especially if more than a single dose of
  midazolam is administered.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Triazolam</span></p>
  </td>
  <td width="17%" colspan=4 valign=top style='width:17.22%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>0.125, single
  dose</span></p>
  </td>
  <td width="13%" colspan=6 valign=top style='width:13.8%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>200, 4 doses</span></p>
  </td>
  <td width="16%" colspan=5 valign=top style='width:16.04%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593;
  &gt;&nbsp;20 fold</span></p>
  </td>
  <td width="12%" colspan=3 valign=top style='width:12.52%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 87%</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Ritonavir
  co-administration is likely to result in increased plasma concentrations of
  triazolam and is therefore <b>contraindicated</b> (see section 4.3).</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Pethidine </span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Norpethidine
  metabolite </span></p>
  </td>
  <td width="17%" colspan=4 valign=top style='width:17.22%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>50, oral single
  dose </span></p>
  </td>
  <td width="13%" colspan=6 valign=top style='width:13.8%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>500 q12h</span></p>
  </td>
  <td width="16%" colspan=5 valign=top style='width:16.04%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8595; 62% </span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'><br>
  &#8593; 47% </span></p>
  </td>
  <td width="12%" colspan=3 valign=top style='width:12.52%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8595; 59% <br>
  <br>
  &#8593; 87% </span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>The use of
  pethidine and ritonavir is <b>contraindicated </b>due to the increased
  concentrations of the metabolite, norpethidine, which has both analgesic and
  CNS stimulant activity. Elevated norpethidine concentrations may increase
  the risk of CNS effects (e.g., seizures), see section 4.3.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>Alprazolam</span></p>
  </td>
  <td width="17%" colspan=4 valign=top style='width:17.22%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>1, single dose </span></p>
  </td>
  <td width="13%" colspan=6 valign=top style='width:13.8%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>200 q12h, 2 days</span></p>
  </td>
  <td width="16%" colspan=5 valign=top style='width:16.04%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&#8593;&nbsp;2.5 fold</span></p>
  </td>
  <td width="12%" colspan=3 valign=top style='width:12.52%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&#8596;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="17%" colspan=4 valign=top style='width:17.22%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="13%" colspan=6 valign=top style='width:13.8%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>500 q12h,<b><i><u> </u></i></b>10 days</span></p>
  </td>
  <td width="16%" colspan=5 valign=top style='width:16.04%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&#8595; 12% </span></p>
  </td>
  <td width="12%" colspan=3 valign=top style='width:12.52%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&#8595; 16% </span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>Alprazolam metabolism was inhibited following the
  introduction of ritonavir. After ritonavir use for 10 days, no inhibitory
  effect of ritonavir was observed. Caution is warranted during the first
  several days when alprazolam is co&#8209;administered with ritonavir dosed as
  an antiretroviral agent or as a pharmacokinetic enhancer, before induction of
  alprazolam metabolism develops.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid;height:56.4pt'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt;
  height:56.4pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Buspirone</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt;
  height:56.4pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Ritonavir dosed
  as a pharmacokinetic enhancer or as an antiretroviral agent inhibits CYP3A
  and as a result is expected to increase the plasma concentrations of
  buspirone. Careful monitoring of therapeutic and adverse effects is recommended
  when buspirone concomitantly administered with ritonavir.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='margin-bottom:6.0pt;page-break-after:avoid'><b><span
  style='color:black'>Sleeping agent</span></b></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Zolpidem</span></p>
  </td>
  <td width="17%" colspan=4 valign=top style='width:17.22%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>5 </span></p>
  </td>
  <td width="13%" colspan=6 valign=top style='width:13.8%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>200, 4 doses</span></p>
  </td>
  <td width="16%" colspan=5 valign=top style='width:16.04%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 28%</span></p>
  </td>
  <td width="12%" colspan=3 valign=top style='width:12.52%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 22%</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Zolpidem and
  ritonavir may be co-administered with careful monitoring for excessive
  sedative effects.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='margin-bottom:6.0pt;page-break-after:avoid'><b><span
  style='color:black'>Smoke cessation</span></b></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Bupropion</span></p>
  </td>
  <td width="17%" colspan=4 valign=top style='width:17.22%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>150 </span></p>
  </td>
  <td width="13%" colspan=6 valign=top style='width:13.8%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>100 q12h</span></p>
  </td>
  <td width="16%" colspan=5 valign=top style='width:16.04%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8595; 22%</span></p>
  </td>
  <td width="12%" colspan=3 valign=top style='width:12.52%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8595; 21%</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="17%" colspan=4 valign=top style='width:17.22%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>150 </span></p>
  </td>
  <td width="13%" colspan=6 valign=top style='width:13.8%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>600 q12h</span></p>
  </td>
  <td width="16%" colspan=5 valign=top style='width:16.04%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8595; 66%</span></p>
  </td>
  <td width="12%" colspan=3 valign=top style='width:12.52%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8595; 62%</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.5pt;color:black'>Bupropion
  is primarily metabolised by CYP2B6. Concurrent administration of bupropion
  with repeated doses of ritonavir is expected to decrease bupropion levels.
  These effects are thought to represent induction of bupropion metabolism.
  However, because ritonavir has also been shown to inhibit CYP2B6 in vitro,
  the recommended dose of bupropion should not be exceeded. In contrast to
  long-term administration of ritonavir, there was no significant interaction
  with bupropion after short-term administration of low doses of ritonavir
  (200&nbsp;mg twice daily for 2 days), suggesting reductions in bupropion
  concentrations may have onset several days after initiation of ritonavir co&#8209;administration.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='margin-bottom:6.0pt;page-break-after:avoid'><b><span
  style='color:black'>Steroids</span></b></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.5pt'>Inhaled,
  injectable or intranasal fluticasone propionate, budesonide, triamcinolone</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Systemic
  corticosteroid effects including Cushing's syndrome and adrenal suppression
  (plasma cortisol levels were noted to be decreased 86% in the above study)
  have been reported in patients receiving ritonavir and inhaled or intranasal
  fluticasone propionate; similar effects could also occur with other
  corticosteroids metabolised by CYP3A e.g., budesonide and triamcinolone.
  Consequently, concomitant administration of ritonavir dosed as an
  antiretroviral agent or as a pharmacokinetic enhancer and these
  glucocorticoids is not recommended unless the potential benefit of treatment
  outweighs the risk of systemic corticosteroid effects (see section 4.4). </span><span
  style='font-size:9.5pt;color:black'>A dose reduction of the glucocorticoid
  should be considered with close monitoring of local and systemic effects or a
  switch to a glucocorticoid, which is not a substrate for CYP3A4 (e.g.,
  beclomethasone). Moreover, in case of withdrawal of glucocorticoids
  progressive dose reduction may be required over a longer period.<span
  style='background:#CCFFFF'> </span></span><span style='font-size:9.5pt;
  color:black'></span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'></span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Dexamethasone</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Ritonavir dosed
  as a pharmacokinetic enhancer or as an antiretroviral agent inhibits CYP3A
  and as a result is expected to increase the plasma concentrations of
  dexamethasone. Careful monitoring of therapeutic and adverse effects is
  recommended when dexamethasone is concomitantly administered with ritonavir.
  </span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Prednisolone</span></p>
  </td>
  <td width="14%" valign=top style='width:14.94%;border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>20</span></p>
  </td>
  <td width="17%" colspan=10 valign=top style='width:17.14%;border:none;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>200 q12h</span></p>
  </td>
  <td width="16%" colspan=5 valign=top style='width:16.04%;border:none;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 28%</span></p>
  </td>
  <td width="11%" colspan=2 valign=top style='width:11.46%;border:none;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 9%</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Careful
  monitoring of therapeutic and adverse effects is recommended when
  prednisolone is concomitantly administered with ritonavir. The AUC of the metabolite
  prednisolone increased by 37 and 28% after 4 and 14 days ritonavir,
  respectively.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoHeading7 style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in'>Thyroid hormone replacement therapy</p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Levothyroxine</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Post&#8209;marketing
  cases have been reported indicating a potential interaction between ritonavir
  containing products and levothyroxine. Thyroid&#8209;stimulating hormone
  (TSH) should be monitored in patients treated with levothyroxine at least the
  first month after starting and/or ending ritonavir treatment.</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>ND: Not
  determined</span></p>
  <p class=MsoNormal style='margin-left:.5in;text-indent:-.25in'><span
  style='font-size:9.5pt;color:black'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
  </span></span><span style='font-size:9.5pt;color:black'>Based on a parallel group
  comparison</span></p>
  <p class=MsoNormal style='margin-left:.5in;text-indent:-.25in'><span
  style='font-size:9.5pt;color:black'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
  </span></span><span style='font-size:9.5pt;color:black'>Sulfamethoxazole was
  co-administered with trimethoprim. </span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr height=0>
  <td width=9 style='border:none'></td>
  <td width=274 style='border:none'></td>
  <td width=2 style='border:none'></td>
  <td width=109 style='border:none'></td>
  <td width=8 style='border:none'></td>
  <td width=1 style='border:none'></td>
  <td width=7 style='border:none'></td>
  <td width=8 style='border:none'></td>
  <td width=4 style='border:none'></td>
  <td width=5 style='border:none'></td>
  <td width=67 style='border:none'></td>
  <td width=9 style='border:none'></td>
  <td width=9 style='border:none'></td>
  <td width=8 style='border:none'></td>
  <td width=8 style='border:none'></td>
  <td width=38 style='border:none'></td>
  <td width=47 style='border:none'></td>
  <td width=17 style='border:none'></td>
  <td width=8 style='border:none'></td>
  <td width=17 style='border:none'></td>
  <td width=67 style='border:none'></td>
  <td width=9 style='border:none'></td>
 </tr>
</table>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black'>Cardiac and neurologic events have
been reported when ritonavir has been co-administered with disopyramide,
mexiletine or nefazodone. The possibility of medicinal product interaction
cannot be excluded.</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black'>In addition to the interactions
listed above, as ritonavir is highly protein bound, the possibility of
increased therapeutic and toxic effects due to protein binding displacement of
concomitant medicinal products should be considered.</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><u><span style='color:black'>Ritonavir dosed as a
pharmacokinetic enhancer</span></u></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black'>Important information regarding
medicinal product interactions when ritonavir is used a pharmacokinetic
enhancer is also contained in the Summary of Product Characteristics of the
co-administered protease inhibitor. </span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB style='color:black'>Proton pump
inhibitors and H<sub>2</sub>-receptor antagonists</span></i></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Proton pump inhibitors
and H<sub>2</sub>-receptor antagonists (e.g. omeprazole or ranitidine) may
reduce concentrations for co&#8209;administered protease inhibitors. For
specific information regarding the impact of co&#8209;administration of acid
reducing agents, refer to the Summary of Product Characteristics of the
co-administered protease inhibitor.</span><span lang=EN-GB style='color:black'>
</span><span lang=EN-GB style='color:black'>Based on interaction studies with
the ritonavir boosted protease inhibitors (lopinavir/ritonavir, atazanavir),
concurrent administration of omeprazole or ranitidine does not significantly
modify ritonavir efficacy as a pharmacokinetic enhancer despite a slight change
of exposure (about 6&nbsp;-&nbsp;18%).</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-family:"Times New Roman Bold",serif;color:black'>4.6 Fertility, pregnancy
and lactation</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-family:"Times New Roman Bold",serif;color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='color:black'>Pregnancy</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='color:black'>A large amount (6100 live births) of pregnant women were
exposed to ritonavir during pregnancy; of these, 2800 live births were exposed
during the first trimester. These data largely refer to exposures where
ritonavir was used in combination therapy and not at therapeutic ritonavir
doses but at lower doses as a pharmacokinetic enhancer for other PIs. These
data indicate no increase in the rate of birth defects compared to rates
observed in population-based birth defect surveillance systems. Animal data
have shown reproductive toxicity (see section 5.3). Norvir can be used during
pregnancy if clinically needed.</span></p>

<p class=MsoNormal><s><span lang=EN-GB style='color:black'><span
 style='text-decoration:none'>&nbsp;</span></span></s></p>

<p class=MsoNormal><span style='color:black'>Ritonavir adversely interacts with
oral contraceptives (OCs). Therefore, an alternative, effective and safe
method of contraception should be used during treatment.</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><u><span style='color:black'>Breastfeeding</span></u></p>

<p class=MsoNormal>Limited published data reports that ritonavir is present in
human milk.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>There is no information on the effects of ritonavir on the
breastfed infant or the effects of the drug on milk production. Because of the
potential for (1) HIV transmission (in HIV-negative infants), (2) developing
viral resistance (in HIV-postive infants) and (3) serious adverse reactions in
a breastfed infant, HIV infected women should not breast feed their infants
under any circumstances if they are receiving Norvir.</p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span style='color:black'>Fertility
</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span style='color:black'>No
human data on the effect of ritonavir on fertility are available. Animal
studies do not indicate harmful effects of ritonavir on fertility (see section
5.3). </span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
color:black'>4.7 Effects on ability to drive and use machines</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
color:black'>&nbsp;</span></b></p>

<p class=MsoNormal><span style='color:black'>No studies on the effects on the
ability to drive and use machines have been performed. Dizziness is a known
undesirable effect that should be taken into account when driving or using
machinery.</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-family:"Times New Roman Bold",serif;color:black'>4.8 Undesirable
effects</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-family:"Times New Roman Bold",serif;color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span style='color:black'>Summary
of the safety profile</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span style='color:black'>Ritonavir
dosed as a pharmacokinetic enhancer</span></i></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black'>Adverse reactions associated with
the use of ritonavir as a pharmacokinetic enhancer are dependent on the
specific co-administered PI. For information on adverse reactions refer to the
SPC of the specific co&#8209;administered PI.</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span style='color:black'>Ritonavir
dosed as an antiretroviral agent</span></i></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><i><u><span style='color:black'>Adverse reactions from
clinical trials and post-marketing experience in adult patients</span></u></i></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black'>The most frequently reported
adverse drug reactions among patients receiving ritonavir alone or in
combination with other antiretroviral drugs were gastrointestinal (including
diarrhoea, nausea, vomiting, abdominal pain (upper and lower)), neurological
disturbances (including paraesthesia and oral paraesthesia) and
fatigue/asthenia.</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><u><span style='color:black'>Tabulated list of adverse
reactions</span></u></p>

<p class=MsoNormal><u><span style='color:black'><span style='text-decoration:
 none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span style='color:black'>The following adverse reactions of
moderate to severe intensity with possible or probable relationship to
ritonavir have been reported. Within each frequency grouping, undesirable
effects are presented in order of decreasing seriousness: very common (&#8805;&nbsp;1/10);
common (&#8805;&nbsp;1/100 to &lt;&nbsp;1/10); uncommon (&#8805;&nbsp;1/1000 to
&lt;&nbsp;1/100); rare (&#8805;&nbsp;1/10,000 to &lt;&nbsp;1/1,000); not known
(cannot be estimated from the available data).</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black'>Events noted as having a frequency
not known were identified via post-marketing surveillance</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width=619 colspan=3 valign=top style='width:464.45pt;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='margin-top:6.0pt;margin-right:0in;
   margin-bottom:6.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
   lang=EN-GB style='color:black'>Adverse reactions in clinical studies and
   post-marketing in adult patients</span></b></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td width=227 valign=top style='width:170.4pt;border:solid windowtext 1.0pt;
   border-top:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-bottom:6.0pt;page-break-after:avoid'><b><span
   style='color:black'>System Order Class</span></b></p>
   </td>
   <td width=110 valign=top style='width:82.5pt;border:none;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='margin-bottom:6.0pt;text-align:center;
   page-break-after:avoid'><b><span lang=EN-GB style='color:black'>Frequency</span></b></p>
   </td>
   <td width=282 valign=top style='width:211.55pt;border:none;border-right:
   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-bottom:6.0pt;page-break-after:avoid'><b><span
   style='color:black'>Adverse reaction</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width=227 rowspan=2 valign=top style='width:170.4pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='color:black'>Blood
  and lymphatic system disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.5pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>Common</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>&nbsp;</span></p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='color:black'>Decreased
  white blood cells, decreased haemoglobin, decreased neutrophils, increased
  eosinophils, thrombocytopenia</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=110 valign=top style='width:82.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>Uncommon</span></p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='color:black'>Increased
  neutrophils </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=227 valign=top style='width:170.4pt;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='color:black'>Immune
  system disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.5pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>Common</span></p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='color:black'>Hypersensitivity,
  including urticaria and face oedema.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=227 valign=top style='width:170.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=110 valign=top style='width:82.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>Rare</span></p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='color:black'>Anaphylaxis</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=227 valign=top style='width:170.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:6.0pt'><span style='color:black'>Metabolism
  and nutrition disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:6.0pt;text-align:center'><span
  lang=EN-GB style='color:black'>Common</span></p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:6.0pt'><span style='color:black'>Hypercholesterolaemia,
  hypertriglyceridaemia, gout, oedema and peripheral oedema, dehydration
  (usually associated with gastrointestinal symptoms)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=227 valign=top style='width:170.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=110 valign=top style='width:82.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='color:black'>Uncommon</span></p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Diabetes mellitus</span></p>
  <p class=MsoNormal><span style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=110 valign=top style='width:82.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='color:black'>Rare</span></p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Hyperglycaemia</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=227 rowspan=2 valign=top style='width:170.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Nervous system disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='color:black'>Very common</span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Dysgeusia, oral and peripheral
  paraesthesia, headache, dizziness, peripheral neuropathy</span></p>
  <p class=MsoNormal><span style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=110 valign=top style='width:82.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='color:black'>Common</span></p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Insomnia, anxiety,
  confusion, disturbance in attention, syncope, seizure</span></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:6.0pt'><span style='color:black'>Eye
  disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:6.0pt;text-align:center'><span
  lang=EN-GB style='color:black'>Common</span></p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:6.0pt'><span style='color:black'>Blurred
  vision</span></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.4pt;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:6.0pt'><span style='color:black'>Cardiac
  disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.5pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:6.0pt;text-align:center'><span
  lang=EN-GB style='color:black'>Uncommon</span></p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:6.0pt'><span style='color:black'>Myocardial
  infarction</span></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.4pt;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Vascular disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.5pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='color:black'>Common</span></p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:6.0pt'><span style='color:black'>Hypertension,
  hypotension including orthostatic hypotension, peripheral coldness</span></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=110 valign=top style='width:82.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Respiratory, thoracic and
  mediastinal disorders</span></p>
  <p class=MsoNormal><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=110 valign=top style='width:82.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='color:black'>Very common</span></p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Pharyngitis, oropharyngeal pain,
  cough </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=227 rowspan=2 valign=top style='width:170.4pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Gastrointestinal disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='color:black'>Very common</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Abdominal pain (upper and
  lower), nausea, diarrhoea (including severe with electrolyte imbalance),
  vomiting, dyspepsia</span></p>
  <p class=MsoNormal><span style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=110 valign=top style='width:82.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='color:black'>Common</span></p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Anorexia, flatulence, mouth
  ulcer, gastrointestinal haemorrhage, gastroesophageal reflux disease,
  pancreatitis</span></p>
  <p class=MsoNormal><span style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.4pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Hepatobiliary disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.5pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='color:black'>Common</span></p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Hepatitis (including increased
  AST, ALT, GGT), blood bilirubin increased (including jaundice)</span></p>
  <p class=MsoNormal><span style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Skin and subcutaneous tissue
  disorders</span></p>
  <p class=MsoNormal><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=110 valign=top style='width:82.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='color:black'>Very common</span></p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Pruritus, rash (including
  erythematous and maculopapular)</span></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=110 valign=top style='width:82.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='color:black'>Common</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Acne</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=227 valign=top style='width:170.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=110 valign=top style='width:82.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='color:black'>Rare</span></p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Stevens Johnson syndrome, toxic
  epidermal necrolysis (TEN)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=227 rowspan=2 valign=top style='width:170.4pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Musculosketal and connective
  tissue disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='color:black'>Very common</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Arthralgia and back pain</span></p>
  <p class=MsoNormal><span style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=110 valign=top style='width:82.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='color:black'>Common</span></p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Myositis, rhabdomyolysis,
  myalgia, myopathy/CPK increased</span></p>
  <p class=MsoNormal><span style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.4pt;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:6.0pt'><span style='color:black'>Renal
  and urinary disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.5pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:6.0pt;text-align:center'><span
  style='color:black'>Common</span></p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-align:justify'><span style='color:black'>Increased
  urination, </span><span lang=EN-GB style='color:black'>renal impairment (e.g.
  oliguria, elevated creatinine)</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:27.8pt'>
  <td width=227 valign=top style='width:170.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:27.8pt'>
  <p class=MsoNormal align=center style='margin-bottom:6.0pt;text-align:center'><span
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=110 valign=top style='width:82.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.8pt'>
  <p class=MsoNormal align=center style='text-align:center'>Uncommon</p>
  <p class=MsoNormal align=center style='text-align:center'>&nbsp;</p>
  <p class=MsoNormal align=center style='text-align:center'>Not known</p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:27.8pt'>
  <p class=MsoNormal style='text-align:justify'><span style='color:black'>Acute
  renal failure</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='color:black'>&nbsp;</span></p>
  <p class=MsoNormal style='text-align:justify'><span style='color:black'>Nephrolithiasis</span></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Reproductive system and breast
  disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='color:black'>Common</span></p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Menorrhagia</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=227 rowspan=2 valign=top style='width:170.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>General disorders and
  administration site conditions</span></p>
  </td>
  <td width=110 valign=top style='width:82.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='color:black'>Very common</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Fatigue including asthenia,
  flushing, feeling hot</span></p>
  <p class=MsoNormal><span style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=110 valign=top style='width:82.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='color:black'>Common</span></p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Fever, weight loss</span></p>
  <p class=MsoNormal><span style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=227 rowspan=2 valign=top style='width:170.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Investigations</span></p>
  </td>
  <td width=110 valign=top style='width:82.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='color:black'>Common</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Increased amylase, decreased
  free and total thyroxine </span></p>
  <p class=MsoNormal><span style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=110 valign=top style='width:82.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='color:black'>Uncommon</span></p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Increased glucose, increased
  magnesium, increased alkaline phosphatase</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><u><span style='color:black'>Description of selected adverse
reactions</span></u></p>

<p class=MsoNormal><u><span style='color:black'><span style='text-decoration:
 none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span style='color:black'>Hepatic transaminase elevations
exceeding five times the upper limit or normal, clinical hepatitis, and
jaundice have occurred in patients receiving ritonavir alone or in combination
with other antiretrovirals.</span></p>

<p class=MsoNormal><u><span style='color:black'><span style='text-decoration:
 none'>&nbsp;</span></span></u></p>

<p class=EMEANormal><u><span lang=EN-GB>Metabolic parameters</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Weight and levels of blood lipids and
glucose may increase during antiretroviral therapy (see section 4.4).</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black'>In HIV-infected patients with
severe immune deficiency at the time of initiation of combination
antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or
residual opportunistic infections may arise. Autoimmune disorders (</span><span
lang=EN-GB style='color:black'>such as Graves disease </span><span lang=EN-GB>and
autoimmune hepatitis</span><span lang=EN-GB style='color:black'>) have also
been reported; however, the reported time to onset is more variable and can
occur many months after initiation of treatment</span><span style='color:black'>
(see section 4.4).</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black'>Pancreatitis has been observed in
patients receiving ritonavir therapy, including those who developed
hypertriglyceridaemia. In some cases fatalities have been observed. Patients
with advanced HIV disease may be at risk of elevated triglycerides and
pancreatitis (see section 4.4).</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black'>Cases of osteonecrosis have been
reported, particularly in patients with generally acknowledged risk factors,
advanced HIV disease or long-term exposure to combination antiretroviral
therapy (CART). The frequency of this is unknown (see section 4.4).</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><i><u>Paediatric
populations</u></i></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><i><u><span
 style='text-decoration:none'>&nbsp;</span></u></i></p>

<p class=MsoNormal style='page-break-after:avoid'>The safety profile of Norvir
in children 2 years of age and older is similar to that seen in adults.</p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='color:black'>Reporting of suspected adverse reactions</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='color:black'>Reporting suspected adverse reactions after authorisation
of the medicinal product is important. It allows continued monitoring of the
benefit/risk balance of the medicinal product. Healthcare professionals are
asked to report any suspected adverse reactions </span><span style='color:black'>via
<span style='background:lightgrey'>the national reporting system listed in </span></span><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='background:lightgrey'>Appendix V</span></a><span style='color:black'>.</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
color:black'>4.9 Overdose</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
color:black'>&nbsp;</span></b></p>

<p class=MsoNormal><u><span style='color:black'>Symptoms</span></u></p>

<p class=MsoNormal><span style='color:black'>Human experience of acute overdose
with ritonavir is limited. One patient in clinical trials took ritonavir
1500&nbsp;mg/day for two days and reported paraesthesia, which resolved after
the dose was decreased. A case of renal failure with eosinophilia has been
reported.</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black'>The signs of toxicity observed in
animals (mice and rats) included decreased activity, ataxia, dyspnoea and
tremors.</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span style='color:black'>Management</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span style='color:black'>There
is no specific antidote for overdose with ritonavir. Treatment of overdose
with ritonavir should consist of general supportive measures including
monitoring of vital signs and observation of the clinical status of the
patient. Due to the solubility characteristics and possibility of
transintestinal elimination, it is proposed that management of overdose could
entail gastric lavage and administration of activated charcoal. Since
ritonavir is extensively metabolised by the liver and is highly protein bound,
dialysis is unlikely to be beneficial in significant removal of the medicine. </span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-family:"Times New Roman Bold",serif;color:black;text-transform:
uppercase'>5. Pharmacological properties</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-family:"Times New Roman Bold",serif;color:black;text-transform:
uppercase'>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-family:"Times New Roman Bold",serif;color:black'>5.1 Pharmacodynamic
properties</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-family:"Times New Roman Bold",serif;color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span style='color:black'>Pharmaco-therapeutic
group: antiviral for systemic use, protease inhibitors ATC code: J05AE03</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span style='color:black'>Ritonavir
dosed as a pharmacokinetic enhancer</span></u></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black'>Pharmacokinetic enhancement by
ritonavir is based on ritonavirs activity as a potent inhibitor of CYP3A&#8209;
mediated metabolism. The degree of enhancement is related to the metabolic
pathway of the co&#8209;administered protease inhibitor and the impact of the
co&#8209;administered protease inhibitor on the metabolism of ritonavir.
Maximal inhibition of metabolism of the co&#8209;administered protease
inhibitor is generally achieved with ritonavir doses of 100&nbsp;mg daily to
200&nbsp;mg twice daily, and is dependent on the co&#8209;administered protease
inhibitor. For </span><span style='color:black'>additional information on the
effect of ritonavir on co&#8209;administered protease inhibitor metabolism, see
section 4.5 and refer to the Summary of Product Characteristics of the
particular co&#8209;administered PIs.</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span style='color:black'>Ritonavir
dosed as an antiretroviral agent</span></u></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black'>Ritonavir is an orally active
peptidomimetic inhibitor of the HIV&#8209;1 and HIV&#8209;2 aspartyl
proteases. Inhibition of HIV protease renders the enzyme incapable of
processing the <i>gag&#8209;pol</i> polyprotein precursor which leads to the
production of HIV particles with immature morphology that are unable to
initiate new rounds of infection. Ritonavir has selective affinity for the HIV
protease and has little inhibitory activity against human aspartyl proteases.</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black'>Ritonavir was the first protease
inhibitor (approved in 1996) for which efficacy was proven in a study with
clinical endpoints. However, due to ritonavirs metabolic inhibitory
properties its use as a pharmacokinetic enhancer of other protease inhibitors
is the prevalent use of ritonavir in clinical practice (see section 4.2). </span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='color:black'>Effects on the Electrocardiogram</span></u><u><span
lang=EN-GB style='color:black'> </span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='color:black'>QTcF interval was evaluated in a randomised, placebo and
active (moxifloxacin 400&nbsp;mg once daily) controlled crossover study in 45
healthy adults, with 10 measurements over 12 hours on Day 3. The maximum mean
(95% upper confidence bound) difference in QTcF from placebo was 5.5 (7.6) for
400&nbsp;mg twice daily ritonavir. The Day 3 ritonavir exposure was
approximately 1.5 fold higher than that observed with the 600&nbsp;mg twice
daily dose at steady state. No subject experienced an increase in QTcF of </span><span
lang=EN-GB style='font-family:Symbol;color:black'></span><span lang=EN-GB
style='color:black'>&nbsp;60 msec from baseline or a QTcF interval exceeding
the potentially clinically relevant threshold of 500 msec.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Modest prolongation of
the PR interval was also noted in subjects receiving ritonavir in the same
study on Day 3. The mean changes from baseline in PR interval ranged from 11.0
to 24.0 msec in the 12 hour interval post dose. Maximum PR interval was 252
msec and no second or third degree heart block was observed (see section 4.4).</span></p>

<p class=MsoNormal><b><span style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span style='color:black'>Resistance</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span style='color:black'>Ritonavir&#8209;resistant
isolates of HIV&#8209;1 have been selected <i>in vitro </i>and isolated from patients
treated with therapeutic doses of ritonavir. </span></p>

<p class=MsoNormal style='text-autospace:none'><span style='color:black'></span></p>

<p class=MsoNormal style='page-break-after:avoid'><span style='color:black'>Reduction
in the antiretroviral activity of ritonavir is primarily associated with the
protease mutations V82A/F/T/S and I84V. Accumulation of other mutations in the
protease gene (including at positions 20, 33, 36, 46, 54, 71, and 90) can also
contribute to ritonavir resistance. </span><span style='color:black'>In
general, as mutations associated with ritonavir resistance accumulate,
susceptibility to select other PIs may decrease due to cross&#8209;resistance.
The Summary of Product Characteristics of other protease inhibitors or official
continuous updates should be consulted for specific information regarding
protease mutations associated with reduced response to these agents.</span></p>

<p class=MsoNormal><span style='color:black'> </span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span style='color:black'>Clinical
pharmacodynamic data</span></u></p>

<p class=MsoNormal><b><span style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal><span style='color:black'>The effects of ritonavir (alone or
combined with other antiretroviral agents) on biological markers of disease
activity such as CD4 cell count and viral RNA were evaluated in several studies
involving HIV-1 infected patients. The following studies are the most
important.</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><i><span style='color:black'>Adult Use</span></i></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black'>A controlled study completed in
1996 with ritonavir as add-on therapy in HIV-1 infected patients extensively
pre-treated with nucleoside analogues and baseline CD4 cell counts </span><span
style='font-family:Symbol;color:black'></span><span style='color:black'>&nbsp;100&nbsp;cells/</span><span
style='font-family:Symbol;color:black'>m</span><span style='color:black'>l
showed a reduction in mortality and AIDS defining events. The mean average
change from baseline over 16 weeks for HIV RNA levels was -0.79&nbsp;log<sub>10</sub><span
style='position:relative;top:2.0pt'> </span>(maximum mean decrease:
1.29&nbsp;log<sub>10</sub>) in the ritonavir group versus-0.01&nbsp;log<sub>10</sub><span
style='position:relative;top:2.0pt'> </span>in the control group. The most
frequently used nucleosides in this study were zidovudine, stavudine,
didanosine and zalcitabine. </span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black'>In a study completed in 1996
recruiting less advanced HIV-1 infected patients (CD4 200-500&nbsp;cells/</span><span
style='font-family:Symbol;color:black'>m</span><span style='color:black'>l)
without previous antiretroviral therapy, ritonavir in combination with
zidovudine or alone reduced viral load in plasma and increased CD4 count. The
mean average change from baseline over 48 weeks for HIV RNA levels was
-0.88&nbsp;log<sub>10</sub> in the ritonavir group versus -0.66&nbsp;log<sub>10</sub><span
style='position:relative;top:2.0pt'> </span>in the ritonavir + zidovudine group
versus -0.42&nbsp;log<sub>10</sub><span style='position:relative;top:2.0pt'> </span>in
the zidovudine group.</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black'>The continuation of ritonavir
therapy should be evaluated by viral load because of the possibility of the
emergence of resistance as described under section 4.1.</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span style='color:black'>Paediatric
Use</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black'>In an open label trial completed
in 1998 in HIV infected, clinically stable children there was a significant
difference (p&nbsp;=&nbsp;0.03) in the detectable RNA levels in favour of a
triple regimen (ritonavir, zidovudine and lamivudine) following 48 weeks
treatment.</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black'>In a study completed in 2003, 50
HIV-1 infected, protease inhibitor and lamivudine nave children age
4&nbsp;weeks to 2&nbsp;years received ritonavir 350 or 450&nbsp;mg/m<sup>2</sup>
every 12&nbsp;hours co&#8209;administered with zidovudine 160&nbsp;mg/m<sup>2</sup>
every 8 hours and lamivudine 4&nbsp;mg/kg every 12 hours. In intent to treat
analyses, 72% and 36% of patients achieved reduction in plasma HIV-1 RNA of </span><span
style='font-family:Symbol;color:black'></span><span style='color:black'>&nbsp;400
copies/ml at Week 16 and 104, respectively. Response was similar in both
dosing regimens and across patient age. </span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>In a study completed in
2000, 76 HIV-1 infected children aged 6 months to 12 years who were protease
inhibitor naive and naive to lamivudine and/or stavudine received ritonavir 350
or 450&nbsp;mg/m<sup>2</sup> every 12 hours co-administered with lamivudine and
stavudine. In intent to treat analyses, 50% and 57% of patients in the 350 and
450&nbsp;mg/m<sup>2</sup> dose groups, respectively, achieved reduction in
plasma HIV-1 RNA to &#8804;&nbsp;400&nbsp;copies/ml at Week 48.</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-family:"Times New Roman Bold",serif;color:black'>5.2 Pharmacokinetic
properties</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-family:"Times New Roman Bold",serif;color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span style='color:black'>Absorption</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span style='color:black'>There
is no parenteral formulation of ritonavir, therefore the extent of absorption
and absolute bioavailability has not been determined. The pharmacokinetics of
ritonavir during multiple dose regimens were studied in non&#8209;fasting
HIV-infected adult volunteers. Upon multiple dosing, ritonavir accumulation is
slightly less than predicted from a single dose due to a time and dose&#8209;related
increase in apparent clearance (Cl/F). Trough concentrations of ritonavir
decrease over time, possibly due to enzyme induction, but appeared to stabilise
by the end of 2 weeks. The time to maximum concentration (T<sub>max</sub>)
remained constant at approximately 4 hours with increasing dose. Renal
clearance averaged less than 0.1&nbsp;l/h and was relatively constant
throughout the dosage range.</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black'>The pharmacokinetic parameters
observed with various dosing schemes of ritonavir alone are shown in the table
below.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=590 colspan=6 valign=top style='width:6.15in;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span style='color:black'>Ritonavir Dosing Regimen</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=98 valign=top style='width:73.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='color:black'>100 mg &nbsp; once daily</span></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='color:black'>100 mg twice daily<sup>1</sup></span></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='color:black'>200 mg once daily</span></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='color:black'>200 mg twice daily</span></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='color:black'>600 mg twice daily</span></p>
  </td>
 </tr>
 <tr>
  <td width=98 valign=top style='width:73.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>C<sub>max </sub>(g/ml)</span></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='color:black'>0.84 </span><span style='font-family:Symbol;color:black'></span><span
  style='color:black'>&nbsp;0.39</span></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='color:black'>0.89</span></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='color:black'>3.4 </span><span style='font-family:Symbol;color:black'></span><span
  style='color:black'> 1.3</span></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='color:black'>4.5&nbsp;</span><span style='font-family:Symbol;
  color:black'></span><span style='color:black'>&nbsp;1.3</span></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='color:black'>11.2&nbsp;</span><span style='font-family:Symbol;
  color:black'></span><span style='color:black'>&nbsp;3.6</span></p>
  </td>
 </tr>
 <tr>
  <td width=98 valign=top style='width:73.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>C<sub>trough </sub>(g/ml)</span></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='color:black'>0.08 </span><span style='font-family:Symbol;color:black'></span><span
  style='color:black'>&nbsp;0.04</span></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='color:black'>0.22</span></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='color:black'>0.16 </span><span style='font-family:Symbol;color:black'></span><span
  style='color:black'> 0.10</span></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='color:black'>0.6 </span><span style='font-family:Symbol;color:black'></span><span
  style='color:black'>&nbsp;0.2</span></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='color:black'>3.7&nbsp;</span><span style='font-family:Symbol;
  color:black'></span><span style='color:black'>&nbsp;2.6</span></p>
  </td>
 </tr>
 <tr>
  <td width=98 valign=top style='width:73.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>AUC<sub>12 or 24</sub> (g</span><span
  style='font-family:Symbol;color:black'></span><span style='color:black'>h/ml)</span></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='color:black'>6.6&nbsp;</span><span style='font-family:Symbol;
  color:black'></span><span style='color:black'>&nbsp;2.4</span></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='color:black'>6.2</span></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='color:black'>20.0 </span><span style='font-family:Symbol;color:black'></span><span
  style='color:black'> 5.6</span></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='color:black'>21.92 </span><span style='font-family:Symbol;color:black'></span><span
  style='color:black'> 6.48</span></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='color:black'>77.5 </span><span style='font-family:Symbol;color:black'></span><span
  style='color:black'> 31.5</span></p>
  </td>
 </tr>
 <tr>
  <td width=98 valign=top style='width:73.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>t<sub></sub> (h)</span></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='color:black'>~5</span></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='color:black'>~5</span></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='color:black'>~4</span></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='color:black'>~8</span></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='color:black'>~3 to 5</span></p>
  </td>
 </tr>
 <tr>
  <td width=98 valign=top style='width:73.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Cl/F (L/h)</span></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='color:black'>17.2 </span><span style='font-family:Symbol;color:black'></span><span
  style='color:black'>&nbsp;6.6</span></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='color:black'>16.1</span></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='color:black'>10.8 </span><span style='font-family:Symbol;color:black'></span><span
  style='color:black'> 3.1</span></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='color:black'>10.0&nbsp;</span><span style='font-family:Symbol;
  color:black'></span><span style='color:black'>&nbsp;3.2</span></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='color:black'>8.8&nbsp;</span><span style='font-family:Symbol;
  color:black'></span><span style='color:black'>&nbsp;3.2</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><sup><span lang=EN-GB style='color:black'>1 </span></sup><span
lang=EN-GB style='color:black'>Values expressed as geometric means. Note: ritonavir
was dosed after a meal for all listed regimens.</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span style='color:black'>Effects
of food on oral absorption</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span style='color:black'>&nbsp;</span></p>

<p class=Heading1Unnumbered style='margin:0in;text-indent:0in'><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;font-weight:normal'>Administration
of a single 100&nbsp;mg dose of ritonavir powder for oral suspension with a
moderate fat meal (617&nbsp;kcal, 29% calories from fat) was associated with a
mean decrease of 23 and 39% in ritonavir AUC<sub>inf</sub> and C<sub>max</sub>
respectively, relative to fasting conditions. Administration with a high fat
meal (917 kcal, 60% calories from fat) was associated with a mean decrease of
32 and 49% in ritonavir AUC<sub>inf</sub> and C<sub>max</sub> respectively,
relative to fasting conditions.</span></p>

<p class=MsoNormal><u><span style='color:black'><span style='text-decoration:
 none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span style='color:black'>Distribution</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span style='color:black'>The
apparent volume of distribution (V<sub>B</sub>/F) of ritonavir is approximately
20&nbsp;-&nbsp;40&nbsp;l after a single 600&nbsp;mg dose. The protein binding
of ritonavir in human plasma is approximately 98&nbsp;&nbsp;99% and is constant
over the concentration range of 1.0&nbsp;&nbsp;100&nbsp;</span><span
style='font-family:Symbol;color:black'>m</span><span style='color:black'>g/ml.
Ritonavir binds to both human alpha 1&#8209;acid glycoprotein (AAG) and human
serum albumin (HSA) with comparable affinities.</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black'>Tissue distribution studies with <sup>14</sup>C&#8209;labelled
ritonavir in rats showed the liver, adrenals, pancreas, kidneys and thyroid to
have the highest concentrations of ritonavir. Tissue to plasma ratios of
approximately 1 measured in rat lymph nodes suggests that ritonavir distributes
into lymphatic tissues. Ritonavir penetrates minimally into the brain.</span></p>

<p class=MsoNormal><u><span style='color:black'><span style='text-decoration:
 none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span style='color:black'>Biotransformation</span></u></p>

<p class=MsoNormal><span style='color:black'>Ritonavir was noted to be
extensively metabolised by the hepatic cytochrome P450 system, primarily by the
CYP3A isozyme family and to a lesser extent by the CYP2D6 isoform. Animal
studies as well as <i>in vitro</i> experiments with human hepatic microsomes
indicated that ritonavir primarily underwent oxidative metabolism. Four
ritonavir metabolites have been identified in man. The isopropylthiazole
oxidation metabolite (M&#8209;2) is the major metabolite and has antiviral
activity similar to that of parent compound. However, the AUC of the M&#8209;2
metabolite was approximately 3% of the AUC of parent compound. </span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black'>Low doses of ritonavir have shown
profound effects on the pharmacokinetics of other protease inhibitors (and
other products metabolised by CYP3A4) and other protease inhibitors may
influence the pharmacokinetics of ritonavir (see section 4.5). </span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><u><span style='color:black'>Elimination</span></u></p>

<p class=MsoNormal><span style='color:black'>Human studies with radiolabelled
ritonavir demonstrated that the elimination of ritonavir was primarily via the
hepatobiliary system; approximately 86% of radiolabel was recovered from stool,
part of which is expected to be unabsorbed ritonavir. In these studies renal
elimination was not found to be a major route of elimination of ritonavir.
This was consistent with the observations in animal studies.</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><u><span style='color:black'>Special populations</span></u></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black'>No clinically significant
differences in AUC or C<sub>max</sub> were noted between males and females.
Ritonavir pharmacokinetic parameters were not statistically significantly
associated with body weight or lean body mass. Ritonavir plasma exposures in
patients 50&nbsp;&nbsp;70 years of age when dosed 100&nbsp;mg in combination
with lopinavir or at higher doses in the absence of other protease inhibitors
is similar to that observed in younger adults.</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><i><span style='color:black'>Patients with impaired liver
function</span></i></p>

<p class=MsoNormal><span style='color:black'>After multiple dosing of ritonavir
to healthy volunteers (500&nbsp;mg twice daily) and subjects with mild to
moderate hepatic impairment (Child Pugh Class A and B, 400&nbsp;mg twice daily)
exposure to ritonavir after dose normalisation was not significantly different
between the two groups. </span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><i><span style='color:black'>Patients with impaired renal
function</span></i></p>

<p class=MsoNormal><span style='color:black'>Ritonavir pharmacokinetic
parameters have not been studied in patients with renal impairment. However,
since the renal clearance of ritonavir is negligible, no changes in the total
body clearance are expected in patients with renal impairment. </span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><i><span style='color:black'>Paediatric patients</span></i></p>

<p class=MsoNormal><span style='color:black'>Ritonavir steady-state
pharmacokinetic parameters were evaluated in HIV infected children above 2
years of age receiving doses ranging from 250&nbsp;mg/m<sup></sup> twice daily
to 400&nbsp;mg/m<sup></sup> twice daily. Ritonavir concentrations obtained
after 350 to 400&nbsp;mg/m<sup></sup> twice daily in paediatric patients were
comparable to those obtained in adults receiving 600&nbsp;mg (approximately
330&nbsp;mg/m<sup></sup>) twice daily. Across dose groups, ritonavir oral
clearance (CL/F/m<sup>2</sup>) was approximately 1.5 to 1.7 times faster in
paediatric patients above 2 years of age than in adult subjects.</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black'>Ritonavir steady-state
pharmacokinetic parameters were evaluated in HIV infected children less than
2&nbsp;years of age receiving doses ranging from 350&nbsp;to 450&nbsp;mg/m
twice daily. Ritonavir concentrations in this study were highly variable and
somewhat lower than those obtained in adults receiving 600&nbsp;mg
(approximately 330&nbsp;mg/m) twice daily. Across dose groups, ritonavir oral
clearance (CL/F/m<sup>2</sup>) declined with age with median values of 9.0
L/h/m<sup>2</sup> in children less than 3 months of age, 7.8&nbsp;L/h/m<sup>2</sup>
in children between 3 and 6 months of age and 4.4 L/h/m<sup>2</sup> in children
between 6 and 24 months of age.</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
color:black'>5.3 Preclinical safety data</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
color:black'>&nbsp;</span></b></p>

<p class=MsoNormal><span style='color:black'>Repeated dose toxicity studies in
animals identified major target organs as the liver, retina, thyroid gland and
kidney. Hepatic changes involved hepatocellular, biliary and phagocytic
elements and were accompanied by increases in hepatic enzymes. Hyperplasia of
the retinal pigment epithelium (RPE) and retinal degeneration have been seen in
all of the rodent studies conducted with ritonavir, but have not been seen in
dogs. Ultrastructural evidence suggests that these retinal changes may be
secondary to phospholipidosis. However, clinical trials revealed no evidence
of medicinal product&#8209;induced ocular changes in humans. All thyroid
changes were reversible upon discontinuation of ritonavir. Clinical
investigation in humans has revealed no clinically significant alteration in
thyroid function tests. Renal changes including tubular degeneration, chronic
inflammation and proteinurea were noted in rats and are felt to be attributable
to species&#8209;specific spontaneous disease. Furthermore, no clinically
significant renal abnormalities were noted in clinical trials.</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black'>Developmental toxicity observed in
rats (embryolethality, decreased foetal body weight and ossification delays and
visceral changes, including delayed testicular descent) occurred mainly at a
maternally toxic dosage. Developmental toxicity in rabbits (embryolethality,
decreased litter size and decreased foetal weights) occurred at a maternally
toxic dosage.</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black'>Ritonavir was not found to be
mutagenic or clastogenic in a battery of <i>in vitro</i> and <i>in vivo</i>
assays including the Ames bacterial reverse mutation assay using <i>S.
typhimurium</i> and <i>E. coli</i>, the mouse lymphoma assay, the mouse
micronucleus test and chromosomal aberration assays in human lymphocytes.</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black'>Long term carcinogenicity studies
of ritonavir in mice and rats revealed tumourigenic potential specific for
these species, but are regarded as of no relevance for humans.</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span style='font-family:"Times New Roman Bold",serif;
color:black;text-transform:uppercase'>6. Pharmaceutical particulars</span></b></p>

<p class=MsoNormal><b><span style='font-family:"Times New Roman Bold",serif;
color:black;text-transform:uppercase'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
color:black'>6.1 List of excipients</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
color:black'>&nbsp;</span></b></p>

<p class=MsoNormal><span style='color:black'>Copovidone<br>
Sorbitan laurate <br>
Silica, colloidal anhydrous </span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
color:black'>6.2 Incompatibilities</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
color:black'>&nbsp;</span></b></p>

<p class=MsoNormal><span style='color:black'>Not applicable.</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
color:black'>6.3 Shelf life</span></b></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black'>36 months.</span></p>

<p><span style='font-size:11.0pt'>Following mixing with food or liquid </span><span
style='font-size:11.0pt;color:black'>as described in section 4.2</span><span
style='font-size:11.0pt'>: consume within 2 hours. </span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-family:"Times New Roman Bold",serif;color:black'>6.4 Special
precautions for storage</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-family:"Times New Roman Bold",serif;color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span style='color:black'>Store
below 30C.</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-family:"Times New Roman Bold",serif;color:black'>6.5 Nature and
contents of container</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-family:"Times New Roman Bold",serif;color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span style='color:black'>Polyethylene/aluminium/polyethylene
terephthalate foil sachet. 30 sachets per carton. Packaged with a mixing cup
and two 10&nbsp;ml calibrated oral dosing syringes. </span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
color:black'>6.6 Special precautions for disposal and other handling</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
color:black'>&nbsp;</span></b></p>

<p class=MsoNormal><span style='color:black'>For details on preparation and
administration of Norvir powder for oral suspension, refer the patient or care
giver to the Package Leaflet, section 3.</span></p>

<p class=MsoNormal><b><i><span style='color:black'>&nbsp;</span></i></b></p>

<p class=MsoNormal><u><span style='color:black'>Administering with </span></u><span
style='color:black'>f<u>ood</u></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>The entire contents of each sachet is to be poured over a small
amount of soft food (e.g. apple sauce or vanilla pudding). All of the mixed
soft food must be administered within 2 hours. </p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span style='color:black'>Administering
with </span></u><span style='color:black'>l<u>iquid</u></span></p>

<p class=MsoNormal style='page-break-after:avoid'><span style='color:black'>The
entire contents of each sachet should be suspended in 9.4&nbsp;ml of liquid
(water, chocolate milk, or infant formula) giving a final concentration of 10&nbsp;mg&nbsp;per&nbsp;ml.
The patient/caregiver is to be instructed to follow the directions below: </span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-size:11.0pt;font-family:Symbol;color:black'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'>The oral dosing syringe and mixing cup should be washed in warm
water and dish soap, then rinsed and allowed to air dry prior to first use. </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span style='font-size:11.0pt;font-family:Symbol;color:black'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'>Draw up 9.4&nbsp;ml of liquid using the provided oral dosing
syringe, remove the bubbles, and transfer the liquid to the mixing cup. All
measuring should be done in ml using the syringe. </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span style='font-size:11.0pt;font-family:Symbol;color:black'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'>Pour the entire contents of 1 sachet (100&nbsp;mg) into the mixing
cup. </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span style='font-size:11.0pt;font-family:Symbol;color:black'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'>Close the lid and shake hard for at least 90 seconds until all the
lumps have dissolved.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span style='font-size:11.0pt;font-family:Symbol;color:black'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'>Let the liquid stand for 10 minutes in order for most of the
bubbles to disappear.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span style='font-size:11.0pt;font-family:Symbol;color:black'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'>Use the provided oral dosing syringe to measure and administer the
prescribed ml volume (see section 4.2). Be sure to remove the bubbles prior to
dose administration.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span style='font-size:11.0pt;font-family:Symbol;color:black'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'>Once the powder is mixed, the prepared suspension should be used
within 2 hours.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span style='font-size:11.0pt;font-family:Symbol;color:black'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'>Discard any mixture remaining in the mixing cup.</span><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'> </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span style='font-size:11.0pt;font-family:Symbol;color:black'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'>The oral dosing syringe and mixing cup should be cleaned
immediately with warm water and dish soap after use. </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt'><span style='font-size:11.0pt;font-family:Symbol;color:black'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'>If the syringe breaks or becomes hard to use, the syringe should
be thrown away and the new one used.</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:28.35pt;text-indent:-10.35pt'><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
color:black;text-transform:uppercase'>7.  Marketing authoriSation holder</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
color:black;text-transform:uppercase'>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>AbbVie Deutschland GmbH &amp; Co. KG</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>Knollstrasse</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>67061 Ludwigshafen</span></p>

<p class=MsoNormal><span lang=EN-GB>Germany</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
color:black;text-transform:uppercase'>8. MARKETING AUTHORISATION NUMBER(S)</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
color:black;text-transform:uppercase'>&nbsp;</span></b></p>

<p class=MsoNormal><span style='color:black'>EU/1/96/016/009</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
color:black;text-transform:uppercase'>9. Date of first
authorisation/renewal of THE authorisation</span></b></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Date of first authorisation: 26 August 1996</p>

<p class=MsoNormal>Date of latest renewal: 26 August 2006</p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
color:black;text-transform:uppercase'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
color:black;text-transform:uppercase'>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-family:"Times New Roman Bold",serif;color:black;text-transform:
uppercase'>10. Date of revision of the text</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>Detailed information on this product is available on the
website of the European Medicines Agency</span></p>

<p class=MsoNormal><a href="http://www.ema.europa.eu">http://www.ema.europa.eu</a></p>

<b><span style='font-size:11.0pt;font-family:"Times New Roman Bold",serif;
color:blue;text-transform:uppercase'><br clear=all style='page-break-before:
always'>
</span></b>

<p class=EMEAHeading1 style='margin:0in'><span lang=EN-GB>1. Name of the
medicinal product </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>Norvir 100&nbsp;mg film-coated tablets</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><u><span style='text-decoration:none'>&nbsp;</span></u></p>

<p class=EMEAHeading1 style='margin:0in'><span lang=EN-GB>2. Qualitative
and quantitative composition </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>Each film-coated tablet contains 100&nbsp;mg ritonavir. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>For the full list of excipients, see section 6.1. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=EMEAHeading1 style='margin:0in'><span lang=EN-GB>3. Pharmaceutical
Form<i> </i></span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>Film-coated tablet.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>White, oval, debossed with [Abbott logo] and NK. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=EMEAHeading1 style='margin:0in'><span lang=EN-GB>4. Clinical
Particulars</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2SPCEmpty style='margin-bottom:0in'><span lang=EN-GB>4.1 Therapeutic
indications</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>Ritonavir is indicated in combination with other
antiretroviral agents for the treatment of HIV-1 infected patients (adults and
children of 2 years of age and older).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB>4.2 Posology
and method of administration</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>Ritonavir should be administered by physicians who are
experienced in the treatment of HIV infection.</p>

<p class=MsoHeader>&nbsp;</p>

<p class=MsoHeader>Ritonavir film-coated tablets are administered orally and
should be ingested with food (see section 5.2).</p>

<p class=MsoHeader>&nbsp;</p>

<p class=MsoHeader>Norvir film-coated tablets should be swallowed whole and not
chewed, broken or crushed.</p>

<p class=MsoHeader>&nbsp;</p>

<p class=MsoHeader><u>Posology</u></p>

<p class=MsoHeader>&nbsp;</p>

<p class=MsoNormal><i>Ritonavir dosed as a pharmacokinetic enhancer </i></p>

<p class=MsoNormal><i>&nbsp;</i></p>

<p class=MsoNormal><span style='font-size:11.5pt;color:black'>When ritonavir is
used as a pharmacokinetic enhancer with other protease inhibitors the Summary
of Product Characteristics for the particular protease inhibitor must be
consulted.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>The following HIV-1 protease inhibitors have been approved
for use with ritonavir as a pharmacokinetic enhancer at the noted doses. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=EMEAHeadingItalic style='margin:0in'><span lang=EN-GB>Adults</span></p>

<p class=MsoNormal style='margin-left:28.35pt'>Amprenavir 600&nbsp;mg twice
daily with ritonavir 100&nbsp;mg twice daily.</p>

<p class=MsoNormal style='margin-left:28.35pt'>Atazanavir 300&nbsp;mg once
daily with ritonavir 100&nbsp;mg once daily.</p>

<p class=MsoNormal style='margin-left:28.35pt'>Fosamprenavir 700&nbsp;mg twice
daily with ritonavir 100&nbsp;mg twice daily.</p>

<p class=MsoNormal style='margin-left:28.35pt'>Lopinavir co&#8209;formulated
with ritonavir (lopinavir/ritonavir) 400&nbsp;mg/100&nbsp;mg or 800&nbsp;mg/200&nbsp;mg.</p>

<p class=MsoNormal style='margin-left:28.35pt'>Saquinavir 1000&nbsp;mg twice
daily with ritonavir 100&nbsp;mg twice daily in ART experienced patients.
Initiate treatment with <span class=msoins0><span lang=EN-GB>saquinavir 500&nbsp;mg
twice daily with ritonavir 100&nbsp;mg twice daily for the first 7 days, then
saquinavir 1000&nbsp;mg twice daily with ritonavir 100&nbsp;mg twice daily</span></span>
in ART-nave patients<span class=msoins0><span lang=EN-GB>.</span></span></p>

<p class=MsoNormal style='margin-left:28.35pt'>Tipranavir 500&nbsp;mg twice
daily with ritonavir 200&nbsp;mg twice daily. Tipranavir with ritonavir should
not be used in treatment-nave patients.</p>

<p class=EMEANormal1 style='margin-left:27.5pt;text-indent:-27.5pt'> Darunavir
600&nbsp;mg twice daily with ritonavir 100&nbsp;mg twice daily in antiretroviral
treatment. (ART) experienced patients. Darunavir 800&nbsp;mg once daily with
ritonavir 100&nbsp;mg once daily<u><span style='color:blue'> </span></u>may be
used in some ART experienced patients. Refer to the darunavir Summary of
Product Characteristics for further information on once daily dosing in ART
experienced patients.</p>

<p class=EMEANormal style='margin-left:27.5pt;text-indent:-27.5pt'> Darunavir
800&nbsp;mg once daily with ritonavir 100&nbsp;mg once daily in ART-nave
patients.</p>

<p class=MsoNormal style='margin-left:28.35pt'>&nbsp;</p>

<p class=MsoNormal><i>Children and adolescents</i></p>

<p class=MsoNormal>Ritonavir is recommended for children 2 years of age and
older. For further dosage recommendations, refer to the product information of
other Protease Inhibitors approved for co-administration with ritonavir. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><u><span style='color:black'>Special populations</span></u></p>

<p class=MsoNormal><u><span style='color:black'><span style='text-decoration:
 none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><i><span style='color:black'>Renal impairment</span></i></p>

<p class=MsoNormal><span style='color:black'>As ritonavir is primarily
metabolised by the liver, ritonavir may be appropriate for use with caution as
a pharmacokinetic enhancer in patients with renal insufficiency depending on
the specific protease inhibitor with which it is co&#8209;administered. </span>However,
since the renal clearance of ritonavir is negligible, the decrease in the total
body clearance is not expected in patients with renal impairment. <span
style='color:black'>For specific dosing information in patients with renal
impairment, refer to the Summary of Product Characteristics (SPC) of the co&#8209;administered
protease inhibitor.</span> </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><i><span style='color:black'>Hepatic impairment</span></i></p>

<p class=MsoNormal>Ritonavir should not be given as a pharmacokinetic enhancer
to patients with decompensated liver disease, (see section 4.3). In the
absence of pharmacokinetic studies in patients with stable severe hepatic
impairment (Child Pugh Grade C) without decompensation, caution should be
exercised when ritonavir is used as a pharmacokinetic enhancer as increased
levels of the co-administered PI may occur.<span style='color:#CC99FF'> </span><span
style='color:black'>Specific recommendations for use of ritonavir as a
pharmacokinetic enhancer in patients with hepatic impairment are dependent on
the protease inhibitor with which it is co&#8209;administered. The SPC of the
co&#8209;administered PI should be reviewed for specific dosing information in
this patient population. </span></p>

<p class=MsoNormal>&nbsp;</p>

<h5><i><span style='text-decoration:none'>Ritonavir dosed as an antiretroviral
agent</span></i></h5>

<p class=MsoNormal><i>&nbsp;</i></p>

<p class=MsoNormal><i>Adults</i></p>

<p class=MsoNormal>The recommended dose of Norvir film-coated tablets is
600&nbsp;mg (6 tablets) twice daily (total of 1200&nbsp;mg per day) by mouth.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Gradually increasing the dose of ritonavir when initiating
therapy may help to improve tolerance. Treatment should be initiated at
300&nbsp;mg (3 tablets) twice daily for a period of three days and increased by
100&nbsp;mg (1&nbsp;tablet) twice daily increments up to 600&nbsp;mg twice daily
over a period of no longer than 14&nbsp;days. Patients should not remain on
300&nbsp;mg twice daily for more than 3&nbsp;days.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><i>Children and adolescents (2 years of age and above)</i></p>

<p class=MsoNormal>The recommended dosage of Norvir in children is
350&nbsp;mg/m<sup></sup> by mouth twice daily and should not exceed 600&nbsp;mg
twice daily. Norvir should be started at 250&nbsp;mg/m<sup></sup> and
increased at 2 to 3 day intervals by 50&nbsp;mg/m<sup></sup> twice daily
(please refer to the Norvir 100&nbsp;mg powder for oral suspension Summary of
Product Characteristics).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>For older children it may be feasible to substitute tablets
for the maintenance dose of the powder for oral suspension. </p>

<p class=MsoEndnoteText>&nbsp;</p>

<p class=pedtablecenter style='page-break-after:avoid'><span lang=EN-GB>Dosage
conversion from powder for oral suspension to tablets for children</span></p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='margin-left:5.4pt;border-collapse:collapse'>
 <tr>
  <td width=303 valign=top style='width:227.1pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b>Powder for oral
  suspension dose</b></p>
  </td>
  <td width=309 valign=top style='width:231.95pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b>Tablet dose</b></p>
  </td>
 </tr>
 <tr>
  <td width=303 valign=top style='width:227.1pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>176 mg (17.6 ml) twice
  daily</p>
  </td>
  <td width=309 valign=top style='width:231.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>200 mg in the morning and
  200 mg in the evening</p>
  </td>
 </tr>
 <tr>
  <td width=303 valign=top style='width:227.1pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>262.5 mg (26.4 ml) twice
  daily</p>
  </td>
  <td width=309 valign=top style='width:231.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>300 mg in the morning and
  300 mg in the evening</p>
  </td>
 </tr>
 <tr>
  <td width=303 valign=top style='width:227.1pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>350 mg (35.0 ml) twice
  daily</p>
  </td>
  <td width=309 valign=top style='width:231.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>400 mg in the morning and
  300 mg in the evening </p>
  </td>
 </tr>
 <tr>
  <td width=303 valign=top style='width:227.1pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>438 mg (43.8 ml) twice
  daily</p>
  </td>
  <td width=309 valign=top style='width:231.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>500 mg in the morning and
  400 mg in the evening</p>
  </td>
 </tr>
 <tr>
  <td width=303 valign=top style='width:227.1pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>526 mg (52.6 ml) twice
  daily</p>
  </td>
  <td width=309 valign=top style='width:231.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>500 mg in the morning and
  500 mg in the evening</p>
  </td>
 </tr>
</table>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Norvir is not recommended in children below 2 years of age
due to lack of data on safety and efficacy.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><u>Special populations</u></p>

<p class=MsoNormal>&nbsp;</p>

<p class=EMEAHeadingUI style='margin:0in'><span lang=EN-GB style='text-decoration:
none'>Elderly</span></p>

<p class=EMEAHeadingUI style='margin:0in'><span lang=EN-GB style='font-style:
normal;text-decoration:none'>Pharmacokinetic data indicated that no dose
adjustment is necessary for elderly patients (see section 5.2).</span></p>

<p class=MsoNormal><i>&nbsp;</i></p>

<p class=MsoNormal><i>Renal impairment</i></p>

<p class=MsoNormal>Currently, there are no data specific to this patient
population and therefore specific dosage recommendations cannot be made. <span
lang=EN-GB>The renal clearance of ritonavir is negligible therefore; a decrease
in the total body clearance is not expected in patients with renal impairment.
</span>Because ritonavir is highly protein bound it is unlikely that it will be
significantly removed by haemodialysis or peritoneal dialysis.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><i>Hepatic impairment</i></p>

<p class=MsoNormal>Ritonavir<i> </i>is principally metabolised and eliminated
by the liver. Pharmacokinetic data indicate that no dose adjustment is
necessary in patients with mild to moderate hepatic impairment (see section
5.2). Ritonavir must not be given to patients with severe hepatic impairment
(see section 4.3). </p>

<p class=MsoNormal><i><span style='background:lime'>&nbsp;</span></i></p>

<p class=MsoNormal><i>Paediatric population</i></p>

<p class=MsoNormal>The safety and efficacy of Norvir in childred aged below 2
years has not been established. Currently available data are described in
sections 5.1 and 5.2 but no recommendation on a posology can be made.</p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in;page-break-after:avoid'><span
lang=EN-GB>4.3 Contraindications</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>Hypersensitivity to the active substance or to any of the
excipients listed in section 6.1. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>When ritonavir is used as a pharmacokinetic enhancer of
other PIs, consult the Summary of Product Characteristics of the co&#8209;administered
protease inhibitor for contraindications.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Ritonavir should not be given as a pharmacokinetic enhancer
or as an antiretroviral agent to patients with decompensated liver disease. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><i>In vitro</i> and <i>in vivo</i> studies have demonstrated
that ritonavir is a potent inhibitor of CYP3A&#8209; and CYP2D6&#8209; mediated
biotransformations. The following medicines are contraindicated when used with
ritonavir and unless otherwise noted, the contraindication is based on the
potential for ritonavir to inhibit metabolism of the co&#8209;administered
medicinal product, resulting in increased exposure to the co&#8209;administered
medicinal product and risk of clinically significant adverse effects.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>The enzyme-modulating effect of ritonavir may be dose
dependent. For some products, contraindications may be more relevant when
ritonavir is used as an antiretroviral agent than when ritonavir is used as a
pharmacokinetic enhancer (e.g. rifabutin and voriconazole):</p>

<p class=MsoNormal>&nbsp;</p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.1pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in'><b>Medicinal Product Class</b></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in'><b>Medicinal Products within Class</b></p>
  </td>
  <td width=310 valign=top style='width:232.25pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoHeading7 style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in'>Rationale</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=3 valign=top style='width:464.45pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoHeading7 style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in'>Concomitant medicinal product levels increased or
  decreased</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='font-family:Symbol'>a</span><sub>1</sub>-Adrenoreceptor
  Antagonist</p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Alfuzosin</p>
  </td>
  <td width=310 valign=top style='width:232.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Increased plasma concentrations of alfuzosin which may
  lead to severe hypotension (see section 4.5).</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Analgesics</p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Pethidine, piroxicam, propoxyphne</p>
  </td>
  <td width=310 valign=top style='width:232.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Increased plasma concentrations of norpethidine, piroxicam
  and propoxyphene. Thereby, increasing the risk of serious respiratory
  depression or haematologic abnormalities, or other serious adverse effects
  from these agents.</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Antianginal</p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=ES-MX>Ranolazine</span></p>
  </td>
  <td width=310 valign=top style='width:232.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Increased plasma concentrations of ranolazine which may
  increase the potential for serious and/or life-threatening reactions (see
  section 4.5).</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 rowspan=2 valign=top style='width:116.1pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Anticancer</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Neratinib</p>
  </td>
  <td width=310 valign=top style='width:232.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Increased plasma concentrations of neratinib which may increase
  the potential for serious and/or life-threatening reactions including
  hepatotoxicity (see section 4.5).</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Venetoclax</p>
  </td>
  <td width=310 valign=top style='width:232.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Increased plasma concentrations of venetoclax. Increased
  risk of tumor lysis syndrome at the dose initiation and during the dose&#8209;titration
  phase (see section 4.5).</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Antiarrhythmics</p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=ES-MX>Amiodarone, bepridil, dronedarone, encainide,
  flecainide, propafenone, quinidine</span></p>
  <p class=MsoNormal><span lang=ES-MX>&nbsp;</span></p>
  </td>
  <td width=310 valign=top style='width:232.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Increased plasma concentrations of amiodarone, bepridil, dronedarone,
  encainide, flecainide, propafenone, quinidine. Thereby, increasing the risk
  of arrhythmias or other serious adverse effects from these agents.</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Antibiotic</p>
  </td>
  <td width=155 valign=top style='width:116.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Fusidic Acid</p>
  </td>
  <td width=310 valign=top style='width:232.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Increased plasma concentrations of fusidic acid and
  ritonavir.</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.1pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=HeaderText><span lang=EN-GB>Antifungal</span></p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Voriconazole</p>
  </td>
  <td width=310 valign=top style='width:232.25pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Concomitant use of ritonavir (400&nbsp;mg twice daily and
  more) and voriconazole is contraindicated due to a reduction in voriconazole
  plasma concentrations and possible loss of effect (see section 4.5).</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Antihistamines</p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Astemizole, terfenadine</p>
  </td>
  <td width=310 valign=top style='width:232.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Increased plasma concentrations of astemizole and terfenadine.
  Thereby, increasing the risk of serious arrhythmias from these agents.</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Anti-gout</p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Colchicine</p>
  </td>
  <td width=310 valign=top style='width:232.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Potential for serious and/or life&#8209;threatening
  reactions in patients with renal and/or hepatic impairment (see sections 4.4
  and 4.5).</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Antimycobacterial</p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Rifabutin</p>
  </td>
  <td width=310 valign=top style='width:232.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Concomitant use of ritonavir (500&nbsp;mg twice daily) dosed
  as an antiretroviral agent and rifabutin due to an increase of rifabutin
  serum concentrations and risk of adverse reactions including uveitis (see
  section 4.4). Recommendations regarding use of ritonavir dosed as a
  pharmacokinetic enhancer with rifabutin are noted in section 4.5. </p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 rowspan=3 valign=top style='width:116.1pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Antipsychotics/ Neuroleptics</p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Lurasidone</p>
  </td>
  <td width=310 valign=top style='width:232.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Increased plasma concentrations of lurasidone which may
  increase the potential for serious and/or life-threatening reactions (see
  section 4.5).</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Clozapine, pimozide</p>
  </td>
  <td width=310 valign=top style='width:232.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Increased plasma concentrations of clozapine and
  pimozide. Thereby, increasing the risk of serious haematologic
  abnormalities, or other serious adverse effects from these agents.</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Quetiapine</p>
  </td>
  <td width=310 valign=top style='width:232.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Increased plasma concentrations of quetiapine which may
  lead to coma. The concomitant administration with quetiapine is
  contraindicated (see section 4.5).</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Ergot Derivatives</p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Dihydroergotamine, ergonovine, ergotamine,
  methylergonovine</p>
  </td>
  <td width=310 valign=top style='width:232.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Increased plasma concentrations of ergot derivatives
  leading to acute ergot toxicity, including vasospasm and ischaemia.</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>GI motility agent</p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Cisapride</p>
  </td>
  <td width=310 valign=top style='width:232.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Increased plasma concentrations of cisapride. Thereby,
  increasing the risk of serious arrhythmias from this agent.</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=3 valign=top style='width:464.45pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span style='color:black'>Lipid-modifying agents</span></p>
  <p class=MsoNormal>&nbsp;</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>HMG Co-A Reductase Inhibitors</p>
  </td>
  <td width=155 valign=top style='width:116.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Lovastatin, simvastatin</p>
  </td>
  <td width=310 valign=top style='width:232.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Increased plasma concentrations of lovastatin and
  simvastatin; thereby, increasing the risk of myopathy including
  rhabdomyolysis (see section 4.5).</p>
  <p class=MsoNormal>&nbsp;</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Microsomal triglyceride transfer protein (MTTP) inhibitor</p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Lomitapide</p>
  </td>
  <td width=310 valign=top style='width:232.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Increased plasma concentrations of lomitapide (see section
  4.5).</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 rowspan=3 valign=top style='width:116.1pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>PDE5 inhibitor</p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Avanafil</p>
  </td>
  <td width=310 valign=top style='width:232.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Increased plasma concentrations of avanafil (see section
  4.4. and 4.5).</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Sildenafil </p>
  </td>
  <td width=310 valign=top style='width:232.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Contraindicated when used for the treatment of pulmonary
  arterial hypertension (PAH) only. Increased plasma concentrations of
  sildenafil. Thereby, increasing the potential for sildenafil-associated
  adverse events (which include hypotension and syncope). See section 4.4 and
  section 4.5 for co&#8209;administration of sildenafil in patients with
  erectile dysfunction.</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=PT-BR>Vardenafil</span></p>
  </td>
  <td width=310 valign=top style='width:232.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Increased plasma concentrations of vardenafil (see section
  4.4. and 4.5).</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Sedatives/hypnotics</p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=PT-BR>Clorazepate, diazepam, estazolam,
  flurazepam, oral midazolam </span><span lang=PT-BR>and triazolam</span></p>
  </td>
  <td width=310 valign=top style='width:232.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Increased plasma concentrations of clorazepate, diazepam,
  estazolam, flurazepam, oral midazolam and triazolam. Thereby, increasing the
  risk of extreme sedation and respiratory depression from these agents. (For
  caution on parenterally administered midazolam, see section 4.5.).</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=3 valign=top style='width:464.45pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in'><b>Ritonavir medicinal product level decreased</b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Herbal Preparation</p>
  </td>
  <td width=155 valign=top style='width:116.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>St. Johns Wort</p>
  </td>
  <td width=310 valign=top style='width:232.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Herbal preparations containing St Johns wort (<i>Hypericum
  perforatum)</i> due to the risk of decreased plasma concentrations and
  reduced clinical effects of ritonavir (see section 4.5).</p>
  </td>
 </tr>
</table>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in;page-break-after:avoid'><span
lang=EN-GB>4.4 Special warnings and precautions for use</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'>Ritonavir is not a cure for
HIV-1 infection or AIDS. Patients receiving Ritonavir or any other
antiretroviral therapy may continue to develop opportunistic infections and
other complications of HIV-1 infection. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>While effective viral suppression with antiretroviral
therapy has been proven to substantially reduce the risk of sexual
transmission, a residual risk cannot be excluded. Precautions to prevent
transmission should be taken in accordance with national guidelines.</p>

<p class=MsoHeader>&nbsp;</p>

<p class=EMEANormal1><span lang=EN-GB>When ritonavir is used as a pharmacokinetic
enhancer with other PIs, full details on the warnings and precautions relevant
to that particular PI should be considered, therefore the Summary of Product
Characteristics for the particular PI must be consulted.</span></p>

<p class=EMEANormal1><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoHeader style='page-break-after:avoid'><i>Ritonavir dosed as an
antiretroviral agent or as a pharmacokinetic enhancer </i></p>

<p class=MsoHeader style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><u>Patients with chronic
diarrhoea or malabsorption</u></p>

<p class=MsoNormal style='page-break-after:avoid'>Extra monitoring is
recommended when diarrhoea occurs. The relatively high frequency of diarrhoea
during treatment with ritonavir may compromise the absorption and efficacy (due
to decreased compliance) of ritonavir or other concurrent medicinal products.
Serious persistent vomiting and/or diarrhoea associated with ritonavir use
might also compromise renal function. It is advisable to monitor renal function
in patients with renal function impairment.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><u>Haemophilia</u></p>

<p class=MsoNormal>There have been reports of increased bleeding, including
spontaneous skin haematomas and haemarthroses, in haemophiliac patients type A
and B treated with protease inhibitors. In some patients additional factor
VIII was given. In more than a half of the reported cases, treatment with
protease inhibitors was continued or reintroduced if treatment had been
discontinued. A causal relationship has been evoked, although the mechanism of
action has not been elucidated. Haemophiliac patients should therefore be made
aware of the possibility of increased bleeding.</p>

<p class=MsoHeader>&nbsp;</p>

<p class=MsoNormal><u><span lang=EN-GB>Weight and metabolic parameters: </span></u></p>

<p class=MsoNormal><span lang=EN-GB>An increase in weight and in levels of
blood lipids and glucose may occur during antiretroviral therapy. Such changes
may in part be linked to disease control and life style. For lipids, there is
in some cases evidence for a treatment effect, while for weight gain there is
no strong evidence relating this to any particular treatment. For monitoring of
blood lipids and glucose, reference is made to established HIV treatment
guidelines. Lipid disorders should be managed as clinically appropriate.</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><u><span style='color:black'>Pancreatitis</span></u></p>

<p class=MsoNormal>Pancreatitis should be considered if clinical symptoms
(nausea, vomiting, abdominal pain) or abnormalities in laboratory values (such
as increased serum lipase or amylase values) suggestive of pancreatitis should
occur. Patients who exhibit these signs or symptoms should be evaluated and
Norvir therapy should be discontinued if a diagnosis of pancreatitis is made
(see section 4.8).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=EMEANormal1><u><span lang=EN-GB>Immune Reconstitution Inflammatory Syndrome</span></u></p>

<p class=EMEANormal1><span lang=EN-GB>In HIV-infected patients with severe
immune deficiency at the time of institution of combination antiretroviral
therapy (CART), an inflammatory reaction to asymtomatic or residual
opportunistic pathogens may arise and cause serious clinical conditions, or
aggravation of symptoms. Typically, such reactions have been observed within
the first few weeks or months of initiation of CART. Relevant examples are cytomegalovirus
retinitis, generalised and/or focal mycobacterial infections, and Pneumocystis
jiroveci pneumonia. Any inflammatory symptoms should be evaluated and
treatment instituted when necessary.</span></p>

<p class=EMEANormal1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal1><span lang=EN-GB>Autoimmune disorders (such as Graves
disease and autoimmune hepatitis) have also been reported to occur in the
setting of immune reconstitution; however, the reported time to onset is more
variable and can occur many months after initiation of treatment.</span></p>

<p class=MsoHeader>&nbsp;</p>

<h2 align=left style='text-align:left;line-height:normal'><u><span
style='font-size:11.0pt;font-weight:normal'>Liver disease</span></u></h2>

<h2 align=left style='text-align:left;line-height:normal'><span
style='font-size:11.0pt;font-weight:normal'>Ritonavir should not be given to
patients with decompensated liver disease (see section 4.2). </span><span
style='font-size:11.0pt;font-weight:normal'></span><span style='font-size:
11.0pt;font-weight:normal'>Patients with chronic hepatitis B or C and treated
with combination antiretroviral therapy are at an increased risk for severe and
potentially fatal hepatic adverse reactions. In case of concomitant antiviral
therapy for hepatitis B or C, please refer to the relevant product information
for these medicinal products.</span></h2>

<p class=MsoHeader>&nbsp;</p>

<p class=MsoNormal><span style='color:black'>Patients with pre-existing liver
dysfunction including chronic active hepatitis have an increased frequency of
liver function abnormalities during combination antiretroviral therapy and
should be monitored according to standard practice. If there is evidence of
worsening liver disease in such patients, interruption or discontinuation of
treatment must be considered.</span></p>

<p class=MsoNormal><i>&nbsp;</i></p>

<p class=MsoNormal style='page-break-after:avoid'><u>Renal disease</u></p>

<p class=MsoNormal style='page-break-after:avoid'>Since the renal clearance of
ritonavir is negligible, the decrease in the total body clearance is not
expected in patients with renal impairment (see also section 4.2).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>Renal failure, renal impairment, elevated
creatinine, hypophosphataemia and proximal tubulopathy (including Fanconi
syndrome) have been reported with the use of tenofovir disoproxil fumarate (DF)
in clinical practice (see section 4.8).</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><u>Osteonecrosis</u></p>

<p class=MsoNormal>Although the aetiology is considered to be multifactorial
(including corticosteroid use, alcohol consumption, severe immunosuppression,
higher body mass index), cases of osteonecrosis have been reported in patients
with advanced HIV&#8209;disease and/or long&#8209;term exposure to combination
antiretroviral therapy (CART). Patients should be advised to seek medical
advice if they experience joint aches and pain, joint stiffness or difficulty
in movement.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=EMEANormal><u><span lang=EN-GB>PR interval prolongation</span></u></p>

<p class=EMEANormal><span lang=EN-GB>Ritonavir has been shown to cause modest
asymptomatic prolongation of the PR interval in some healthy adult subjects.</span><span
lang=EN-GB> </span><span lang=EN-GB>Rare reports of 2<sup>nd</sup> or 3<sup>rd</sup>
degree atrioventricular block in patients with underlying structural heart
disease and pre</span>&#8209;<span lang=EN-GB>existing conduction system
abnormalities or in patients receiving medicinal products known to prolong the
PR interval (such as verapamil or atazanavir) have been reported in patients
receiving ritonavir. </span><span lang=EN-GB></span><span lang=EN-GB>Norvir
should be used with caution in such patients</span> (see section 5.1).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=EMEANormal1><u><span lang=EN-GB>Interactions with other medicinal
products</span></u></p>

<p class=MsoNormal><i>&nbsp;</i></p>

<p class=EMEANormal1><i><span lang=EN-GB>Ritonavir dosed as an antiretroviral
agent</span></i></p>

<p class=EMEANormal1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal1><span lang=EN-GB>The following warnings and precautions
should be considered when ritonavir is used as an antiretroviral agent. When
ritonavir is used as a pharmacokinetic enhancer at the 100&nbsp;mg and
200&nbsp;mg level it cannot be assumed that the following warnings and
precautions will also apply. <span style='color:black'>When ritonavir is used
as a pharmacokinetic enhancer, full details on the warnings and precautions
relevant to that particular PI must be considered, therefore the Summary of
Product Characteristics, section&nbsp;4.4, for the particular PI must be
consulted to determine if the information below is applicable.</span></span></p>

<p class=MsoNormal><i>&nbsp;</i></p>

<p class=MsoNormal><i>PDE5 inhibitors</i></p>

<p class=MsoNormal>Particular caution should be used when prescribing sildenafil
or tadalafil for the treatment of erectile dysfunction in patients receiving
ritonavir. Co-administration of ritonavir with these medicinal products is
expected to substantially increase their concentrations and may result in
associated adverse reactions such as hypotension and prolonged erection (see
section 4.5). Concomitant use of avanafil or vardenafil with ritonavir is
contraindicated (see section 4.3). Concomitant use of sildenafil with
ritonavir is contraindicated in pulmonary arterial hypertension patients (see
section 4.3).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><i>HMG-CoA reductase
inhibitors</i></p>

<p class=MsoNormal style='page-break-after:avoid'>The HMG-CoA reductase
inhibitors simvastatin and lovastatin are highly dependent on CYP3A for
metabolism, thus concomitant use of ritonavir with simvastatin or lovastatin is
not recommended due to an increased risk of myopathy including rhabdomyolysis.
Caution must also be exercised and reduced doses should be considered if
ritonavir is used concurrently with atorvastatin, which is metabolised to a
lesser extent by CYP3A. While rosuvastatin elimination is not dependent on
CYP3A, an elevation of rosuvastatin exposure has been reported with ritonavir
co-administration. The mechanism of this interaction is not clear, but may be
the result of transporter inhibition. When used with ritonavir dosed as a
pharmacokinetic enhancer or as an antiretroviral agent, the lowest doses of
atorvastatin or rosuvastatin should be administered. The metabolism of
pravastatin and fluvastatin is not dependent of CYP3A, and interactions are not
expected with ritonavir. If treatment with an HMG-CoA reductase inhibitor is
indicated, pravastatin or fluvastatin is recommended (see section 4.5).</p>

<p class=EMEANormal1><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=EMEANormal1 style='page-break-after:avoid'><i><span lang=EN-GB>Colchicine</span></i></p>

<p class=EMEANormal1 style='page-break-after:avoid'><span lang=EN-GB>Life-threatening
and fatal drug interactions have been reported in patients treated with colchicine
and strong inhibitors of CYP3A like ritonavir (see sections 4.3 and 4.5).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><i><span lang=EN-GB>Digoxin</span></i></p>

<p class=EMEANormal><span lang=EN-GB>Particular caution should be used when
prescribing ritonavir in patients taking digoxin since co&#8209;administration
of ritonavir with digoxin is expected to increase digoxin levels. The
increased digoxin levels may lessen over time (see section 4.5).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>In patients who are already taking digoxin
when ritonavir is introduced, the digoxin dose should be reduced to one-half of
the patients normal dose and patients need to be followed more closely than
usual for several weeks after initiating co-administration of ritonavir and
digoxin.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>In patients who are already taking ritonavir when digoxin is
introduced, digoxin should be introduced more gradually than usual. Digoxin levels
should be monitored more intensively than usual during this period, with dose
adjustments made, as necessary, based on clinical, electrocardiographic and
digoxin level findings. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><i><span style='color:black'>Ethinyl
estradiol</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span style='color:black'>Barrier
or other non-hormonal methods of contraception should be considered when
administering ritonavir at therapeutic or low doses as ritonavir is likely to
reduce the effect and change the uterine bleeding profile when co-administered
with estradiol-containing contraceptives.</span></p>

<p class=MsoHeader>&nbsp;</p>

<p class=EMEANormal><i><span lang=EN-GB>Glucocorticoids</span></i></p>

<p class=EMEANormal><span lang=EN-GB>Concomitant use of ritonavir and
fluticasone or other glucocorticoids that are metabolised by CYP3A4 is not
recommended unless the potential benefit of treatment outweighs the risk of
systemic corticosteroid effects, including Cushings syndrome and adrenal
suppression (see section 4.5).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i>Trazodone</i></p>

<p class=MsoNormal>Particular caution should be used when prescribing ritonavir
in patients using trazodone. Trazodone is a CYP3A4 substrate and
co-administration of ritonavir is expected to increase trazodone levels.
Adverse reactions of nausea, dizziness, hypotension and syncope have been
observed in single dose interaction studies in healthy volunteers (see section
4.5)</p>

<p class=MsoNormal>&nbsp;</p>

<p class=EMEANormal1 style='page-break-after:avoid'><i><span lang=EN-GB>Rivaroxaban</span></i></p>

<p class=EMEANormal1 style='page-break-after:avoid'><span lang=EN-GB>It is not
recommended to use ritonavir in patients receiving rivaroxaban, due to the risk
of increased bleeding (see section 4.5).</span></p>

<p class=EMEANormal1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal1><i><span lang=EN-GB>Riociguat</span></i></p>

<p class=EMEANormal1><span lang=EN-GB>The concomitant use of ritonavir is not
recommended due to potential increase in riociguat exposure (see section 4.5).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal1><i><span lang=EN-GB>Vorapaxar</span></i></p>

<p class=EMEANormal1><span lang=EN-GB>The concomitant use of ritonavir is not
recommended due to potential increase in vorapaxar exposure (see section 4.5).</span></p>

<p class=EMEANormal1><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i>Bedaquiline</i></p>

<p class=MsoNormal style='page-break-after:avoid'>Strong CYP3A4 inhibitors such
as protease inhibitors may increase bedaquiline exposure which could
potentially increase the risk of bedaquiline-related adverse reactions.
Therefore, combination of bedaquiline with ritonavir should be avoided. However,
if the benefit outweighs the risk, co-administration of bedaquiline with
ritonavir must be done with caution. More frequent electrocardiogram monitoring
and monitoring of transaminases is recommended (see section 4.5 and refer to
the bedaquiline Summary of Product Characteristics).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><i>Delamanid</i></p>

<p class=MsoNormal style='page-break-after:avoid'>Co&#8209;administration of
delamanid with a strong inhibitor of CYP3A (ritonavir) may increase exposure to
delamanid metabolite, which has been associated with QTc prolongation.
Therefore, if co&#8209;administration of delamanid with ritonavir is considered
necessary, very frequent ECG monitoring throughout the full delamanid treatment
period is recommended (see section 4.5 and refer to the delamanid Summary of
Product Characteristics). </p>

<p class=MsoNormal>&nbsp;</p>

<p class=EMEAHeadingItalic style='margin:0in'><span lang=EN-GB>Ritonavir dosed
as a pharmacokinetic enhancer</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal1><span lang=EN-GB>The interaction profiles of HIV-protease
inhibitors, co-administered with low dose ritonavir, are dependant on the
specific co&#8209;administered protease inhibitor. </span></p>

<p class=EMEANormal1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal1><span lang=EN-GB>For a description of the mechanisms and
potential mechanisms contributing to the interaction profile of the PIs, see
section 4.5. Please also review the <span style='color:black'>Summary of
Product Characteristics for the particular boosted PI.</span></span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><i><span lang=EN-GB>Saquinavir</span></i></p>

<p class=EMEANormal><span lang=EN-GB>Doses of ritonavir higher than 100&nbsp;mg
twice daily should not be used. Higher doses of ritonavir have been shown to
be associated with an increased incidence of adverse reactions. Co&#8209;administration
of saquinavir and ritonavir has led to severe adverse reactions, mainly
diabetic ketoacidosis and liver disorders, especially in patients with
pre-existing liver disease. </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Saquinavir/ritonavir should not be given
together with rifampicin, due to the risk of severe hepatotoxicity (presenting
as increased hepatic transaminases) if the three medicines are given together
(see section 4.5).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><i><span lang=EN-GB>Tipranavir</span></i></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Co-administration
of tipranavir with 200&nbsp;mg of ritonavir has been associated with reports of
clinical hepatitis and hepatic decompensation including some fatalities. Extra
vigilance is warranted in patients with chronic hepatitis B or hepatitis C
co-infection, as these patients have an increased risk of hepatotoxicity. </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Doses of ritonavir lower than 200&nbsp;mg
twice daily should not be used as they might alter the efficacy profile of the
combination. </span></p>

<p class=EMEANormal><span lang=EN-GB></span></p>

<p class=EMEANormal style='page-break-after:avoid'><i><span lang=EN-GB>Fosamprenavir</span></i></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Co-administration
of fosamprenavir with ritonavir in doses greater than 100&nbsp;mg twice daily
has not been clinically evaluated. The use of higher ritonavir doses might
alter the safety profile of the combination and therefore is not recommended.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal1><i><span lang=EN-GB>Atazanavir</span></i></p>

<p class=EMEANormal1><span lang=EN-GB>Co-administration of atazanavir with
ritonavir at doses greater than 100&nbsp;mg once daily has not been clinically
evaluated. The use of higher ritonavir doses may alter the safety profile of
atazanavir (cardiac effects, hyperbilirubinemia) and therefore is not
recommended. Only when atazanavir with ritonavir is co-administered with
efavirenz, a dose increase of ritonavir to 200mg once daily could be
considered. In this instance, close clinical monitoring is warranted. Refer to
the Summary of Product Characteristics for atazanavir for further details.</span></p>

<p class=EMEANormal1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in;page-break-after:avoid'><span
lang=EN-GB>4.5 Interaction with other medicinal products and other forms of
interaction</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<h1><span style='font-weight:normal'>Ritonavir dosed as a pharmacokinetic
enhancer or as an antiretroviral agent</span></h1>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'>Ritonavir has a high affinity
for several cytochrome P450 (CYP) isoforms and may inhibit oxidation with the
following ranked order: CYP3A4 &gt;&nbsp;CYP2D6. Co-administration of ritonavir
and medicinal products primarily metabolised by CYP3A may result in increased
plasma concentrations of the other medicinal product, which could increase or
prolong its therapeutic and adverse effects. For selected medicinal products (e.g.
alprazolam) the inhibitory effects of ritonavir on CYP3A4 may decrease over
time. Ritonavir also has a high affinity for P&#8209;glycoprotein and may
inhibit this transporter. The inhibitory effect of ritonavir (with or without
other protease inhibitors) on P&#8209;gp activity may decrease over time (e.g.
digoxin and fexofenadine-see table Ritonavir effects on non-antiretroviral
medicinal products below). Ritonavir may induce glucuronidation and oxidation
by CYP1A2, CYP2C8, CYP2C9 and CYP2C19 thereby increasing the biotransformation
of some medicinal products metabolised by these pathways, and may result in
decreased systemic exposure to such medicinal products, which could decease or
shorten their therapeutic effect. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Important information regarding medicinal product
interactions when ritonavir is used as a pharmacokinetic enhancer is also
contained in the Summary of Product Characteristics of the co&#8209;administered
protease inhibitor.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoBodyText2 align=left style='text-align:left'><u>Medicinal products
that affect ritonavir levels</u></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoBodyText2 align=left style='text-align:left'>Serum levels of
ritonavir can be reduced by concomitant use of herbal preparations containing
St&nbsp;Johns wort (<i>Hypericum perforatum). </i>This is due to the
induction of medicinal product metabolising enzymes by St Johns wort. Herbal
preparations containing St Johns wort must not be used in combination with
ritonavir. If a patient is already taking St Johns wort, St Johns wort should
be stopped and if possible check viral levels. Ritonavir levels may increase
on stopping St Johns wort. The dose of ritonavir may need adjusting. The
inducing effect may persist for at least 2 weeks after cessation of treatment with
St Johns wort (see section 4.3). </p>

<p class=MsoEndnoteText>&nbsp;</p>

<p class=MsoBodyText2 align=left style='text-align:left'>Serum levels of
ritonavir may be affected by select co&#8209;administered medicinal products (e.g.
delavirdine, efavirenz, phenytoin and rifampicin). These interactions are
noted in the medicinal product interaction tables below.</p>

<p class=MsoNormal>&nbsp;</p>

<h6><u><span style='font-style:normal'>Medicinal products that are affected by
the use of ritonavir</span></u></h6>

<p class=MsoNormal><i>&nbsp;</i></p>

<p class=MsoNormal>Interactions between ritonavir and protease inhibitors,
antiretroviral agents other than protease inhibitors and other
non-antiretroviral medicinal products are listed in the tables below. <span
style='color:black'>This list is not intended to be inclusive or
comprehensive. Individual SmPCs should be consulted.</span></p>

<p class=MsoNormal>&nbsp;</p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="98%"
 style='width:98.96%;border-collapse:collapse'>
 <tr>
  <td colspan=12 style='border:none;border-bottom:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'><br clear=all style='page-break-before:always'>
  </span>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span style='font-size:10.5pt;color:black'>Medicinal Product
  Interactions  Ritonavir with Protease Inhibitors</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span style='font-size:10.5pt;color:black'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="15%" colspan=3 valign=top style='width:15.7%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span class=bold1><span style='font-size:9.5pt;color:black'>Co-administered
  Medicinal Product</span></span></p>
  </td>
  <td width="26%" colspan=2 valign=top style='width:26.62%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span class=bold1><span style='font-size:9.5pt;color:black'>Dose of
  Co-administered Medicinal Product (mg)</span></span></p>
  </td>
  <td width="18%" colspan=2 valign=top style='width:18.44%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span class=bold1><span style='font-size:9.5pt;color:black'>Dose of
  NORVIR (mg)</span></span></p>
  </td>
  <td width="14%" colspan=2 valign=top style='width:14.34%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span style='font-size:9.5pt;color:black'>Medicinal Product Assessed</span></b></p>
  </td>
  <td width="12%" colspan=2 valign=top style='width:12.8%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span class=bold1><span style='font-size:9.5pt;color:black'>AUC</span></span></p>
  </td>
  <td width="12%" valign=top style='width:12.1%;border:none;border-bottom:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span class=bold1><span
  style='font-size:9.5pt;color:black'>C</span></span><span class=sub1><b><sub><span
  style='font-size:9.5pt;color:black'>min</span></sub></b></span></p>
  </td>
 </tr>
 <tr>
  <td width="15%" colspan=3 valign=top style='width:15.7%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>Amprenavir</span></p>
  </td>
  <td width="26%" colspan=2 valign=top style='width:26.62%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>600 q12h</span></p>
  </td>
  <td width="18%" colspan=2 valign=top style='width:18.44%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>100 q12h</span></p>
  </td>
  <td width="14%" colspan=2 valign=top style='width:14.34%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:9.5pt;color:black'>Amprenavir<sup>1</sup></span></p>
  </td>
  <td width="12%" colspan=2 valign=top style='width:12.8%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&#8593; 64%</span></p>
  </td>
  <td width="12%" valign=top style='width:12.1%;border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&#8593; 5 fold</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="15%" colspan=3 valign=top style='width:15.7%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="84%" colspan=9 valign=top style='width:84.3%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>Ritonavir increases the serum levels of amprenavir as a
  result of CYP3A4 inhibition. Clinical trials confirmed the safety and
  efficacy of 600&nbsp;mg amprenavir twice daily with ritonavir 100&nbsp;mg
  twice daily. For further information, physicians should refer to the Summary
  of Product Characteristics for amprenavir.</span></p>
  </td>
 </tr>
 <tr>
  <td width="15%" colspan=3 valign=top style='width:15.7%;border:none;
  border-top:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>Atazanavir</span></p>
  </td>
  <td width="26%" colspan=2 valign=top style='width:26.62%;border:none;
  border-top:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>300 q24h</span></p>
  </td>
  <td width="18%" colspan=2 valign=top style='width:18.44%;border:none;
  border-top:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>100 q24h</span></p>
  </td>
  <td width="14%" colspan=2 valign=top style='width:14.34%;border:none;
  border-top:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:9.5pt;color:black'>Atazanavir</span></p>
  </td>
  <td width="12%" colspan=2 valign=top style='width:12.8%;border:none;
  border-top:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&#8593; 86%</span></p>
  </td>
  <td width="12%" valign=top style='width:12.1%;border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&#8593; 11 fold</span></p>
  </td>
 </tr>
 <tr>
  <td width="15%" colspan=3 valign=top style='width:15.7%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="26%" colspan=2 valign=top style='width:26.62%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="18%" colspan=2 valign=top style='width:18.44%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="14%" colspan=2 valign=top style='width:14.34%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:9.5pt;color:black'>Atazanavir<sup>2</sup></span></p>
  </td>
  <td width="12%" colspan=2 valign=top style='width:12.8%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&#8593; 2 fold</span></p>
  </td>
  <td width="12%" valign=top style='width:12.1%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&#8593; 3-7 fold</span></p>
  </td>
 </tr>
 <tr>
  <td width="15%" colspan=3 valign=top style='width:15.7%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="84%" colspan=9 valign=top style='width:84.3%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>Ritonavir increases the serum levels of atazanavir as a
  result of CYP3A4 inhibition. Clinical trials confirmed the safety and
  efficacy of 300&nbsp;mg atazanavir once daily with ritonavir 100&nbsp;mg once
  daily in treatment experienced patients. For further information, physicians
  should refer to the Summary of Product Characteristics for atazanavir.</span></p>
  </td>
 </tr>
 <tr>
  <td width="15%" colspan=3 valign=top style='width:15.7%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>Darunavir</span></p>
  </td>
  <td width="26%" colspan=2 valign=top style='width:26.62%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>600, single</span></p>
  </td>
  <td colspan=2 valign=top style='border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>100 q12h</span></p>
  </td>
  <td width="14%" colspan=2 valign=top style='width:14.34%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:9.5pt;color:black'>Darunavir</span></p>
  </td>
  <td width="12%" colspan=2 valign=top style='width:12.8%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&#8593; 14 fold</span></p>
  </td>
  <td width="12%" valign=top style='width:12.1%;border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="15%" colspan=3 valign=top style='width:15.7%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="84%" colspan=9 valign=top style='width:84.3%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>Ritonavir increases the serum levels of darunavir as a
  result of CYP3A inhibition. Darunavir must be given with ritonavir to ensure
  its therapeutic effect. Ritonavir doses higher than 100&nbsp;mg twice daily
  have not been studied with darunavir. For further information, refer to the
  Summary of Product Characteristics for darunavir.</span></p>
  </td>
 </tr>
 <tr>
  <td width="15%" colspan=3 valign=top style='width:15.7%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Fosamprenavir</span></p>
  </td>
  <td width="26%" colspan=2 valign=top style='width:26.62%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>700 q12h</span></p>
  </td>
  <td colspan=2 valign=top style='border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>100 q12h</span></p>
  </td>
  <td width="14%" colspan=2 valign=top style='width:14.34%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.5pt;color:black'>Amprenavir</span></p>
  </td>
  <td width="12%" colspan=2 valign=top style='width:12.8%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 2.4 fold</span></p>
  </td>
  <td width="12%" valign=top style='width:12.1%;border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 11 fold</span></p>
  </td>
 </tr>
 <tr>
  <td width="15%" colspan=3 valign=top style='width:15.7%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="84%" colspan=9 valign=top style='width:84.3%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Ritonavir
  increases the serum levels of amprenavir (from fosamprenavir) as a result of
  CYP3A4 inhibition. Fosamprenavir must be given with ritonavir to ensure its
  therapeutic effect. Clinical trials confirmed the safety and efficacy of
  fosamprenavir 700&nbsp;mg twice daily with ritonavir 100&nbsp;mg twice
  daily. Ritonavir doses higher than 100&nbsp;mg twice daily have not been
  studied with fosamprenavir. For further information, physicians should refer
  to the Summary of Product Characteristics for fosamprenavir.</span></p>
  </td>
 </tr>
 <tr>
  <td width="15%" colspan=3 valign=top style='width:15.7%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Indinavir</span></p>
  </td>
  <td width="26%" colspan=2 valign=top style='width:26.62%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>800 q12h</span></p>
  </td>
  <td colspan=2 valign=top style='border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>100 q12h</span></p>
  </td>
  <td width="14%" colspan=2 valign=top style='width:14.34%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.5pt;color:black'>Indinavir</span><span class=sup1><sup><span
  style='font-size:9.5pt;color:black'>3</span></sup></span></p>
  </td>
  <td width="12%" colspan=2 valign=top style='width:12.8%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 178%</span></p>
  </td>
  <td width="12%" valign=top style='width:12.1%;border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>ND</span></p>
  </td>
 </tr>
 <tr>
  <td width="15%" colspan=3 valign=top style='width:15.7%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="26%" colspan=2 valign=top style='width:26.62%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td colspan=2 valign=top style='padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="14%" colspan=2 valign=top style='width:14.34%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.5pt;color:black'>Ritonavir</span></p>
  </td>
  <td width="12%" colspan=2 valign=top style='width:12.8%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 72%</span></p>
  </td>
  <td width="12%" valign=top style='width:12.1%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>ND</span></p>
  </td>
 </tr>
 <tr>
  <td width="15%" colspan=3 valign=top style='width:15.7%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="26%" colspan=2 valign=top style='width:26.62%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>400 q12h</span></p>
  </td>
  <td colspan=2 valign=top style='padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>400 q12h</span></p>
  </td>
  <td width="14%" colspan=2 valign=top style='width:14.34%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.5pt;color:black'>Indinavir</span><span class=sup1><sup><span
  style='font-size:9.5pt;color:black'>3</span></sup></span></p>
  </td>
  <td width="12%" colspan=2 valign=top style='width:12.8%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8596;</span></p>
  </td>
  <td width="12%" valign=top style='width:12.1%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 4 fold </span></p>
  </td>
 </tr>
 <tr>
  <td width="15%" colspan=3 valign=top style='width:15.7%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="26%" colspan=2 valign=top style='width:26.62%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td colspan=2 valign=top style='padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="14%" colspan=2 valign=top style='width:14.34%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.5pt;color:black'>Ritonavir</span></p>
  </td>
  <td width="12%" colspan=2 valign=top style='width:12.8%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8596;</span></p>
  </td>
  <td width="12%" valign=top style='width:12.1%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8596;</span></p>
  </td>
 </tr>
 <tr>
  <td width="15%" colspan=3 valign=top style='width:15.7%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="84%" colspan=9 valign=top style='width:84.3%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Ritonavir
  increases the serum levels of indinavir as a result of CYP3A4 inhibition.
  Appropriate doses for this combination, with respect to efficacy and safety,
  have not been established. Minimal benefit of ritonavir-mediated
  pharmacokinetic enhancement is achieved with doses higher than 100&nbsp;mg
  twice daily. In cases of co&#8209;administration of ritonavir (100&nbsp;mg
  twice daily) and indinavir (800&nbsp;mg twice daily) caution is warranted as
  the risk of nephrolithiasis may be increased. </span></p>
  </td>
 </tr>
 <tr>
  <td width="15%" colspan=3 valign=top style='width:15.7%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Nelfinavir</span></p>
  </td>
  <td width="26%" colspan=2 valign=top style='width:26.62%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>1250 q12h </span></p>
  </td>
  <td colspan=2 valign=top style='border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>100 q12h</span></p>
  </td>
  <td colspan=2 valign=top style='border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.5pt;color:black'>Nelfinavir</span></p>
  </td>
  <td colspan=2 valign=top style='border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 20to39%</span></p>
  </td>
  <td width="12%" valign=top style='width:12.1%;border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>ND</span></p>
  </td>
 </tr>
 <tr>
  <td width="15%" colspan=3 valign=top style='width:15.7%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="26%" colspan=2 valign=top style='width:26.62%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>750, single</span></p>
  </td>
  <td colspan=2 valign=top style='padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>500 q12h</span></p>
  </td>
  <td colspan=2 valign=top style='padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.5pt;color:black'>Nelfinavir</span></p>
  </td>
  <td colspan=2 valign=top style='padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 152%</span></p>
  </td>
  <td width="12%" valign=top style='width:12.1%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>ND</span></p>
  </td>
 </tr>
 <tr>
  <td width="15%" colspan=3 valign=top style='width:15.7%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="26%" colspan=2 valign=top style='width:26.62%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td colspan=2 valign=top style='padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td colspan=2 valign=top style='padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.5pt;color:black'>Ritonavir</span></p>
  </td>
  <td colspan=2 valign=top style='padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8596;</span></p>
  </td>
  <td width="12%" valign=top style='width:12.1%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8596;</span></p>
  </td>
 </tr>
 <tr>
  <td width="15%" colspan=3 valign=top style='width:15.7%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="84%" colspan=9 valign=top style='width:84.3%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Ritonavir
  increases the serum levels of nelfinavir as a result of CYP3A4 inhibition.
  Appropriate doses for this combination, with respect to efficacy and safety,
  have not been established. Minimal benefit of ritonavir-mediated
  pharmacokinetic enhancement is achieved with doses higher than 100&nbsp;mg
  twice daily.</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.88%;border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>Saquinavir</span></p>
  </td>
  <td width="25%" colspan=3 valign=top style='width:25.26%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>1000 q12h</span></p>
  </td>
  <td colspan=2 valign=top style='border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>100 q12h</span></p>
  </td>
  <td colspan=2 valign=top style='border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:9.5pt;color:black'>Saquinavir<sup>4</sup></span></p>
  </td>
  <td colspan=2 valign=top style='border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&#8593; 15-fold</span></p>
  </td>
  <td width="16%" colspan=2 valign=top style='width:16.52%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&#8593; 5-fold</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.88%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="25%" colspan=3 valign=top style='width:25.26%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td colspan=2 valign=top style='padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td colspan=2 valign=top style='padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:9.5pt;color:black'>Ritonavir</span></p>
  </td>
  <td colspan=2 valign=top style='padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&#8596;</span></p>
  </td>
  <td width="16%" colspan=2 valign=top style='width:16.52%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&#8596;</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.88%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="25%" colspan=3 valign=top style='width:25.26%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>400 q12h </span></p>
  </td>
  <td colspan=2 valign=top style='padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>400 q12h </span></p>
  </td>
  <td colspan=2 valign=top style='padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:9.5pt;color:black'>Saquinavir<sup>4</sup></span></p>
  </td>
  <td colspan=2 valign=top style='padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&#8593; 17-fold </span></p>
  </td>
  <td width="16%" colspan=2 valign=top style='width:16.52%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>ND</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.88%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="25%" colspan=3 valign=top style='width:25.26%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td colspan=2 valign=top style='padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td colspan=2 valign=top style='padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:9.5pt;color:black'>Ritonavir</span></p>
  </td>
  <td colspan=2 valign=top style='padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&#8596;</span></p>
  </td>
  <td width="16%" colspan=2 valign=top style='width:16.52%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&#8596;</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.88%;border:none;border-bottom:
  solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="85%" colspan=11 valign=top style='width:85.12%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>Ritonavir increases the serum levels of saquinavir as a
  result of CYP3A4 inhibition. Saquinavir should only be given in combination
  with ritonavir. Ritonavir100&nbsp;mg twice daily with saquinavir 1000&nbsp;mg
  twice daily provides saquinavir systemic exposure over 24 hours similar to or
  greater than those achieved with saquinavir 1200&nbsp;mg three times daily
  without ritonavir. </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>In a clinical study investigating the interaction of
  rifampicin 600&nbsp;mg once daily and saquinavir 1000&nbsp;mg with ritonavir
  100&nbsp;mg twice daily in healthy volunteers, severe hepatocellular toxicity
  with transaminase elevations up to &gt;&nbsp;20&#8209;fold the upper limit of
  normal after 1 to 5 days of co&#8209;administration was noted. Due to the
  risk of severe hepatoxicity, saquinavir/ritonavir should not be given
  together with rifampicin.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>For further information, physicians should refer to the
  Summary of Product Characteristics for saquinavir.</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.88%;border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Tipranavir</span></p>
  </td>
  <td width="25%" colspan=3 valign=top style='width:25.26%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>500 q12h</span></p>
  </td>
  <td colspan=2 valign=top style='border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>200 q12h</span></p>
  </td>
  <td colspan=2 valign=top style='border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.5pt;color:black'>Tipranavir</span></p>
  </td>
  <td colspan=2 valign=top style='border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 11 fold</span></p>
  </td>
  <td width="16%" colspan=2 valign=top style='width:16.52%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 29 fold</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.88%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="25%" colspan=3 valign=top style='width:25.26%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td colspan=2 valign=top style='padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td colspan=2 valign=top style='padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.5pt;color:black'>Ritonavir</span></p>
  </td>
  <td colspan=2 valign=top style='padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8595; 40%</span></p>
  </td>
  <td width="16%" colspan=2 valign=top style='width:16.52%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>ND</span></p>
  </td>
 </tr>
 <tr>
  <td width="15%" colspan=2 valign=top style='width:15.22%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="84%" colspan=10 valign=top style='width:84.78%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Ritonavir
  increases the serum levels of tipranavir as a result of CYP3A inhibition.
  Tipranavir must be given with low dose ritonavir to ensure its therapeutic
  effect. Doses of ritonavir less than 200&nbsp;mg twice daily should not be
  used with tipranavir as they might alter the efficacy of the combination.
  For further information, physicians should refer to the Summary of Product
  Characteristics for tipranavir.</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.88%;border:none;border-bottom:
  solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="85%" colspan=11 valign=top style='width:85.12%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>ND: Not
  determined.</span></p>
  <p class=MsoNormal style='margin-left:.25in'><span style='font-size:9.5pt;
  color:black'>1. Based on cross-study comparison to 1200&nbsp;mg amprenavir
  twice daily alone.</span></p>
  <p class=MsoNormal style='margin-left:.25in'><span style='font-size:9.5pt;
  color:black'>2. Based on cross-study comparison to 400&nbsp;mg atazanavir
  once daily alone.</span></p>
  <p class=MsoNormal style='margin-left:.25in'><span style='font-size:9.5pt;
  color:black'>3. Based on cross-study comparison to 800&nbsp;mg indinavir
  three times daily alone.</span></p>
  <p class=MsoNormal style='margin-left:.25in'><span style='font-size:9.5pt;
  color:black'>4. Based on cross-stud y comparison to 600&nbsp;mg saquinavir
  three times daily alone.</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=104 style='border:none'></td>
  <td width=2 style='border:none'></td>
  <td width=3 style='border:none'></td>
  <td width=171 style='border:none'></td>
  <td width=15 style='border:none'></td>
  <td width=65 style='border:none'></td>
  <td width=65 style='border:none'></td>
  <td width=50 style='border:none'></td>
  <td width=50 style='border:none'></td>
  <td width=45 style='border:none'></td>
  <td width=45 style='border:none'></td>
  <td width=85 style='border:none'></td>
 </tr>
</table>

<p class=MsoNormal>&nbsp;</p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="98%"
 style='width:98.96%;border-collapse:collapse'>
 <tr>
  <td width="100%" colspan=6 valign=top style='width:100.0%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span style='font-size:10.5pt;color:black'>Medicinal product interactions
   Ritonavir with antiretroviral agents other than protease inhibitors</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.2%;border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span class=bold1><span
  style='font-size:9.5pt;color:black'>Co-administered Medicinal Product</span></span></p>
  </td>
  <td width="20%" valign=top style='width:20.76%;border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span class=bold1><span
  style='font-size:9.5pt;color:black'>Dose of Co-administered Medicinal Product
  (mg)</span></span></p>
  </td>
  <td valign=top style='border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span class=bold1><span
  style='font-size:9.5pt;color:black'>Dose of NORVIR (mg)</span></span></p>
  </td>
  <td valign=top style='border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span style='font-size:9.5pt;color:black'>Medicinal Product</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span style='font-size:9.5pt;color:black'>Assessed</span></b></p>
  </td>
  <td valign=top style='border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span class=bold1><span
  style='font-size:9.5pt;color:black'>AUC</span></span></p>
  </td>
  <td width="8%" valign=top style='width:8.4%;border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span class=bold1><span
  style='font-size:9.5pt;color:black'>C</span></span><span class=sub1><b><sub><span
  style='font-size:9.5pt;color:black'>min</span></sub></b></span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.2%;border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Didanosine</span></p>
  </td>
  <td width="20%" valign=top style='width:20.76%;border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>200 q12h</span></p>
  </td>
  <td valign=top style='border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>600 q12h 2 h
  later</span></p>
  </td>
  <td valign=top style='border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.5pt;color:black'>Didanosine</span></p>
  </td>
  <td valign=top style='border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8595; 13% </span></p>
  </td>
  <td width="8%" valign=top style='width:8.4%;border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8596;</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.2%;border:none;border-bottom:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="85%" colspan=5 valign=top style='width:85.8%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>As ritonavir is
  recommended to be taken with food and didanosine should be taken on an empty
  stomach, dosing should be separated by 2.5 h. Dose alterations should not be
  necessary.</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.2%;border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Delavirdine</span></p>
  </td>
  <td width="20%" valign=top style='width:20.76%;border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>400 q8h</span></p>
  </td>
  <td valign=top style='border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>600 q12h</span></p>
  </td>
  <td valign=top style='border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.5pt;color:black'>Delavirdine<sup>1</sup></span></p>
  </td>
  <td valign=top style='border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.4%;border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8596;</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.2%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="20%" valign=top style='width:20.76%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td valign=top style='padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td valign=top style='padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.5pt;color:black'>Ritonavir</span></p>
  </td>
  <td valign=top style='padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 50%</span></p>
  </td>
  <td width="8%" valign=top style='width:8.4%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 75%</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.2%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="85%" colspan=5 valign=top style='width:85.8%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Based on
  comparison to historical data, the pharmacokinetics of delavirdine did not
  appear to be affected by ritonavir. When used in combination with
  delavirdine, dose reduction of ritonavir may be considered.</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.2%;border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Efavirenz</span></p>
  </td>
  <td width="20%" valign=top style='width:20.76%;border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>600 q24h</span></p>
  </td>
  <td valign=top style='border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>500 q12h</span></p>
  </td>
  <td valign=top style='border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.5pt;color:black'>Efavirenz</span></p>
  </td>
  <td valign=top style='border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 21%</span></p>
  </td>
  <td width="8%" valign=top style='width:8.4%;border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.2%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="20%" valign=top style='width:20.76%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td valign=top style='padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td valign=top style='padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.5pt;color:black'>Ritonavir</span></p>
  </td>
  <td valign=top style='padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 17%</span></p>
  </td>
  <td width="8%" valign=top style='width:8.4%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.2%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="85%" colspan=5 valign=top style='width:85.8%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>A higher frequency
  of adverse reactions (e.g., dizziness, nausea, paraesthesia) and laboratory
  abnormalities (elevated liver enzymes) have been observed when efavirenz is
  co-administered with ritonavir dosed as an antiretroviral agent.</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.2%;border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Maraviroc</span></p>
  </td>
  <td width="20%" valign=top style='width:20.76%;border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>100&nbsp;q12h</span></p>
  </td>
  <td valign=top style='border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>100 q12h</span></p>
  </td>
  <td width="18%" valign=top style='width:18.6%;border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.5pt;color:black'>Maraviroc</span></p>
  </td>
  <td width="16%" valign=top style='width:16.04%;border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 161%</span></p>
  </td>
  <td width="8%" valign=top style='width:8.4%;border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 28%</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="14%" valign=top style='width:14.2%;border:none;border-bottom:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="85%" colspan=5 valign=top style='width:85.8%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Ritonavir
  increases the serum levels of maraviroc as a result of CYP3A inhibition.
  Maraviroc may be given with ritonavir to increase the maraviroc exposure.
  For further information, refer to the Summary of Product Characteristics for maraviroc.</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.2%;border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Nevirapine</span></p>
  </td>
  <td width="20%" valign=top style='width:20.76%;border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>200 q12h</span></p>
  </td>
  <td valign=top style='border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>600 q12h</span></p>
  </td>
  <td valign=top style='border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.5pt;color:black'>Nevirapine</span></p>
  </td>
  <td valign=top style='border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.4%;border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8596;</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.2%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="20%" valign=top style='width:20.76%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td valign=top style='padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td valign=top style='padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.5pt;color:black'>Ritonavir</span></p>
  </td>
  <td valign=top style='padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.4%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8596;</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.2%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="85%" colspan=5 valign=top style='width:85.8%;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Co-administration
  of ritonavir with nevirapine does not lead to clinically relevant changes in
  the pharmacokinetics of either nevirapine or ritonavir.</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.22%;border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>Raltegravir</span></p>
  </td>
  <td width="20%" valign=top style='width:20.76%;border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>400 single </span></p>
  </td>
  <td valign=top style='border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>100 q12h</span></p>
  </td>
  <td width="18%" valign=top style='width:18.48%;border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='font-size:9.5pt'>Raltegravir</span></p>
  </td>
  <td width="16%" valign=top style='width:16.08%;border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>&#8595; 16%</span></p>
  </td>
  <td width="8%" valign=top style='width:8.4%;border:none;border-top:solid windowtext 1.0pt;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>&#8595; 1%</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.22%;border:none;border-bottom:
  solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>&nbsp;</span></p>
  </td>
  <td width="85%" colspan=5 valign=top style='width:85.78%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>Co-adminsitration of
  ritonavir and raltegravir results in a minor reduction in raltegravir levels</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.22%;border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>Zidovudine</span></p>
  </td>
  <td width="20%" valign=top style='width:20.76%;border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>200 q8h</span></p>
  </td>
  <td valign=top style='border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>300 q6h</span></p>
  </td>
  <td width="18%" valign=top style='width:18.48%;border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:9.5pt;color:black'>Zidovudine</span></p>
  </td>
  <td width="16%" valign=top style='width:16.08%;border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&#8595; 25% </span></p>
  </td>
  <td width="8%" valign=top style='width:8.4%;border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>ND</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.22%;border:none;border-bottom:
  solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="85%" colspan=5 valign=top style='width:85.78%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>Ritonavir may induce the glucuronidation of zidovudine,
  resulting in slightly decreased levels of zidovudine. Dose alterations
  should not be necessary.</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.22%;border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="85%" colspan=5 valign=top style='width:85.78%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>ND: Not
  determined</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>1. Based on
  parallel group comparison.</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="103%"
 style='margin-left:-6.0pt;border-collapse:collapse;border:none'>
 <thead>
  <tr>
   <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
   <td width="97%" colspan=20 valign=top style='width:97.42%;border-top:solid windowtext 1.0pt;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
   padding:.75pt 6.0pt .75pt 6.0pt'>
   <p class=MsoNormal align=center style='margin-top:6.0pt;margin-right:0in;
   margin-bottom:6.0pt;margin-left:0in;text-align:center'><b><span
   style='color:black'>Ritonavir effects on Non-antiretroviral Co-administered
   Medicinal Products</span></b></p>
   </td>
   <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  </tr>
  <tr>
   <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
   <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
   border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
   <p class=MsoNormal><span class=bold1><span style='font-size:9.5pt;
   font-family:"Times New Roman Bold",serif;color:black'>Co-administered
   Medicinal Products</span></span></p>
   </td>
   <td width="16%" colspan=3 valign=top style='width:16.22%;border:none;
   border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
   <p class=MsoNormal><span class=bold1><span style='font-size:9.5pt;
   font-family:"Times New Roman Bold",serif;color:black'>Dose of
   Co-administered Medicinal Products (mg)</span></span></p>
   </td>
   <td width="12%" colspan=5 valign=top style='width:12.4%;border:none;
   border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
   <p class=MsoNormal><span class=bold1><span style='font-size:9.5pt;
   font-family:"Times New Roman Bold",serif;color:black'>Dose of NORVIR (mg)</span></span></p>
   </td>
   <td width="16%" colspan=6 valign=top style='width:16.14%;border:none;
   border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
   <p class=MsoNormal><span class=bold1><span style='font-size:9.5pt;
   font-family:"Times New Roman Bold",serif;color:black'>Effect on
   Co-administered Medicinal Products AUC </span></span></p>
   </td>
   <td width="14%" colspan=4 valign=top style='width:14.82%;border:none;
   border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
   <p class=MsoNormal><span class=bold1><span style='font-size:9.5pt;
   font-family:"Times New Roman Bold",serif;color:black'>Effect on
   Co-administered Medicinal Products C</span></span><span class=sub1><b><sub><span
   style='font-size:9.5pt;font-family:"Times New Roman Bold",serif;color:black'>max</span></sub></b></span><span
   class=bold1><span style='font-size:9.5pt;font-family:"Times New Roman Bold",serif;
   color:black'> </span></span></p>
   </td>
   <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid;height:2.75pt'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt;
  height:2.75pt'>
  <p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in'><b>Alpha</b><b><sub>1</sub></b><b>-Adrenoreceptor
  Antagonist</b></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt;
  height:2.75pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>Alfuzosin</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>Ritonavir co-administration
  is likely to result in increased plasma concentrations of alfuzosin and is
  therefore <b>contraindicated </b>(see section 4.3). </span></p>
  <p class=MsoNormal><span style='font-size:9.5pt'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <h3 align=left style='margin-top:6.0pt;margin-right:0in;margin-bottom:6.0pt;
  margin-left:0in;text-align:left'>Amphetamine Derivatives</h3>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in'><span style='font-size:9.5pt'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid;height:45.15pt'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt;
  height:45.15pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Amphetamine </span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt;
  height:45.15pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>Ritonavir dosed as an
  antiretroviral agent is likely to inhibit CYP2D6 and as a result is expected
  to increase concentrations of amphetamine and its derivatives. Careful
  monitoring of therapeutic and adverse effects is recommended when these
  medicines are concomitantly administered with antiretroviral doses of ritonavir
  (see section 4.4).</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoHeading7 style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in'>Analgesics</p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>Buprenorphine</span></p>
  </td>
  <td width="18%" colspan=6 valign=top style='width:18.84%;border:none;
  border-top:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>16 q24h</span></p>
  </td>
  <td width="19%" colspan=7 valign=top style='width:19.5%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>100 q12h</span></p>
  </td>
  <td width="12%" colspan=4 valign=top style='width:12.14%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 57%</span></p>
  </td>
  <td width="9%" valign=top style='width:9.12%;border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 77%</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Norbuprenorphine</span></p>
  </td>
  <td width="18%" colspan=6 valign=top style='width:18.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="19%" colspan=7 valign=top style='width:19.5%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="12%" colspan=4 valign=top style='width:12.14%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 33%</span></p>
  </td>
  <td width="9%" valign=top style='width:9.12%;border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 108%</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Glucuronide
  metabolites</span></p>
  </td>
  <td width="18%" colspan=6 valign=top style='width:18.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="19%" colspan=7 valign=top style='width:19.5%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="12%" colspan=4 valign=top style='width:12.14%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;font-family:Symbol;
  color:black'></span></p>
  </td>
  <td width="9%" valign=top style='width:9.12%;border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;font-family:Symbol;
  color:black'></span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>&nbsp;</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>The increases of plasma
  levels of buprenorphine and its active metabolite did not lead to clinically
  significant pharmacodynamic changes in a population of opioid tolerant
  patients. Adjustment to the dose of buprenorphine or ritonavir may therefore
  not be necessary when the two are dosed together. When ritonavir is used in
  combination with another protease inhibitor and buprenorphine, the SPC of the
  co&#8209;administered protease inhibitor should be reviewed for specific
  dosing information.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>Pethidine, piroxicam,
  propoxyphene</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>Ritonavir co-administration
  is likely to result in increased plasma concentrations of pethidine,
  piroxicam, and propoxyphene and is therefore <b>contraindicated </b>(see
  section 4.3).</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Fentanyl</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Ritonavir dosed
  as a pharmacokinetic enhancer or as an antiretroviral agent inhibits CYP3A4
  and as a result is expected to increase the plasma concentrations of
  fentanyl. </span><span style='font-size:9.5pt'>Careful monitoring of
  therapeutic and adverse effects (including respiratory depression) is
  recommended when fentanyl is concomitantly administered with ritonavir.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Methadone</span><span
  class=sup1><sup><span style='font-size:9.5pt;color:black'>1</span></sup></span></p>
  </td>
  <td width="18%" colspan=6 valign=top style='width:18.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>5, single dose </span></p>
  </td>
  <td width="19%" colspan=7 valign=top style='width:19.5%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>500 q12h, </span></p>
  </td>
  <td width="12%" colspan=4 valign=top style='width:12.14%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8595; 36% </span></p>
  </td>
  <td width="9%" valign=top style='width:9.12%;border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8595; 38% </span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Increased
  methadone dose may be necessary when concomitantly administered with
  ritonavir dosed as an antiretroviral agent or as a pharmacokinetic enhancer
  due to induction of glucuronidation. Dose adjustment should be considered
  based on the patients clinical response to methadone therapy. </span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Morphine</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Morphine levels
  may be decreased due to induction of glucuronidation by co-administered
  ritonavir dosed as an antiretroviral agent or as a pharmacokinetic enhancer.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoHeading7 style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in'>Antianginal</p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span lang=ES-MX style='font-size:9.5pt;color:black'>Ranolazine</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Due to CYP3A
  inhibition by ritonavir, concentrations of ranolazine are expected to
  increase. The concomitant administration with ranolazine is contraindicated
  (see section 4.3).</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoHeading7 style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in'>Antiarrthymics</p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span lang=IT style='font-size:9.5pt'>Amiodarone,
  bepridil, dronedarone, encainide, flecainide, propafenone, quinidine</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>Ritonavir co-administration
  is likely to result in increased plasma concentrations of amiodarone,
  bepridil, dronedarone, encainide, flecainide, propafenone, and quinidine and
  is therefore <b>contraindicated </b>(see section 4.3).</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Digoxin</span></p>
  </td>
  <td width="18%" colspan=5 valign=top style='width:18.32%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>0.5 single IV
  dose</span></p>
  </td>
  <td width="20%" colspan=8 valign=top style='width:20.02%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>300 q12h, 3 days
  </span></p>
  </td>
  <td width="12%" colspan=4 valign=top style='width:12.14%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 86%</span></p>
  </td>
  <td width="9%" valign=top style='width:9.12%;border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>ND</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="18%" colspan=5 valign=top style='width:18.32%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>0.4 single oral
  dose</span></p>
  </td>
  <td width="20%" colspan=8 valign=top style='width:20.02%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>200 q12h, 13
  days</span></p>
  </td>
  <td width="12%" colspan=4 valign=top style='width:12.14%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 22%</span></p>
  </td>
  <td width="9%" valign=top style='width:9.12%;border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;font-family:Symbol;
  color:black'></span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>This interaction
  may be due to modification of P-glycoprotein mediated digoxin efflux by
  ritonavir dosed as an antriretroviral agent or as a pharmacokinetic
  enhancer. Increased digoxin levels observed in patients receiving ritonavir
  may lessen over time as induction develops </span><span style='font-size:
  9.5pt;color:black'>(see section 4.4). </span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoHeading7 style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in'>Antiasthmatic</p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Theophylline<sup>1</sup></span></p>
  </td>
  <td width="16%" colspan=2 valign=top style='width:16.04%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>3 mg/kg q8h</span></p>
  </td>
  <td width="12%" colspan=6 valign=top style='width:12.6%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>500 q12h </span></p>
  </td>
  <td width="16%" colspan=6 valign=top style='width:16.14%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8595; 43% </span></p>
  </td>
  <td width="14%" colspan=4 valign=top style='width:14.82%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8595; 32% </span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>An increased
  dose of theophyline may be required when co-administered with ritonavir, due
  to induction of CYP1A2.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoHeading7 style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in'>Anticancer agents<span style='color:black'> and kinase
  inhibitors</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 rowspan=2 valign=top style='width:37.84%;
  border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Afatinib</span></p>
  </td>
  <td width="16%" colspan=2 valign=top style='width:16.04%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>20 mg, single
  dose</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>40 mg, single
  dose</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>40 mg, single
  dose</span></p>
  </td>
  <td width="12%" colspan=6 valign=top style='width:12.6%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>200 q12h/1h
  before</span></p>
  <p class=MsoNormal style='margin-right:-4.6pt'><span style='font-size:9.5pt;
  color:black'>200 q12h/ co-administered</span></p>
  <p class=MsoNormal style='margin-right:-4.6pt'><span style='font-size:9.5pt;
  color:black'>200 q12h/6h after</span></p>
  </td>
  <td width="16%" colspan=6 valign=top style='width:16.14%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 48% </span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 19%</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 11%</span></p>
  </td>
  <td width="14%" colspan=4 valign=top style='width:14.82%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 39% </span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 4%</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 5%</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Serum
  concentrations may be increased due to </span><span class=st1><span
  style='font-size:9.5pt'>Breast Cancer Resistance Protein (BCRP) </span></span><span
  style='font-size:9.5pt;color:black'>and acute P&#8209;gp inhibition by
  ritonavir. The extent of increase in AUC and C<sub>max</sub> depends on the
  timing of ritonavir administration. Caution should be exercised in
  administering afatinib with Norvir (refer to the afatinib SmPC). Monitor for
  ADRs related to afatinib.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Abemaciclib</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Serum
  concentrations may be increased due to CYP3A4 inhibition by ritonavir.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.5pt'>Co&#8209;administration
  of abemaciclib and Norvir should be avoided. If this co&#8209;administration
  is judged unavoidable, refer to the abemaciclib SmPC for dosage adjustment
  recommendations. Monitor for ADRs related to abemaciclib.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Apalutamide</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Apalutamide is a
  moderate to strong CYP3A4 inducer and this may lead to a decreased exposure
  of ritonavir and potential loss of virologic response. In addition, serum
  concentrations may be increased when co&#8209;administered with ritonavir resulting
  in the potential for serious adverse events including seizure. </span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Concomitant use
  of ritonavir with apalutamide is not recommended.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Ceritinib</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Serum
  concentrations may be increased due to CYP3A and P-gp inhibition by ritonavir.
  Caution should be exercised in administering ceritinib with Norvir. Refer to
  the ceritinib SmPC for dosage adjustment recommendations. Monitor for ADRs
  related to ceritinib.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Dasatinib,
  nilotinib, vincristine, vinblastine</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Serum concentrations
  may be increased when co&#8209;administered with ritonavir resulting in the
  potential for increased incidence of adverse reactions.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Encorafenib</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Serum
  concentrations may be increased when co&#8209;administered with ritonavir
  which may increase the risk of toxicity, including the risk of serious
  adverse events such as QT interval prolongation. Co&#8209;administration of
  encorafenib and ritonavir should be avoided. If the benefit is considered to
  outweigh the risk and ritonavir must be used, patients should be carefully
  monitored for safety.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width="38%" colspan=2 valign=top style='width:38.82%;border:none;
  background:white;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='margin-left:7.1pt'><span style='font-size:9.5pt;
  color:black'>Fostamatinib</span></p>
  </td>
  <td width="61%" colspan=20 valign=top style='width:61.18%;border:none;
  background:white;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='margin-left:2.4pt'><span style='font-size:9.5pt;
  color:black'>Co-administration of fostamatinib with ritonavir may increase
  fostamatinib metabolite R406 exposure resulting in dose-related adverse
  events such as hepatotoxicity, neutropenia, hypertension, or diarrhoea. Refer
  to the fostamatinib SmPC for dose reduction recommendations if such events
  occur.</span></p>
  <p class=MsoNormal style='margin-left:2.4pt'><span style='font-size:9.5pt;
  color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Ibrutinib</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Serum
  concentrations of ibrutinib may be increased due to CYP3A inhibition by
  ritonavir, resulting in increased risk for toxicity including risk of tumor
  lysis syndrome. Co&#8209;administration of ibrutinib and ritonavir should be
  avoided. If the benefit is considered to outweigh the risk and ritonavir
  must be used, reduce the ibrutinib dose to 140&nbsp;mg and monitor patient
  closely for toxicity.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Neratinib</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Serum
  concentrations may be increased due to CYP3A4 inhibition by ritonavir.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Concomitant use
  of neratinib with Norvir is contraindicated due to serious and/or life&#8209;threatening
  potential reactions including hepatotoxicity (see section 4.3).</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Venetoclax</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Serum
  concentrations may be increased due to CYP3A inhibition by ritonavir, resulting
  in increased risk of tumor lysis syndrome at the dose initiation and during
  the ramp&#8209;up phase (see section 4.3 and refer to the venetoclax SmPC).</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt'>For patients who have
  completed the ramp&#8209;up phase and are on a steady daily dose of venetoclax,
  reduce the venetoclax dose by at least 75% when used with strong CYP3A
  inhibitors (refer to the venetoclax SmPC for dosing instructions).</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoHeading7 style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in'>Anticoagulants</p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=DE
  style='font-size:9.5pt'>Rivaroxaban</span></p>
  </td>
  <td width="16%" colspan=2 valign=top style='width:16.04%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt'>10, single dose</span></p>
  </td>
  <td width="12%" colspan=6 valign=top style='width:12.6%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt'>600 q12h</span></p>
  </td>
  <td width="16%" colspan=6 valign=top style='width:16.14%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt'>&#8593; 153%</span></p>
  </td>
  <td width="14%" colspan=4 valign=top style='width:14.82%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt'>&#8593; 55% </span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-top:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span lang=DE style='font-size:9.5pt'>&nbsp;</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-top:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>Inhibition of CYP3A and P-gp
  lead to increased plasma levels and pharmacodynamic effects of rivaroxaban
  which may lead to an increased bleeding risk. Therefore, the use of ritonavir
  is not recommended in patients receiving rivaroxaban.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span lang=DE style='font-size:9.5pt;color:black'>Vorapaxar</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Serum
  concentrations may be increased due to CYP3A inhibition by ritonavir. The co&#8209;administration
  of vorapaxar with Norvir is not recommended (see section 4.4 and refer to the
  vorapaxar SmPC).</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span lang=DE style='font-size:9.5pt;color:black'>Warfarin</span></p>
  <p class=MsoNormal><span lang=DE style='font-size:9.5pt;color:black'>S-Warfarin
  <br>
  R-Warfarin</span></p>
  </td>
  <td width="16%" colspan=2 valign=top style='width:16.04%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>5, single dose </span></p>
  </td>
  <td width="12%" colspan=6 valign=top style='width:12.6%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>400 q12h </span></p>
  </td>
  <td width="16%" colspan=6 valign=top style='width:16.14%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'><br>
  &#8593; 9% <br>
  &#8595; 33% </span></p>
  </td>
  <td width="14%" colspan=4 valign=top style='width:14.82%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'><br>
  &#8595; 9% <br>
  &#8596; </span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Induction of
  CYP1A2 and CYP2C9 lead to decreased levels of R-warfarin while little
  pharmacokinetic effect is noted on S- warfarin when co-administered with
  ritonavir. Decreased R-warfarin levels may lead to reduced anticoagulation,
  therefore it is recommended that anticoagulation parameters are monitored
  when warfarin is co&#8209;administered with ritonavir dosed as an
  antiretroviral agent or as a pharmacokinetic enhancer.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoHeading7 style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in'>Anticonvulsants</p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Carbamazepine</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Ritonavir dosed
  as a pharmacokinetic enhancer or as an antiretroviral agent inhibits CYP3A4
  and as a result is expected to increase the plasma concentrations of
  carbamazepine. </span><span style='font-size:9.5pt'>Careful monitoring of
  therapeutic and adverse effects is recommended when carbamazepine is
  concomitantly administered with ritonavir.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Divalproex,
  lamotrigine, phenytoin</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Ritonavir dosed
  as a pharmacokinetic enhancer or as an antiretroviral agent induces oxidation
  by CYP2C9 and glucuronidation and as a result is expected to decrease the
  plasma concentrations of anticonvulsants. </span><span style='font-size:9.5pt'>Careful
  monitoring of serum levels or therapeutic effects is recommended when these
  medicines are concomitantly administered with ritonavir. Phenytoin may
  decrease serum levels of ritonavir.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoHeading7 style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in'>Antidepressants</p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span lang=FR style='font-size:9.5pt;color:black'>A</span><span
  lang=FR style='font-size:9.5pt'>mitriptyline, fluoxetine, imipramine,
  nortriptyline, paroxetine, sertraline</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>Ritonavir dosed as an
  antiretroviral agent is likely to inhibit CYP2D6 and as a result is expected
  to increase concentrations of imipramine, amitriptyline, nortriptyline,
  fluoxetine, paroxetine or sertraline. Careful monitoring of therapeutic and
  adverse effects is recommended when these medicines are concomitantly
  administered with antiretroviral doses of ritonavir (see section 4.4).</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Desipramine</span></p>
  </td>
  <td width="19%" colspan=7 valign=top style='width:19.46%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>100, single oral
  dose</span></p>
  </td>
  <td width="13%" colspan=5 valign=top style='width:13.76%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>500 q12h</span></p>
  </td>
  <td width="14%" colspan=4 valign=top style='width:14.94%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 145%</span></p>
  </td>
  <td width="11%" colspan=2 valign=top style='width:11.44%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 22%</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>The AUC and C<sub>max</sub>
  of the 2-hydroxy metabolite were decreased 15 and 67%, respectively. Dosage
  reduction of desipramine is recommended when co-administered with ritonavir
  dosed as an antiretroviral agent.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>Trazodone</span></p>
  </td>
  <td width="16%" colspan=2 valign=top style='width:16.04%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>50, single dose </span></p>
  </td>
  <td width="12%" colspan=6 valign=top style='width:12.6%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>200 q12h </span></p>
  </td>
  <td width="16%" colspan=6 valign=top style='width:16.14%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&#8593; 2.4-fold</span></p>
  </td>
  <td width="14%" colspan=4 valign=top style='width:14.82%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&#8593; 34%</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>An increase in the incidence in trazodone-related adverse
  reactions was noted when co-administered with ritonavir dosed as an
  antiretroviral agent or as a pharmacokinetic enhancer. If trazodone is
  co-administered with ritonavir, the combination should be used with caution,
  initiating trazodone at the lowest dosage and monitoring for clinical
  response and tolerability.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoHeading7 style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in'>Anti-gout treatments</p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoHeading7><span style='font-size:9.5pt;font-weight:normal'>Colchicine</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>Concentrations of colchicine
  are expected to increase when coadministered with ritonavir.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt'>Life-threatening and fatal
  drug interactions have been reported in patients treated with colchicine and
  ritonavir (CYP3A4 and P-gp inhibition) in patients with renal and/or hepatic
  impairment (see sections 4.3 and 4.4). Refer to the colchicine prescribing
  information.</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoHeading7 style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in'>Antihistamines</p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Astemizole,
  terfenadine</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>Ritonavir co-administration
  is likely to result in increased plasma concentrations of astemizole and
  terfenadine and is therefore <b>contraindicated </b>(see section 4.3).</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Fexofenadine</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Ritonavir may
  modify P-glycoprotein mediated fexofenadine efflux when dosed as an
  antriretroviral agent or as a pharmacokinetic enhancer resulting in increased
  concentrations of fexofenadine. Increased fexofenadine levels may lessen
  over time as induction develops.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Loratadine</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Ritonavir dosed
  as a pharmacokinetic enhancer or as an antiretroviral agent inhibits CYP3A
  and as a result is expected to increase the plasma concentrations of
  loratadine. </span><span style='font-size:9.5pt'>Careful monitoring of
  therapeutic and adverse effects is recommended when loratidine is
  concomitantly administered with ritonavir.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoHeading7 style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in'>Anti&#8209;infectives</p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Fusidic Acid</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>Ritonavir co-administration
  is likely to result in increased plasma concentrations of both fusidic acid
  and ritonavir and is therefore <b>contraindicated </b>(see section 4.3).</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span lang=IT style='font-size:9.5pt;color:black'>Rifabutin</span><span
  class=sup1><sup><span lang=IT style='font-size:9.5pt;color:black'>1</span></sup></span><span
  lang=IT style='font-size:9.5pt;color:black'><br>
  <br>
  </span></p>
  <p class=MsoNormal><span lang=IT style='font-size:9.5pt;color:black'>25-<span
  class=italics1>O</span>-desacetyl rifabutin metabolite </span></p>
  </td>
  <td width="14%" valign=top style='width:14.94%;border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>150 daily </span></p>
  </td>
  <td width="16%" colspan=9 valign=top style='width:16.1%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>500 q12h, </span></p>
  </td>
  <td width="16%" colspan=5 valign=top style='width:16.04%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 4-fold </span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'><br>
  &#8593; 38-fold </span></p>
  </td>
  <td width="12%" colspan=3 valign=top style='width:12.5%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 2.5-fold
  </span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'><br>
  &#8593; 16-fold</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Due to the large
  increase in rifabutin AUC, the concomitant use of rifabutin with ritonavir
  dosed as an antiretroviral agent is <b>contraindicated </b>(see section
  4.3). </span><span style='font-size:9.5pt'>The reduction of the rifabutin
  dose to 150&nbsp;mg 3 times per week</span><span style='font-size:9.5pt'> may
  be indicated for select PIs when co&#8209;administered with ritonavir as a
  pharmacokinetic enhancer. </span><span style='font-size:9.5pt;color:black'>The
  Summary of Product Characteristics of the co&#8209;administered protease
  inhibitor should be consulted for specific recommendations. </span><span
  style='font-size:9.5pt'>Consideration should be given to official guidance on
  the appropriate treatment of tuberculosis in HIV-infected patients. </span><span
  style='font-size:9.5pt'></span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Rifampicin</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>Although rifampicin may
  induce metabolism of ritonavir, limited data indicate that when high doses of
  ritonavir (600&nbsp;mg twice daily) is co&#8209;administered with rifampicin,
  the additional inducing effect of rifampicin (next to that of ritonavir
  itself) is small and may have no clinical relevant effect on ritonavir levels
  in high-dose ritonavir therapy. The effect of ritonavir on rifampicin is not
  known.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Voriconazole</span></p>
  </td>
  <td width="14%" valign=top style='width:14.94%;border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>200 q12h</span></p>
  </td>
  <td width="16%" colspan=9 valign=top style='width:16.1%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>400 q12h </span></p>
  </td>
  <td width="16%" colspan=5 valign=top style='width:16.04%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8595; 82%</span></p>
  </td>
  <td width="12%" colspan=3 valign=top style='width:12.5%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8595; 66%</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='color:black'>&nbsp;</span></p>
  </td>
  <td width="14%" valign=top style='width:14.94%;border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>200 q12h</span></p>
  </td>
  <td width="16%" colspan=9 valign=top style='width:16.1%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>100 q12h</span></p>
  </td>
  <td width="16%" colspan=5 valign=top style='width:16.04%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8595; 39%</span></p>
  </td>
  <td width="12%" colspan=3 valign=top style='width:12.5%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8595; 24%</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Concomitant use
  of ritonavir dosed as an antiretroviral agent and voriconazole is <b>contraindicated</b>
  due to reduction in voriconazole concentrations (see section 4.3). </span><span
  style='font-size:9.5pt'>Co-administration of voriconazole and ritonavir dosed
  as a pharmacokinetic enhancer should be avoided, unless an assessment of the
  benefit/risk to the patient justifies the use of voriconazole.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Atovaquone</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Ritonavir dosed
  as a pharmacokinetic enhancer or as an antiretroviral agent induces
  glucuronidation and as a result is expected to decrease the plasma
  concentrations of atovaquone. </span><span style='font-size:9.5pt'>Careful
  monitoring of serum levels or therapeutic effects is recommended when
  atovaquone is concomitantly administered with ritonavir.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='text-align:justify'><span style='font-size:9.5pt;
  color:black'>Bedaquiline</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>No interaction study is
  available with ritonavir only. In an interaction study of single-dose
  bedaquiline and multiple dose lopinavir/ritonavir, the AUC of bedaquiline was
  increased by 22%. This increase is likely due to ritonavir and a more
  pronounced effect may be observed during prolonged co-administration. Due to
  the risk of bedaquiline related adverse events, co-administration should be
  avoided. If the benefit outweighs the risk, co-administration of bedaquiline
  with ritonavir must be done with caution. More frequent electrocardiogram
  monitoring and monitoring of transaminases is recommended (see section 4.4
  and refer to the bedaquiline</span><span style='font-size:9.5pt'> </span><span
  style='font-size:9.5pt'>Summary<span style='color:black'> of Product
  Characteristics</span>).</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>Clarithromycin<br>
  <br>
  14-OH clarithromycin metabolite </span></p>
  </td>
  <td width="16%" colspan=2 valign=top style='width:16.04%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>500 q12h </span></p>
  </td>
  <td width="12%" colspan=6 valign=top style='width:12.6%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>200 q8h</span></p>
  </td>
  <td width="16%" colspan=6 valign=top style='width:16.14%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&#8593; 77% <br>
  <br>
  &#8595; 100% </span></p>
  </td>
  <td width="14%" colspan=4 valign=top style='width:14.82%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&#8593; 31% <br>
  <br>
  &#8595; 99% </span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>Due to the large therapeutic window of clarithromycin no
  dose reduction should be necessary in patients with normal renal function. Clarithromycin
  doses greater than 1 g per day should not be co-administered with ritonavir
  dosed as an antiretroviral agent or as a pharmacokinetic enhancer. For
  patients with renal impairment, a clarithromycin dose reduction should be
  considered: for patients with creatinine clearance of 30 to 60&nbsp;ml/min
  the dose should be reduced by 50%, for patients with creatinine clearance
  less than 30&nbsp;ml/min the dose should be reduced by 75%.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Delamanid</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>No interaction
  study is available with ritonavir only. In a healthy volunteer drug
  interaction study of delamanid 100&nbsp;mg twice daily and
  lopinavir/ritonavir 400/100&nbsp;mg twice daily for 14 days, the exposure of
  the delamanid metabolite DM-6705 was 30% increased. Due to the risk of QTc
  prolongation associated with DM&#8209;6705, if co&#8209;administration of
  delamanid with ritonavir is considered necessary, very frequent ECG
  monitoring throughout the full delamanid treatment period is recommended (see
  section 4.4 and refer to the delamanid Summary of Product Characteristics).</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Erythromycin,
  itraconazole</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Ritonavir dosed
  as a pharmacokinetic enhancer or as an antiretroviral agent inhibits CYP3A4
  and as a result is expected to increase the plasma concentrations of
  erythromycin and itraconazole. </span><span style='font-size:9.5pt'>Careful
  monitoring of therapeutic and adverse effects is recommended when
  erythromycin or itraconazole is used concomitantly administered with
  ritonavir.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Ketoconazole</span></p>
  </td>
  <td width="16%" colspan=2 valign=top style='width:16.04%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>200 daily</span></p>
  </td>
  <td width="12%" colspan=6 valign=top style='width:12.6%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>500 q12h</span></p>
  </td>
  <td width="16%" colspan=6 valign=top style='width:16.14%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 3.4-fold
  </span></p>
  </td>
  <td width="14%" colspan=4 valign=top style='width:14.82%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 55% </span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Ritonavir
  inhibits CYP3A-mediated metabolism of ketoconazole. Due to an increased
  incidence of gastrointestinal and hepatic adverse reactions, a dose reduction
  of ketoconazole should be considered when co-administered with ritonavir
  dosed as an antiretroviral agent or as a pharmacokinetic enhancer.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Sulfamethoxazole/Trimethoprim</span><span
  class=sup1><sup><span style='font-size:9.5pt;color:black'>2</span></sup></span></p>
  </td>
  <td width="16%" colspan=2 valign=top style='width:16.04%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>800/160, single
  dose </span></p>
  </td>
  <td width="12%" colspan=6 valign=top style='width:12.6%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>500 q12h </span></p>
  </td>
  <td width="16%" colspan=6 valign=top style='width:16.14%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8595; 20% / &#8593;
  20%</span></p>
  </td>
  <td width="14%" colspan=4 valign=top style='width:14.82%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8596;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Dose alteration
  of sulfamethoxazole/trimethoprim during concomitant ritonavir therapy should
  not be necessary.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoHeading7 style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in'>Antipsychotics/Neuroleptics</p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>Clozapine, pimozide</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>Ritonavir co-administration
  is likely to result in increased plasma concentrations of clozapine or
  pimozide and is therefore <b>contraindicated </b>(see section 4.3).</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>Haloperidol, risperidone,
  thioridazine</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>Ritonavir dosed as an
  antiretroviral agent is likely to inhibit CYP2D6 and as a result is expected
  to increase concentrations of haloperidol, risperidone and thioridazine.
  Careful monitoring of therapeutic and adverse effects is recommended when
  these medicines are concomitantly administered with antiretroviral doses of ritonavir.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Lurasidone</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.5pt;color:black'>Due
  to CYP3A inhibition by ritonavir, concentrations of lurasidone are expected
  to increase. The concomitant administration with lurasidone is
  contraindicated (see section 4.3).</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>Quetiapine</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.5pt'>Due to CYP3A
  inhibition by ritonavir, concentrations of quetiapine are expected to
  increase. Concomitant administration of Norvir and quetiapine is
  contraindicated as it may increase quetiapine-related toxicity </span><span
  style='font-size:9.5pt'>(see section 4.3)</span><span lang=EN-GB
  style='font-size:9.5pt'>.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoHeading7 style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in'>&#946;2-agonist (long acting)</p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><b>&nbsp;</b></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>Salmeterol</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>Ritonavir inhibits CYP3A4
  and as a result a pronounced increase in the plasma concentrations of
  salmeterol is expected. Therefore concomitant use is not recommended.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoHeading7 style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in'>Calcium channel antagonists</p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span lang=IT style='font-size:9.5pt;color:black'>Amlodipine,
  diltiazem, nifedipine</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Ritonavir dosed
  as a pharmacokinetic enhancer or as an antiretroviral agent inhibits CYP3A4
  and as a result is expected to increase the plasma concentrations of calcium
  channel antagonists. </span><span style='font-size:9.5pt'>Careful monitoring
  of therapeutic and adverse effects is recommended when these medicines are
  concomitantly administered with ritonavir.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoHeading7 style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in'>Endothelin antagonists</p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoHeading7><span style='font-size:9.5pt;font-weight:normal'>Bosentan</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>Co-administration of
  bosentan and ritonavir may increase steady state</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt'>bosentan maximum concentr
  ations (C<sub>max</sub>) and area under the curve</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt'>(AUC).</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoHeading7 style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in'><span style='font-size:9.5pt;font-weight:normal'>Riociguat</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='text-autospace:none'><span style='font-size:9.5pt;
  font-family:"TimesNewRoman\,Italic"'>Serum concentrations may be increased
  due to CYP3A and P-gp inhibition by ritonavir. The co&#8209;administration
  of riociguat with Norvir is not recommended (see section 4.4 and refer to
  riociguat SmPC).</span></p>
  <p class=MsoNormal style='text-autospace:none'><span style='font-size:9.5pt;
  font-family:"TimesNewRoman\,Italic"'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoHeading7 style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in'>Ergot Derivatives</p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span lang=IT style='font-size:9.5pt;color:black'>Dihydroergotamine,
  ergonovine, ergotamine, methylergonovine</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>Ritonavir co-administration
  is likely to result in increased plasma concentrations of ergot derivatives
  and is therefore <b>contraindicated </b>(see section 4.3).</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoHeading7 style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in'>GI motility agent</p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span lang=IT style='font-size:9.5pt;color:black'>Cisapride</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>Ritonavir co-administration
  is likely to result in increased plasma concentrations of cisapride and is
  therefore <b>contraindicated </b>(see section 4.3).</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><b>HCV Direct Acting Antiviral</b></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>Glecaprevir/pibrentasvir</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='margin-right:-1.0pt;text-autospace:none'><span
  style='font-size:9.5pt'>Serum concentrations may be increased due to <span
  style='color:black'>P-glycoprotein, BCRP and OATP1B</span></span><span
  style='color:black'> </span><span style='font-size:9.5pt'>inhibition by
  ritonavir.</span></p>
  <p class=MsoNormal style='margin-right:-1.0pt;text-autospace:none'><span
  style='font-size:9.5pt'>&nbsp;</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt'>Concomitant administration
  of glecaprevir/pibrentasvir and Norvir is not recommended due to an increased
  risk of ALT elevations associated with increased glecaprevir exposure.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><b>HCV Protease Inhibitor</b></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>Simeprevir</span></p>
  </td>
  <td width="14%" valign=top style='width:14.94%;border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>200 qd</span></p>
  </td>
  <td width="14%" colspan=8 valign=top style='width:14.9%;border:none;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>100 q12h</span></p>
  </td>
  <td width="14%" colspan=5 valign=top style='width:14.92%;border:none;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>&#8593; 7.2-fold</span></p>
  </td>
  <td width="14%" colspan=4 valign=top style='width:14.82%;border:none;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>&#8593; 4.7-fold</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span lang=IT style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='margin-right:-1.0pt;text-autospace:none'><span
  style='font-size:9.5pt'>Ritonavir increases plasma concentrations of
  simeprevir as a result of CYP3A4 inhibition. </span><span style='font-size:
  9.5pt;letter-spacing:-.15pt'>It is not recommended to co-administer </span><span
  style='font-size:9.5pt;letter-spacing:.05pt'>ritonavir</span><span
  style='font-size:9.5pt;letter-spacing:-.15pt'> with simeprevir.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoHeading7 style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in'>HMG Co-A Reductase Inhibitors</p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span lang=SV style='font-size:9.5pt;color:black'>Atorvastatin,
  Fluvastatin, Lovastatin, Pravstatin, Rosuvastatin, Simvastatin</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>HMG-CoA
  reductase inhibitors which are highly dependent on CYP3A metabolism, such as
  lovastatin and simvastatin, are expected to have markedly increased plasma
  concentrations when co-administered with ritonavir dosed as an antiretroviral
  agent or as a pharmacokinetic enhancer. Since increased concentrations of
  lovastatin and simvastatin may predispose patients to myopathies, including
  rhabdomyolysis, the combination of these medicinal products with ritonavir is
  <b>contraindicated</b> (see section 4.3). Atorvastatin is less dependent on
  CYP3A for metabolism. While rosuvastatin elimination is not dependent on
  CYP3A, an elevation of rosuvastatin exposure has been reported with ritonavir
  co-administration. </span><span style='font-size:9.5pt'>The mechanism of
  this interaction is not clear, but may be the result of transporter
  inhibition. </span><span style='font-size:9.5pt;color:black'>When used with
  ritonavir dosed as a pharmacokinetic enhancer or as an antiretroviral agent,
  the lowest possible doses of atorvastatin or rosuvastatin should be
  administered. The metabolism of pravastatin and fluvastatin is not dependent
  on CYP3A, and interactions are not expected with ritonavir. If treatment
  with an HMG-CoA reductase inhibitor is indicated, pravastatin or fluvastatin
  is recommended.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoHeading7 style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in'>Hormonal contraceptive</p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>Ethinyl estradiol</span></p>
  </td>
  <td width="17%" colspan=4 valign=top style='width:17.22%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>50 g, single dose </span></p>
  </td>
  <td width="13%" colspan=6 valign=top style='width:13.82%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>500 q12h</span></p>
  </td>
  <td width="16%" colspan=5 valign=top style='width:16.04%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&#8595; 40% </span></p>
  </td>
  <td width="12%" colspan=3 valign=top style='width:12.5%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&#8595; 32% </span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Due to
  reductions in ethinyl estradiol concentrations, barrier or other non-hormonal
  methods of contraception should be considered with concomitant ritonavir use
  when dosed as an antiretroviral agent or as a pharmacokinetic enhancer.
  Ritonavir is likely to change the uterine bleeding profile and reduce the
  effectiveness of estradiol-containing contraceptives (see section 4.4).</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoHeading7 style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in'>Immunosupressants</p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Cyclosporine, tacrolimus,
  everolimus</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Ritonavir dosed
  as a pharmacokinetic enhancer or as an antiretroviral agent inhibits CYP3A4
  and as a result is expected to increase the plasma concentrations of
  cyclosporine, tacrolimus or everolimus. </span><span style='font-size:9.5pt'>Careful
  monitoring of therapeutic and adverse effects is recommended when these
  medicines are concomitantly administered with ritonavir.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoHeading7 style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in'>Lipid-modifying agents</p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Lomitapide</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>CYP3A4
  inhibitors increase the exposure of lomitapide, with strong inhibitors
  increasing exposure approximately 27&#8209;fold. Due to CYP3A inhibition by
  ritonavir, concentrations of lomitapide are expected to increase.
  Concomitant use of Norvir with lomitapide is contraindicated (see prescribing
  information for lomitapide) (see section 4.3).</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoHeading7 style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in'>Phosphodiesterase (PDE5) inhibitors</p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 rowspan=2 valign=top style='width:37.84%;
  border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Avanafil</span></p>
  </td>
  <td width="17%" colspan=4 valign=top style='width:17.22%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>50, single dose</span></p>
  </td>
  <td width="13%" colspan=6 valign=top style='width:13.82%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>600 q12h</span></p>
  </td>
  <td width="16%" colspan=5 valign=top style='width:16.04%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 13-fold</span></p>
  </td>
  <td width="12%" colspan=3 valign=top style='width:12.5%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 2.4-fold</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Concomitant use
  of avanafil with ritonavir is contraindicated (see section 4.3).</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Sildenafil</span></p>
  </td>
  <td width="17%" colspan=4 valign=top style='width:17.22%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>100, single dose
  </span></p>
  </td>
  <td width="13%" colspan=6 valign=top style='width:13.82%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>500 q12h</span></p>
  </td>
  <td width="16%" colspan=5 valign=top style='width:16.04%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 11-fold</span></p>
  </td>
  <td width="12%" colspan=3 valign=top style='width:12.5%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 4-fold</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>Concomitant use of
  sildenafil for the treatment of erectile dysfunction with ritonavir dosed as
  an antiretroviral agent or as a pharmacokinetic enhancer should be with
  caution and in no instance should sildenafil doses exceed 25&nbsp;mg in 48
  hours (see also section 4.4). Concomitant use of sildenafil with ritonavir
  is <b>contraindicated</b> in pulmonary arterial hypertension patients (see
  section 4.3).</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>Tadalafil</span></p>
  </td>
  <td width="17%" colspan=4 valign=top style='width:17.22%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>20, single dose </span></p>
  </td>
  <td width="13%" colspan=6 valign=top style='width:13.82%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>200 q12h </span></p>
  </td>
  <td width="16%" colspan=5 valign=top style='width:16.04%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&#8593; 124%</span></p>
  </td>
  <td width="12%" colspan=3 valign=top style='width:12.5%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&#8596;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>The concomitant use of tadalafil for the treatment of erectile
  dysfunction with ritonavir dosed as an antiretroviral agent or as a
  pharmacokinetic enhancer should be with caution at reduced doses of no more
  than 10&nbsp;mg tadalafil every 72 hours with increased monitoring for
  adverse reactions (see section 4.4).</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&nbsp;</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>When tadalafil is used concurrently with ritonavir in
  patients with pulmonary arterial hypertension, refer to the tadalafil Summary
  of Product Characteristics.</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Vardenafil</span></p>
  </td>
  <td width="17%" colspan=4 valign=top style='width:17.22%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>5, single dose</span></p>
  </td>
  <td width="13%" colspan=6 valign=top style='width:13.82%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>600 q12h</span></p>
  </td>
  <td width="16%" colspan=5 valign=top style='width:16.04%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 49-fold</span></p>
  </td>
  <td width="12%" colspan=3 valign=top style='width:12.5%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 13-fold</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Concomitant use
  of vardenafil with ritonavir is contraindicated (see section 4.3).</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoHeading7 style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in'>Sedatives/hypnotics</p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-top:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span lang=PT-BR style='font-size:9.5pt;color:black'>Clorazepate,
  diazepam, estazolam, flurazepam, oral and parenteral midazolam </span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-top:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>Ritonavir co-administration
  is likely to result in increased plasma concentrations of <span
  style='color:black'>clorazepate, diazepam, estazolam and flurazepam </span>and
  is therefore <b>contraindicated </b>(see section 4.3). </span></p>
  <p class=MsoNormal><span style='font-size:9.5pt'>Midazolam is extensively
  metabolised by CYP3A4. Co&#8209;administration with Norvir may cause a large
  increase in the concentration of this benzodiazepine. No medicinal product
  interaction study has been performed for the co&#8209;administration of
  Norvir with benzodiazepines. Based on data for other CYP3A4 inhibitors,
  plasma concentrations of midazolam are expected to be significantly higher
  when midazolam is given orally. Therefore, Norvir should not be co&#8209;administered
  with orally administered midazolam (see section 4.3), whereas caution should
  be used with co&#8209;administration of Norvir and parenteral midazolam.
  Data from concomitant use of parenteral midazolam with other protease
  inhibitors suggest a possible 3&nbsp;&nbsp;4 fold increase in midazolam
  plasma levels. If Norvir is co&#8209;administered with parenteral midazolam,
  it should be done in an intensive care unit (ICU) or similar setting which
  ensures close clinical monitoring and appropriate medical management in case
  of respiratory depression and/or prolonged sedation. Dosage adjustment for
  midazolam should be considered, especially if more than a single dose of
  midazolam is administered.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Triazolam</span></p>
  </td>
  <td width="17%" colspan=4 valign=top style='width:17.22%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>0.125, single
  dose</span></p>
  </td>
  <td width="13%" colspan=6 valign=top style='width:13.82%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>200, 4 doses</span></p>
  </td>
  <td width="16%" colspan=5 valign=top style='width:16.04%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593;
  &gt;&nbsp;20 fold</span></p>
  </td>
  <td width="12%" colspan=3 valign=top style='width:12.5%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 87%</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Ritonavir
  co-administration is likely to result in increased plasma concentrations of
  triazolam and is therefore <b>contraindicated</b> (see section 4.3).</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Pethidine <br>
  <br>
  Norpethidine metabolite </span></p>
  </td>
  <td width="17%" colspan=4 valign=top style='width:17.22%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>50, oral single
  dose </span></p>
  </td>
  <td width="13%" colspan=6 valign=top style='width:13.82%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>500 q12h</span></p>
  </td>
  <td width="16%" colspan=5 valign=top style='width:16.04%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8595; 62% </span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'><br>
  &#8593; 47% </span></p>
  </td>
  <td width="12%" colspan=3 valign=top style='width:12.5%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8595; 59% <br>
  <br>
  &#8593; 87% </span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>The use of
  pethidine and ritonavir is <b>contraindicated </b>due to the increased
  concentrations of the metabolite, norpethidine, which has both analgesic and
  CNS stimulant activity. Elevated norpethidine concentrations may increase
  the risk of CNS effects (e.g., seizures), see section 4.3.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>Alprazolam</span></p>
  </td>
  <td width="17%" colspan=4 valign=top style='width:17.22%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>1, single dose </span></p>
  </td>
  <td width="13%" colspan=6 valign=top style='width:13.82%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>200 q12h, 2 days</span></p>
  </td>
  <td width="16%" colspan=5 valign=top style='width:16.04%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&#8593;&nbsp;2.5 fold</span></p>
  </td>
  <td width="12%" colspan=3 valign=top style='width:12.5%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&#8596;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="17%" colspan=4 valign=top style='width:17.22%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="13%" colspan=6 valign=top style='width:13.82%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>500 q12h,<b><i><u> </u></i></b>10 days</span></p>
  </td>
  <td width="16%" colspan=5 valign=top style='width:16.04%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&#8595; 12% </span></p>
  </td>
  <td width="12%" colspan=3 valign=top style='width:12.5%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&#8595; 16% </span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>Alprazolam metabolism was inhibited following the
  introduction of ritonavir. After ritonavir use for 10 days, no inhibitory
  effect of ritonavir was observed. Caution is warranted during the first
  several days when alprazolam is co&#8209;administered with ritonavir dosed as
  an antiretroviral agent or as a pharmacokinetic enhancer, before induction of
  alprazolam metabolism develops.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span style='font-size:
  9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid;height:56.4pt'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt;
  height:56.4pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Buspirone</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt;
  height:56.4pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Ritonavir dosed
  as a pharmacokinetic enhancer or as an antiretroviral agent inhibits CYP3A
  and as a result is expected to increase the plasma concentrations of
  buspirone. </span><span style='font-size:9.5pt'>Careful monitoring of
  therapeutic and adverse effects is recommended when buspirone concomitantly
  administered with ritonavir.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoHeading7 style='margin-bottom:6.0pt'>Sleeping agent</p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Zolpidem</span></p>
  </td>
  <td width="17%" colspan=4 valign=top style='width:17.22%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>5 </span></p>
  </td>
  <td width="13%" colspan=6 valign=top style='width:13.82%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>200, 4 doses</span></p>
  </td>
  <td width="16%" colspan=5 valign=top style='width:16.04%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 28%</span></p>
  </td>
  <td width="12%" colspan=3 valign=top style='width:12.5%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 22%</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Zolpidem and
  ritonavir may be co-administered with careful monitoring for excessive
  sedative effects.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoHeading7 style='margin-bottom:6.0pt'>Smoke cessation</p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Bupropion</span></p>
  </td>
  <td width="17%" colspan=4 valign=top style='width:17.22%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>150 </span></p>
  </td>
  <td width="13%" colspan=6 valign=top style='width:13.82%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>100 q12h</span></p>
  </td>
  <td width="16%" colspan=5 valign=top style='width:16.04%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8595; 22%</span></p>
  </td>
  <td width="12%" colspan=3 valign=top style='width:12.5%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8595; 21%</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="17%" colspan=4 valign=top style='width:17.22%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>150 </span></p>
  </td>
  <td width="13%" colspan=6 valign=top style='width:13.82%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>600 q12h</span></p>
  </td>
  <td width="16%" colspan=5 valign=top style='width:16.04%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8595; 66%</span></p>
  </td>
  <td width="12%" colspan=3 valign=top style='width:12.5%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8595; 62%</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoHeader><span lang=EN-GB style='font-size:9.5pt'>Bupropion is
  primarily metabolised by CYP2B6. Concurrent administration of bupropion with
  repeated doses of ritonavir is expected to decrease bupropion levels. These
  effects are thought to represent induction of bupropion metabolism. However,
  because ritonavir has also been shown to inhibit CYP2B6 <i>in vitro</i>, the
  recommended dose of bupropion should not be exceeded. In contrast to
  long-term administration of ritonavir, there was no significant interaction
  with bupropion after short-term administration of low doses of ritonavir
  (200&nbsp;mg twice daily for 2 days), suggesting reductions in bupropion
  concentrations may have onset several days after initiation of ritonavir co&#8209;administration.</span></p>
  <p class=MsoHeader><span lang=EN-GB style='font-size:9.5pt'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoHeading7 style='margin-bottom:6.0pt'>Steroids</p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:9.5pt'>Inhaled,
  injectable or intranasal fluticasone propionate, budesonide, triamcinolone</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Systemic
  corticosteroid effects including Cushing's syndrome and adrenal suppression
  (plasma cortisol levels were noted to be decreased 86% in the above study)
  have been reported in patients receiving ritonavir and inhaled or intranasal
  fluticasone propionate; similar effects could also occur with other
  corticosteroids metabolised by CYP3A e.g., budesonide and triamcinolone.
  Consequently, concomitant administration of ritonavir dosed as an antiretroviral
  agent or as a pharmacokinetic enhancer and these glucocorticoids is not
  recommended unless the potential benefit of treatment outweighs the risk of
  systemic corticosteroid effects (see section 4.4). </span><span
  style='font-size:9.5pt'>A dose reduction of the glucocorticoid should be
  considered with close monitoring of local and systemic effects or a switch to
  a glucocorticoid, which is not a substrate for CYP3A4 (e.g.,
  beclomethasone). Moreover, in case of withdrawal of glucocorticoids
  progressive dose reduction may be required over a longer period.<span
  style='color:black;background:#CCFFFF'> </span></span><span style='font-size:
  9.5pt;color:black'></span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Dexamethasone</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Ritonavir dosed
  as a pharmacokinetic enhancer or as an antiretroviral agent inhibits CYP3A
  and as a result is expected to increase the plasma concentrations of
  dexamethasone. </span><span style='font-size:9.5pt'>Careful monitoring of
  therapeutic and adverse effects is recommended when dexamethasone is
  concomitantly administered with ritonavir. </span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Prednisolone</span></p>
  </td>
  <td width="14%" valign=top style='width:14.94%;border:none;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>20</span></p>
  </td>
  <td width="17%" colspan=10 valign=top style='width:17.16%;border:none;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>200 q12h</span></p>
  </td>
  <td width="16%" colspan=5 valign=top style='width:16.04%;border:none;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 28%</span></p>
  </td>
  <td width="11%" colspan=2 valign=top style='width:11.44%;border:none;
  padding:.75pt .75pt .75pt .75pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&#8593; 9%</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Careful
  monitoring of therapeutic and adverse effects is recommended when
  prednisolone is concomitantly administered with ritonavir. </span><span
  style='font-size:9.5pt'>The AUC of the metabolite prednisolone increased by
  37 and 28% after 4 and 14 days ritonavir, respectively.</span></p>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoHeading7 style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in'>Thyroid hormone replacement therapy</p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  border-bottom:solid windowtext 1.0pt;padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt'>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Levothyroxine</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>Post&#8209;marketing
  cases have been reported indicating a potential interaction between ritonavir
  containing products and levothyroxine. Thyroid&#8209;stimulating hormone
  (TSH) should be monitored in patients treated with levothyroxine at least the
  first month after starting and/or ending ritonavir treatment.</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
  <td width="37%" colspan=2 valign=top style='width:37.84%;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>&nbsp;</span></p>
  </td>
  <td width="59%" colspan=18 valign=top style='width:59.58%;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:.75pt 6.0pt .75pt 6.0pt'>
  <p class=MsoNormal><span style='font-size:9.5pt;color:black'>ND: Not
  determined</span></p>
  <p class=MsoNormal style='margin-left:.5in;text-indent:-.25in'><span
  style='font-size:9.5pt;color:black'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
  </span></span><span style='font-size:9.5pt;color:black'>Based on a parallel
  group comparison</span></p>
  <p class=MsoNormal style='margin-left:.5in;text-indent:-.25in'><span
  style='font-size:9.5pt;color:black'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
  </span></span><span style='font-size:9.5pt;color:black'>Sulfamethoxazole was
  co-administered with trimethoprim. </span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width="1%"><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr height=0>
  <td width=9 style='border:none'></td>
  <td width=274 style='border:none'></td>
  <td width=2 style='border:none'></td>
  <td width=109 style='border:none'></td>
  <td width=8 style='border:none'></td>
  <td width=1 style='border:none'></td>
  <td width=7 style='border:none'></td>
  <td width=8 style='border:none'></td>
  <td width=4 style='border:none'></td>
  <td width=5 style='border:none'></td>
  <td width=67 style='border:none'></td>
  <td width=9 style='border:none'></td>
  <td width=9 style='border:none'></td>
  <td width=8 style='border:none'></td>
  <td width=8 style='border:none'></td>
  <td width=37 style='border:none'></td>
  <td width=47 style='border:none'></td>
  <td width=17 style='border:none'></td>
  <td width=8 style='border:none'></td>
  <td width=17 style='border:none'></td>
  <td width=67 style='border:none'></td>
  <td width=9 style='border:none'></td>
 </tr>
</table>

<p class=MsoHeader>&nbsp;</p>

<p class=MsoHeader>Cardiac and neurologic events have been reported when
ritonavir has been co-administered with disopyramide, mexiletine or nefazodone.
The possibility of medicinal product interaction cannot be excluded.</p>

<p class=MsoHeader>&nbsp;</p>

<p class=MsoHeader>In addition to the interactions listed above, as ritonavir
is highly protein bound, the possibility of increased therapeutic and toxic
effects due to protein binding displacement of concomitant medicinal products
should be considered.</p>

<p class=MsoHeader>&nbsp;</p>

<p class=MsoHeader><u>Ritonavir dosed as a pharmacokinetic enhancer</u></p>

<p class=MsoHeader>&nbsp;</p>

<p class=EMEANormal>Important information regarding medicinal product
interactions when ritonavir is used a pharmacokinetic enhancer is also
contained in the Summary of Product Characteristics of the co-administered
protease inhibitor.</p>

<p class=EMEANormal>&nbsp;</p>

<p class=EMEANormal><i><span lang=EN-GB>Proton pump inhibitors and H<sub>2</sub>-receptor
antagonists</span></i></p>

<p class=EMEANormal><span lang=EN-GB>Proton pump inhibitors and H<sub>2</sub>-receptor
antagonists (e.g. omeprazole or ranitidine) may reduce concentrations for co&#8209;administered
protease inhibitors. For specific information regarding the impact of co&#8209;administration
of acid reducing agents, refer to the Summary of Product Characteristics of the
co-administered protease inhibitor.</span><span lang=EN-GB> </span><span
lang=EN-GB>Based on interaction studies with the ritonavir boosted protease
inhibitors (lopinavir/ritonavir, atazanavir), concurrent administration of
omeprazole or ranitidine does not significantly modify ritonavir efficacy as a
pharmacokinetic enhancer despite a slight change of exposure (about
6&nbsp;-&nbsp;18%). </span></p>

<p class=EMEANormal>&nbsp;</p>

<p class=EMEAHeading2SPC style='margin:0in;page-break-after:avoid'><span
lang=EN-GB>4.6 Fertility, pregnancy and lactation</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal1 style='page-break-after:avoid'><u><span lang=EN-GB
style='color:black'>Pregnancy</span></u></p>

<p class=EMEANormal1><span lang=EN-GB style='color:black'>A large amount (6100
live births) of pregnant women were exposed to ritonavir during pregnancy; of
these, 2800 live births were exposed during the first trimester. These data
largely refer to exposures where ritonavir was used in combination therapy and
not at therapeutic ritonavir doses but at lower doses as a pharmacokinetic
enhancer for other PIs. These data indicate no increase in the rate of birth
defects compared to rates observed in population-based birth defect
surveillance systems.</span><span lang=EN-GB> Animal data have shown
reproductive toxicity (see section 5.3). Norvir can be used during pregnancy
if clinically needed.</span></p>

<p class=EMEANormal1><s><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></s></p>

<p class=MsoNormal>Ritonavir adversely interacts with oral contraceptives
(OCs). Therefore, an alternative, effective and safe method of contraception
should be used during treatment.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><u>Breastfeeding</u></p>

<p class=MsoNormal>Limited published data reports that ritonavir is present in
human milk.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>There is no information on the effects of ritonavir on the
breastfed infant or the effects of the drug on milk production. Because of the
potential for (1) HIV transmission (in HIV-negative infants), (2) developing
viral resistance (in HIV-postive infants) and (3) serious adverse reactions in
a breastfed infant, HIV infected women should not breast feed their infants
under any circumstances if they are receiving Norvir. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><u>Fertility</u></p>

<p class=MsoNormal>No human data on the effect of ritonavir on fertility are
available. Animal studies do not indicate harmful effects of ritonavir on
fertility (see section 5.3).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB>4.7 Effects on
ability to drive and use machines</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>No studies on the effects on the ability to drive and use
machines have been performed. Dizziness is a known undesirable effect that
should be taken into account when driving or using machinery.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=EMEAHeading2SPC style='margin:0in;page-break-after:avoid'><span
lang=EN-GB>4.8 Undesirable effects</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><u><span lang=EN-GB>Summary
of the safety profile</span></u></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<h6>Ritonavir dosed as a pharmacokinetic enhancer</h6>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Adverse reactions associated with the use of ritonavir as a
pharmacokinetic enhancer are dependent on the specific co-administered PI. For
information on adverse reactions refer to the SPC of the specific co&#8209;administered
PI.</p>

<p class=MsoNormal>&nbsp;</p>

<h6>Ritonavir dosed as an antiretroviral agent</h6>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><i><u>Adverse reactions from clinical trials and
post-marketing experience in adult patients</u></i></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>The most frequently reported adverse drug reactions among
patients receiving ritonavir alone or in combination with other antiretroviral
drugs were gastrointestinal (including diarrhea, nausea, vomiting, abdominal
pain (upper and lower)), neurological disturbances (including paresthesia and
oral paresthesia) and fatigue/asthenia.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><u>Tabulated list of adverse
reactions</u></p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'>The following adverse
reactions of moderate to severe intensity with possible or probable
relationship to ritonavir have been reported. Within each frequency grouping,
undesirable effects are presented in order of decreasing seriousness: very
common (&#8805;&nbsp;1/10); common (&#8805;&nbsp;1/100 to &lt;&nbsp;1/10);
uncommon (&#8805;&nbsp;1/1000 to &lt;&nbsp;1/100); rare (&#8805;&nbsp;1/10,000
to &lt;&nbsp;1/1,000); not known (cannot be estimated from the available data).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Events noted as having frequency not known were identified
via post-marketing surveillance.</p>

<p class=MsoNormal>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=3 valign=top style='width:464.45pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=pedtablecenter style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in;page-break-after:avoid'><b><span lang=EN-GB>Adverse
  reactions in clinical studies and post-marketing in adult patients</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=227 valign=top style='width:170.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:6.0pt;page-break-after:avoid'><b>System
  Order Class</b></p>
  </td>
  <td width=110 valign=top style='width:82.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=pedtablecenter style='margin-bottom:6.0pt;page-break-after:avoid'><b><span
  lang=EN-GB>Frequency</span></b></p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:6.0pt;page-break-after:avoid'><b>Adverse
  reaction</b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=227 rowspan=2 valign=top style='width:170.4pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Blood and lymphatic system
  disorders</p>
  </td>
  <td width=110 valign=top style='width:82.5pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=pedtablecenter style='page-break-after:avoid'><span lang=EN-GB>Common</span></p>
  <p class=pedtablecenter style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Decreased white blood cells,
  decreased haemoglobin, decreased neutrophils, increased eosinophils,
  thrombocytopenia</p>
  <p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=110 valign=top style='width:82.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=pedtablecenter style='page-break-after:avoid'><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Increased neutrophils </p>
  <p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=227 valign=top style='width:170.4pt;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Immune system disorders</p>
  </td>
  <td width=110 valign=top style='width:82.5pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=pedtablecenter style='page-break-after:avoid'><span lang=EN-GB>Common</span></p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Hypersensitivity including
  urticaria, and face oedema</p>
  <p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=227 valign=top style='width:170.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=110 valign=top style='width:82.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=pedtablecenter style='page-break-after:avoid'><span lang=EN-GB>Rare</span></p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Anaphylaxis</p>
  <p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Metabolism and nutrition disorders</p>
  </td>
  <td width=110 valign=top style='width:82.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=pedtablecenter><span lang=EN-GB>Common</span></p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Hypercholesterolaemia, hypertriglyceridaemia, gout, oedema
  and peripheral oedema, dehydration (usually associated with gastrointestinal
  symptoms)</p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>&nbsp;</p>
  </td>
  <td width=110 valign=top style='width:82.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=pedtablecenter><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Diabetes mellitus </p>
  <p class=MsoNormal>&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>&nbsp;</p>
  </td>
  <td width=110 valign=top style='width:82.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=pedtablecenter><span lang=EN-GB>Rare</span></p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Hyperglycaemia</p>
  <p class=MsoNormal>&nbsp;</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=227 rowspan=2 valign=top style='width:170.4pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Nervous system disorders</p>
  </td>
  <td width=110 valign=top style='width:82.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=pedtablecenter style='page-break-after:avoid'><span lang=EN-GB>Very
  common</span></p>
  <p class=pedtablecenter style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=pedtablecenter style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Dysgeusia, oral and
  peripheral paraesthesia, headache, dizziness, peripheral neuropathy</p>
  <p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=110 valign=top style='width:82.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=pedtablecenter style='page-break-after:avoid'><span lang=EN-GB>Common</span></p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Insomnia, anxiety, confusion,
  disturbance in attention, syncope, seizure</p>
  <p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.4pt;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:6.0pt'>Eye disorders</p>
  </td>
  <td width=110 valign=top style='width:82.5pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=pedtablecenter style='margin-bottom:6.0pt'><span lang=EN-GB>Common</span></p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Blurred vision</p>
  <p class=MsoNormal>&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.4pt;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:6.0pt'>Cardiac disorders</p>
  </td>
  <td width=110 valign=top style='width:82.5pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=pedtablecenter style='margin-bottom:6.0pt'><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Myocardial infarction</p>
  <p class=MsoNormal>&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.4pt;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Vascular disorders</p>
  </td>
  <td width=110 valign=top style='width:82.5pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=pedtablecenter><span lang=EN-GB>Common</span></p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Hypertension, hypotension including orthostatic
  hypotension, peripheral coldness</p>
  <p class=MsoNormal>&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.4pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Respiratory, thoracic and mediastinal disorders</p>
  <p class=MsoNormal>&nbsp;</p>
  </td>
  <td width=110 valign=top style='width:82.5pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=pedtablecenter><span lang=EN-GB>Very common</span></p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Pharyngitis, oropharyngeal pain, cough </p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=227 rowspan=2 valign=top style='width:170.4pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Gastrointestinal disorders</p>
  </td>
  <td width=110 valign=top style='width:82.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'>Very common</p>
  <p class=MsoNormal align=center style='text-align:center'>&nbsp;</p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Abdominal pain (upper and lower), nausea, diarrhoea
  (including severe with electrolyte imbalance), vomiting, dyspepsia</p>
  <p class=MsoNormal>&nbsp;</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=110 valign=top style='width:82.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'>Common</p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Anorexia, flatulence, mouth ulcer, gastrointestinal
  haemorrhage, gastroesophageal reflux disease, pancreatitis</p>
  <p class=MsoNormal>&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.4pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Hepatobiliary disorders</p>
  </td>
  <td width=110 valign=top style='width:82.5pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal1 align=center style='text-align:center'><span lang=EN-GB>Common</span></p>
  <p class=EMEANormal1 align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Hepatitis (including increased AST, ALT, GGT), blood
  bilirubin increased (including jaundice)</p>
  <p class=MsoNormal>&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Skin and subcutaneous
  tissue disorders</p>
  </td>
  <td width=110 valign=top style='width:82.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>Very common</p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Pruritus, rash (including
  erythematous and maculopapular)</p>
  <p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>
  <p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=110 valign=top style='width:82.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>Common</p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Acne</p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=110 valign=top style='width:82.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>Rare</p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Stevens Johnson syndrome,
  toxic epidermal necrolysis (TEN)</p>
  <p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=227 rowspan=2 valign=top style='width:170.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Musculosketal and connective tissue disorders</p>
  </td>
  <td width=110 valign=top style='width:82.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'>Very common</p>
  <p class=MsoNormal align=center style='text-align:center'>&nbsp;</p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Arthralgia and back pain</p>
  <p class=MsoNormal>&nbsp;</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=110 valign=top style='width:82.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'>Common</p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Myositis, rhabdomyolysis, myalgia, myopathy/CPK increased</p>
  <p class=MsoNormal>&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:6.0pt;page-break-after:avoid'>Renal
  and urinary disorders </p>
  </td>
  <td width=110 valign=top style='width:82.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:6.0pt;text-align:center;
  page-break-after:avoid'><span lang=EN-GB>Common</span></p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Increased urination, <span
  lang=EN-GB>renal impairment (e.g. oliguria, elevated creatinine)</span></p>
  <p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:6.0pt'>&nbsp;</p>
  </td>
  <td width=110 valign=top style='width:82.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'>Uncommon</p>
  <p class=MsoNormal align=center style='text-align:center'>&nbsp;</p>
  <p class=MsoNormal align=center style='text-align:center'>Not known</p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Acute renal failure</p>
  <p class=MsoNormal>&nbsp;</p>
  <p class=MsoNormal><span style='color:black'>Nephrolithiasis</span></p>
  </td>
 </tr>
 <tr>
  <td width=227 valign=top style='width:170.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Reproductive system and breast disorders</p>
  <p class=MsoNormal>&nbsp;</p>
  </td>
  <td width=110 valign=top style='width:82.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>Common</span></p>
  <p class=MsoNormal align=center style='text-align:center'>&nbsp;</p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Menorrhagia</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=227 rowspan=2 valign=top style='width:170.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>General disorders and administration site conditions</p>
  </td>
  <td width=110 valign=top style='width:82.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'>Very common</p>
  <p class=MsoNormal align=center style='text-align:center'>&nbsp;</p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Fatigue including asthenia, flushing, feeling hot</p>
  <p class=MsoNormal>&nbsp;</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=110 valign=top style='width:82.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'>Common</p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Fever, weight loss</p>
  <p class=MsoNormal>&nbsp;</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=227 rowspan=2 valign=top style='width:170.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Investigations</p>
  </td>
  <td width=110 valign=top style='width:82.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'>Common</p>
  <p class=MsoNormal align=center style='text-align:center'>&nbsp;</p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Increased amylase, decreased free and total thyroxin </p>
  <p class=MsoNormal>&nbsp;</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=110 valign=top style='width:82.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'>Uncommon</p>
  </td>
  <td width=282 valign=top style='width:211.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Increased glucose, increased magnesium, increased alkaline
  phosphatase</p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span style='text-transform:uppercase'>&nbsp;</span></p>

<p class=MsoNormal><u>Description of selected adverse reactions</u></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Hepatic transaminase elevations exceeding five times the
upper limit or normal, clinical hepatitis, and jaundice have occurred in
patients receiving ritonavir alone or in combination with other
antiretrovirals.</p>

<p class=EMEANormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEANormal><u><span lang=EN-GB>Metabolic parameters</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Weight and levels of blood lipids and
glucose may increase during antiretroviral therapy (see section 4.4).</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal>In HIV-infected patients with severe immune deficiency at
the time of initiation of combination antiretroviral therapy (CART), an
inflammatory reaction to asymptomatic or residual opportunistic infections may
arise. Autoimmune disorders (<span lang=EN-GB>such as Graves disease and
autoimmune hepatitis) have also been reported; however, the reported time to
onset is more variable and can occur many months after initiation of treatment</span>
(see section 4.4).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Pancreatitis has been observed in patients receiving
ritonavir therapy, including those who developed hypertriglyceridemia. In some
cases fatalities have been observed. Patients with advanced HIV disease may be
at risk of elevated triglycerides and pancreatitis (see section 4.4).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Cases of osteonecrosis have been reported, particularly in
patients with generally acknowledged risk factors, advanced HIV disease or
long-term exposure to combination antiretroviral therapy (CART). The frequency
of this is unknown (see section 4.4).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><i>Paediatric populations</i></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>The safety profile of Norvir in children 2 years of age and
older is similar to that seen in adults.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=EMEANormal1><u><span lang=EN-GB>Reporting of suspected adverse
reactions</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Reporting suspected adverse reactions after
authorisation of the medicinal product is important. It allows continued
monitoring of the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions </span>via <span
style='background:lightgrey'>the national reporting system listed in </span><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='background:lightgrey'>Appendix</span></a><span style='color:blue;
background:lightgrey'> V.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=EMEAHeading2SPC style='margin:0in;page-break-after:avoid'><span
lang=EN-GB>4.9 Overdose</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u>Symptoms</u></p>

<p class=MsoNormal style='page-break-after:avoid'>Human experience of acute
overdose with ritonavir is limited. One patient in clinical trials took
ritonavir 1500&nbsp;mg/day for two days and reported paraesthesia, which
resolved after the dose was decreased. A case of renal failure with
eosinophilia has been reported.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>The signs of toxicity observed in animals (mice and rats)
included decreased activity, ataxia, dyspnoea and tremors.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><u>Management</u></p>

<p class=MsoNormal>There is no specific antidote for overdose with ritonavir.
Treatment of overdose with ritonavir should consist of general supportive
measures including monitoring of vital signs and observation of the clinical
status of the patient. Due to the solubility characteristics and possibility
of transintestinal elimination, it is proposed that management of overdose
could entail gastric lavage and administration of activated charcoal. Since
ritonavir is extensively metabolised by the liver and is highly protein bound,
dialysis is unlikely to be beneficial in significant removal of the medicine. </p>

<p class=EMEAHeading1 style='margin:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin:0in'><span lang=EN-GB>5. Pharmacological
properties</span></p>

<p class=EMEAHeading2SPCEmpty style='margin-bottom:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2SPCEmpty style='margin-bottom:0in'><span lang=EN-GB>5.1 Pharmacodynamic
properties</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>Pharmacotherapeutic group: antivirals for systemic use,
protease inhibitors ATC code: J05AE03</p>

<p class=MsoNormal>&nbsp;</p>

<p class=EMEAHeadingUI style='margin:0in'><span lang=EN-GB style='font-style:
normal'>Ritonavir dosed as a pharmacokinetic enhancer</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Pharmacokinetic enhancement by ritonavir is based on
ritonavirs activity as a potent inhibitor of CYP3A&#8209; mediated
metabolism. The degree of enhancement is related to the metabolic pathway of
the co&#8209;administered protease inhibitor and the impact of the co&#8209;administered
protease inhibitor on the metabolism of ritonavir. Maximal inhibition of
metabolism of the co&#8209;administered protease inhibitor is generally
achieved with ritonavir doses of 100&nbsp;mg daily to 200&nbsp;mg twice daily,
and is dependent on the co&#8209;administered protease inhibitor. For <span
style='color:black'>additional information on the effect of ritonavir on co&#8209;administered
protease inhibitor metabolism, see section 4.5 and refer to the Summary of
Product Characteristics of the particular co&#8209;administered PIs.</span></p>

<p class=MsoNormal>&nbsp;</p>

<h6><u><span style='font-style:normal'>Ritonavir dosed as an antiretroviral
agent </span></u></h6>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal>Ritonavir is an orally active peptidomimetic inhibitor of
the HIV&#8209;1 and HIV&#8209;2 aspartyl proteases. Inhibition of HIV protease
renders the enzyme incapable of processing the <i>gag&#8209;pol</i> polyprotein
precursor which leads to the production of HIV particles with immature
morphology that are unable to initiate new rounds of infection. Ritonavir has
selective affinity for the HIV protease and has little inhibitory activity
against human aspartyl proteases.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=EMEANormal>Ritonavir was the first protease inhibitor<span
style='color:blue'> </span>(approved in 1996) for which efficacy was proven in
a study with clinical endpoints. However, due to ritonavirs metabolic
inhibitory properties<span style='color:blue'> </span>its use as a
pharmacokinetic enhancer of other protease inhibitors is the prevalent use of
ritonavir in clinical practice (see section 4.2).</p>

<p class=EMEANormal>&nbsp;</p>

<p class=EMEANormal><u><span lang=EN-GB>Effects on the Electrocardiogram</span></u><span
lang=EN-GB> </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>QTcF interval was evaluated in a
randomised, placebo and active (moxifloxacin 400&nbsp;mg once daily) controlled
crossover study in 45 healthy adults, with 10 measurements over 12 hours on Day
3. The maximum mean (95% upper confidence bound) difference in QTcF from
placebo was 5.5 (7.6) for 400&nbsp;mg twice daily ritonavir. The Day 3
ritonavir exposure was approximately 1.5 fold higher than that observed with
the 600&nbsp;mg twice daily dose at steady state. No subject experienced an
increase in QTcF of </span><span lang=EN-GB style='font-family:Symbol'></span><span
lang=EN-GB>&nbsp;60 msec from baseline or a QTcF interval exceeding the
potentially clinically relevant threshold of 500 msec.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Modest prolongation of the PR interval was
also noted in subjects receiving ritonavir in the same study on Day 3. The
mean changes from baseline in PR interval ranged from 11.0 to 24.0 msec in the
12 hour interval post dose. Maximum PR interval was 252 msec and no second or
third degree heart block was observed (see section 4.4).</span></p>

<p class=MsoNormal><b>&nbsp;</b></p>

<h5>Resistance</h5>

<p class=MsoNormal><b>&nbsp;</b></p>

<p class=MsoNormal>Ritonavir&#8209;resistant isolates of HIV&#8209;1 have been
selected <i>in vitro </i>and isolated from patients treated with therapeutic
doses of ritonavir<i>. </i></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'>Reduction in the
antiretroviral activity of ritonavir is primarily associated with the protease
mutations V82A/F/T/S and I84V. Accumulation of other mutations in the protease
gene (including at positions 20, 33, 36, 46, 54, 71, and 90) can also
contribute to ritonavir resistance. In general, as mutations associated with
ritonavir resistance accumulate, susceptibility to select other PIs may
decrease due to cross&#8209;resistance. The Summary of Product Characteristics
of other protease inhibitors or official continuous updates should be consulted
for specific information regarding protease mutations associated with reduced
response to these agents.</p>

<p class=MsoNormal>&nbsp;</p>

<h5>Clinical pharmacodynamic data</h5>

<p class=MsoNormal><b>&nbsp;</b></p>

<p class=MsoNormal>The effects of ritonavir (alone or combined with other
antiretroviral agents) on biological markers of disease activity such as CD4
cell count and viral RNA were evaluated in several studies involving HIV-1
infected patients. The following studies are the most important.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><i>Adult Use</i></p>

<p class=MsoHeader>&nbsp;</p>

<p class=MsoNormal>A controlled study completed in 1996 with ritonavir as
add-on therapy in HIV-1 infected patients extensively pre-treated with
nucleoside analogues and baseline CD4 cell counts <span style='font-family:
Symbol'></span> 100 cells/<span style='font-family:Symbol'>m</span>l showed a
reduction in mortality and AIDS defining events. The mean average change from
baseline over 16 weeks for HIV RNA levels was -0.79&nbsp;log<sub>10</sub><span
style='position:relative;top:2.0pt'> </span>(maximum mean decrease:
1.29&nbsp;log<sub>10</sub>) in the ritonavir group versus &#8209;0.01&nbsp;log<sub>10</sub><span
style='position:relative;top:2.0pt'> </span>in the control group. The most
frequently used nucleosides in this study were zidovudine, stavudine,
didanosine and zalcitabine. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>In a study completed in 1996 recruiting less advanced HIV-1
infected patients (CD4 200-500&nbsp;cells/<span style='font-family:Symbol'>m</span>l)
without previous antiretroviral therapy, ritonavir in combination with
zidovudine or alone reduced viral load in plasma and increased CD4 count. The
mean average change from baseline over 48 weeks for HIV RNA levels was
-0.88&nbsp;log<sub>10</sub> in the ritonavir group versus -0.66&nbsp;log<sub>10</sub><span
style='position:relative;top:2.0pt'> </span>in the ritonavir + zidovudine group
versus -0.42&nbsp;log<sub>10</sub><span style='position:relative;top:2.0pt'> </span>in
the zidovudine group.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>The continuation of ritonavir therapy should be evaluated by
viral load because of the possibility of the emergence of resistance as
described under section 4.1.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><i>Paediatric Use</i></p>

<p class=MsoHeader style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'>In an open label trial
completed in 1998 in HIV infected, clinically stable children there was a
significant difference (p&nbsp;=&nbsp;0.03) in the detectable RNA levels in
favour of a triple regimen (ritonavir, zidovudine and lamivudine) following 48
weeks treatment.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>In a study completed in 2003, 50 HIV-1 infected, protease
inhibitor and lamivudine nave children age 4&nbsp;weeks to 2&nbsp;years
received ritonavir 350 or 450&nbsp;mg/m<sup>2</sup> every 12&nbsp;hours co&#8209;administered
with zidovudine 160&nbsp;mg/m<sup>2</sup> every 8 hours and lamivudine
4&nbsp;mg/kg every 12&nbsp;hours. In intent to treat analyses, 72% and 36% of
patients achieved reduction in plasma HIV-1 RNA of <span style='font-family:
Symbol'></span>&nbsp;400 copies/ml at Week 16 and 104, respectively. Response
was similar in both dosing regimens and across patient age. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>In a study completed in 2000, 76 HIV-1
infected children aged 6 months to 12 years who were protease inhibitor naive
and naive to lamivudine and/or stavudine received ritonavir 350 or 450&nbsp;mg/m<sup>2</sup>
every 12 hours co-administered with lamivudine and stavudine. In intent to treat
analyses, 50% and 57% of patients in the 350 and 450&nbsp;mg/m<sup>2</sup> dose
groups, respectively, achieved reduction in plasma HIV-1 RNA to &#8804;&nbsp;400&nbsp;copies/ml
at Week 48.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=EMEAHeading2SPC style='margin:0in;page-break-after:avoid'><span
lang=EN-GB>5.2 Pharmacokinetic properties</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u>Absorption</u></p>

<p class=MsoNormal style='page-break-after:avoid'>There is no parenteral
formulation of ritonavir, therefore the extent of absorption and absolute bioavailability
have not been determined. The pharmacokinetics of ritonavir during multiple
dose regimens were studied in non&#8209;fasting HIV-infected adult volunteers.
Upon multiple dosing, ritonavir accumulation is slightly less than predicted
from a single dose due to a time and dose&#8209;related increase in apparent
clearance (Cl/F). Trough concentrations of ritonavir decrease over time,
possibly due to enzyme induction, but appeared to stabilise by the end of 2
weeks. The time to maximum concentration (T<sub>max</sub>) remained constant
at approximately 4 hours with increasing dose. Renal clearance averaged less
than 0.1&nbsp;l/h and was relatively constant throughout the dosage range.</p>

<p class=MsoHeader>&nbsp;</p>

<p class=MsoNormal>The pharmacokinetic parameters observed with various dosing
schemes of ritonavir alone are shown in the table below. Plasma concentrations
of ritonavir after administration of a single 100&nbsp;mg dose tablet are
similar to the 100&nbsp;mg soft gelatin capsule under fed conditions.</p>

<p class=MsoNormal>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=590 colspan=6 valign=top style='width:6.15in;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <h3 style='margin-top:6.0pt;margin-right:0in;margin-bottom:6.0pt;margin-left:
  0in'>Ritonavir Dosing Regimen</h3>
  </td>
 </tr>
 <tr>
  <td width=98 valign=top style='width:73.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>&nbsp;</p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'>100 mg &nbsp; once
  daily</p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'>100 mg twice daily<sup>1</sup></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'>200 mg once daily</p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'>200 mg twice daily</p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'>600 mg twice daily</p>
  </td>
 </tr>
 <tr>
  <td width=98 valign=top style='width:73.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>C<sub>max </sub>(g/ml)</p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'>0.84 <span
  style='font-family:Symbol'></span>&nbsp;0.39</p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'>0.89</p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'>3.4 <span
  style='font-family:Symbol'></span> 1.3</p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'>4.5&nbsp;<span
  style='font-family:Symbol'></span>&nbsp;1.3</p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'>11.2&nbsp;<span
  style='font-family:Symbol'></span>&nbsp;3.6</p>
  </td>
 </tr>
 <tr>
  <td width=98 valign=top style='width:73.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>C<sub>trough </sub>(g/ml)</p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'>0.08 <span
  style='font-family:Symbol'></span>&nbsp;0.04</p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'>0.22</p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'>0.16 <span
  style='font-family:Symbol'></span> 0.10</p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'>0.6 <span
  style='font-family:Symbol'></span>&nbsp;0.2</p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'>3.7&nbsp;<span
  style='font-family:Symbol'></span>&nbsp;2.6</p>
  </td>
 </tr>
 <tr>
  <td width=98 valign=top style='width:73.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>AUC<sub>12 or 24</sub> (g<span style='font-family:Symbol'></span>h/ml)</p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='color:black'>6.6&nbsp;</span><span style='font-family:Symbol'></span>&nbsp;2.4</p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoCommentText align=center style='text-align:center'><span
  style='font-size:11.0pt'>6.2</span></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'>20.0 <span
  style='font-family:Symbol'></span> 5.6</p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='color:black'>21.92 </span><span style='font-family:Symbol'></span><span
  style='color:black'> 6.48</span></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span
  style='color:black'>77.5 </span><span style='font-family:Symbol'></span><span
  style='color:black'> 31.5</span></p>
  </td>
 </tr>
 <tr>
  <td width=98 valign=top style='width:73.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>t<sub></sub> (h)</p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'>~5</p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'>~5</p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'>~4</p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'>~8</p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'>~3 to 5</p>
  </td>
 </tr>
 <tr>
  <td width=98 valign=top style='width:73.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Cl/F (L/h)</p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'>17.2 <span
  style='font-family:Symbol'></span>&nbsp;6.6</p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'>16.1</p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'>10.8 <span
  style='font-family:Symbol'></span> 3.1</p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'>10.0&nbsp;<span
  style='font-family:Symbol'></span>&nbsp;3.2</p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'>8.8&nbsp;<span
  style='font-family:Symbol'></span>&nbsp;3.2</p>
  </td>
 </tr>
</table>

<p class=MsoNormal><sup>1 </sup>Values expressed as geometric means. Note:
ritonavir was dosed after a meal for all listed regimens.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoEndnoteText><u>Effects of food on oral absorption</u></p>

<p class=MsoEndnoteText>Food slightly decreases the bioavailability of the
Norvir tablet. Administration of a single 100&nbsp;mg dose of Norvir tablet
with a moderate fat meal (857 kcal, 31% calories from fat) or a high fat meal
(907 kcal, 52% calories from fat) was associated with a mean decrease of 20-23%
in ritonavir AUC and C<sub>max</sub>.</p>

<p class=MsoEndnoteText>&nbsp;</p>

<p class=EMEAHeadingUnderline style='margin:0in;page-break-after:avoid'>Distribution</p>

<p class=MsoNormal>The apparent volume of distribution (V<sub>B</sub>/F) of
ritonavir is approximately 20&nbsp;-&nbsp;40&nbsp;l after a single 600&nbsp;mg
dose. The protein binding of ritonavir in human plasma is approximately
98&nbsp;&nbsp;99% and is constant over the concentration range of
1.0&nbsp;&nbsp;100&nbsp;<span style='font-family:Symbol'>m</span>g/ml.
Ritonavir binds to both human alpha 1&#8209;acid glycoprotein (AAG) and human
serum albumin (HSA) with comparable affinities.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Tissue distribution studies with <sup>14</sup>C&#8209;labelled
ritonavir in rats showed the liver, adrenals, pancreas, kidneys and thyroid to
have the highest concentrations of ritonavir. Tissue to plasma ratios of
approximately 1 measured in rat lymph nodes suggests that ritonavir distributes
into lymphatic tissues. Ritonavir penetrates minimally into the brain.</p>

<p class=MsoNormal><u><span style='text-decoration:none'>&nbsp;</span></u></p>

<p class=MsoNormal><u><span style='color:black'>Biotransformation</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'>Ritonavir was noted to be
extensively metabolised by the hepatic cytochrome P450 system, primarily by the
CYP3A isozyme family and to a lesser extent by the CYP2D6 isoform. Animal
studies as well as <i>in vitro</i> experiments with human hepatic microsomes
indicated that ritonavir primarily underwent oxidative metabolism. Four
ritonavir metabolites have been identified in man. The isopropylthiazole
oxidation metabolite (M&#8209;2) is the major metabolite and has antiviral
activity similar to that of parent compound. However, the AUC of the M&#8209;2
metabolite was approximately 3% of the AUC of parent compound. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Low doses of ritonavir have shown profound effects on the
pharmacokinetics of other protease inhibitors (and other products metabolised
by CYP3A4) and other protease inhibitors may influence the pharmacokinetics of
ritonavir (see section 4.5). </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><u>Elimination</u></p>

<p class=MsoNormal style='page-break-after:avoid'>Human studies with
radiolabelled ritonavir demonstrated that the elimination of ritonavir was
primarily via the hepatobiliary system; approximately 86% of radiolabel was
recovered from stool, part of which is expected to be unabsorbed ritonavir. In
these studies renal elimination was not found to be a major route of
elimination of ritonavir. This was consistent with the observations in animal
studies.</p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal><u>Special populations</u> </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>No clinically significant differences in AUC or C<sub>max</sub>
were noted between males and females. Ritonavir pharmacokinetic parameters
were not statistically significantly associated with body weight or lean body
mass. Ritonavir plasma exposures in patients 50&nbsp;&nbsp;70 years of age
when dosed 100&nbsp;mg in combination with lopinavir or at higher doses in the
absence of other protease inhibitors is similar to that observed in younger
adults.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><i><span style='color:black'>Patients with impaired liver
function</span></i></p>

<p class=MsoNormal><span style='color:black'>After multiple dosing of ritonavir
to healthy volunteers (500&nbsp;mg twice daily) and subjects with mild to
moderate hepatic impairment (Child Pugh Class A and B, 400&nbsp;mg twice daily)
exposure to ritonavir after dose normalisation was not significantly different
between the two groups. </span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><i><span style='color:black'>Patients with impaired renal
function</span></i></p>

<p class=MsoNormal><span style='color:black'>Ritonavir pharmacokinetic
parameters have not been studied in patients with renal impairment. However,
since the renal clearance of ritonavir is negligible, no changes in the total
body clearance are expected in patients with renal impairment.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><i>Paediatric patients</i></p>

<p class=MsoNormal>Ritonavir steady-state pharmacokinetic parameters were
evaluated in HIV infected children above 2 years of age receiving doses ranging
from 250&nbsp;mg/m<sup></sup> twice daily to 400&nbsp;mg/m<sup></sup> twice
daily. Ritonavir concentrations obtained after 350 to 400&nbsp;mg/m<sup></sup>
twice daily in paediatric patients were comparable to those obtained in adults
receiving 600&nbsp;mg (approximately 330&nbsp;mg/m<sup></sup>) twice daily. Across
dose groups, ritonavir oral clearance (CL/F/m<sup>2</sup>) was approximately
1.5 to 1.7 times faster in paediatric patients above 2 years of age than in
adult subjects.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=EMEANormal1>Ritonavir steady-state pharmacokinetic parameters were
evaluated in HIV infected children less than 2&nbsp;years of age receiving
doses ranging from 350&nbsp;to 450&nbsp;mg/m twice daily. Ritonavir
concentrations in this study were highly variable and somewhat lower than those
obtained in adults receiving 600&nbsp;mg (approximately 330&nbsp;mg/m) twice
daily. Across dose groups, ritonavir oral clearance (CL/F/m<sup>2</sup>)
declined with age with median values of 9.0 L/h/m<sup>2</sup> in children less
than 3 months of age, 7.8&nbsp;L/h/m<sup>2</sup> in children between 3 and 6
months of age and 4.4 L/h/m<sup>2</sup> in children between 6 and 24 months of
age.</p>

<p class=EMEANormal1>&nbsp;</p>

<p class=EMEAHeading2SPC style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='font-weight:normal'>5.3 Preclinical safety data</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'>Repeated dose toxicity
studies in animals identified major target organs as the liver, retina, thyroid
gland and kidney. Hepatic changes involved hepatocellular, biliary and
phagocytic elements and were accompanied by increases in hepatic enzymes. Hyperplasia
of the retinal pigment epithelium (RPE) and retinal degeneration have been seen
in all of the rodent studies conducted with ritonavir, but have not been seen
in dogs. Ultrastructural evidence suggests that these retinal changes may be
secondary to phospholipidosis. However, clinical trials revealed no evidence
of medicinal product&#8209;induced ocular changes in humans. All thyroid
changes were reversible upon discontinuation of ritonavir. Clinical
investigation in humans has revealed no clinically significant alteration in
thyroid function tests. Renal changes including tubular degeneration, chronic
inflammation and proteinurea were noted in rats and are felt to be attributable
to species&#8209;specific spontaneous disease. Furthermore, no clinically
significant renal abnormalities were noted in clinical trials.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Developmental toxicity observed in rats (embryolethality,
decreased foetal body weight and ossification delays and visceral changes,
including delayed testicular descent) occurred mainly at a maternally toxic
dosage. Developmental toxicity in rabbits (embryolethality, decreased litter
size and decreased foetal weights) occurred at a maternally toxic dosage.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Ritonavir was not found to be mutagenic or clastogenic in a
battery of <i>in vitro</i> and <i>in vivo</i> assays including the Ames
bacterial reverse mutation assay using <i>S. typhimurium</i> and <i>E. coli</i>,
the mouse lymphoma assay, the mouse micronucleus test and chromosomal
aberration assays in human lymphocytes.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Long term carcinogenicity studies of ritonavir in mice and
rats revealed tumourigenic potential specific for these species, but are
regarded as of no relevance for humans.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=EMEAHeading1 style='margin:0in'><span lang=EN-GB>6. Pharmaceutical
particulars</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2SPCEmpty style='margin-bottom:0in'><span lang=EN-GB>6.1 List
of excipients</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingUnderline style='margin:0in'>Tablet:</p>

<p class=MsoNormal>Copovidone</p>

<p class=MsoNormal>Sorbitan laurate</p>

<p class=MsoNormal>Calcium hydrogen phosphate, anhydrous</p>

<p class=MsoNormal>Silica, colloidal anhydrous</p>

<p class=MsoNormal>Sodium stearyl fumarate</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><u>Film-coating:</u></p>

<p class=MsoNormal>Hypromellose</p>

<p class=MsoNormal>Titanium dioxide (E171)</p>

<p class=MsoNormal>Macrogols </p>

<p class=MsoNormal>Hydroxypropyl cellulose</p>

<p class=MsoNormal>Talc</p>

<p class=MsoNormal>Silica, colloidal anhydrous</p>

<p class=MsoNormal>Polysorbate 80</p>

<p class=MsoNormal>&nbsp;</p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB>6.2 Incompatibilities</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>Not applicable.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=EMEAHeading2SPC style='margin:0in;page-break-after:avoid'><span
lang=EN-GB>6.3 Shelf life</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>2 years.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB>6.4 Special
precautions for storage</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>This medicinal product does not require any special
temperature storage conditions. Store in the original bottle in order to
protect from moisture. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB>6.5 Nature and
contents of container</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>Norvir tablets are supplied in white high density
polyethylene (HDPE) bottles closed with polypropylene caps. </p>

<p class=MsoNormal></p>

<p class=MsoNormal style='page-break-after:avoid'>Three pack sizes are
available for Norvir tablets:</p>

<p class=EMEABullet style='page-break-after:avoid'><span style='font-family:
Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>1 bottle of 30 tablets </p>

<p class=EMEABullet><span style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>1 bottle of 60 tablets</p>

<p class=EMEABullet><span style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Multipack containing 90 (3 bottles of 30) film-coated tablets </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Not all pack sizes may be marketed.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=EMEAHeading2SPC style='margin:0in;page-break-after:avoid'><span
lang=EN-GB>6.6 Special precautions for disposal</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'>No special requirements.</p>

<p class=EMEAHeading1 style='margin:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin:0in'><span lang=EN-GB>7. Marketing
authoriSation holder</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>AbbVie Deutschland GmbH &amp; Co. KG</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>Knollstrasse</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>67061 Ludwigshafen</span></p>

<p class=MsoNormal><span lang=EN-GB>Germany</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin:0in'><span lang=EN-GB>8. MARKETING AUTHORISATION
NUMBER(S)</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>EU/1/96/016/005-007</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=EMEAHeading1 style='margin:0in'><span lang=EN-GB>9. Date of first
authorisation/renewal of THE authorisation</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>Date of first authorisation: 26 August 1996</p>

<p class=MsoNormal>Date of latest renewal: 26 August 2006</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=EMEAHeading1 style='margin:0in'><span lang=EN-GB>10. Date of
revision of the text</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=EMEANormal>Detailed information on this product is available on the
website of the European Medicines Agency <span style='color:blue'>http://www.ema.europa.eu</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle><span lang=EN-GB>ANNEX II</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt'>&nbsp;</p>

<p class=TitleB style='margin-top:0in;margin-right:28.4pt;margin-bottom:12.0pt;
margin-left:78.0pt;text-indent:-21.3pt'>A.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE </p>

<p class=TitleB style='margin-top:0in;margin-right:28.4pt;margin-bottom:0in;
margin-left:78.0pt;margin-bottom:.0001pt;text-indent:-21.3pt'>B.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span>CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND <br>
USE </p>

<p class=TitleB style='margin-top:0in;margin-right:28.4pt;margin-bottom:0in;
margin-left:56.7pt;margin-bottom:.0001pt'>&nbsp;</p>

<p class=TitleB style='margin-top:0in;margin-right:28.4pt;margin-bottom:0in;
margin-left:78.0pt;margin-bottom:.0001pt;text-indent:-21.3pt'>C.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>OTHER
CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION <br>
<br>
</p>

<p class=TitleB style='margin-top:0in;margin-right:42.55pt;margin-bottom:0in;
margin-left:78.0pt;margin-bottom:.0001pt;text-indent:-21.3pt'>D.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>CONDITIONS
OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL
PRODUCT</p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:56.7pt;margin-bottom:.0001pt'><b>&nbsp;</b></p>

<p class=MsoNormal><span style='text-transform:uppercase'>&nbsp;</span></p>

<b><span style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=BMLeftAligned>A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE </p>

<p class=EMEAHeading1 style='margin:0in'><span style='font-family:"Times New Roman",serif;
text-transform:none'>&nbsp;</span></p>

<h5>Name and address of the manufacturer responsible for batch release</h5>

<p class=MsoNormal style='margin-right:70.8pt'>&nbsp;</p>

<h6>Film-coated tablets and powder for oral suspension</h6>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>AbbVie Deutschland GmbH &amp; Co. KG, Knollstrasse, 67061
Ludwigshafen, Germany</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='text-align:justify'><i><span lang=EN-GB>Powder for
oral suspension only</span></i></p>

<p class=MsoNormal style='text-align:justify'><span style='layout-grid-mode:
line'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB>AbbVie Logistics
B.V., Zuiderzeelaan 53, 8017 JV Zwolle, The Netherlands</span></p>

<h6><span style='font-style:normal'>&nbsp;</span></h6>

<p class=MsoNormal>The printed package leaflet of the medicinal product must
state the name and address of the manufacturer responsible for the release of
the concerned batch.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=BMLeftAligned>B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND
USE<span style='font-weight:normal'> </span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Medicinal product subject to restricted medical prescription
(See Annex I: Summary of Product Characteristics, section 4.2).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:30.0pt;text-indent:-30.0pt'>&nbsp;</p>

<p class=BMLeftAligned style='margin-left:28.35pt;text-indent:-28.35pt'>C.  OTHER
CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION</p>

<p class=MsoNormal><b>&nbsp;</b></p>

<h4 style='background:transparent'><span style='font-family:Symbol;font-weight:
normal'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Periodic safety update reports (PSURs)</h4>

<p class=MsoNormal style='margin-left:30.0pt;text-indent:-30.0pt'>&nbsp;</p>

<p class=MsoNormal>The marketing authorisation holder (MAH) shall submit PSURs for
this product in accordance with the requirements set out in the list of Union reference
dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC
and published on the European medicines web&#8209;portal.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=BMLeftAligned style='margin-left:28.35pt;text-indent:-28.35pt'>D.  CONDITIONS
OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL
PRODUCT </p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='font-size:11.0pt'>Risk management plan
(RMP) </span></b></p>

<p class=MsoNormal>&nbsp;</p>

<p class=EMEAHeadingItalic style='margin:0in'><span style='font-style:normal'>The
MAH shall perform the required pharmacovigilance activities and interventions
detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation
and any agreed subsequent updates of the RMP.</span></p>

<p class=EMEANormal1>&nbsp;</p>

<p class=EMEANormal1>An updated RMP should be submitted:</p>

<p class=MsoNormal style='text-autospace:none'><span style='font-family:Symbol;
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:1.4pt;
margin-left:28.35pt;text-indent:-28.35pt;text-autospace:none'><span
style='font-family:Symbol;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='color:black'>At the request of the European
Medicines Agency; </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:1.4pt;
margin-left:28.35pt;text-indent:-28.35pt;text-autospace:none'><span
style='font-family:Symbol;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='color:black'>Whenever the risk management system is
modified, especially as the result of new information being received that may
lead to a significant change to the benefit/risk profile or as the result of an
important (pharmacovigilance or risk minimisation) milestone being reached. </span></p>

<p class=MsoNormal style='margin-bottom:1.4pt;text-autospace:none'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:1.4pt;text-autospace:none'><span
style='color:black'>If the dates for submission of a PSUR and the update of a
RMP conincide, they can be submitted at the same time.</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle><span lang=EN-GB>ANNEX III</span></p>

<p class=MsoNormal align=center style='text-align:center'><b>&nbsp;</b></p>

<p class=MsoNormal align=center style='text-align:center'><b>LABELLING AND
PACKAGE LEAFLET</b></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=BMCENTRED><span lang=EN-GB>A. LABELLING</span></p>

<span style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 6.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b>PARTICULARS TO APPEAR ON
THE OUTER PACKAGING </b></p>

<p class=MsoNormal style='border:none;padding:0in'><b>&nbsp;</b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=FR>NORVIR POWDER
FOR ORAL SUSPENSION - Carton containing 30 sachets each containing 100mg
ritonavir</span></b></p>

</div>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.05pt;text-indent:-28.05pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
text-transform:uppercase'>1. NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Norvir 100&nbsp;mg powder
for oral suspension</span></p>

<p class=MsoNormal>ritonavir</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
text-transform:uppercase'>2. STATEMENT OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Each sachet contains 100&nbsp;mg of ritonavir.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
text-transform:uppercase'>3. LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
text-transform:uppercase'>4. PHARMACEUTICAL </span></b><span lang=EN-GB
style='font-family:"Times New Roman Bold",serif;text-transform:uppercase'>FORM<b>
AND CONTENTS</b></span></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>30 sachets </span><span
lang=EN-GB>of powder for oral suspension</span></p>

<p class=MsoNormal><span style='color:black'>Carton also contains 1 mixing cup
and 2 </span>oral<span style='color:red'> </span><span style='color:black'>dosing
syringes</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
text-transform:uppercase'>5. METHOD AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Read the package
leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Oral use</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:25.0pt;text-indent:-25.0pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
text-transform:uppercase'>6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT
MUST BE STORED OUT OF THE Sight AND reach OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Keep out of the sight and reach of children.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
text-transform:uppercase'>7. OTHER SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
text-transform:uppercase'>8. EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
text-transform:uppercase'>9. SPECIAL STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Store below 30C</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:30.05pt;text-indent:-30.05pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
text-transform:uppercase'>10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED
MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF
APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.05pt;text-indent:-28.05pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
text-transform:uppercase'>11. NAME AND ADDRESS OF THE MARKETING
AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>AbbVie Deutschland GmbH &amp; Co. KG</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>Knollstrasse</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>67061 Ludwigshafen</span></p>

<p class=MsoNormal><span lang=EN-GB>Germany</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
text-transform:uppercase'>12. MARKETING AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>EU/1/96/016/009</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
text-transform:uppercase'>13. BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
text-transform:uppercase'>14. GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.05pt;text-indent:-28.05pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
text-transform:uppercase'>15. INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='color:black;text-transform:uppercase'>16. Information in braille</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Norvir 100&nbsp;mg </span></p>

<p class=EMEANormal><span lang=FR>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:30.0pt'><span lang=EN-GB>17. UNIQUE IDENTIFIER
 2D BARCODE</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>2D barcode carrying the unique identifier
included.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:30.0pt'><span lang=EN-GB>18. UNIQUE IDENTIFIER
 HUMAN READABLE DATA</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PC</span></p>

<p class=MsoNormal><span lang=EN-GB>SN</span></p>

<p class=MsoNormal><span style='background:lightgrey'>NN</span><span
lang=EN-GB><br clear=all style='page-break-before:always'>
</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB
style='color:black;text-transform:uppercase'>MINIMUM PARTICULARS TO APPEAR ON SMALL
PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b>&nbsp;</b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b>NORVIR POWDER FOR ORAL SUSPENSION - Sachet Label Text</b></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.05pt;text-indent:-28.05pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
text-transform:uppercase'>1. NAME OF THE MEDICINAL PRODUCT AND ROUTE OF
ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>Norvir 100&nbsp;mg powder for oral suspension</span></p>

<p class=MsoNormal><span lang=FR>ritonavir</span></p>

<p class=MsoNormal><span lang=FR>Oral use</span></p>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
text-transform:uppercase'>2. MEthod of administration </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
text-transform:uppercase'>3. Expiry date</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>EXP</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
text-transform:uppercase'>4. batch number</span></b></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Lot</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
text-transform:uppercase'>5. contents by unit</span></b></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>100&nbsp;mg</p>

<span style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in;text-indent:0in'><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING </span></p>

<p class=EMEAHeadingBoxedTitle style='margin:0in;text-indent:0in'><span
lang=EN-GB><br>
Norvir film-coated tablets - CARTON WITH BLUE BOX</span></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.05pt;text-indent:-28.05pt'><span lang=EN-GB>1. NAME OF
THE MEDICINAL PRODUCT</span></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Norvir 100&nbsp;mg film-coated tablets</p>

<p class=MsoNormal>ritonavir</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.1pt'><span lang=EN-GB>2. STATEMENT OF ACTIVE
SUBSTANCE(S)</span></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Each tablet contains 100&nbsp;mg ritonavir.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.1pt'><span lang=EN-GB>3. LIST OF EXCIPIENTS</span></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.05pt;text-indent:-28.05pt'><span lang=EN-GB>4. PHARMACEUTICAL
FORM AND CONTENTS</span></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>30 film-coated tablets</p>

<p class=MsoNormal>60 film-coated tablets</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.1pt'><span lang=EN-GB>5. METHOD AND ROUTE(S) OF ADMINISTRATION</span></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal>Oral use</p>

<p class=MsoNormal>Norvir tablets should be taken with food. </p>

<p class=MsoNormal>The tablets should be swallowed whole and not chewed, broken
or crushed.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:30.0pt;text-indent:-30.0pt'><span lang=EN-GB>6. SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Keep out of the sight and reach of children.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.1pt'><span lang=EN-GB>7. OTHER SPECIAL WARNING(S), IF
NECESSARY</span></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Child resistant closure</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.1pt'><span lang=EN-GB>8. EXPIRY DATE</span></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>EXP</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.1pt'><span lang=EN-GB>9. SPECIAL STORAGE CONDITIONS</span></p>

</div>

<p class=MsoBodyText2 align=left style='text-align:left'>&nbsp;</p>

<p class=MsoBodyText2 align=left style='text-align:left'>Store in the original
bottle in order to protect from moisture.</p>

<p class=MsoBodyText2 align=left style='text-align:left'>&nbsp;</p>

<p class=MsoBodyText2 align=left style='text-align:left'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:24.95pt;text-indent:-24.95pt'><span lang=EN-GB>10. SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.05pt;text-indent:-28.05pt'><span lang=EN-GB>11. NAME AND
ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>AbbVie Deutschland GmbH &amp; Co. KG</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>Knollstrasse</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>67061 Ludwigshafen</span></p>

<p class=MsoNormal><span lang=EN-GB>Germany</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.1pt'><span lang=EN-GB>12. MARKETING AUTHORISATION
NUMBER(S)</span></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>EU/1/96/016/005</p>

<p class=MsoNormal>EU/1/96/016/006</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.1pt'><span lang=EN-GB>13. BATCH NUMBER</span></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Lot</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.1pt'><span lang=EN-GB>14. GENERAL CLASSIFICATION FOR
SUPPLY</span></p>

</div>

<p class=TableText style='line-height:12.0pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=TableText style='line-height:12.0pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.05pt;text-indent:-28.05pt'><span lang=EN-GB>15. INSTRUCTIONS
ON USE</span></p>

</div>

<p class=TableText style='line-height:12.0pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=TableText style='line-height:12.0pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in;text-indent:0in'><span
lang=EN-GB>16. Information in braille</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Norvir 100&nbsp;mg tablets</span></p>

<p class=EMEANormal><span lang=FR>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:30.0pt'><span lang=EN-GB>17. UNIQUE IDENTIFIER
 2D BARCODE</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>2D barcode carrying the unique identifier
included.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:30.0pt'><span lang=EN-GB>18. UNIQUE IDENTIFIER
 HUMAN READABLE DATA</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'>PC</p>

<p class=MsoNormal style='text-autospace:none'>SN</p>

<p class=EMEANormal><span style='background:lightgrey'>NN</span><br clear=all
style='page-break-before:always'>
</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in;text-indent:0in'><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b>&nbsp;</b></p>

<p class=MsoHeading8 style='border:none;padding:0in'>NORVIR FILM-COATED TABLETS
- Bottle Label Text</p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.05pt;text-indent:-28.05pt'><span lang=EN-GB>1. NAME OF THE
MEDICINAL PRODUCT</span></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Norvir 100&nbsp;mg film-coated tablets</p>

<p class=MsoNormal>ritonavir</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.1pt'><span lang=EN-GB>2. STATEMENT OF ACTIVE
SUBSTANCE(S)</span></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Each tablet contains 100&nbsp;mg ritonavir.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.1pt'><span lang=EN-GB>3. LIST OF EXCIPIENTS</span></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.05pt;text-indent:-28.05pt'><span lang=EN-GB>4. PHARMACEUTICAL
FORM AND CONTENTS</span></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>30 film-coated tablets</p>

<p class=MsoNormal>60 film-coated tablets</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.1pt'><span lang=EN-GB>5. METHOD AND ROUTE(S) OF
ADMINISTRATION</span></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal>Oral use</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:25.0pt;text-indent:-25.0pt'><span lang=EN-GB>6. SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Keep out of the sight and reach of children.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.1pt'><span lang=EN-GB>7. OTHER SPECIAL WARNING(S), IF
NECESSARY</span></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.05pt;text-indent:-28.05pt'><span lang=EN-GB>8. EXPIRY
DATE</span></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>EXP</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.1pt'><span lang=EN-GB>9. SPECIAL STORAGE CONDITIONS</span></p>

</div>

<p class=TableText style='line-height:12.0pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=TableText style='line-height:12.0pt'><b><span lang=EN-GB
style='font-size:11.0pt'>Store in the original bottle</span></b></p>

<p class=TableText style='line-height:12.0pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoBodyText2 align=left style='margin-left:28.35pt;text-align:left;
text-indent:-28.35pt'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:24.95pt;text-indent:-24.95pt'><span lang=EN-GB>10. SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.05pt;text-indent:-28.05pt'><span lang=EN-GB>11. NAME AND
ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>AbbVie Deutschland GmbH &amp; Co. KG</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>Knollstrasse</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>67061 Ludwigshafen</span></p>

<p class=MsoNormal><span lang=EN-GB>Germany</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.1pt'><span lang=EN-GB>12. MARKETING AUTHORISATION
NUMBER(S)</span></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>EU/1/96/016/005</p>

<p class=MsoNormal>EU/1/96/016/006</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.1pt'><span lang=EN-GB>13. BATCH NUMBER</span></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Lot</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.1pt'><span lang=EN-GB>14. GENERAL CLASSIFICATION FOR
SUPPLY</span></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.05pt;text-indent:-28.05pt'><span lang=EN-GB>15. INSTRUCTIONS
ON USE</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in;text-indent:0in'><span
lang=EN-GB>16. Information in braille</span></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:30.0pt'><span lang=EN-GB>17. </span><span
lang=EN-GB>UNIQUE IDENTIFIER  2D BARCODE</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black;background:#CCCCCC'>Not applicable</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:30.0pt'><span lang=EN-GB>18. </span><span
lang=EN-GB>UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span style='color:black;background:#CCCCCC'>Not applicable</span></p>

<p class=MsoNormal><span style='background:#CCCCCC'>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black;text-transform:uppercase'><br clear=all style='page-break-before:
always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in;text-indent:0in'><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING </span></p>

<p class=EMEAHeadingBoxedTitle style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:30.05pt;text-indent:-30.05pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingBoxedTitle style='margin:0in;text-indent:0in'><span
lang=EN-GB>NORVIR FILM-COATED TABLETS - M</span><span lang=EN-GB
style='font-family:"Times New Roman Bold",serif;text-transform:none'>ultipack
containing 90 (3 bottles of 30) film-coated tablets with blue box</span></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.05pt;text-indent:-28.05pt'><span lang=EN-GB>1. NAME OF
THE MEDICINAL PRODUCT</span></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Norvir 100 mg film-coated tablets</p>

<p class=MsoNormal>ritonavir</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.1pt'><span lang=EN-GB>2. STATEMENT OF ACTIVE
SUBSTANCE(S)</span></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Each tablet contains 100&nbsp;mg ritonavir.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.1pt'><span lang=EN-GB>3. LIST OF EXCIPIENTS</span></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.05pt;text-indent:-28.05pt'><span lang=EN-GB>4. PHARMACEUTICAL
FORM AND CONTENTS</span></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Multipack: 90 (3 bottles of 30) film-coated tablets </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.1pt'><span lang=EN-GB>5. METHOD AND ROUTE(S) OF
ADMINISTRATION</span></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal>Oral use</p>

<p class=MsoNormal>Norvir tablets should be taken with food. </p>

<p class=MsoNormal>The tablets should be swallowed whole and not chewed, broken
or crushed.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:30.0pt;text-indent:-30.0pt'><span lang=EN-GB>6. SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Keep out of the sight and reach of children.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.1pt'><span lang=EN-GB>7. OTHER SPECIAL WARNING(S), IF
NECESSARY</span></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Child resistant closure</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.1pt'><span lang=EN-GB>8. EXPIRY DATE</span></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>EXP</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.1pt'><span lang=EN-GB>9. SPECIAL STORAGE CONDITIONS</span></p>

</div>

<p class=MsoBodyText2 align=left style='text-align:left'>&nbsp;</p>

<p class=MsoBodyText2 align=left style='text-align:left'><b>Store in the
original bottle in order to protect from moisture.</b></p>

<p class=MsoBodyText2 align=left style='text-align:left'>&nbsp;</p>

<p class=MsoBodyText2 align=left style='text-align:left'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:24.95pt;text-indent:-24.95pt'><span lang=EN-GB>10. SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.05pt;text-indent:-28.05pt'><span lang=EN-GB>11. NAME AND
ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>AbbVie Deutschland GmbH &amp; Co. KG</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>Knollstrasse</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>67061 Ludwigshafen</span></p>

<p class=MsoNormal><span lang=EN-GB>Germany</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.1pt'><span lang=EN-GB>12. MARKETING AUTHORISATION
NUMBER(S)</span></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>EU/1/96/016/007</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.1pt'><span lang=EN-GB>13. BATCH NUMBER</span></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Lot</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.1pt'><span lang=EN-GB>14. GENERAL CLASSIFICATION FOR
SUPPLY</span></p>

</div>

<p class=TableText style='line-height:12.0pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=TableText style='line-height:12.0pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.05pt;text-indent:-28.05pt'><span lang=EN-GB>15. INSTRUCTIONS
ON USE</span></p>

</div>

<p class=TableText style='line-height:12.0pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=TableText style='line-height:12.0pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in;text-indent:0in'><span
lang=EN-GB>16. Information in braille</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Norvir 100&nbsp;mg tablets</span></p>

<p class=EMEANormal><span lang=FR>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:30.0pt'><span lang=EN-GB>17. UNIQUE IDENTIFIER
 2D BARCODE</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>2D barcode carrying the unique identifier
included.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:30.0pt'><span lang=EN-GB>18. UNIQUE IDENTIFIER
 HUMAN READABLE DATA</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'>PC</p>

<p class=MsoNormal style='text-autospace:none'>SN</p>

<p class=EMEANormal><span style='background:lightgrey'>NN</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black;text-transform:uppercase'><br clear=all style='page-break-before:
always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in;text-indent:0in'><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b>&nbsp;</b></p>

<p class=MsoHeading8 style='border:none;padding:0in'>NORVIR FILM-COATED TABLETS
BOTTLE LABEL TEXT  3 BOTTLES</p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.05pt;text-indent:-28.05pt'><span lang=EN-GB>1. NAME OF
THE MEDICINAL PRODUCT</span></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Norvir 100&nbsp;mg film-coated tablets</p>

<p class=MsoNormal>ritonavir</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin:0in;text-indent:0in'><span lang=EN-GB>2. STATEMENT
OF ACTIVE SUBSTANCE(S)</span></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Each tablet contains 100&nbsp;mg ritonavir.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.1pt'><span lang=EN-GB>3. LIST OF EXCIPIENTS</span></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.05pt;text-indent:-28.05pt'><span lang=EN-GB>4. PHARMACEUTICAL
FORM AND CONTENTS</span></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>30 film-coated tablets</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.1pt'><span lang=EN-GB>5. METHOD AND ROUTE(S) OF ADMINISTRATION</span></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal>Oral use</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:25.0pt;text-indent:-25.0pt'><span lang=EN-GB>6. SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Keep out of the sight and reach of children.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.1pt'><span lang=EN-GB>7. OTHER SPECIAL WARNING(S), IF
NECESSARY</span></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.05pt;text-indent:-28.05pt'><span lang=EN-GB>8. EXPIRY
DATE</span></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>EXP</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.1pt'><span lang=EN-GB>9. SPECIAL STORAGE CONDITIONS</span></p>

</div>

<p class=TableText style='line-height:12.0pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=TableText style='line-height:12.0pt'><b><span lang=EN-GB
style='font-size:11.0pt'>Store in the original bottle</span></b></p>

<p class=TableText style='line-height:12.0pt'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoBodyText2 align=left style='margin-left:28.35pt;text-align:left;
text-indent:-28.35pt'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:24.95pt;text-indent:-24.95pt'><span lang=EN-GB>10. SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.05pt;text-indent:-28.05pt'><span lang=EN-GB>11. NAME AND
ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>AbbVie Deutschland GmbH &amp; Co. KG</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>Knollstrasse</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>67061 Ludwigshafen</span></p>

<p class=MsoNormal><span lang=EN-GB>Germany</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.1pt'><span lang=EN-GB>12. MARKETING AUTHORISATION
NUMBER(S)</span></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>EU/1/96/016/007</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.1pt'><span lang=EN-GB>13. BATCH NUMBER</span></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Lot</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.1pt'><span lang=EN-GB>14. GENERAL CLASSIFICATION FOR
SUPPLY</span></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.05pt;text-indent:-28.05pt'><span lang=EN-GB>15. INSTRUCTIONS
ON USE</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in;text-indent:0in'><span
lang=EN-GB>16. Information in braille</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:30.0pt'><span lang=EN-GB>17. </span><span
lang=EN-GB>UNIQUE IDENTIFIER  2D BARCODE</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black;background:#CCCCCC'>Not applicable</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:30.0pt'><span lang=EN-GB>18. </span><span
lang=EN-GB>UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span style='color:black;background:#CCCCCC'>Not applicable</span></p>

<p class=MsoNormal><span style='background:#CCCCCC'>&nbsp;</span></p>

<span style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle><span lang=EN-GB>&nbsp;</span></p>

<p class=BMCENTRED><span lang=EN-GB>B. PACKAGE LEAFLET</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>Package
leaflet: Information for the user</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=FR>Norvir
100&nbsp;mg powder for oral suspension </span></b></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=FR>ritonavir</span></p>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b>Read all of this leaflet
carefully before you start taking this medicine because it contains important
information for you or your child.</b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;margin-bottom:.0001pt;text-indent:0in'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it
again.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:0in;margin-bottom:.0001pt;text-indent:0in'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have any further questions, ask your
doctor or pharmacist.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>This medicine has been prescribed for you only.
Do not pass it on to others. It may harm them, even if their signs of illness
are the same as yours.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you get any side effects, talk to your doctor
or pharmacist. This includes any possible side effects not listed in this
leaflet. See section 4.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span style='color:black'>What
is in this leaflet</span></b><span style='color:black'>: </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
style='color:black'>1. What Norvir is and what it is used for</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
style='color:black'>2. What you need to know before you or your child takes
Norvir</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
style='color:black'>3. How to take Norvir</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
style='color:black'>4. Possible side effects</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
style='color:black'>5. How to store Norvir</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
style='color:black'>6. Contents of the pack and other information</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
text-transform:uppercase'>1. </span></b><b><span lang=EN-GB
style='font-family:"Times New Roman Bold",serif'>What Norvir is and what it is
used for</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
text-transform:uppercase'>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Norvir contains the active substance
ritonavir. Norvir is a protease inhibitor used to control HIV infection.
Norvir is used in combination with other anti-HIV medicines (antiretrovirals)
to control your HIV infection. Your doctor will discuss with you the best
combination of medicines for you</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Norvir is used by children 2 years of age
or older, adolescents and adults who are infected with HIV, the virus which
causes AIDS. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
text-transform:uppercase'>2. </span></b><b><span lang=EN-GB
style='font-family:"Times New Roman Bold",serif'>What you need to know before
you or your child takes Norvir</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
text-transform:uppercase'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif'>Do
not take Norvir</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif'>&nbsp;</span></b></p>

<p class=EMEABullet><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are allergic to ritonavir or any of the
other ingredients of Norvir (see section 6). </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='color:black'>&nbsp;</span></p>

<p class=EMEABullet><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have severe liver disease.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='color:black'>&nbsp;</span></p>

<p class=EMEABullet><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are currently taking any of the following
medicines:</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>astemizole or terfenadine (commonly used to
treat allergy symptoms  these medicines may be available without
prescription);</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>amiodarone, bepridil, dronedarone, encainide,
flecainide, propafenone, quinidine (used to correct irregular heartbeats);</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>dihydroergotamine, ergotamine (used to treat
migraine headache);</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ergonovine, methylergonovine (used to stop
excessive bleeding that may occur following childbirth or an abortion);</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>clorazepate, diazepam, estazolam, flurazepam,
triazolam or oral (taken by mouth) midazolam (used to help you sleep and/or
relieve anxiety);</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>clozapine, pimozide, (used to treat abnormal
thoughts or feelings);</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>quetiapine (used to treat schizophrenia, bipolar
disorder and major depressive disorder);</span></p>

<p class=EMEABullet style='margin-left:56.7pt'><span lang=EN-GB
style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>lurasidone (used to treat depression);</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ranolazine (used to treat chronic chest pain [angina]);</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>pethidine, piroxicam, propoxyphene (used to
relieve pain);</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>cisapride (used to relieve certain stomach
problems);</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>rifabutin (used to prevent/treat certain
infections)*;</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>voriconazole (used to treat fungal infections)*;</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>simvastatin, lovastatin (used to lower blood
cholesterol);</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>neratinib (used to treat breast cancer);</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>lomitapide (used to lower blood cholesterol);</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>alfuzosin (used to treat enlarged prostate
gland);</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>fusidic acid (used to treat bacterial
infections);</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>sildenafil if you suffer from a lung disease
called pulmonary arterial hypertension that makes breathing difficult.
Patients without this disease may use sildenafil for impotence (erectile
dysfunction) under their doctors supervision (see the section on <b>Other
medicines and Norvir</b>); </span></p>

<p class=EMEABullet style='margin-left:56.7pt'><span lang=EN-GB
style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>avanafil or vardenafil (used to treat erectile
dysfunction); </span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>colchicine (used to treat gout) if you have
kidney and/or liver problems (see the section on <b>Other medicines and Norvir</b>);</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>products containing St Johns wort (<i>Hypericum
perforatum</i>) as this may stop Norvir from working properly. St Johns wort
is often used in herbal medicines that you can buy yourself.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'>&nbsp;</p>

<p class=MsoNormal style='margin-left:16.5pt;text-indent:-16.5pt'>* Your
doctor may decide that you can take rifabutin and/or voriconazole with a
booster (lower dose) of Norvir but a full dose of Norvir must not be taken
together with these two medicines. </p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>If you are currently taking any of these
medicines, ask your doctor about switching to a different medicine while you
are taking Norvir. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Also read the list of medicines under
Other medicines and Norvir for use with certain other medicines which require
special care.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif'>Warnings
and precautions</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif'>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Talk to your doctor
before taking Norvir.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Important information</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:27.75pt;text-indent:-27.75pt'><span
lang=EN-GB>- If Norvir is taken in combination with other antiretroviral
medicines, it is important that you also carefully read the leaflets that are
provided with these other medicines. There may be additional information in
those leaflets about situations when Norvir should be avoided. If you have any
further questions about Norvir (ritonavir) or the other medicines prescribed,
please ask your doctor or pharmacist.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>- Norvir is not a cure for HIV infection or AIDS.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>- People taking Norvir may still develop infections or other
illnesses associated with HIV infection or AIDS. It is therefore important
that you remain under the supervision of your doctor while taking Norvir.</span></p>

<p class=EMEABullet><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>You can still pass on HIV when taking this
medicine, although the risk is lowered by effective antiretroviral therapy.
Discuss with your physician the precautions needed to avoid infecting other
people.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Tell your doctor if you have/had:</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>A history of <b>liver disease</b>. </span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Hepatitis B or C</span></b><span lang=EN-GB>
and are being treated with a combination of antiretroviral agents, as you are
at a greater risk of a severe and potentially life threatening reaction because
of the effect on the liver. Regular blood tests may be required to check your
liver is working properly.</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Haemophilia</span></b><span lang=EN-GB>, as
there have been reports of increased bleeding in patients with haemophilia who
are taking this type of medicine (protease inhibitors). The reason for this is
not known. You may need additional medicine to help your blood clot (factor
VIII), in order to control any bleeding.</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Erectile dysfunction</span></b><span
lang=EN-GB>, as the medicines used to treat erectile dysfunction can cause
hypotension and prolonged erection.</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Diabetes</span></b><span lang=EN-GB>, as
there have been reports of worsening of or the development of diabetes
(diabetes mellitus) in some patients taking protease inhibitors.</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='color:black'>Kidney (renal) disease,</span></b><span
lang=EN-GB style='color:black'> since your doctor may need to check the dose of
your other medicines (such as protease inhibitors)</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Tell your doctor if you experience:</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Diarrhoea</span></b><span lang=EN-GB> <b>or</b>
<b>vomiting</b> that is not improving (persistent), as this may reduce how well
the medicines you are taking work.</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Feeling sick</span></b><span lang=EN-GB>
(nausea), <b>vomiting</b> or have <b>stomach pain</b>, because these may be
signs of inflammation of the pancreas (pancreatitis). Some patients taking
Norvir can develop serious problems with their pancreas. Tell your doctor as
soon as possible if this applies to you.</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Symptoms of infection</span></b><span
lang=EN-GB>  inform your doctor immediately. Some patients with advanced HIV
infection (AIDS) </span>who then start anti-HIV treatment may develop the
symptoms of infections they have had in the past even if they didnt know they
had had them. It is believed that this happens because the body's immune
response improves and helps the body to fight these infections<span lang=EN-GB>.</span></p>

<p class=MsoNormal style='margin-left:28.35pt'><span lang=EN-GB>In addition to
the opportunistic infections, autoimmune disorders (a condition that occurs
when the immune system attacks healthy body tissue) may also occur after you
start taking medicines for the treatment of your HIV infection. Autoimmune
disorders may occur many months after the start of treatment. </span><span
lang=EN-GB>If you notice any symptoms of infection or other symptoms such as
muscle weakness, weakness beginning in the hands and feet and moving up towards
the trunk of the body, palpitations, tremor or hyperactivity, please inform
your doctor immediately to seek necessary treatment.</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span><b>Joint stiffness, aches and pains</b> (especially of the hip, knee and
shoulder) and difficulty moving, tell your doctor, as this may be a sign of a
problem that can destroy bone (osteonecrosis). Some patients taking a number
of antiretroviral medicines may develop this disease. </p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b>Muscle pain, tenderness or weakness</b>, particularly in
combination with antiretroviral therapy including protease inhibitors and
nucleoside analogues. On rare occasions these muscle disorders have been
serious. (See section 4. <b>Possible side effects</b>)</p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Dizziness, lightheadedness, fainting spells
or abnormal heartbeat. </span></b><span lang=EN-GB>Some patients taking Norvir
may experience changes in the electrocardiogram (ECG). Tell your doctor if you
have a heart defect or conduction defect.</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have any other health concerns, discuss
these with your doctor as soon as you can.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Children and adolescents</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Norvir is not recommended in children below
2 years of age.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Other medicines and Norvir</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'>Tell your doctor or pharmacist
if you are taking, have recently taken or might take any other medicines,
including medicines obtained without a prescription. There are some medicines
you cannot take at all with Norvir. These are listed earlier in section 2,
under <b>Do not take Norvir</b>. There are some other medicines that can
only be used under certain circumstances as described below.</p>

<p class=MsoNormal style='text-autospace:none'>&nbsp;</p>

<p class=MsoNormal>The following warnings apply when Norvir is taken as a full
dose. However, these warnings may also apply when Norvir is used in lower
doses (a booster) with other medicines. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><b>Tell your doctor if you
are taking any of the medicines listed below, as special care should be taken.</b></p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;page-break-after:
avoid'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Sildenafil or tadalafil</span></b><span
lang=EN-GB> for impotence (erectile dysfunction). <br>
The dose and/or frequency of use of these medicines may need to be reduced to
avoid hypotension and prolonged erection. You must not take Norvir with
sildenafil if you suffer from pulmonary arterial hypertension (see also section
2. </span><b><span lang=EN-GB>What you need to know before you or your child</span></b><b><span
lang=EN-GB> takes Norvir</span></b><span lang=EN-GB>). </span>Tell your doctor
if you are taking tadalafil for pulmonary arterial hypertension.</p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Colchicine </span></b><span lang=EN-GB>(for
gout) as Norvir may raise the blood levels of this medicine. You must not take
Norvir with colchicine if you have kidney and/or liver problems (see also </span><span
lang=EN-GB><b>Do not take Norvir</b> above).</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Digoxin</span></b><span lang=EN-GB> (heart
medicine). Your doctor may need to adjust the dose of digoxin and monitor you
while you are taking digoxin and Norvir in order to avoid heart problems.</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Hormonal contraceptives</span></b><span
lang=EN-GB> containing ethinyl oestradiol as Norvir may reduce the effectiveness
of these medicines. It is recommended that a condom or other non-hormonal
method of contraception is used instead. You may also notice irregular uterine
bleeding if you are taking this type of hormonal contraceptive with Norvir.</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Atorvastatin or rosuvastatin</span></b><span
lang=EN-GB> (for high cholesterol) as Norvir may raise the blood levels of
these medicines. Talk to your doctor before you take any cholesterol-reducing
medicines with Norvir (see also <b>Do not take Norvir</b> above).</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Steroids</span></b><span lang=EN-GB> (e.g.
dexamethasone, fluticasone propionate, prednisolone, </span><span lang=EN-GB>triamcinolone</span><span
lang=EN-GB>) as Norvir may raise the blood levels of these medicines which may
lead to Cushings syndrome (development of a rounded face) and reduce
production of the hormone cortisol. Your doctor may wish to reduce the steroid
dose or monitor your side effects more closely.</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Trazodone</span></b><span lang=EN-GB> (a
medicine for depression) as, unwanted effects like nausea, dizziness, low blood
pressure and fainting can occur when taken with Norvir. </span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Rifampicin and saquinavir</span></b><span
lang=EN-GB> (used for tuberculosis and HIV, respectively) as serious liver
damage can occur when taken with Norvir.</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;text-autospace:
none'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span style='font-family:"TimesNewRoman\,BoldItalic"'>Bosentan,
riociguat </span></b><span style='font-family:"TimesNewRoman\,Italic"'>(used
for pulmonary arterial hypertension) as Norvir may increase the blood levels of
this medicine.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span style='font-family:"EFPPNA+TimesNewRoman",serif;
color:black'>There are medicines that may not mix with Norvir because their
effects could increase or decrease when taken together. In some cases your
doctor may need to perform certain tests, change the dose or monitor you
regularly. This is why you should tell your doctor if you are taking any
medicines, including those you have bought yourself or herbal products, but it
is especially important to mention these: </span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt'>&nbsp;</p>

<p class=MsoNormal style='margin-left:26.95pt;text-indent:-26.95pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>amphetamine or amphetamine derivatives;</span></p>

<p class=MsoNormal style='margin-left:26.95pt;text-indent:-26.95pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>antibiotics (e.g. erythromycin, clarithromycin);
</span></p>

<p class=MsoNormal style='margin-left:26.95pt;text-indent:-26.95pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>anticancer treatments (e.g. abemaciclib, </span><span
lang=EN-GB>afatinib, apalutamide, ceritinib, encorafenib, </span>dasatinib, ibrutinib,
nilotinib<i>,</i> <span lang=EN-GB>venetoclax, vincristine, vinblastine);</span></p>

<p class=MsoNormal style='margin-left:26.95pt;text-indent:-26.95pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=PT-BR>medicines used to treat low blood platelet count
(e.g. fostamatinib);</span></p>

<p class=MsoNormal style='margin-left:26.95pt;text-indent:-26.95pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>anticoagulants (e.g. rivaroxaban, vorapaxar, warfarin);</span></p>

<p class=MsoNormal style='margin-left:26.95pt;text-indent:-26.95pt'><span
lang=FR>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=FR>antidepressants (e.g. amitriptyline, desipramine,
fluoxetine, imipramine, nefazodone, nortriptyline, paroxetine, sertraline,
trazodone);</span></p>

<p class=MsoNormal style='margin-left:26.95pt;text-indent:-26.95pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>antifungals (e.g. ketoconazole, itraconazole); </span></p>

<p class=MsoNormal style='margin-left:26.95pt;text-indent:-26.95pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>antihistamines (e.g. loratadine, fexofenadine); </span></p>

<p class=MsoNormal style='margin-left:26.95pt;text-indent:-26.95pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>antiretroviral medicines, including HIV&#8209;protease
inhibitors (</span>amprenavir, <span lang=EN-GB>atazanavir, darunavir,
fosamprenavir, </span>indinavir, nelfinavir,<span lang=EN-GB> saquinavir, </span>tipranavir),<span
lang=EN-GB> non-nucleoside reverse transcriptase inhibitors (NNRTI) (</span>delavirdine,
efavirenz, nevirapine),<span lang=EN-GB> and others (didanosine, maraviroc,
raltegravir, zidovudine); </span></p>

<p class=MsoNormal style='margin-left:26.95pt;text-indent:-26.95pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>anti-tuberculosis medicine (bedaquiline and
delamanid);</span></p>

<p class=MsoNormal style='margin-left:26.95pt;text-indent:-26.95pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>antiviral medicine used to </span>treat chronic
hepatitis C virus (HCV) infection in adults (e.g. glecaprevir/pibrentasvir and simeprevir);</p>

<p class=MsoNormal style='margin-left:26.95pt;text-indent:-26.95pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>anxiety medicine, buspirone; </span></p>

<p class=MsoNormal style='margin-left:26.95pt;text-indent:-26.95pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>asthma medicine, theophylline, salmeterol; </span></p>

<p class=MsoNormal style='margin-left:26.95pt;text-indent:-26.95pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>atovaquone, a medicine used to treat a certain
type of pneumonia and malaria;</span></p>

<p class=MsoNormal style='margin-left:26.95pt;text-indent:-26.95pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>buprenorphine, a medicine used for the treatment
of chronic pain;</span></p>

<p class=MsoNormal style='margin-left:26.95pt;text-indent:-26.95pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>bupropion, a medicine used to help you stop
smoking;</span></p>

<p class=MsoNormal style='margin-left:26.95pt;text-indent:-26.95pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>epilepsy medicines (e.g. carbamazepine,
divalproex, lamotrigine, phenytoin);</span></p>

<p class=MsoNormal style='margin-left:26.95pt;text-indent:-26.95pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>heart medicines (e.g. disopyramide, mexiletine
and calcium channel antagonists such as amlodipine, diltiazem and nifedipine); </span></p>

<p class=MsoNormal style='margin-left:26.95pt;text-indent:-26.95pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>immune system medicines (e.g. cyclosporine,
tacrolimus, everolimus); </span></p>

<p class=MsoNormal style='margin-left:26.95pt;text-indent:-26.95pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>levothyroxine (used to treat thyroid problems);</span></p>

<p class=MsoNormal style='margin-left:26.95pt;text-indent:-26.95pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>morphine and morphine-like medicines used to
treat severe pain (e.g. methadone, fentanyl);</span></p>

<p class=MsoNormal style='margin-left:26.95pt;text-indent:-26.95pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>sleeping pills (e.g. alprazolam, zolpidem) and
also midazolam administered by injection; </span></p>

<p class=MsoNormal style='margin-left:26.95pt;text-indent:-26.95pt'><span
lang=IT>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=IT>tranquillisers (e.g. haloperidol, risperidone,
thioridazine); </span></p>

<p class=MsoNormal style='margin-left:26.95pt;text-indent:-26.95pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>colchicine, a treatment for gout.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>There are some medicines you cannot take at
all with Norvir. These are listed earlier in section 2, under <b>Do not take
Norvir</b>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif'>Taking
Norvir with food and drink</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'>See section 3.</p>

<p class=MsoNormal style='margin-right:-.1pt'>&nbsp;</p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif'>Pregnancy
and breast-feeding</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>If you are pregnant or breast-feeding,
think you may be pregnant or are planning to have a baby, it is very important
that you ask your doctor for advice before taking this medicine.</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>There is a large amount of information on
the use of ritonavir (the active ingredient in Norvir) during pregnancy. In
general, pregnant mothers received ritonavir after the first three months of
pregnancy at a lower dose (booster) along with other protease inhibitors.
Norvir did not appear to increase the chance of developing birth defects compared
to the general population.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Norvir can pass into breast milk. To avoid
transmitting the infection, mothers with HIV must not breast feed their babies.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif'>Driving
and using machines</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif'>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Norvir can cause dizziness. If you are
affected do not drive or use machinery. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
text-transform:uppercase'>3. </span></b><b><span lang=EN-GB
style='font-family:"Times New Roman Bold",serif'>How to take Norvir</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
text-transform:uppercase'>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Always take this medicine exactly as your
doctor or pharmacist has told you. Check with your doctor or pharmacist if you
are not sure. Take this medicine one or two times a day every day with food.</span><span
lang=EN-GB style='font-size:12.0pt'> </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For doses of exactly 100&nbsp;mg amounts
(100, 200, 300, 400, 500, or 600&nbsp;mg) pour the entire content of each
sachet over soft food (apple sauce or vanilla pudding) or mix with a small
amount of liquid (water, chocolate milk, or infant formula) and consume entire
serving. </span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><b>For doses less than 100&nbsp;mg amounts or doses between 100&nbsp;mg
amounts, the content of the entire sachet is to be mixed with a liquid and then
dosed by the appropriate ml volume as told to you by your doctor using the oral
dosing syringe. &nbsp;</b></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoCommentText><span style='font-size:11.0pt'>For administration using
a feeding tube follow the instructions in section </span><span lang=EN-GB
style='font-size:11.0pt'>How do I take the correct dose of Norvir powder for
oral suspension mixed with liquid? <b>Use water to mix the medicine </b>and
follow the feeding tube instructions to administer the medicine.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'>Recommended doses of Norvir
are:</p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='margin-left:27.5pt;text-indent:-27.5pt;page-break-after:
avoid'><span style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>if Norvir is used to boost the effects of other anti-HIV
medicines, the typical dose for adults is 1 or 2 sachets once or twice daily.
For more detailed dose recommendations, including those for children, see the
Package Leaflet of the anti&#8209;HIV medicines Norvir is given in combination
with.</p>

<p class=MsoNormal style='margin-left:28.35pt;page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='margin-left:27.5pt;text-indent:-27.5pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>if your doctor prescribes a full dose, adults may be started on a
dose of 3 sachets in the morning and 3 sachets 12 hours later, gradually
increasing over a period of up to 14 days to the full dose of 6 sachets twice
daily. <b></b>Children (2  12 years of age) will start with a dose smaller
than this and continue up to the maximum allowed for their size. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Your doctor will advise you on the dosage to be taken.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Norvir</span><span lang=EN-GB> should be
taken every day to help control your HIV, no matter how much better you feel.
If a side effect is preventing you from taking Norvir, tell your doctor
straight away. During episodes of diarrhoea your doctor may decide that extra
monitoring is needed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Always keep enough Norvir on hand so you
don't run out. When you travel or need to stay in the hospital, make sure you
have enough Norvir to last until you can get a new supply.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Norvir</span><span lang=EN-GB> powder for
oral suspension has a lingering aftertaste. </span>Eating peanut butter,
hazelnut chocolate spread, or black currant syrup immediately after taking the
medication may help clear the aftertaste from your mouth. </p>

<p class=MsoNormal><b><span style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Prepare only one dose at a time using the
correct number of sachets. When mixing the powder with food or liquid, be sure
to take the whole dose within 2 hours. Do not mix<b> </b>Norvir with anything
else without talking to your doctor or pharmacist. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>How do I take the correct dose of Norvir
powder for oral suspension mixed with food (full sachet)? </span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Follow the instructions below:</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=605
 style='width:6.3in;margin-left:5.4pt;border-collapse:collapse'>
 <tr>
  <td width=297 valign=top style='width:222.95pt;border:none;border-bottom:
  dotted windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><img border=0 width=283 height=136
  src="Norvir_files/image001.gif"></p>
  </td>
  <td width=308 valign=top style='width:230.65pt;border:none;border-bottom:
  dotted windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Step 1. <span lang=EN-GB>Before mixing dose of Norvir,
  collect the following supplies: </span>(see Figure 1).</p>
  <p class=MsoNormal>&nbsp;</p>
  <p class=MsoNormal>Step 2. Check prescription for number of sachets or call
  your doctor or pharmacist.</p>
  </td>
 </tr>
 <tr style='height:30.6pt'>
  <td width=297 valign=top style='width:222.95pt;border-top:none;border-left:
  dotted windowtext 1.0pt;border-bottom:dotted windowtext 1.0pt;border-right:
  none;padding:0in 5.4pt 0in 5.4pt;height:30.6pt'>
  <p class=MsoNormal><i>Figure 1</i></p>
  </td>
  <td width=308 valign=top style='width:230.65pt;border-top:none;border-left:
  none;border-bottom:dotted windowtext 1.0pt;border-right:dotted windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:30.6pt'>
  <p class=MsoNormal align=center style='text-align:center'><b>&nbsp;</b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Step 3. Before first using the mixing cup, wash the cup in
warm water and dish soap. Rinse and allow to air dry.</p>

<p class=MsoNormal>&nbsp;</p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='margin-left:5.4pt;border-collapse:collapse'>
 <tr>
  <td width=252 valign=top style='width:189.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><img border=0 width=180 height=164 id="Picture 2"
  src="Norvir_files/image002.gif"></p>
  </td>
  <td width=353 valign=top style='width:264.6pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:12.0pt;margin-right:0in;margin-bottom:
  12.0pt;margin-left:0in'>Step 4. Put a small serving of soft food (applesauce
  or vanilla pudding) in a cup (see Figure 2).</p>
  </td>
 </tr>
 <tr>
  <td width=252 valign=top style='width:189.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><i>Figure 2</i></p>
  </td>
  <td width=353 valign=top style='width:264.6pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:12.0pt;margin-right:0in;margin-bottom:
  12.0pt;margin-left:0in'><b>&nbsp;</b></p>
  </td>
 </tr>
 <tr>
  <td width=252 valign=top style='width:189.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><img border=0 width=174 height=174
  src="Norvir_files/image003.jpg"></b></p>
  </td>
  <td width=353 valign=top style='width:264.6pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Step 5. Tear open sachet (see Figure 3).</p>
  <p class=MsoNormal><b>&nbsp;</b></p>
  </td>
 </tr>
 <tr style='height:22.5pt'>
  <td width=252 valign=top style='width:189.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:22.5pt'>
  <p class=MsoNormal><b>&nbsp;</b></p>
  <p class=MsoNormal><i>Figure 3</i></p>
  </td>
  <td width=353 valign=top style='width:264.6pt;padding:0in 5.4pt 0in 5.4pt;
  height:22.5pt'>
  <p class=MsoNormal align=center style='text-align:center'><b>&nbsp;</b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal>&nbsp;</p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=605
 style='width:6.3in;margin-left:5.4pt;border-collapse:collapse'>
 <tr>
  <td width=252 valign=top style='width:189.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><img border=0 width=193 height=174 id="Picture 4"
  src="Norvir_files/image004.gif"></b></p>
  </td>
  <td width=353 valign=top style='width:264.6pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Step 6. Pour ALL powder from sachet onto food (see Figure
  4). </p>
  <p class=MsoNormal><b>&nbsp;</b></p>
  </td>
 </tr>
 <tr style='height:22.5pt'>
  <td width=252 valign=top style='width:189.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:22.5pt'>
  <p class=MsoNormal><b>&nbsp;</b></p>
  <p class=MsoNormal><i>Figure 4</i></p>
  </td>
  <td width=353 valign=top style='width:264.6pt;padding:0in 5.4pt 0in 5.4pt;
  height:22.5pt'>
  <p class=MsoNormal align=center style='text-align:center'><b>&nbsp;</b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal>&nbsp;</p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=605
 style='width:6.3in;margin-left:5.4pt;border-collapse:collapse'>
 <tr>
  <td width=252 valign=top style='width:189.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><img border=0 width=193 height=174
  src="Norvir_files/image005.gif"></b></p>
  </td>
  <td width=353 valign=top style='width:264.6pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Step 7. Mix thoroughly (see Figure 5).</p>
  <p class=MsoNormal><b>&nbsp;</b></p>
  </td>
 </tr>
 <tr style='height:22.5pt'>
  <td width=252 valign=top style='width:189.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:22.5pt'>
  <p class=MsoNormal><b>&nbsp;</b></p>
  <p class=MsoNormal><i>Figure 5</i></p>
  </td>
  <td width=353 valign=top style='width:264.6pt;padding:0in 5.4pt 0in 5.4pt;
  height:22.5pt'>
  <p class=MsoNormal align=center style='text-align:center'><b>&nbsp;</b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-top:12.0pt;margin-right:0in;margin-bottom:
12.0pt;margin-left:0in;text-indent:193.5pt'>Step 8. Feed serving to patient.</p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=605
 style='width:6.3in;margin-left:5.4pt;border-collapse:collapse'>
 <tr>
  <td width=252 valign=top style='width:189.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><img border=0 width=189 height=174 id="Picture 6"
  src="Norvir_files/image006.gif"></b></p>
  </td>
  <td width=353 valign=top style='width:264.6pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Step 9. ENTIRE serving must be eaten (see Figure 6). If <b>powder
  residue</b> is left, add more spoonfuls of food and serve to patient. <i>Use
  within 2 hours.</i></p>
  <p class=MsoNormal><b>&nbsp;</b></p>
  </td>
 </tr>
 <tr style='height:22.5pt'>
  <td width=252 valign=top style='width:189.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:22.5pt'>
  <p class=MsoNormal><b>&nbsp;</b></p>
  <p class=MsoNormal><i>Figure 6</i></p>
  <p class=MsoNormal><b>&nbsp;</b></p>
  </td>
  <td width=353 valign=top style='width:264.6pt;padding:0in 5.4pt 0in 5.4pt;
  height:22.5pt'>
  <p class=MsoNormal align=center style='text-align:center'><b>&nbsp;</b></p>
  </td>
 </tr>
 <tr>
  <td width=252 valign=top style='width:189.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><img border=0 width=189 height=174 id="Picture 7"
  src="Norvir_files/image007.gif"></b></p>
  </td>
  <td width=353 valign=top style='width:264.6pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Step 10. Place empty sachet in rubbish. Wash and dry
  preparation area. Immediately wash the spoon and cup in warm water and dish
  soap (see Figure 7). Rinse and allow to air dry.</p>
  <p class=MsoNormal><b>&nbsp;</b></p>
  </td>
 </tr>
 <tr style='height:22.5pt'>
  <td width=252 valign=top style='width:189.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:22.5pt'>
  <p class=MsoNormal><b>&nbsp;</b></p>
  <p class=MsoNormal><i>Figure 7</i></p>
  </td>
  <td width=353 valign=top style='width:264.6pt;padding:0in 5.4pt 0in 5.4pt;
  height:22.5pt'>
  <p class=MsoNormal align=center style='text-align:center'><b>&nbsp;</b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:115%'><b><span lang=EN-GB
style='line-height:115%'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>How do I take the correct dose of Norvir
powder for oral suspension mixed with liquid? </span></b></p>

<p class=MsoNormal style='line-height:115%'><b><span lang=EN-GB
style='line-height:115%'>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Follow the instructions below:</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=605
 style='width:6.3in;margin-left:5.4pt;border-collapse:collapse'>
 <tr>
  <td width=297 colspan=2 valign=top style='width:222.95pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:12.0pt;margin-right:0in;margin-bottom:
  12.0pt;margin-left:0in'><span lang=EN-GB><img border=0 width=274 height=149
  id="Picture 3" src="Norvir_files/image008.gif"></span></p>
  <p class=MsoNormal><i>Figure 1</i></p>
  </td>
  <td width=308 valign=top style='width:230.65pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b>What you need</b></p>
  <p class=MsoNormal><b>&nbsp;</b></p>
  <p class=MsoNormal>Before mixing a dose of Norvir, collect the items shown in
  Figure 1.</p>
  <p class=MsoNormal>&nbsp;</p>
  <p class=MsoNormal><span style='color:#000101'>You may need more than 1
  sachet for each dose. Check the prescription label on the carton or call your
  doctor or pharmacist if you are not sure. If you do need more than 1 sachet,
  repeat all the steps with each sachet.</span><span style='font-family:"ArialMT",sans-serif;
  color:#000101'> </span></p>
  </td>
 </tr>
 <tr style='height:22.5pt'>
  <td width=297 colspan=2 valign=top style='width:222.95pt;padding:0in 5.4pt 0in 5.4pt;
  height:22.5pt'>
  <p class=MsoNormal style='margin-top:12.0pt;margin-right:0in;margin-bottom:
  12.0pt;margin-left:0in'><span style='color:#1D1D1B'><img border=0 width=120
  height=73 id="Picture 11" src="Norvir_files/image009.gif"></span></p>
  </td>
  <td width=308 valign=top style='width:230.65pt;padding:0in 5.4pt 0in 5.4pt;
  height:22.5pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span style='color:#1D1D1B'>Using
  the syringe</span></b></p>
  <p class=MsoNormal style='text-autospace:none'>Before first using the dosing
  syringe, wash the syringe in warm water and dish soap. Rinse and allow to air
  dry.</p>
  <p class=MsoNormal style='text-autospace:none'><b><span style='color:#1D1D1B'>&nbsp;</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><b><span style='color:#1D1D1B'>Reading
  the scale</span></b></p>
  <p class=MsoListParagraphCxSpFirst style='margin-left:27.05pt;text-indent:
  -27.05pt;text-autospace:none'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif;color:#000101'>a.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  color:#000101'>Each millilitre (ml) is shown as a number with a big line.</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-left:27.05pt;text-indent:
  -27.05pt;text-autospace:none'><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif;color:#000101'>b.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  color:#000101'>Each 0.2 ml is shown</span><span lang=EN-GB style='font-size:
  11.0pt;font-family:"Times New Roman",serif;color:#1D1D1B'> as a smaller line
  between the numbers.</span><span lang=EN-GB style='font-size:11.0pt;
  font-family:"Times New Roman",serif;color:#1D1D1B'> </span></p>
  <p class=MsoNormal style='text-autospace:none'><span style='color:#1D1D1B'>&nbsp;</span></p>
  <p class=MsoNormal style='text-autospace:none'><b><span style='color:#1D1D1B'>Check
  the syringe before each use</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span style='color:#1D1D1B'>You
  will need to use a new syringe if:</span></p>
  <p class=MsoListParagraphCxSpFirst style='margin-left:.25in;text-indent:-.25in;
  text-autospace:none'><span lang=EN-GB style='font-size:11.0pt;font-family:
  Symbol;color:#000101'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  color:#000101'>you cannot clean the syringe</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:
  -.25in;text-autospace:none'><span lang=EN-GB style='font-size:11.0pt;
  font-family:Symbol;color:#000101'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  color:#000101'>you cannot read the scale</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:
  -.25in;text-autospace:none'><span lang=EN-GB style='font-size:11.0pt;
  font-family:Symbol;color:#000101'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  color:#000101'>you cannot move the plunger</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:
  -.25in;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'><span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  color:#000101'>the syringe is damaged or leaking.</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-left:0in;text-autospace:none'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=294 valign=top style='width:220.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:12.0pt;margin-right:0in;margin-bottom:
  12.0pt;margin-left:0in'><span style='font-family:"ArialMT",sans-serif;
  color:#000101'><img border=0 width=107 height=108 id="Picture 5"
  src="Norvir_files/image010.gif"></span></p>
  <p class=MsoNormal style='margin-top:12.0pt;margin-right:0in;margin-bottom:
  12.0pt;margin-left:0in'><i>Figure 2</i></p>
  </td>
  <td width=311 colspan=2 valign=top style='width:233.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b>Step 1. Fill the syringe</b></p>
  <p class=MsoNormal style='text-autospace:none'>&nbsp;</p>
  <p class=MsoNormal style='text-autospace:none'><span style='color:#000101'>a.
  Push the plunger all the way into syringe.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span style='color:#000101'>b.
  Place the syringe tip into the liquid.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span style='color:#000101'>c.
  Slowly pull the plunger back to the 10&nbsp;ml mark on the syringe</span>
  (see Figure 2).</p>
  <p class=MsoNormal style='margin-top:12.0pt;margin-right:0in;margin-bottom:
  0in;margin-left:.5in;margin-bottom:.0001pt'>&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width=294 valign=top style='width:220.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:12.0pt;margin-right:0in;margin-bottom:
  12.0pt;margin-left:0in'><span style='font-family:"ArialMT",sans-serif;
  color:#000101'><img border=0 width=103 height=204 id="Picture 13"
  src="Norvir_files/image011.gif"></span></p>
  <p class=MsoNormal style='margin-bottom:12.0pt'><i>Figure 3</i></p>
  </td>
  <td width=311 colspan=2 valign=top style='width:233.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b>Step 2. Move any bubbles to
  the tip of the syringe</b></p>
  <p class=MsoNormal style='text-autospace:none'>&nbsp;</p>
  <p class=MsoNormal style='text-autospace:none'><span style='color:#000101'>a.
  Hold the syringe with the tip pointing up.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span style='color:#000101'>b.
  Tap the syringe with your</span></p>
  <p class=MsoNormal style='text-autospace:none'><span style='color:#000101'>other
  hand. This will move any bubbles to the tip. </span></p>
  <p class=MsoNormal style='text-autospace:none'><span style='color:#000101'>c.
  Pull the plunger down.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span style='color:#000101'>Be
  careful not to pull the plunger out.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span style='color:#000101'>d.
  Tap the syringe again. This will help to break up the bubbles and make sure
  they are all at the tip (see Figure 3).</span></p>
  <p class=MsoNormal style='margin-top:12.0pt;margin-right:0in;margin-bottom:
  12.0pt;margin-left:0in'>&nbsp;</p>
  </td>
 </tr>
 <tr style='height:22.5pt'>
  <td width=294 valign=top style='width:220.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:22.5pt'>
  <p class=MsoNormal style='margin-top:12.0pt;margin-right:0in;margin-bottom:
  12.0pt;margin-left:0in'><span style='font-family:"ArialMT",sans-serif;
  color:#000101'><img border=0 width=103 height=103 id="Picture 14"
  src="Norvir_files/image012.gif"></span></p>
  <p class=MsoNormal><i>Figure 4</i></p>
  </td>
  <td width=311 colspan=2 valign=top style='width:233.1pt;padding:0in 5.4pt 0in 5.4pt;
  height:22.5pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span style='color:#000101'>Step
  3. Measure the liquid</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span style='font-family:"ArialMT",sans-serif;
  color:#000101'>&nbsp;</span></p>
  <p class=MsoNormal style='text-autospace:none'><span style='color:#000101'>a.
  Keep the syringe pointed up.</span></p>
  <p class=MsoNormal><span style='color:#000101'>b. Slowly push the plunger up
  until the top of the plunger is at 9.4&nbsp;ml - this will remove any bubbles
  from the syringe (see Figure 4).</span></p>
  </td>
 </tr>
 <tr>
  <td width=294 valign=top style='width:220.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:12.0pt;margin-right:0in;margin-bottom:
  12.0pt;margin-left:0in'><span style='font-family:"ArialMT",sans-serif;
  color:#000101'><img border=0 width=91 height=88 id="Picture 9"
  src="Norvir_files/image013.gif"></span></p>
  <p class=MsoNormal><i>Figure 5</i></p>
  </td>
  <td width=311 colspan=2 valign=top style='width:233.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:12.0pt'><b>Step 4. Empty the syringe</b></p>
  <p class=MsoNormal>a. Slowly push the plunger to empty the liquid from the
  syringe into the mixing cup (see Figure 5).</p>
  </td>
 </tr>
 <tr>
  <td width=294 valign=top style='width:220.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:12.0pt;margin-right:0in;margin-bottom:
  12.0pt;margin-left:0in'><img border=0 width=96 height=95 id="Picture 12"
  src="Norvir_files/image014.gif"></p>
  <p class=MsoNormal><i>Figure 6</i></p>
  </td>
  <td width=311 colspan=2 valign=top style='width:233.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b>Step 5. Pour the powder
  into the cup</b></p>
  <p class=MsoNormal style='text-autospace:none'>&nbsp;</p>
  <p class=MsoNormal style='text-autospace:none'><span style='color:#000101'>a.
  Tear open the sachet.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span style='color:#000101'>b.
  Pour all of the powder into the mixing cup.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span style='color:#000101'>c.
  Check if the sachet is empty.</span></p>
  <p class=MsoNormal style='margin-top:12.0pt;margin-right:0in;margin-bottom:
  12.0pt;margin-left:0in'><b><span style='color:#1D1D1B'>Be careful not to
  spill any powder outside of the mixing cup</span></b> (see Figure 6).</p>
  </td>
 </tr>
 <tr>
  <td width=294 valign=top style='width:220.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:12.0pt;margin-right:0in;margin-bottom:
  12.0pt;margin-left:0in'><span style='font-family:"ArialMT",sans-serif;
  color:#000101'><img border=0 width=130 height=169 id="Picture 15"
  src="Norvir_files/image015.gif"></span></p>
  <p class=MsoNormal style='margin-top:12.0pt;margin-right:0in;margin-bottom:
  12.0pt;margin-left:0in'><i>Figure 7</i></p>
  </td>
  <td width=311 colspan=2 valign=top style='width:233.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span style='color:#000101'>Step
  6. Mix the powder and liquid</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><b><span style='color:#000101'>&nbsp;</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span style='color:#000101'>a.Tightly
  screw on the lid and keep shaking the</span></p>
  <p class=MsoNormal style='text-autospace:none'><span style='color:#000101'>mixing
  cup hard for at least 90 seconds until all the lumps have gone.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span style='color:#000101'>b.
  Check for any lumps of powder. If there are still lumps, keep shaking until they
  have all gone</span>. </p>
  <p class=MsoNormal style='text-autospace:none'><span style='color:#000101'>c.
  The liquid may look cloudy - this is okay.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span style='color:#000101'>d.
  Let the liquid stand for 10 minutes and most of the bubbles will disappear.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span style='color:#000101'>e.
  You may see some small bubbles on top of the liquid - this is also okay (see
  Figure 7).</span></p>
  </td>
 </tr>
 <tr>
  <td width=294 valign=top style='width:220.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:12.0pt'><span style='font-family:"ArialMT",sans-serif;
  color:#000101'><img border=0 width=135 height=182
  src="Norvir_files/image016.gif"></span></p>
  <p class=MsoNormal style='margin-top:12.0pt'><i>Figure 8</i></p>
  </td>
  <td width=311 colspan=2 valign=top style='width:233.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b>Step 7. Fill the syringe</b></p>
  <p class=MsoNormal style='text-autospace:none'>&nbsp;</p>
  <p class=MsoNormal style='text-autospace:none'><span style='color:#000101'>a.
  Push the plunger completely into the syringe.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span style='color:#000101'>b.
  Place the syringe tip at the bottom of the mixing cup.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span style='color:#000101'>c.
  Slowly pull the plunger back to the 10&nbsp;ml mark - try not to pull any
  bubbles into the syringe (see Figure 8).</span></p>
  </td>
 </tr>
 <tr>
  <td width=294 valign=top style='width:220.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:12.0pt;margin-right:0in;margin-bottom:
  12.0pt;margin-left:0in'><span style='font-family:"ArialMT",sans-serif;
  color:#000101'><img border=0 width=95 height=183 id="Picture 8"
  src="Norvir_files/image017.gif"></span></p>
  <p class=MsoNormal style='margin-top:12.0pt;margin-right:0in;margin-bottom:
  12.0pt;margin-left:0in'><i>Figure 9</i></p>
  </td>
  <td width=311 colspan=2 valign=top style='width:233.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span style='color:#000101'>Step
  8. Remove any bubbles</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span style='font-family:"ArialMT",sans-serif;
  color:#000101'>&nbsp;</span></p>
  <p class=MsoNormal style='text-autospace:none'><span style='color:#000101'>a.
  Hold the syringe with the tip pointing up.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span style='color:#000101'>b.
  Tap the syringe with your other hand. This will move any bubbles to the tip.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span style='color:#000101'>c.
  Pull the plunger down. Be careful not to pull the plunger out.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span style='color:#000101'>d.
  Tap the syringe again to break up the bubbles so they are all at the tip (see
  Figure 9).</span></p>
  <p class=MsoNormal style='text-autospace:none'><span style='color:#000101'>e.
  Slowly push the plunger until you see a small amount of liquid at the tip of
  the syringe.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span style='color:#000101'>f.
  If there are any large air bubbles, empty the liquid from the syringe into
  the mixing cup and start again from Step 7.</span></p>
  </td>
 </tr>
 <tr>
  <td width=294 valign=top style='width:220.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:12.0pt;margin-right:0in;margin-bottom:
  12.0pt;margin-left:0in;page-break-after:avoid'><img border=0 width=108
  height=105 id="Picture 10" src="Norvir_files/image018.gif"></p>
  <p class=MsoNormal style='margin-top:12.0pt;margin-right:0in;margin-bottom:
  12.0pt;margin-left:0in;page-break-after:avoid'><i>Figure 10</i></p>
  </td>
  <td width=311 colspan=2 valign=top style='width:233.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b>Step
  9. Measure the dose</b></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'>&nbsp;</p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  style='color:#000101'>a. Check the prescription label on the carton for the
  dose in ml. If you are not sure, call your doctor or pharmacist.</span></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  style='color:#000101'>b. Point the syringe into the mixing cup and slowly
  push the plunger to the correct ml for the dose (see Figure 10).</span></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  style='color:#000101'>c. </span>If you push out too much liquid, start again
  from Step 7. Be careful not to spill the liquid outside of the mixing cup.</p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'>&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width=294 valign=top style='width:220.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:12.0pt;margin-right:0in;margin-bottom:
  12.0pt;margin-left:0in'><img border=0 width=188 height=185 id="Picture 16"
  src="Norvir_files/image019.gif"></p>
  <p class=MsoNormal style='margin-top:12.0pt;margin-right:0in;margin-bottom:
  12.0pt;margin-left:0in'><i>Figure 11</i></p>
  </td>
  <td width=311 colspan=2 valign=top style='width:233.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span style='letter-spacing:-.05pt'>Step 10. Give the
  medicine to the patient</span></b></p>
  <p class=MsoNormal><span style='letter-spacing:-.05pt'>&nbsp;</span></p>
  <p class=MsoNormal><span style='letter-spacing:-.05pt'>a. Place the syringe
  tip against the inside of the patients cheek.</span></p>
  <p class=MsoNormal><span style='letter-spacing:-.05pt'>b. Slowly push the plunger
  to give all of the dose (see Figure 11).</span></p>
  <p class=MsoNormal><span style='letter-spacing:-.05pt'>c. Give the patient
  the full dose within 2 hours of opening the sachet<i>.</i></span></p>
  <p class=MsoNormal style='margin-top:12.0pt;margin-right:0in;margin-bottom:
  12.0pt;margin-left:0in;line-height:125%'><span style='font-size:12.0pt;
  line-height:125%'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=294 valign=top style='width:220.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:12.0pt;margin-right:0in;margin-bottom:
  12.0pt;margin-left:0in'>&nbsp;</p>
  </td>
  <td width=311 colspan=2 valign=top style='width:233.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span style='letter-spacing:
  -.05pt'>Step 11. (If required)</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span style='letter-spacing:
  -.05pt'>&nbsp;</span></p>
  <p class=MsoNormal><span style='letter-spacing:-.05pt'>If you need to use more
  than one sachet, repeat the process from the beginning.</span></p>
  <p class=MsoNormal>&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width=294 valign=top style='width:220.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:12.0pt;margin-right:0in;margin-bottom:
  12.0pt;margin-left:0in'>&nbsp;</p>
  </td>
  <td width=311 colspan=2 valign=top style='width:233.1pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span style='color:#000101'>Step
  12. After you have finished</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span style='color:#000101'>&nbsp;</span></p>
  <p class=MsoNormal style='text-autospace:none'><span style='color:#000101'>a.
  Place the empty sachet and any left over medicine from the mixing cup into a
  rubbish bag.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span style='color:#000101'>b.
  Remove the plunger from the syringe.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span style='color:#000101'>c.
  Hand wash the syringe, plunger, and mixing cup and lid in warm water and dish
  soap. Rinse with water and allow to air dry. Do not wash these in the
  dishwasher.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span style='color:#000101'>d.
  Wash and dry the area used to mix the medicine.</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=294 style='border:none'></td>
  <td width=3 style='border:none'></td>
  <td width=308 style='border:none'></td>
 </tr>
</table>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif'>If
you take more Norvir than you should</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif'>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Numbness, tingling, or a pins and needles
sensation may occur if you take too much Norvir. If you realise you have taken
more Norvir than you were supposed to, contact your doctor or the Accident and
Emergency Department of your nearest hospital straight away. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif'>If
you forget to take Norvir</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif'>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>If you miss a dose, take the missed dose as
soon as possible. If it is nearly time for the next dose, just take that one.
Do not take a double dose to make up for a forgotten dose.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>If you
stop taking Norvir</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Even if you
feel better, do not stop taking Norvir without talking to your doctor. Taking Norvir
as recommended should give you the best chance of delaying resistance to the
medicines.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
text-transform:uppercase'>4. </span></b><b><span lang=EN-GB
style='font-family:"Times New Roman Bold",serif'>Possible side effects</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
text-transform:uppercase'>&nbsp;</span></b></p>

<p class=EMEANormal><span lang=EN-GB>During HIV therapy there may be an increase
in weight and in levels of blood lipids and glucose. This is partly linked to
restored health and life style, and in the case of blood lipids sometimes to
the HIV medicines themselves. Your doctor will test for these changes.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Like all medicines, Norvir can cause side
effects, although not everybody gets them. Also, the side effects of Norvir
when used with other antiretroviral medicines are dependent on the other
medicines. So it is important that you carefully read the side effects section
of the leaflets that are provided with these other medicines.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Very common: </span></b><span
lang=EN-GB>may<b> </b></span><span lang=EN-GB>affect more than 1 in 10 people</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:27.5pt;text-indent:-27.5pt'><span
  lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>upper or lower stomach ache  </span></p>
  <p class=MsoNormal style='margin-left:27.5pt;text-indent:-27.5pt'><span
  lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>vomiting </span></p>
  <p class=MsoNormal style='margin-left:27.5pt;text-indent:-27.5pt'><span
  lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>diarrhoea (may be severe) </span></p>
  <p class=MsoNormal style='margin-left:27.5pt;text-indent:-27.5pt'><span
  lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>feeling sick (nausea)</span></p>
  <p class=MsoNormal style='margin-left:27.5pt;text-indent:-27.5pt'><span
  lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>flushing, feeling hot </span></p>
  <p class=MsoNormal style='margin-left:27.5pt;text-indent:-27.5pt'><span
  lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>headache </span></p>
  <p class=MsoNormal style='margin-left:27.5pt;text-indent:-27.5pt'><span
  lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>dizziness</span></p>
  <p class=MsoNormal style='margin-left:27.5pt;text-indent:-27.5pt'><span
  lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>pain in the throat</span></p>
  <p class=MsoNormal style='margin-left:27.5pt;text-indent:-27.5pt'><span
  lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>cough</span></p>
  <p class=MsoNormal style='margin-left:27.5pt;text-indent:-27.5pt'><span
  lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>upset stomach or indigestion </span></p>
  </td>
  <td width=310 valign=top style='width:232.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:30.05pt;text-indent:-29.95pt'><span
  lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>a tingling sensation or numbness in <br>
  the hands, feet or around the lips and mouth</span></p>
  <p class=MsoNormal style='margin-left:30.05pt;text-indent:-29.95pt'><span
  lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>feeling weak/tired</span></p>
  <p class=MsoNormal style='margin-left:30.05pt;text-indent:-29.95pt'><span
  lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>bad taste in the mouth</span></p>
  <p class=MsoNormal style='margin-left:30.05pt;text-indent:-29.95pt'><span
  lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span>damage to the nerves that can cause weakness and pain</p>
  <p class=MsoNormal style='margin-left:30.05pt;text-indent:-29.95pt'><span
  lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>itching</span></p>
  <p class=MsoNormal style='margin-left:30.05pt;text-indent:-29.95pt'><span
  lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>rash</span></p>
  <p class=MsoNormal style='margin-left:30.05pt;text-indent:-29.95pt'><span
  lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>joint pain and back pain</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Common: </span></b><span
lang=EN-GB>may </span><span lang=EN-GB>affect up to 1 in 10 people </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:27.5pt;text-indent:-27.5pt;page-break-after:
  avoid'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>allergic reactions including skin <br>
  rashes (may be red, raised, itchy), <br>
  severe swelling of the skin and <br>
  other tissues</span></p>
  <p class=MsoNormal style='margin-left:27.5pt;text-indent:-27.5pt;page-break-after:
  avoid'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>inability to sleep (insomnia)</span></p>
  <p class=MsoNormal style='margin-left:27.5pt;text-indent:-27.5pt;page-break-after:
  avoid'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>anxiety</span></p>
  <p class=MsoNormal style='margin-left:27.5pt;text-indent:-27.5pt;page-break-after:
  avoid'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>increase in cholesterol</span></p>
  <p class=MsoNormal style='margin-left:27.5pt;text-indent:-27.5pt;page-break-after:
  avoid'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>increase in triglycerides</span></p>
  <p class=MsoNormal style='margin-left:27.5pt;text-indent:-27.5pt;page-break-after:
  avoid'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>gout</span></p>
  <p class=MsoNormal style='margin-left:27.5pt;text-indent:-27.5pt;page-break-after:
  avoid'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>stomach bleeding</span></p>
  <p class=MsoNormal style='margin-left:27.5pt;text-indent:-27.5pt;page-break-after:
  avoid'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>inflammation of the liver and yellowing of
  skin or whites of the eyes</span></p>
  <p class=MsoNormal style='margin-left:27.5pt;text-indent:-27.5pt;page-break-after:
  avoid'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>increase in urination</span></p>
  <p class=MsoNormal style='margin-left:27.5pt;text-indent:-27.5pt;page-break-after:
  avoid'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>reduced kidney function</span></p>
  <p class=MsoNormal style='margin-left:27.5pt;text-indent:-27.5pt;page-break-after:
  avoid'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>seizures (fits)</span></p>
  <p class=MsoNormal style='margin-left:27.5pt;text-indent:-27.5pt;page-break-after:
  avoid'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB style='color:black'>low levels of blood
  platelets</span></p>
  <p class=MsoNormal style='margin-left:27.5pt;text-indent:-27.5pt;page-break-after:
  avoid'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB style='color:black'>thirst (dehydration)</span></p>
  <p class=MsoNormal style='margin-left:27.5pt;text-indent:-27.5pt;page-break-after:
  avoid'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB style='color:black'>abnormally heavy periods</span></p>
  </td>
  <td width=310 valign=top style='width:232.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:30.05pt;text-indent:-29.95pt;
  page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'><span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>wind (flatulence)</span></p>
  <p class=MsoNormal style='margin-left:30.05pt;text-indent:-29.95pt;
  page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'><span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>loss of appetite</span></p>
  <p class=MsoNormal style='margin-left:30.05pt;text-indent:-29.95pt;
  page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'><span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>mouth ulcer</span></p>
  <p class=MsoNormal style='margin-left:30.05pt;text-indent:-29.95pt;
  page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'><span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>muscle aches (pain), tenderness or weakness</span></p>
  <p class=MsoNormal style='margin-left:30.05pt;text-indent:-29.95pt;
  page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'><span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>fever</span></p>
  <p class=MsoNormal style='margin-left:30.05pt;text-indent:-29.95pt;
  page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'><span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>weight loss</span></p>
  <p class=MsoNormal style='margin-left:30.05pt;text-indent:-29.95pt;
  page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'><span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>laboratory test results:<br>
  changes in blood test results <br>
  (such as blood chemistry and <br>
  blood count)</span></p>
  <p class=MsoNormal style='margin-left:30.05pt;text-indent:-29.95pt;
  page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'><span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>confusion</span></p>
  <p class=MsoNormal style='margin-left:30.05pt;text-indent:-29.95pt;
  page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'><span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>difficulty paying attention</span></p>
  <p class=MsoNormal style='margin-left:30.05pt;text-indent:-29.95pt;
  page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'><span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>fainting</span></p>
  <p class=MsoNormal style='margin-left:30.05pt;text-indent:-29.95pt;
  page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'><span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>blurred vision</span></p>
  <p class=MsoNormal style='margin-left:30.05pt;text-indent:-29.95pt;
  page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'><span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>swelling of the hands and feet</span></p>
  <p class=MsoNormal style='margin-left:30.05pt;text-indent:-29.95pt;
  page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'><span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>high blood pressure</span></p>
  <p class=MsoNormal style='margin-left:30.05pt;text-indent:-29.95pt;
  page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'><span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>low blood pressure and feeling faint when
  getting up</span></p>
  <p class=MsoNormal style='margin-left:30.05pt;text-indent:-29.95pt;
  page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'><span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>coldness in the hands and feet</span></p>
  <p class=MsoNormal style='margin-left:30.05pt;text-indent:-29.95pt;
  page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'><span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>acne</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Uncommon:
</span></b><span lang=EN-GB>may affect up to 1 in 100 people</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:27.5pt;text-indent:-27.5pt;page-break-after:
  avoid'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB style='color:black'>heart attack</span><span
  lang=EN-GB> </span></p>
  <p class=MsoNormal style='margin-left:27.5pt;text-indent:-27.5pt;page-break-after:
  avoid'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>diabetes</span></p>
  </td>
  <td width=310 valign=top style='width:232.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:31.8pt;text-indent:-31.7pt;page-break-after:
  avoid'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB style='color:black'>kidney failure</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Rare: </span></b><span lang=EN-GB>may </span><span
lang=EN-GB>affect up to 1 in 1,000 people</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:27.5pt;text-indent:-27.5pt'><span
  lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>severe or life threatening skin <br>
  reaction including blisters<br>
  (Stevens Johnson syndrome, toxic epidermal necrolysis)</span></p>
  </td>
  <td width=310 valign=top style='width:232.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:31.8pt;text-indent:-31.7pt'><span
  lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>serious allergic reaction (anaphylaxis)</span></p>
  <p class=MsoNormal style='margin-left:31.8pt;text-indent:-31.7pt'><span
  lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>high levels of sugar in the blood</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Not known: </span></b><span lang=EN-GB>frequency<b>
</b></span><span style='color:black'>cannot be estimated from the available
data</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:27.5pt;text-indent:-27.5pt'><span
lang=EN-GB style='font-family:Symbol;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>kidney stones</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Tell your doctor if you
feel sick (nauseous), are vomiting, or have stomach pain, because these may be
signs of an inflamed pancreas. Also tell your doctor if you experience joint
stiffness, aches and pains (especially of the hip, knee and shoulder) and
difficulty moving, as this may be a sign of osteonecrosis. See also section <b>2.</b>
</span><b><span lang=EN-GB>What you need to know before you or your child<span
style='color:black'> takes Norvir</span></span></b><span lang=EN-GB
style='color:black'>.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In patients with haemophilia types A and B,
there have been reports of increased bleeding while taking this treatment or
another protease inhibitor. Should this happen to you, seek immediate advice
from your doctor. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Abnormal liver function
tests, hepatitis (inflammation of the liver), and rarely jaundice, have been
reported in patients taking Norvir. Some people had other illnesses or were
taking other medicines. People with liver disease or hepatitis may have
worsening of liver disease. </span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>There have been reports
of muscle pain, tenderness or weakness, particularly when taking medicines to
lower cholesterol in combination with antiretroviral therapy, including
protease inhibitors and nucleoside analogues. On rare occasions these muscle
disorders have been serious (rhabdomyolysis). In the event of unexplained or
continual muscle pain, tenderness, weakness or cramps, stop taking the
medicine, contact your doctor as soon as possible or go to the Accident and
Emergency Department of your nearest hospital.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Inform your doctor as soon as possible if
you experience any symptoms that suggest an allergic reaction after taking Norvir
such as rash, hives or breathing difficulties.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>If any of the side effects gets serious,
or if you notice any side effects not listed in this leaflet, contact your
doctor, pharmacist, Accident and Emergency department or if it is urgent get
immediate medical help.</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>Reporting of side effects</span></b></p>

<p class=MsoNormal><b><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal><span lang=EN-GB>If you get any side effects, talk to your
doctor or pharmacist. This includes any possible side effects not listed in
this leaflet. You can also report side effects directly via <span
style='background:lightgrey'>the national reporting system listed in </span></span><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
lang=EN-GB style='background:lightgrey'>Appendix V</span></a><span lang=EN-GB>.
By reporting side effects, you can help provide more information on the safety
of this medicine.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
text-transform:uppercase'>5. </span></b><b><span lang=EN-GB
style='font-family:"Times New Roman Bold",serif'>How to store Norvir</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
text-transform:uppercase'>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Keep this medicine out of the sight and
reach of children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not use Norvir powder for oral
suspension after the expiry date on the sachet and carton. The expiry date
refers to the last day of the month.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Norvir</span><span lang=EN-GB> powder for
oral suspension should be stored below 30</span><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB>C. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not use this medicine if you notice the
powder is not beige/pale yellow to yellow.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoCommentText><span style='font-size:11.0pt'>Do not throw away any
medicines via wastewater. Ask your pharmacist how to throw away medicines you
no longer use. These measures will help protect the environment.</span></p>

<p class=MsoCommentText><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoCommentText>&nbsp;</p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
text-transform:uppercase'>6. </span></b><b><span lang=EN-GB
style='font-family:"Times New Roman Bold",serif'>Contents of the pack and other
information</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
text-transform:uppercase'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>What Norvir contains</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
115%'><span lang=EN-GB style='line-height:115%'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='line-height:115%'>The active substance is
ritonavir. Each sachet of Norvir contains 100&nbsp;mg ritonavir. </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
115%'><span lang=EN-GB style='line-height:115%'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='line-height:115%'>The other ingredients
are </span><span lang=EN-GB style='line-height:115%'>copovidone; sorbitan
laurate; silica, colloidal anhydrous. </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>What Norvir looks like and contents of the pack</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Norvir</span><span
lang=EN-GB> powder for oral suspension comes in individual sachets containing
100&nbsp;mg ritonavir. 30&nbsp;sachets are packed in a carton together with 1&nbsp;mixing
cup and 2&nbsp;oral dosing syringes. </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>Not all pack
sizes may be marketed.</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>Norvir is also
supplied </span>as a film-coated tablet containing 100&nbsp;mg ritonavir<span
lang=EN-GB>.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Marketing
Authorisation Holder</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>AbbVie Deutschland GmbH &amp; Co. KG, Knollstrasse, 67061
Ludwigshafen, Germany</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Manufacturers</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=DE>AbbVie
Deutschland GmbH &amp; Co. KG, Knollstrasse, </span><span lang=EN-GB>67061
Ludwigshafen, Germany</span><span lang=EN-GB style='color:black'> </span></p>

<p class=MsoNormal><span lang=EN-GB style='background:lightgrey'>AbbVie
Logistics B.V., Zuiderzeelaan 53, 8017 JV Zwolle, The Netherlands</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-3.45in'><span lang=EN-GB>For any
information about this medicine, please contact the local representative of the
</span></p>

<p class=MsoNormal style='margin-right:-3.45in'><span lang=EN-GB>Marketing
Authorisation Holder:</span></p>

<p class=MsoNormal>&nbsp;</p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624
 style='margin-left:-1.7pt;border-collapse:collapse'>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR-BE>Belgi/Belgique/Belgien</span></b></p>
  <p class=MsoNormal><span lang=FR>AbbVie SA</span></p>
  <p class=MsoNormal style='line-height:13.0pt'><span lang=FR>Tl/Tel: +32 10 </span><span
  lang=FR>477811</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=LT>Lietuva</span></b></p>
  <p class=MsoNormal><span lang=LV>AbbVie UAB </span></p>
  <p class=MsoNormal style='text-align:justify'><span lang=LV>Tel: +370 5 205
  3023</span></p>
  <p class=MsoNormal style='text-align:justify'><span lang=LV>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=BG>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=BG>&#1040;&#1073;&#1042;&#1080;
  &#1045;&#1054;&#1054;&#1044;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>&#1058;&#1077;&#1083;.</span><span
  lang=IT style='color:black'>: +359 2 90 30 430</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal><span lang=DE>AbbVie SA</span></p>
  <p class=MsoNormal><span lang=DE>Belgique/Belgien</span></p>
  <p class=MsoNormal><span lang=FR>Tl/Tel: +32 10 477811</span></p>
  <p class=MsoNormal><span lang=FR>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE>&#268;esk republika</span></b></p>
  <p class=MsoNormal><span lang=DE>AbbVie s.r.o. </span></p>
  <p class=MsoNormal><span lang=DE>Tel: +420 233 098 111</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=HU>Magyarorszg</span></b></p>
  <p class=MsoNormal><span lang=HU>AbbVie Kft.</span></p>
  <p class=MsoNormal><span lang=HU>Tel.: +36 1 455 8600</span></p>
  <p class=MsoNormal><span lang=HU>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Danmark</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>AbbVie A/S</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tlf: +45 72 30-20-28</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=MT>Malta</span></b></p>
  <p class=MsoNormal><span lang=SV>V.J.Salomone Pharma Limited </span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +356 22983201</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE>Deutschland</span></b></p>
  <p class=MsoNormal><span lang=DE>AbbVie Deutschland GmbH &amp; Co. KG</span></p>
  <p class=MsoNormal><span lang=DE>Tel: 00800 222843 33 (gebhrenfrei)</span></p>
  <p class=MsoNormal><span lang=DE>Tel: +49 (0) 611&nbsp;/&nbsp;1720-0</span></p>
  <p class=MsoNormal><span lang=DE>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL>Nederland</span></b></p>
  <p class=MsoNormal><span lang=DE>AbbVie B.V.</span></p>
  <p class=MsoNormal><span lang=DE>Tel: +31 (0)88 322 2843</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=ET>Eesti</span></b></p>
  <p class=MsoNormal><span lang=ET>AbbVie O </span></p>
  <p class=MsoNormal><span lang=ET>Tel: +372 623 1011</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NO-BOK>Norge</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>AbbVie AS</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tlf: +47 67 81 80 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EL>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal><span lang=ET>AbbVie </span><span lang=EL>&#934;&#913;&#929;&#924;&#913;&#922;&#917;&#933;&#932;&#921;&#922;&#919;
  &#913;.&#917;.</span></p>
  <p class=MsoNormal><span lang=EL>&#932;&#951;&#955;: +30 </span><span
  lang=EN-GB>214 4165 555</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE>sterreich</span></b></p>
  <p class=MsoNormal><span lang=DE>AbbVie GmbH </span></p>
  <p class=MsoNormal><span lang=DE>Tel: +43 1 20589-0</span></p>
  <p class=MsoNormal><span lang=DE>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=ES>Espaa</span></b></p>
  <p class=MsoNormal><span lang=PT>AbbVie Spain, S.L.U. </span></p>
  <p class=MsoNormal><span lang=PT>Tel: +34 9 1 384 0910</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PL>Polska</span></b></p>
  <p class=MsoNormal><span lang=PL>AbbVie Polska Sp. z o.o.</span></p>
  <p class=MsoNormal><span lang=ES>Tel.: </span>+48 22 372 78 00 </p>
  <p class=MsoNormal><span lang=ES>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:37.45pt'>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:37.45pt'>
  <p class=MsoNormal><b><span lang=FR>France</span></b></p>
  <p class=MsoNormal><span lang=FR>AbbVie</span></p>
  <p class=MsoNormal><span lang=FR>Tl: +33 (0)1 45 60 13 00</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:37.45pt'>
  <p class=MsoNormal><b><span lang=PT>Portugal</span></b></p>
  <p class=MsoNormal><span lang=FR>AbbVie, Lda. </span></p>
  <p class=MsoNormal><span lang=FR>Tel: +351 (0)21 1908400</span></p>
  <p class=MsoNormal><span lang=FR>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:33.95pt'>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:33.95pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=PT>Hrvatska </span></b></p>
  <p class=MsoNormal><span lang=HR>AbbVie d.o.o.</span></p>
  <p class=MsoNormal><span lang=HR>Tel: +385 (0)1 </span>5625 501</p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:33.95pt'>
  <p class=MsoNormal><b>Romnia</b></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>AbbVie S.R.L.</span></p>
  <p class=MsoNormal><span lang=PL>Tel: +40 21 529 30 35</span></p>
  <p class=MsoNormal><span lang=PL>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Ireland</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>AbbVie Limited </span></p>
  <p class=MsoNormal><span lang=PT>Tel: +353 (0)1 4287900</span></p>
  <p class=MsoNormal><span lang=IT>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SL>Slovenija</span></b></p>
  <p class=MsoNormal><span lang=SL>AbbVie Biofarmacevtska druba d.o.o.</span></p>
  <p class=MsoNormal><span lang=SL>Tel: +386 (1)32 08 060</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=IS>sland</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Vistor hf.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Tel: +354
  535 7000</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=SK>Slovensk
  republika</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=SK>AbbVie s.r.o.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=SK>Tel: +421 2
  5050 0777</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=SK>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT>Italia</span></b></p>
  <p class=MsoNormal style='line-height:13.0pt'><span lang=PT>AbbVie S.r.l. </span></p>
  <p class=MsoNormal style='line-height:13.0pt'><span lang=FR>Tel: +39 06
  928921</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FI>Suomi/Finland</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>AbbVie</span><span lang=EN-GB> </span><span
  lang=EN-GB>Oy</span><span lang=EN-GB> </span></p>
  <p class=MsoNormal><span lang=EN-GB>Puh/Tel: +358 (0) </span><span lang=IT>10
  2411 200</span></p>
  <p class=MsoNormal><span lang=FI>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EL>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=IT>Lifepharma
  (Z.A.M.) Ltd</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EL>&#932;&#951;&#955;:
  +357 22 34 74 40</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=SV>Sverige</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=PT>AbbVie AB</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=DA>Tel: +46 (0)8
  684 44 600</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=SV>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:36.15pt'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:36.15pt'>
  <p class=MsoNormal><b><span lang=LV>Latvija</span></b></p>
  <p class=MsoNormal><span lang=LV>AbbVie SIA </span></p>
  <p class=MsoNormal><span lang=LV>Tel: +371 67605000</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:36.15pt'>
  <p class=MsoNormal><b><span lang=EN-GB>United Kingdom</span></b><b><span
  lang=EN-GB> </span></b><b><span lang=PT>(Northern Ireland)</span></b></p>
  <p class=MsoNormal>AbbVie Deutschland GmbH &amp; Co. KG</p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +44 (0)1628 561090</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=2 style='border:none'></td>
  <td width=310 style='border:none'></td>
  <td width=312 style='border:none'></td>
 </tr>
</table>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><b>This leaflet was last approved
in {MM/YYYY}</b></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Detailed information on this medicine is available on the
European Medicines Agency web site: <a href="http://www.ema.europa.eu">http://www.ema.europa.eu</a></p>

<u><span style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:blue'><br clear=all style='page-break-before:always'>
</span></u>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>Package
leaflet: Information for the user</span></b></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoBodyText align=center style='margin-bottom:0in;text-align:center'><b><span
lang=EN-GB>Norvir 100&nbsp;mg</span></b><span lang=EN-GB> <b>film-coated
tablets</b></span></p>

<p class=MsoBodyText align=center style='margin-bottom:0in;text-align:center'><span
lang=EN-GB>ritonavir</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b>Read all of this leaflet
carefully before you start taking this medicine because it contains important
information for you or your child.</b></p>

<p class=EMEABullet><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it
again.</span></p>

<p class=EMEABullet><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have any further questions, ask your
doctor or pharmacist.</span></p>

<p class=EMEABullet><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>This medicine has been prescribed for you. Do
not pass it on to others. It may harm them, even if their signs of illness are
the same as yours.</span></p>

<p class=EMEABullet><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you get any side effects, talk to your doctor
or pharmacist. This includes any possible side effects not listed in this
leaflet. See section 4.</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span style='color:black'>What
is in this leaflet</span></b><span style='color:black'>: </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
style='color:black'>1. What Norvir is and what it is used for</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
style='color:black'>2. What you need to know before you or your child takes
Norvir</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
style='color:black'>3. How to take Norvir</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
style='color:black'>4. Possible side effects</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
style='color:black'>5. How to store Norvir</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
style='color:black'>6. Contents of the pack and other information</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.45pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
style='color:black'>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin:0in'><span lang=EN-GB>1. W</span><span
lang=EN-GB style='text-transform:none'>hat</span><span lang=EN-GB> N</span><span
lang=EN-GB style='text-transform:none'>orvir</span><span lang=EN-GB> </span><span
lang=EN-GB style='text-transform:none'>is and what it is used for</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>Norvir contains
the active substance ritonavir. Norvir is a protease inhibitor used to control
HIV infection. Norvir is used in combination with other anti-HIV medicines
(antiretrovirals) to control your HIV infection. Your doctor will discuss with
you the best combination of medicines for you.</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>Norvir is used
by children 2 years of age or older, adolescents and adults who are infected
with HIV, the virus which causes AIDS. </span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin:0in'><span lang=EN-GB>2. </span><span
style='text-transform:none'>What you need to know before you or your child takes
Norvir</span></p>

<p class=EMEANormal>&nbsp;</p>

<p class=EMEAHeading2SPCEmpty style='margin-bottom:0in'><span lang=EN-GB>Do not
take Norvir</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are allergic to ritonavir or any of the
other ingredients of Norvir (see section 6). </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='color:black'>&nbsp;</span></p>

<p class=EMEABullet><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have severe liver disease.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='color:black'>&nbsp;</span></p>

<p class=EMEABullet><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are currently taking any of the following
medicines:</span></p>

<p class=EMEABullet style='margin-left:56.7pt'><span lang=EN-GB
style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>astemizole or terfenadine (commonly used to
treat allergy symptoms  these medicines may be available without
prescription);</span></p>

<p class=EMEABullet style='margin-left:56.7pt'><span lang=EN-GB
style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>amiodarone, bepridil, dronedarone, encainide,
flecainide, propafenone, quinidine (used to correct irregular heartbeats);</span></p>

<p class=EMEABullet style='margin-left:56.7pt'><span lang=EN-GB
style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>dihydroergotamine, ergotamine (used to treat
migraine headache);</span></p>

<p class=EMEABullet style='margin-left:56.7pt'><span lang=EN-GB
style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ergonovine, methylergonovine (used to stop
excessive bleeding that may occur following childbirth or an abortion);</span></p>

<p class=EMEABullet style='margin-left:56.7pt'><span lang=EN-GB
style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>clorazepate, diazepam, estazolam, flurazepam,
triazolam or oral (taken by mouth) midazolam (used to help you sleep and/or
relieve anxiety);</span></p>

<p class=EMEABullet style='margin-left:56.7pt'><span lang=EN-GB
style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>clozapine, pimozide, (used to treat abnormal
thoughts or feelings); </span></p>

<p class=EMEABullet style='margin-left:56.7pt;page-break-after:avoid'><span
lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>quetiapine (used to treat schizophrenia, bipolar
disorder and major depressive disorder);</span></p>

<p class=EMEABullet style='margin-left:56.7pt;page-break-after:avoid'><span
lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>lurasidone (used to treat depression);</span></p>

<p class=EMEABullet style='margin-left:56.7pt;page-break-after:avoid'><span
lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ranolazine (used to treat chronic chest pain
[angina]);</span></p>

<p class=EMEABullet style='margin-left:56.7pt;page-break-after:avoid'><span
lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>pethidine, piroxicam, propoxyphene (used to
relieve pain);</span></p>

<p class=EMEABullet style='margin-left:56.7pt'><span lang=EN-GB
style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>cisapride (used to relieve certain stomach
problems);</span></p>

<p class=EMEABullet style='margin-left:56.7pt'><span lang=EN-GB
style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>rifabutin (used to prevent/treat certain
infections)*;</span></p>

<p class=EMEABullet style='margin-left:56.7pt'><span lang=EN-GB
style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>voriconazole (used to treat fungal infections)*;</span></p>

<p class=EMEABullet style='margin-left:56.7pt'><span lang=EN-GB
style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>simvastatin, lovastatin (used to lower blood
cholesterol);</span></p>

<p class=EMEABullet style='margin-left:56.7pt'><span lang=EN-GB
style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>neratinib (used to treat breast cancer);</span></p>

<p class=EMEABullet style='margin-left:56.7pt'><span lang=EN-GB
style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>lomitapide (used to lower blood cholesterol);</span></p>

<p class=EMEABullet style='margin-left:56.7pt'><span lang=EN-GB
style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>alfuzosin (used to treat enlarged prostate
gland);</span></p>

<p class=EMEABullet style='margin-left:56.7pt'><span lang=EN-GB
style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>fusidic acid (used to treat bacterial
infections);</span></p>

<p class=EMEABullet style='margin-left:56.7pt'><span lang=EN-GB
style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>sildenafil if you suffer from a lung disease
called pulmonary arterial hypertension that makes breathing difficult.
Patients without this disease may use sildenafil for impotence (erectile
dysfunction) under their doctors supervision (see the section on <b>Other
medicines and Norvir</b>);</span></p>

<p class=EMEABullet style='margin-left:56.7pt'><span lang=EN-GB
style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>avanafil or vardenafil (used to treat erectile
dysfunction); </span></p>

<p class=EMEABullet style='margin-left:56.7pt'><span lang=EN-GB
style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>colchicine (used to treat gout) if you have
kidney and/or liver problems (see the section on <b>Other medicines and Norvir</b>);</span></p>

<p class=EMEABullet style='margin-left:56.7pt'><span lang=EN-GB
style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>products containing St Johns wort (<i>Hypericum
perforatum</i>) as this may stop Norvir from working properly. St Johns wort
is often used in herbal medicines that you can buy yourself.</span></p>

<p class=MsoBodyTextIndent style='margin-left:28.35pt;text-indent:-28.35pt'>&nbsp;</p>

<p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:21.3pt;text-indent:-21.3pt'>*  Your doctor may decide that you
can take rifabutin and/or voriconazole with a booster (lower dose) of Norvir
but a full dose of Norvir must not be taken together with these two medicines.</p>

<p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:21.3pt;text-indent:-21.3pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>If you are
currently taking any of these medicines, ask your doctor about switching to a
different medicine while you are taking Norvir. </span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>Also read the
list of medicines under Other medicines and Norvir for use with certain other
medicines which require special care.</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif'>Warnings
and precautions</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif'>&nbsp;</span></b></p>

<p class=EMEANormal><span lang=EN-GB style='color:black'>Talk to your doctor
before taking Norvir.</span></p>

<p class=EMEANormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=EMEANormal><b><span lang=EN-GB>Important information</span></b></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If Norvir is taken in combination with other antiretroviral
medicines, it is important that you also carefully read the leaflets that are
provided with these other medicines. There may be additional information in
those leaflets about situations when Norvir should be avoided. If you have any
further questions about Norvir (ritonavir) or the other medicines prescribed,
please ask your doctor or pharmacist.</span></p>

<p class=EMEABullet><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Norvir is not a cure for HIV infection or AIDS.</span></p>

<p class=EMEABullet><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>People taking Norvir may still develop
infections or other illnesses associated with HIV infection or AIDS. It is
therefore important that you remain under the supervision of your doctor while
taking Norvir.</span></p>

<p class=EMEABullet><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>You can still pass on HIV when taking this
medicine, although the risk is lowered by effective antiretroviral therapy.
Discuss with your physician the precautions needed to avoid infecting other
people.</span></p>

<p class=EMEANormal1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal1 style='page-break-after:avoid'><b><span lang=EN-GB>Tell
your doctor if you have/had:</span></b></p>

<p class=EMEANormal1 style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='page-break-after:avoid'><span lang=EN-GB
style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>A history of <b>liver disease</b>. </span></p>

<p class=EMEABullet style='page-break-after:avoid'><span lang=EN-GB
style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Hepatitis B or C</span></b><span lang=EN-GB>
and are being treated with a combination of antiretroviral agents, as you are
at a greater risk of a severe and potentially life threatening reaction because
of the effect on the liver. Regular blood tests may be required to check your
liver is working properly.</span></p>

<p class=EMEABullet><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Haemophilia</span></b><span lang=EN-GB>, as
there have been reports of increased bleeding in patients with haemophilia who
are taking this type of medicine (protease inhibitors). The reason for this is
not known. You may need additional medicine to help your blood clot (factor
VIII), in order to control any bleeding.</span></p>

<p class=EMEABullet><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Erectile dysfunction, </span></b><span
lang=EN-GB>as the medicines used to treat erectile dysfunction can cause
hypotension and prolonged erection.</span></p>

<p class=EMEABullet><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Diabetes</span></b><span lang=EN-GB>, as
there have been reports of worsening of or the development of diabetes
(diabetes mellitus) in some patients taking protease inhibitors.</span></p>

<p class=EMEABullet><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='color:black'>Kidney (renal) disease,</span></b><span
lang=EN-GB style='color:black'> since your doctor may need to check the dose of
your other medicines (such as protease inhibitors)</span><span lang=EN-GB>.</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><b><span
lang=EN-GB>Tell your doctor if you experience:</span></b></p>

<p class=EMEANormal1><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Diarrhoea</span></b><span lang=EN-GB> <b>or</b>
<b>vomiting</b> that is not improving (persistent), as this may reduce how well
the medicines you are taking work.</span></p>

<p class=EMEABullet><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Feeling sick</span></b><span lang=EN-GB> (nausea),
<b>vomiting</b> or have <b>stomach pain</b>, because these may be signs of
inflammation of the pancreas (pancreatitis). Some patients taking Norvir can
develop serious problems with their pancreas. Tell your doctor as soon as possible
if this applies to you.</span></p>

<p class=EMEABullet><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Symptoms of infection</span></b><span
lang=EN-GB>  inform your doctor immediately. Some patients with advanced HIV
infection (AIDS) </span>who then start anti-HIV treatment may develop the
symptoms of infections they have had in the past even if they didnt know they
had had them. It is believed that this happens because the body's immune
response improves and helps the body to fight these infections<span lang=EN-GB>.<br>
</span><span lang=EN-GB>In addition to the opportunistic infections, autoimmune
disorders (a condition that occurs when the immune system attacks healthy body
tissue) may also occur after you start taking medicines for the treatment of
your HIV infection. Autoimmune disorders may occur many months after the start
of treatment. </span><span lang=EN-GB>If you notice any symptoms of infection
or other symptoms such as muscle weakness, weakness beginning in the hands and
feet and moving up towards the trunk of the body, palpitations, tremor or
hyperactivity, please inform your doctor immediately to seek necessary
treatment.</span></p>

<p class=EMEABullet><span style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b>Joint stiffness, aches and pains</b> (especially of the hip,
knee and shoulder) and difficulty moving, tell your doctor, as this may be a
sign of a problem that can destroy bone (osteonecrosis). Some patients taking
a number of antiretroviral medicines may develop this disease. </p>

<p class=EMEABullet><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b>Muscle pain, tenderness or weakness</b>, particularly in
combination with antiretroviral therapy including protease inhibitors and
nucleoside analogues. On rare occasions these muscle disorders have been
serious. (See section 4 <b>Possible side effects</b>)</p>

<p class=EMEABullet style='margin-left:27.5pt;text-indent:-27.5pt'><span
lang=EN-GB>- <b>Dizziness, lightheadedness, fainting spells or abnormal
heartbeat. </b>Some patients taking Norvir may experience changes in the
electrocardiogram (ECG). Tell your doctor if you have a heart defect or
conduction defect.<b> </b></span></p>

<p class=EMEABullet><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have any other health concerns, discuss
these with your doctor as soon as you can.</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b>Children and adolescents</b></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Norvir is not recommended in children below 2 years of age.</p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in;page-break-after:
avoid'><b><span lang=EN-GB>Other medicines and Norvir</span></b></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'>Tell your
doctor or pharmacist if you are taking or have recently taken or might take any
other medicines, including medicines obtained without a prescription. There
are some medicines you cannot take at all with Norvir. These are listed
earlier in section 2, under <b>Do not take Norvir</b>. There are some other
medicines that can only be used under certain circumstances as described
below. </p>

<p class=MsoNormal style='text-autospace:none'>&nbsp;</p>

<p class=MsoNormal>The following warnings apply when Norvir is taken as a full
dose. However, these warnings may also apply when Norvir is used in lower
doses (a booster) with other medicines. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=EMEAHeading1 style='margin:0in;page-break-after:avoid'><span
style='font-family:"Times New Roman",serif;text-transform:none'>Tell your
doctor if you are taking any of the medicines listed below, as special care
should be taken.</span></p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=EMEABullet style='page-break-after:avoid'><span lang=EN-GB
style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Sildenafil or tadalafil</span></b><span
lang=EN-GB> for impotence (erectile dysfunction). <br>
The dose and/or frequency of use of these medicines may need to be reduced to
avoid hypotension and prolonged erection. You must not take Norvir with
sildenafil if you suffer from pulmonary arterial hypertension (see also section
2. <b>What you need to know before you or your child takes Norvir</b>). </span><span
style='font-family:"TimesNewRoman\,Italic"'>Tell your doctor if you are taking
tadalafil for pulmonary arterial hypertension.</span></p>

<p class=EMEABullet><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Colchicine </span></b><span lang=EN-GB>(for
gout) as Norvir may raise the blood levels of this medicine. You must not take
Norvir with colchicine if you have kidney and/or liver problems (see also </span><span
lang=EN-GB><b>Do not take Norvir</b> above).</span></p>

<p class=EMEABullet><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Digoxin</span></b><span lang=EN-GB> (heart
medicine). Your doctor may need to adjust the dose of digoxin and monitor you
while you are taking digoxin and Norvir in order to avoid heart problems.</span></p>

<p class=EMEABullet><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Hormonal contraceptives</span></b><span
lang=EN-GB> containing ethinyl oestradiol as Norvir may reduce the
effectiveness of these medicines. It is recommended that a condom or other
non-hormonal method of contraception is used instead. You may also notice
irregular uterine bleeding if you are taking this type of hormonal
contraceptive with Norvir.</span></p>

<p class=EMEABullet><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Atorvastatin or rosuvastatin</span></b><span
lang=EN-GB> (for high cholesterol) as Norvir may raise the blood levels of
these medicines. Talk to your doctor before you take any cholesterol-reducing
medicines with Norvir (see also <b>Do not take Norvir</b> above).</span></p>

<p class=EMEABullet><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Steroids</span></b><span lang=EN-GB> (e.g.
dexamethasone, fluticasone propionate, prednisolone, triamcinolone) as Norvir
may raise the blood levels of these medicines which may lead to Cushings
syndrome (development of a rounded face) and reduce production of the hormone
cortisol. Your doctor may wish to reduce the steroid dose or monitor your side
effects more closely.</span></p>

<p class=EMEABullet><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Trazodone</span></b><span lang=EN-GB> (a
medicine for depression) as, unwanted effects like nausea, dizziness, low blood
pressure and fainting can occur when taken with Norvir. </span></p>

<p class=EMEABullet><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Rifampicin and saquinavir</span></b><span
lang=EN-GB> (used for tuberculosis and HIV, respectively) as serious liver
damage can occur when taken with Norvir.</span></p>

<p class=EMEABullet><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Bosentan, riociguat </span></b><span
lang=EN-GB>(used for pulmonary arterial hypertension) as Norvir may increase
the blood levels of this medicine.</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABodyText><span style='font-size:11.0pt;color:black'>There are
medicines that may not mix with Norvir because their effects could increase or
decrease when taken together. In some cases your doctor may need to perform
certain tests, change the dose or monitor you regularly. This is why you
should tell your doctor if you are taking any medicines, including those you
have bought yourself or herbal products, but it is especially important to
mention these: </span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=EMEABullet><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>amphetamine or amphetamine derivatives;</span></p>

<p class=EMEABullet><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>antibiotics (e.g. erythromycin, clarithromycin);
</span></p>

<p class=EMEABullet><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>anticancer treatments (e.g. abemaciclib; afatinib,
apalutamide, ceritinib, encorafenib, dasatinib, ibrutinib, nilotinib, venetoclax,
vincristine, vinblastine);</span></p>

<p class=EMEABullet><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=PT-BR>medicines used to treat low blood platelet count
(e.g. fostamatinib);</span></p>

<p class=EMEABullet><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>anticoagulants (e.g. rivaroxaban, vorapaxar, warfarin);</span></p>

<p class=EMEABullet><span lang=FR style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=FR>antidepressants (e.g. amitriptyline, desipramine,
fluoxetine, imipramine, nefazodone, nortriptyline, paroxetine, sertraline,
trazodone);</span></p>

<p class=EMEABullet><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>antifungals (e.g. ketoconazole, itraconazole); </span></p>

<p class=EMEABullet><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>antihistamines (e.g. loratidine, fexofenadine); </span></p>

<p class=EMEABullet><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>antiretroviral medicines including HIV&#8209;protease
inhibitors (</span>amprenavir, <span lang=EN-GB>atazanavir, darunavir,
fosamprenavir, </span>indinavir, nelfinavir,<span lang=EN-GB> saquinavir, </span>tipranavir)
<span lang=EN-GB>non-nucleoside reverse transcriptase inhibitors( NNRTI) (</span>delavirdine,
efavirenz, nevirapine),<span lang=EN-GB> and others (didanosine, maraviroc,
raltegravir, zidovudine); </span></p>

<p class=EMEABullet><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>anti-tuberculosis medicine (bedaquiline and
delamanid);</span></p>

<p class=EMEABullet><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>antiviral medicine used to treat chronic hepatitis C virus (HCV)
infection in adults (e.g. glecaprevir/pibrentasvir and simeprevir);</p>

<p class=EMEABullet><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>anxiety medicine, buspirone; </span></p>

<p class=EMEABullet><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>asthma medicine, theophylline, salmeterol;</span></p>

<p class=EMEABullet><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>atovaquone, a medicine used to treat a certain
type of pneumonia and malaria;</span></p>

<p class=EMEABullet><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>buprenorphine, a medicine used for the treatment
of chronic pain;</span></p>

<p class=EMEABullet><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>bupropion, a medicine used to help you stop
smoking;</span></p>

<p class=EMEABullet><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>epilepsy medicines (e.g. carbamazepine,
divalproex, lamotrigine, phenytoin);</span></p>

<p class=EMEABullet><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>heart medicines (e.g. disopyramide, mexiletine
and calcium channel antagonists such as amlodipine, diltiazem and nifedipine); </span></p>

<p class=EMEABullet><span lang=DA style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=DA>immune system (e.g. cyclosporine, tacrolimus,
everolimus); </span></p>

<p class=EMEABullet><span lang=DA style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=DA>levothyroxine (used to treat thyroid problems);</span></p>

<p class=EMEABullet><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>morphine and morphine-like medicines used to
treat severe pain (e.g. methadone, fentanyl);</span></p>

<p class=EMEABullet><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>sleeping pills (e.g. alprazolam, zolpidem) and also
midazolam administered by injection; </span></p>

<p class=EMEABullet><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>tranquillisers (e.g. haloperidol, risperidone,
thioridazine); </span></p>

<p class=EMEABullet><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>colchicine, a treatment for gout.</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>There are some
medicines you cannot take at all with Norvir. These are listed earlier in
section 2, under <b>Do not take Norvir</b>.</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><span lang=EN-GB>Taking Norvir
with food and drink</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'>Norvir tablets should be taken
with food.</p>

<p class=MsoNormal style='margin-right:-.1pt'>&nbsp;</p>

<p class=EMEAHeadingLeaflet style='margin:0in;page-break-after:avoid'><span
lang=EN-GB>Pregnancy and breast-feeding</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><b><span lang=EN-GB>If you are pregnant or breast-feeding,
think you may be pregnant or are planning to have a baby, it is very important
that you ask your doctor for advice before taking this medicine.</span></b></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>There is a
large amount of information on the use of ritonavir (the active ingredient in
Norvir) during pregnancy. In general, pregnant mothers received ritonavir
after the first three months of pregnancy at a lower dose (booster) along with
other protease inhibitors. Norvir did not appear to increase the chance of
developing birth defects compared to the general population.</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>Norvir can pass
into breast milk. To avoid transmitting the infection, mothers with HIV must
not breast feed their babies.</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><span lang=EN-GB>Driving and
using machines</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>Norvir can
cause dizziness. If you are affected do not drive or use machinery. </span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin:0in'><span lang=EN-GB>3. </span><span
lang=EN-GB style='text-transform:none'>How to take Norvir</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>Always take this
medicine exactly as your doctor or pharmacist has told you. Check with your
doctor or pharmacist if you are not sure. Take this medicine one or two times
a day every day with food. </span></p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'>It is important that Norvir
tablets are swallowed whole and not chewed, broken or crushed.</p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'>Recommended doses of Norvir
are:</p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='margin-left:27.5pt;text-indent:-27.5pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>if Norvir is used to boost the effects of certain other anti-HIV
medicines the typical dose for adults is 1 to 2 tablets once or twice daily.
For more detailed dose recommendations, including those for children, see the
Package Leaflet of the anti-HIV medicines Norvir is given in combination with.</p>

<p class=MsoHeader>&nbsp;</p>

<p class=MsoNormal style='margin-left:27.5pt;text-indent:-27.5pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>if your doctor prescribes a full dose, adults may be started on a
dose of 3 tablets in the morning and 3 tablets 12 hours later, gradually
increasing over a period of up to 14 days to the full dose of 6 tablets twice
daily (totaling 1,200mg per day). <b></b>Children (2  12 years of age) will
start with a dose smaller than this and continue up to the maximum allowed for
their size. </p>

<p class=MsoHeader>&nbsp;</p>

<p class=MsoNormal>Your doctor will advise you on the dosage to be taken.</p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>Norvir should
be taken every day to help control your HIV, no matter how much better you
feel. If a side effect is preventing you from taking Norvir as directed, tell
your doctor straight away. During episodes of diarrhoea your doctor may decide
that extra monitoring is needed.</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>Always keep
enough Norvir on hand so you don't run out. When you travel or need to stay in
the hospital, make sure you have enough Norvir to last until you can get a new
supply.</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><span lang=EN-GB>If you take
more Norvir than you should</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>Numbness,
tingling, or a pins and needles sensation may occur if you take too much
Norvir. If you realise you have taken more Norvir than you were supposed to,
contact your doctor or the Accident and Emergency Department of your nearest
hospital straight away. </span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><span lang=EN-GB>If you forget
to take Norvir</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>If you miss a
dose, take the missed dose as soon as possible. If it is nearly time for the
next dose, just take that one. Do not take a double dose to make up for a
forgotten dose.</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><b><span lang=EN-GB>If you stop
taking Norvir</span></b></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>Even if you
feel better, do not stop taking Norvir without talking to your doctor. Taking
Norvir as recommended should give you the best chance of delaying resistance to
the medicines. </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin:0in'><span lang=EN-GB>4. </span><span
lang=EN-GB style='text-transform:none'>Possible side effects</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>During HIV therapy there may be an
increase in weight and in levels of blood lipids and glucose. This is partly
linked to restored health and life style, and in the case of blood lipids
sometimes to the HIV medicines themselves. Your doctor will test for these
changes.</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>Like all
medicines, Norvir can cause side effects, although not everybody gets them.
Also, the side effects of Norvir when used with other antiretroviral medicines
are dependent on the other medicines. So it is important that you carefully
read the side effects section of the leaflets that are provided with these
other medicines.</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><b><span lang=EN-GB>Very common:
</span></b><span lang=EN-GB>may affect more than 1 in 10 people</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:27.5pt;text-indent:-27.5pt'><span lang=EN-GB
  style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>upper or lower stomach ache  </span></p>
  <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:27.5pt;text-indent:-27.5pt'><span lang=EN-GB
  style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>vomiting </span></p>
  <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:27.5pt;text-indent:-27.5pt'><span lang=EN-GB
  style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>diarrhoea (may be severe)</span></p>
  <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:27.5pt;text-indent:-27.5pt'><span lang=EN-GB
  style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>feeling sick (nausea) </span></p>
  <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:27.5pt;text-indent:-27.5pt'><span lang=EN-GB
  style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>flushing, feeling hot</span></p>
  <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:27.5pt;text-indent:-27.5pt'><span lang=EN-GB
  style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>headache</span></p>
  <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:27.5pt;text-indent:-27.5pt'><span lang=EN-GB
  style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>dizziness</span></p>
  <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:27.5pt;text-indent:-27.5pt'><span lang=EN-GB
  style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>pain in the throat</span></p>
  <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:27.5pt;text-indent:-27.5pt'><span lang=EN-GB
  style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>cough</span></p>
  <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:27.5pt;text-indent:-27.5pt'><span lang=EN-GB
  style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>upset stomach or indigestion</span></p>
  </td>
  <td width=310 valign=top style='width:232.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:31.8pt;text-indent:-31.7pt'><span lang=EN-GB
  style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>a tingling sensation or numbness in <br>
  the hands, feet or around the lips and mouth</span></p>
  <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:31.8pt;text-indent:-31.7pt'><span lang=EN-GB
  style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>feeling weak/tired</span></p>
  <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:31.8pt;text-indent:-31.7pt'><span lang=EN-GB
  style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>bad taste in the mouth</span></p>
  <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:31.8pt;text-indent:-31.7pt'><span lang=EN-GB
  style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span>damage to the nerves that can cause weakness and pain</p>
  <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:31.8pt;text-indent:-31.7pt'><span lang=EN-GB
  style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>itching</span></p>
  <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:31.8pt;text-indent:-31.7pt'><span lang=EN-GB
  style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>rash</span></p>
  <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:31.8pt;text-indent:-31.7pt'><span lang=EN-GB
  style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>joint pain and back pain</span></p>
  </td>
 </tr>
</table>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoBodyText style='margin-bottom:0in;page-break-after:avoid'><b><span
lang=EN-GB>Common: </span></b><span lang=EN-GB>may affect up to 1 in 10 people</span><span
lang=EN-GB> </span></p>

<p class=MsoBodyText style='margin-bottom:0in;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:27.5pt;text-indent:-27.5pt;page-break-after:avoid'><span
  lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>allergic reactions including skin <br>
  rashes (may be red, raised, itchy), <br>
  severe swelling of the skin and <br>
  other tissues</span></p>
  <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:27.5pt;text-indent:-27.5pt;page-break-after:avoid'><span
  lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>inability to sleep (insomnia)</span></p>
  <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:27.5pt;text-indent:-27.5pt;page-break-after:avoid'><span
  lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>anxiety</span></p>
  <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:27.5pt;text-indent:-27.5pt;page-break-after:avoid'><span
  lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>increase in cholesterol</span></p>
  <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:27.5pt;text-indent:-27.5pt;page-break-after:avoid'><span
  lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>increase in triglycerides</span></p>
  <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:27.5pt;text-indent:-27.5pt;page-break-after:avoid'><span
  lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>gout</span></p>
  <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:27.5pt;text-indent:-27.5pt;page-break-after:avoid'><span
  lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>stomach bleeding</span></p>
  <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:27.5pt;text-indent:-27.5pt;page-break-after:avoid'><span
  lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>inflammation of the liver and yellowing of
  skin or whites of the eyes</span></p>
  <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:27.5pt;text-indent:-27.5pt;page-break-after:avoid'><span
  lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>increase in urination</span></p>
  <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:27.5pt;text-indent:-27.5pt;page-break-after:avoid'><span
  lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>reduced kidney function</span></p>
  <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:27.5pt;text-indent:-27.5pt;page-break-after:avoid'><span
  lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB style='color:black'>seizures (fits)</span></p>
  <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:27.5pt;text-indent:-27.5pt;page-break-after:avoid'><span
  lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB style='color:black'>low levels of blood
  platelets</span></p>
  <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:27.5pt;text-indent:-27.5pt;page-break-after:avoid'><span
  lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB style='color:black'>thirst (dehydration) </span></p>
  <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:27.5pt;text-indent:-27.5pt;page-break-after:avoid'><span
  lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB style='color:black'>abnormally heavy periods</span></p>
  </td>
  <td width=310 valign=top style='width:232.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:31.8pt;text-indent:-31.7pt;page-break-after:avoid'><span
  lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>wind (flatulence)</span></p>
  <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:31.8pt;text-indent:-31.7pt;page-break-after:avoid'><span
  lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>loss of appetite</span></p>
  <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:31.8pt;text-indent:-31.7pt;page-break-after:avoid'><span
  lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>mouth ulcer</span></p>
  <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:31.8pt;text-indent:-31.7pt;page-break-after:avoid'><span
  lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>muscle aches (pain), tenderness or weakness</span></p>
  <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:31.8pt;text-indent:-31.7pt;page-break-after:avoid'><span
  lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>fever</span></p>
  <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:31.8pt;text-indent:-31.7pt;page-break-after:avoid'><span
  lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>weight loss</span></p>
  <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:31.8pt;text-indent:-31.7pt;page-break-after:avoid'><span
  lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>laboratory test results:<br>
  changes in blood test results <br>
  (such as blood chemistry and <br>
  blood count)</span></p>
  <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:31.8pt;text-indent:-31.7pt;page-break-after:avoid'><span
  lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>confusion</span></p>
  <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:31.8pt;text-indent:-31.7pt;page-break-after:avoid'><span
  lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>difficulty paying attention</span></p>
  <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:31.8pt;text-indent:-31.7pt;page-break-after:avoid'><span
  lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>fainting</span></p>
  <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:31.8pt;text-indent:-31.7pt;page-break-after:avoid'><span
  lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>blurred vision</span></p>
  <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:31.8pt;text-indent:-31.7pt;page-break-after:avoid'><span
  lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>swelling of the hands and feet</span></p>
  <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:31.8pt;text-indent:-31.7pt;page-break-after:avoid'><span
  lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>high blood pressure</span></p>
  <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:31.8pt;text-indent:-31.7pt;page-break-after:avoid'><span
  lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>low blood pressure and feeling faint when
  getting up</span></p>
  <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:31.8pt;text-indent:-31.7pt;page-break-after:avoid'><span
  lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>coldness in the hands and feet</span></p>
  <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:31.8pt;text-indent:-31.7pt;page-break-after:avoid'><span
  lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>acne</span></p>
  </td>
 </tr>
</table>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><b><span lang=EN-GB>Uncommon: </span></b><span
lang=EN-GB>may affect up to 1 in 100 people</span><span lang=EN-GB> </span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:31.8pt;text-indent:-31.7pt'><span lang=EN-GB
  style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB style='color:black'>heart attack</span><span
  lang=EN-GB> </span></p>
  <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:27.5pt;text-indent:-27.5pt'><span lang=EN-GB
  style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>diabetes</span></p>
  </td>
  <td width=310 valign=top style='width:232.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:31.8pt;text-indent:-31.7pt'><span lang=EN-GB
  style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB style='color:black'>kidney failure</span><span
  lang=EN-GB> </span></p>
  </td>
 </tr>
</table>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><b><span lang=EN-GB>Rare: </span></b><span
lang=EN-GB>may affect up to 1 in 1,000 people</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:27.5pt;text-indent:-27.5pt'><span lang=EN-GB
  style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>severe or life threatening skin <br>
  reaction including blisters<br>
  (Stevens Johnson syndrome, toxic epidermal necrolysis)</span></p>
  </td>
  <td width=310 valign=top style='width:232.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:31.8pt;text-indent:-31.7pt'><span lang=EN-GB
  style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>serious allergic reaction (anaphylaxis)</span></p>
  <p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:31.8pt;text-indent:-31.7pt'><span lang=EN-GB
  style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><span lang=EN-GB>high levels of sugar in the blood</span></p>
  </td>
 </tr>
</table>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Not known: </span></b><span lang=EN-GB>frequency<b>
</b></span><span style='color:black'>cannot be estimated from the available
data</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoBodyText style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:31.8pt;text-indent:-31.7pt'><span lang=EN-GB style='font-family:
Symbol;color:black'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>kidney stones</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB
style='color:black'>Tell your doctor if you feel sick (nauseous), are vomiting,
or have stomach pain, because these may be signs of an inflamed pancreas. Also
tell your doctor if you experience joint stiffness, aches and pains (especially
of the hip, knee and shoulder) and difficulty moving, as this may be a sign of
osteonecrosis. See also section 2. </span><b><span lang=EN-GB>What you need to
know before you or your child<span style='color:black'> takes Norvir</span></span></b><span
lang=EN-GB style='color:black'>.</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>In patients
with haemophilia type A and B, there have been reports of increased bleeding
while taking this treatment or another protease inhibitor. Should this happen
to you, seek immediate advice from your doctor. </span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB
style='color:black'>Abnormal liver function tests, hepatitis (inflammation of
the liver), and rarely jaundice, have been reported in patients taking Norvir.
Some people had other illnesses or were taking other medicines. People with
liver disease or hepatitis may have worsening of liver disease. </span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB
style='color:black'>There have been reports of muscle pain, tenderness or
weakness, particularly when taking medicines to lower cholesterol in
combination with antiretroviral therapy, including protease inhibitors and
nucleoside analogues. On rare occasions these muscle disorders have been
serious (rhabdomyolysis). In the event of unexplained or continual muscle
pain, tenderness, weakness or cramps, stop taking the medicine, contact your
doctor as soon as possible or go to the Accident and Emergency Department of
your nearest hospital.</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>Inform your
doctor as soon as possible if you experience any symptoms that suggest an
allergic reaction after taking Norvir such as rash, hives or breathing
difficulties.</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><b><span lang=EN-GB>If any of the side effects gets
serious, or if you notice any side effects not listed in this leaflet, contact
your doctor, pharmacist, Accident and Emergency department or if it is urgent
get immediate medical help.</span></b></p>

<p class=EMEANormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEANormal1><b><span lang=EN-GB>Reporting of side effects</span></b></p>

<p class=EMEANormal1><b><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=EMEANormal><span lang=EN-GB>If you get any side effects, talk to your
doctor or pharmacist. This includes any possible side effects not listed in
this leaflet. You can also report side effects directly via <span
style='background:lightgrey'>the national reporting system listed in </span></span><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
lang=EN-GB style='background:lightgrey'>Appendix V</span></a><span lang=EN-GB
style='background:lightgrey'>.</span><span lang=EN-GB> By reporting side
effects you can help provide more information on the safety of this medicine.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin:0in'><span lang=EN-GB>5. H</span><span
lang=EN-GB style='text-transform:none'>ow to store </span><span lang=EN-GB>N</span><span
lang=EN-GB style='text-transform:none'>orvir</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Keep this medicine out of the sight and
reach of children.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>Do not use
Norvir after the expiry date on the label. The expiry date refers to the last
day of that month.</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>This medicinal product does not require any
special temperature storage conditions. </span>Store in the original bottle in
order to protect from moisture.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>Do not use this medicine if you notice any discolouration.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Do not throw away any medicines via wastewater. Ask your
pharmacist how to throw away medicines you no longer use. These measures will
help the environment.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=EMEAHeading1 style='margin:0in;page-break-after:avoid'><span
lang=EN-GB>6. </span><span lang=EN-GB style='text-transform:none'>Contents
of the pack and other</span><span lang=EN-GB> </span><span lang=EN-GB
style='text-transform:none'>information</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoBodyText style='margin-bottom:0in;page-break-after:avoid'><b><span
lang=EN-GB>What Norvir contains</span></b></p>

<p class=MsoBodyText style='margin-bottom:0in;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The active substance is ritonavir. Each
film-coated tablet contains 100&nbsp;mg ritonavir.</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=EMEABullet><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The other tablet ingredients are: copovidone,
sorbitan laurate, anhydrous calcium hydrogen phosphate, colloidal anhydrous
silica, sodium stearyl fumarate. </span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet><span lang=EN-GB style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The tablet coating is composed of: </span>hypromellose,
titanium dioxide, macrogols, hydroxypropyl cellulose, talc, colloidal anhydrous
silica, polysorbate 80<span lang=EN-GB>.</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><b><span lang=EN-GB>What Norvir
looks like and contents of the pack</span></b></p>

<p class=MsoBodyText style='margin-bottom:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal>Norvir film-coated tablets are white debossed with [Abbott
logo] and the code NK.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Three pack sizes are available for Norvir tablets: </p>

<p class=EMEABullet><span style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>1 bottle of 30 tablets</p>

<p class=EMEABullet><span style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>1 bottle of 60&nbsp;tablets</p>

<p class=EMEABullet><span style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Multipacks comprising 3 bottles each containing 30 film-coated
tablets (90 tablets)</p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'>&nbsp;</p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'>Not all pack sizes
may be marketed.</p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB
style='color:black'>Norvir</span><span lang=EN-GB> </span><span lang=EN-GB>is
also supplied </span>as a powder for oral suspension containing 100&nbsp;mg of
ritonavir<span lang=EN-GB>.</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoBodyText style='margin-bottom:0in'><b><span lang=EN-GB>Marketing
Authorisation Holder </span></b></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>AbbVie Deutschland GmbH &amp; Co. KG, Knollstrasse, 67061
Ludwigshafen, Germany</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><b><span lang=EN-GB>Manufacturers</span></b></p>

<p class=MsoBodyText style='margin-bottom:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoBodyText style='margin-bottom:0in'><span class=Fill-In><span
style='color:black'>AbbVie Deutschland GmbH &amp; Co. KG</span></span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span class=Fill-In><span
style='color:black'>Knollstrasse</span></span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span class=Fill-In><span
style='color:black'>67061 Ludwigshafen</span></span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span class=Fill-In><span
style='color:black'>Germany</span></span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoBodyText style='margin-bottom:0in'><span lang=EN-GB>For any
information about this medicine, please contact the local representative of the
Marketing Authorisation Holder:</span></p>

<p class=MsoNormal>&nbsp;</p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624
 style='margin-left:-1.7pt;border-collapse:collapse'>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR-BE>Belgi/Belgique/Belgien</span></b></p>
  <p class=MsoNormal><span lang=FR>AbbVie SA</span></p>
  <p class=MsoNormal style='line-height:13.0pt'><span lang=FR>Tl/Tel: +32 10 </span><span
  lang=FR>477811</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=LT>Lietuva</span></b></p>
  <p class=MsoNormal><span lang=LV>AbbVie UAB </span></p>
  <p class=MsoNormal style='text-align:justify'><span lang=LV>Tel: +370 5 205
  3023</span></p>
  <p class=MsoNormal style='text-align:justify'><span lang=LV>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=BG>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=BG>&#1040;&#1073;&#1042;&#1080;
  &#1045;&#1054;&#1054;&#1044;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>&#1058;&#1077;&#1083;.</span><span
  lang=IT style='color:black'>: +359 2 90 30 430</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal><span lang=DE>AbbVie SA</span></p>
  <p class=MsoNormal><span lang=DE>Belgique/Belgien</span></p>
  <p class=MsoNormal><span lang=FR>Tl/Tel: +32 10 477811</span></p>
  <p class=MsoNormal><span lang=FR>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE>&#268;esk republika</span></b></p>
  <p class=MsoNormal><span lang=DE>AbbVie s.r.o. </span></p>
  <p class=MsoNormal><span lang=DE>Tel: +420 233 098 111</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=HU>Magyarorszg</span></b></p>
  <p class=MsoNormal><span lang=HU>AbbVie Kft.</span></p>
  <p class=MsoNormal><span lang=HU>Tel.: +36 1 455 8600</span></p>
  <p class=MsoNormal><span lang=HU>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Danmark</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>AbbVie A/S</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tlf: +45 72 30-20-28</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=MT>Malta</span></b></p>
  <p class=MsoNormal><span lang=SV>V.J.Salomone Pharma Limited </span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +356 22983201</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE>Deutschland</span></b></p>
  <p class=MsoNormal><span lang=DE>AbbVie Deutschland GmbH &amp; Co. KG</span></p>
  <p class=MsoNormal><span lang=DE>Tel: 00800 222843 33 (gebhrenfrei)</span></p>
  <p class=MsoNormal><span lang=DE>Tel: +49 (0) 611&nbsp;/&nbsp;1720-0</span></p>
  <p class=MsoNormal><span lang=DE>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL>Nederland</span></b></p>
  <p class=MsoNormal><span lang=DE>AbbVie B.V.</span></p>
  <p class=MsoNormal><span lang=DE>Tel: +31 (0)88 322 2843</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=ET>Eesti</span></b></p>
  <p class=MsoNormal><span lang=ET>AbbVie O </span></p>
  <p class=MsoNormal><span lang=ET>Tel: +372 623 1011</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NO-BOK>Norge</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>AbbVie AS</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tlf: +47 67 81 80 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EL>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=ET>AbbVie </span><span
  lang=EL>&#934;&#913;&#929;&#924;&#913;&#922;&#917;&#933;&#932;&#921;&#922;&#919;
  &#913;.&#917;.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EL>&#932;&#951;&#955;:
  +30 </span><span lang=EN-GB>214 4165 555</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=DE>sterreich</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=DE>AbbVie GmbH </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=DE>Tel: +43 1
  20589-0</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=DE>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=ES>Espaa</span></b></p>
  <p class=MsoNormal><span lang=PT>AbbVie Spain, S.L.U. </span></p>
  <p class=MsoNormal><span lang=PT>Tel: +34 9 1 384 0910</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PL>Polska</span></b></p>
  <p class=MsoNormal><span lang=PL>AbbVie Polska Sp. z o.o.</span></p>
  <p class=MsoNormal><span lang=ES>Tel.: </span>+48 22 372 78 00 </p>
  <p class=MsoNormal><span lang=ES>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:39.25pt'>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:39.25pt'>
  <p class=MsoNormal><b><span lang=FR>France</span></b></p>
  <p class=MsoNormal><span lang=FR>AbbVie</span></p>
  <p class=MsoNormal><span lang=FR>Tl: +33 (0)1 45 60 13 00</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:39.25pt'>
  <p class=MsoNormal><b><span lang=PT>Portugal</span></b></p>
  <p class=MsoNormal><span lang=FR>AbbVie, Lda. </span></p>
  <p class=MsoNormal><span lang=FR>Tel: +351 (0)21 1908400</span></p>
  <p class=MsoNormal><span lang=FR>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:35.55pt'>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:35.55pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=PT>Hrvatska </span></b></p>
  <p class=MsoNormal><span lang=HR>AbbVie d.o.o.</span></p>
  <p class=MsoNormal><span lang=HR>Tel: +385 (0)1 </span>5625 501</p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:35.55pt'>
  <p class=MsoNormal><b>Romnia</b></p>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>AbbVie S.R.L.</span></p>
  <p class=MsoNormal><span lang=PL>Tel: +40 21 529 30 35</span></p>
  <p class=MsoNormal><span lang=PL>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Ireland</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>AbbVie Limited </span></p>
  <p class=MsoNormal><span lang=PT>Tel: +353 (0)1 4287900</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SL>Slovenija</span></b></p>
  <p class=MsoNormal><span lang=SL>AbbVie Biofarmacevtska druba d.o.o.</span></p>
  <p class=MsoNormal><span lang=SL>Tel: +386 (1)32 08 060</span></p>
  <p class=MsoNormal><span lang=SL>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IS>sland</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Vistor hf.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +354 535 7000</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SK>Slovensk republika</span></b></p>
  <p class=MsoNormal><span lang=SK>AbbVie s.r.o.</span></p>
  <p class=MsoNormal><span lang=SK>Tel: +421 2 5050 0777</span></p>
  <p class=MsoNormal><span lang=SK>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT>Italia</span></b></p>
  <p class=MsoNormal style='line-height:13.0pt'><span lang=PT>AbbVie S.r.l. </span></p>
  <p class=MsoNormal style='line-height:13.0pt'><span lang=FR>Tel: +39 06
  928921</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FI>Suomi/Finland</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>AbbVie</span><span lang=EN-GB> </span><span
  lang=EN-GB>Oy</span><span lang=EN-GB> </span></p>
  <p class=MsoNormal><span lang=EN-GB>Puh/Tel: +358 (0) </span><span lang=IT>10
  2411 200</span></p>
  <p class=MsoNormal><span lang=FI>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EL>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal><span lang=IT>Lifepharma (Z.A.M.) Ltd</span></p>
  <p class=MsoNormal><span lang=EL>&#932;&#951;&#955;: +357 22 34 74 40</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SV>Sverige</span></b></p>
  <p class=MsoNormal><span lang=PT>AbbVie AB</span></p>
  <p class=MsoNormal><span lang=DA>Tel: +46 (0)8 684 44 600</span></p>
  <p class=MsoNormal><span lang=SV>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:35.7pt'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:35.7pt'>
  <p class=MsoNormal><b><span lang=LV>Latvija</span></b></p>
  <p class=MsoNormal><span lang=LV>AbbVie SIA </span></p>
  <p class=MsoNormal><span lang=LV>Tel: +371 67605000</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:35.7pt'>
  <p class=MsoNormal><b><span lang=EN-GB>United Kingdom</span></b><b><span
  lang=EN-GB> </span></b><b><span lang=PT>(Northern Ireland)</span></b></p>
  <p class=MsoNormal>AbbVie Deutschland GmbH &amp; Co. KG</p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +44 (0)1628 561090</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=2 style='border:none'></td>
  <td width=310 style='border:none'></td>
  <td width=312 style='border:none'></td>
 </tr>
</table>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><b>This leaflet was last revised in {MM/YYYY}</b></p>

<p class=MsoNormal><b>&nbsp;</b></p>

<p class=MsoNormal>Detailed information on this medicine is available on the
European Medicines Agency web site: <a href="http://www.ema.europa.eu">http://www.ema.europa.eu</a></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center'><b>&nbsp;</b></p>

</div>

</body>

</html>
